0001999371-25-003471.txt : 20250331 0001999371-25-003471.hdr.sgml : 20250331 20250331135746 ACCESSION NUMBER: 0001999371-25-003471 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250331 DATE AS OF CHANGE: 20250331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 25791495 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-K 1 solesence_10k-123124.htm ANNUAL REPORT
false 2024 FY --12-31 0000883107 0000883107 2024-01-01 2024-12-31 0000883107 2024-06-30 0000883107 2025-03-28 0000883107 2024-12-31 0000883107 2023-12-31 0000883107 2023-01-01 2023-12-31 0000883107 us-gaap:ProductMember 2024-01-01 2024-12-31 0000883107 us-gaap:ProductMember 2023-01-01 2023-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000883107 us-gaap:PreferredStockMember 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-12-31 0000883107 2022-12-31 0000883107 us-gaap:PreferredStockMember 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-12-31 0000883107 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000883107 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0000883107 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000883107 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000883107 us-gaap:PreferredStockMember 2024-12-31 0000883107 us-gaap:CommonStockMember 2024-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000883107 us-gaap:RetainedEarningsMember 2024-12-31 0000883107 us-gaap:EquipmentMember srt:MinimumMember 2024-12-31 0000883107 us-gaap:EquipmentMember srt:MaximumMember 2024-12-31 0000883107 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2024-12-31 0000883107 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2024-12-31 0000883107 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember srt:MinimumMember 2024-12-31 0000883107 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember srt:MaximumMember 2024-12-31 0000883107 nanx:PrepaymentsFromCertainCustomersPerCompanyPolicyMember 2024-12-31 0000883107 nanx:PrepaymentsFromProductDevelopmentAgreementWithAPersonalCareIngredientCustomerMember 2024-12-31 0000883107 us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000883107 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2024-01-01 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2024-01-01 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2024-01-01 2024-12-31 0000883107 nanx:BeachcorpLLCMember 2024-12-31 0000883107 nanx:BeachcorpLLCMember 2023-12-31 0000883107 nanx:BeachcorpLLCOneMember 2024-01-01 2024-12-31 0000883107 nanx:BeachcorpLLCOneMember 2024-12-31 0000883107 nanx:BeachcorpLLCOneMember 2024-12-30 0000883107 nanx:BeachcorpLLCOneMember 2023-12-31 0000883107 nanx:StrandlerLLCMember 2024-01-01 2024-12-31 0000883107 nanx:StrandlerLLCMember 2024-12-31 0000883107 nanx:StrandlerLLCMember 2023-12-31 0000883107 nanx:StrandlerLLCOneMember 2024-01-01 2024-12-31 0000883107 nanx:StrandlerLLCOneMember 2024-12-31 0000883107 nanx:StrandlerLLCOneMember 2023-12-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2021-12-21 2024-12-31 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-26 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2024-02-29 2024-03-01 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:ReplacementPromissoryNoteMember nanx:BeachcorpLLCMember 2023-11-13 0000883107 nanx:BusinessLoanAgreementMember nanx:ReplacementPromissoryNoteMember nanx:BeachcorpLLCMember 2023-11-12 2023-11-13 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2023-11-12 2023-11-13 0000883107 nanx:BusinessLoanAgreementMember nanx:ReplacementPromissoryNoteMember nanx:BeachcorpLLCMember 2024-02-29 2024-03-01 0000883107 nanx:TermLoanMember nanx:StrandlerLLCMember 2022-01-27 2022-01-28 0000883107 nanx:TermLoanMember nanx:StrandlerLLCMember 2024-02-29 2024-03-01 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember 2023-11-13 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember 2023-11-12 2023-11-13 0000883107 us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0000883107 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000883107 us-gaap:RelatedPartyMember 2024-12-31 0000883107 us-gaap:RelatedPartyMember 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2023-01-01 2023-12-31 0000883107 nanx:StrandlerLLCMember 2023-01-01 2023-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2024-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000883107 us-gaap:OfficeEquipmentMember 2024-12-31 0000883107 us-gaap:OfficeEquipmentMember 2023-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2024-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2024-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883107 us-gaap:ConstructionInProgressMember 2024-12-31 0000883107 us-gaap:ConstructionInProgressMember 2023-12-31 0000883107 nanx:Expiring2025To2037Member 2024-12-31 0000883107 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0000883107 us-gaap:TaxYear2018Member 2024-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-12-31 0000883107 nanx:SeriesXPreferredStockMember 2024-02-29 2024-03-01 0000883107 nanx:SeriesXPreferredStockMember 2024-03-01 0000883107 2024-03-01 0000883107 nanx:SeriesXPreferredStockMember 2024-06-18 2024-06-20 0000883107 us-gaap:CommonStockMember 2024-06-18 2024-06-20 0000883107 us-gaap:EmployeeStockOptionMember nanx:PriorTo2019PlanMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember nanx:Options2019PlanMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember nanx:Options2010PlanMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-12-31 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerOneMember 2024-12-31 0000883107 nanx:CustomerOneMember 2023-12-31 0000883107 nanx:CustomerTwoMember 2024-12-31 0000883107 nanx:CustomerTwoMember 2023-12-31 0000883107 nanx:CustomerThreeMember 2024-12-31 0000883107 nanx:CustomerThreeMember 2023-12-31 0000883107 us-gaap:SupplyCommitmentMember 2024-12-31 0000883107 nanx:EmployeeCostsMember 2024-01-01 2024-12-31 0000883107 nanx:EmployeeCostsMember 2023-01-01 2023-12-31 0000883107 nanx:ContractorsAndProfessionalServicesMember 2024-01-01 2024-12-31 0000883107 nanx:ContractorsAndProfessionalServicesMember 2023-01-01 2023-12-31 0000883107 nanx:MaterialsAndSuppliesMember 2024-01-01 2024-12-31 0000883107 nanx:MaterialsAndSuppliesMember 2023-01-01 2023-12-31 0000883107 nanx:DepreciationMember 2024-01-01 2024-12-31 0000883107 nanx:DepreciationMember 2023-01-01 2023-12-31 0000883107 us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0000883107 us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000883107 us-gaap:OtherIncomeMember 2024-01-01 2024-12-31 0000883107 us-gaap:OtherIncomeMember 2023-01-01 2023-12-31 0000883107 nanx:TaxExpenseMember 2024-01-01 2024-12-31 0000883107 nanx:TaxExpenseMember 2023-01-01 2023-12-31 0000883107 nanx:FacilitiesMember 2024-01-01 2024-12-31 0000883107 nanx:FacilitiesMember 2023-01-01 2023-12-31 0000883107 nanx:ShippingMember 2024-01-01 2024-12-31 0000883107 nanx:ShippingMember 2023-01-01 2023-12-31 0000883107 nanx:TestingMember 2024-01-01 2024-12-31 0000883107 nanx:TestingMember 2023-01-01 2023-12-31 0000883107 nanx:ITServicesMember 2024-01-01 2024-12-31 0000883107 nanx:ITServicesMember 2023-01-01 2023-12-31 0000883107 nanx:InsuranceMember 2024-01-01 2024-12-31 0000883107 nanx:InsuranceMember 2023-01-01 2023-12-31 0000883107 nanx:ManufacturingOtherExpenseMember 2024-01-01 2024-12-31 0000883107 nanx:ManufacturingOtherExpenseMember 2023-01-01 2023-12-31 0000883107 nanx:SellingGeneralAndAdministrativeOtherExpenseMember 2024-01-01 2024-12-31 0000883107 nanx:SellingGeneralAndAdministrativeOtherExpenseMember 2023-01-01 2023-12-31 0000883107 us-gaap:NonUsMember 2024-01-01 2024-12-31 0000883107 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000883107 nanx:ConsumerProductsMember 2024-01-01 2024-12-31 0000883107 nanx:ConsumerProductsMember 2023-01-01 2023-12-31 0000883107 nanx:PersonalCareIngredientsMember 2024-01-01 2024-12-31 0000883107 nanx:PersonalCareIngredientsMember 2023-01-01 2023-12-31 0000883107 nanx:AdvancedMaterialsMember 2024-01-01 2024-12-31 0000883107 nanx:AdvancedMaterialsMember 2023-01-01 2023-12-31 0000883107 nanx:ARRevolverInventoryFacilityAndNewTermLoanMember 2024-12-29 2024-12-31 0000883107 nanx:ARRevolverInventoryFacilityAndNewTermLoanMember us-gaap:SubsequentEventMember 2025-01-01 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2024

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM_____ TO_____

 

COMMISSION FILE NUMBER 000-22333

 

SOLESENCE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 36-3687863
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)  

 

1319 Marquette Drive, Romeoville, Illinois 60446

(Address of principal executive offices) (zip code)

 

Registrant’s telephone number, including area code: (630) 771-6708

 

NANOPHASE TECHNOLOGIES CORPORATION

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $.01 per share

 

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting stock held by non-affiliates of the registrant based upon the last reported sale price of the registrant’s common stock on June 30, 2024 was $27,254,231 as of such date.

 

The number of shares outstanding of the registrant’s common stock, par value $.01, as of March 28, 2025 was 70,103,279.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

 

   PART I  
Item 1. General 2
  Company Background 2
  Consumer Products 2
  Personal Care Ingredients 3
  Advanced Materials 3
  Sources and Availability of Raw Materials 3
  Markets and Distribution 4
  Research and Development 4
  Competitive Advantage 4
  Manufacturing Operations 5
  Intellectual Property and Proprietary Rights 5
  Competition 5
  Governmental Regulations, Including Climate Change 6
  Employees 6
  Backlog 6
  Business Segment and Geographical Information 6
  Key Customers 7
  Forward-Looking Statements 7
  Investor Information 7
Item 1A. Risk Factors 8
Item 1B. Unresolved Staff Comments 8
Item 1C. Cybersecurity 8
Item 2. Properties 8
Item 3. Legal Proceedings 9
Item 4. Mine Safety Disclosures 9
     
  PART II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 10
Item 6. Selected Financial Data 10
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 10
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 14
Item 8. Financial Statements and Supplementary Data 14
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 14
Item 9A. Controls and Procedures 14
Item 9B. Other Information 15
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 15
     
  PART III  
     
Item 10. Directors, Executive Officers and Corporate Governance 16
Item 11. Executive Compensation 18
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 22
Item 13. Certain Relationships and Related Transactions, and Director Independence 23
Item 14. Principal Accounting Fees and Services 24
     
  PART IV  
     
Item 15. Exhibits and Financial Statement Schedules 25
Item 16. Form 10-K Summary 25

 

1 

 

 

PART I

 

Item 1. General

 

Company Background

 

On March 7, 2025, Nanophase Technologies Corporation announced its rebranding as Solesence, Inc. (“Solésence,” “Company,” “we,” “our,” or “us”), marking a new chapter in its commitment to innovation, self-expression, and inclusivity in skin health. The company’s stock will continue to trade under the NANX ticker symbol. Its corporate website transitioned to solesence.com. Investor relations information, including historic Nanophase financials and disclosures, is available at ir.solesence.com. Nanophase Technologies Corporation changed its legal name to Solesence, Inc. by amending its certificate of incorporation with the state of Delaware on March 10, 2025.

 

Solésence, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence consumer products subsidiary”), is a leading innovator in scientifically-driven health care solutions across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. Skin health, addressed through both our Solesence consumer products and our Active Pharmaceutical Ingredients (“APIs”), currently make up the great majority of our business, with additional revenue being generated from other legacy advanced materials applications. The Company was incorporated in Illinois on November 25, 1989 and became a Delaware corporation during November 1997. Our common stock trades on the OTCQB marketplace under the symbol NANX. We have development and application laboratories, and manufacturing capacity in three locations in the Chicago, Illinois area.

 

Leveraging a platform of integrated patented and proprietary technologies, we create products with unique performance to enhance end-consumers’ health and well-being. We offer comprehensive production, from engineered materials, formulation development, and finished product development, to commercial manufacturing and packaging capabilities. Our expertise in materials engineering allows us to effectively coat and disperse materials on a nano and “non-nano” scale for use in a variety of markets in skin health, including for use in sunscreens as APIs. We believe our innovative approach to creating these materials gives us technological and market advantages. We also leverage expertise to develop skin care, sun care, and color cosmetics products (“Solésence consumer products”) that offer unique skin health benefits. We offer these for sale to brands who ultimately sell products to consumers in both prestige and mass markets within the beauty industry. Our Solésence consumer products have received broad acceptance in the marketplace. Due to the enhanced efficacy and aesthetic qualities offered by our proprietary technology platform, Solésence consumer products satisfy growing consumer demands for “clean” and inclusive beauty across a range of product formats and categories. The vertically integrated nature of our Solésence consumer products helps us to develop ingredient technologies and formulas in tandem. We have leveraged this to develop specialized formulation know-how with our unique ingredients, improve efficiency, and avoid potential major supply chain challenges, while also addressing ongoing sustainability efforts.

 

Given our technological position, in addition to the historical market acceptance of our APIs for use in skin health products and sunscreens, we have seen rapidly growing sales for our suite of Solésence consumer products. Due to the expanding demand from our brand partners, we have further refined our strategy to reflect our view that consumer products should be the major focus of our growth strategy. Management believes that this growth is happening now due to a confluence of our technology and market conditions that favor the types of products we produce. We continue to see unprecedented demand for these products. Coupled with our expanded and growing expertise in these areas, we believe we are well positioned to enjoy growth into the future. This success had led us to focus our combined business-, ingredient technology-, and product-development capabilities on products that bring unique performance to this area. While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus, and we expect it to make up less of our total business over time. We may develop additional technologies or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth.

 

Consumer Products

 

During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Original Active Stress Defense™ Technology. This has become the cornerstone of our new product development in our consumer product line, with first revenue recognized during 2017. In 2020, Solésence consumer products revenue doubled revenue from our personal care ingredients products.

 

We now offer a suite of three technologies under our Active Stress Defense™ platform, each of which offers a distinct market advantage in terms of performance, aesthetics, and/or “clean” positioning in UV and environmental protection. We design and market flexible formulas that allow for adoption by a range of brands with different market positions. In 2020, consumer products surpassed our personal care APIs in terms of total revenue. We believe that Solésence consumer products offer the greatest growth potential of any product line in any market in the Company’s history.

 

We continue to develop and expand our in-house formulating capability, through which we have created, and now sold, more than 250 SKUs of fully formulated finished cosmetics products in markets focused on skin health, with the majority in prestige beauty. Products developed and sold through our Solésence consumer product line are all produced under the requirements of current Good Manufacturing Standards (“cGMP”), as enforced by the U.S. Food and Drug Administration (“FDA”), which enables us to leverage the expertise we developed in the manufacture of personal care ingredients. Although our Solésence products are fully formulated for consumer use, we do not sell directly to consumers or distribute products to consumers under the Solésence brand through intermediaries or resellers. Instead, we sell our Solésence consumer products to brand partners as market-ready products, as customized white label products, or as custom-developed products, in each case, for sale or distribution to consumers under our customers’ brand names.

 

2 

 

 

The extent to which we grow will be dependent upon our ability to effectively expand our capabilities during 2025. As a result, we plan to continue investments in facilities and equipment as well as in human resources, in 2025 and beyond. We are prioritizing operational efficiencies, facilities expansion, and capital investment in this product line to allow for continued growth, and increased profitability. 

 

In 2022, Solésence was granted site clearance by Australia’s Therapeutic Goods Administration (“TGA”) for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. TGA site clearance is legally required for brands to market Solésence-made products as primary sunscreens in Australia. Our initial focus continues to be on establishing a footprint with both new and existing Solésence brand partners, to enable the sale of our patented skin health products as primary sunscreens. Also in 2022, Solésence was granted a patent in Korea for the Kleair™ technology used exclusively in Solésence products. Shortly thereafter, Solésence received two industry accolades. In July 2022 at Cosmoprof North America, Solésence was awarded the Cosmopack Award for best Formulation for its product Multi-Cultural Magic SPF 50+ Featuring Kleair™ technology, acknowledging the Company’s technology, formulation and marketing know-how. In September 2022, Solésence was awarded the Cosmetics & Toiletries Allē Award for Most Significant Active Ingredient in Sun/Light Protection for Kleair™ technology, a further acknowledgment of the company’s technology know-how, as well as a recognition for the Company in the areas of innovation and impact. In early 2023, Solésence was named number 2 in the Beauty category of Fast Company’s World’s Most Innovative Companies list. This is a prestigious award that recognizes the impact we have on the industry we serve and the lives of the people who use our products. In July of 2023, Solésence was again awarded the Cosmopack Award for best Formulation, this time for its product Natural Glow Face Oil SPF 40+ featuring Kleair™ and Bloom™ technology, recognizing our continued innovative approach to formulation and product development. In 2023, Solésence also won the 2023 Beauty Matter NEXT Award for Best Contract Manufacturer and was a winner of the 22nd Chicago Innovation Awards. In 2024, Solésence won its third consecutive Cosmopack Award for best Formulation for its Lip Oil, SPF 40+ and its second Cosmetics & Toiletries Allē Award in the Finished Formula-Prestige category for its market-ready product, Soft Glow SPF 50+. Most recently in March 2025, Solésence won its third consecutive Cosmetics & Toiletries Allē Award and its second in the Finished Formula-Prestige category for its finished formula Au Lait Face Milk SPF 50+.

 

Personal Care Ingredients

 

Prior to 2020, our largest of products had been the manufacture and sale of APIs in the skin health and sun care markets, which we deliver to customers through strategic partnerships. We continue to manufacture and supply hundreds of metric tons of surface engineered zinc oxide and titanium dioxide ingredients to our customers annually, and these are used by major global consumer products companies for sunscreens and skin health-focused personal care products. We produce these products using proprietary coating and dispersion technologies that comply with the requirements of cGMP and are classified as Active Pharmaceutical Ingredients, or APIs, by the FDA.

 

Advanced Materials

 

A third product for us has historically been the manufacture and sale of advanced nanoparticle materials, including a material used in life science applications to enhance the performance of PCR test methods. We continue to service other profitable markets where we have had a degree of success in the past, including applications in food packaging and coatings, but they are not our strategic focus and related future development in these areas are not being prioritized.

 

Sources and Availability of Raw Materials

 

Most of the raw materials we use are readily commercially available. In some cases, we rely on sole-source processors of materials that utilize an array of worldwide sources for the raw materials that they process to our specifications. However, we require very high purity zinc for our personal care applications that have occasionally seen shortages in prior years. Although we currently believe we have developed adequate commercial relationships to supply the necessary raw materials for our business which are not readily commercially available, our business is subject to the pricing and availability of certain raw materials.

 

Some of the raw materials that are critical to the production of our products and parts that are critical to the operation of our equipment are sourced from single suppliers, suppliers from China and Korea. However, we do not knowingly source any materials from the Xinjiang region of China. We continue to monitor delays in shipping exports from China and Korea. The Company is monitoring the potential impacts of Chinese tariffs on our cost of materials sourced from China. Despite the Russian invasion of Ukraine, we do not anticipate any directly related supply disruptions as we do not knowingly source any materials directly from either country. Additionally, we could be disrupted by conditions unrelated to our business operations or that are beyond our control, including but not limited to international trade restrictions and conditions related to epidemics. We typically maintain no less than one month’s supply of raw materials and parts that are sourced from sole suppliers and make efforts to identify additional suppliers who may be able to provide such raw materials or parts. The Company is actively taking steps to reduce the number of singularly sourced raw materials.

 

3 

 

 

Markets and Distribution

 

Consumer Products

 

We partner with brands on a global basis to develop, manufacture and market products that enhance lives through healthy skin. These products are fully formulated solutions built around proprietary Solésence technologies, which are designed to improve skin health for all human beings, and are aligned with consumer demand for “clean” and inclusive beauty products that enhance skin health. Our consumer products clients, or brand partners, are positioned in skin care, makeup/cosmetics, and sun care markets, with the majority of our partners operating in the prestige beauty segment with retail, direct-to-consumer, and/or omnichannel strategies. This represents a move downstream from our previous position — one of providing ingredients to manufacturers — to offering finished consumer products that we believe offer a clear and distinct market advantage relative to both aesthetics and performance. With our first Solésence consumer product revenue recognized during 2017, we had our first material amounts of consumer product revenue in 2018, and saw significant expansion in these sales through 2024. Solésence brand partners have experienced strong growth as our products have seen broad acceptance from retailers, adoption by consumers, and recognition by third-party media outlets through awards and accolades. We expect our consumer product group to enhance both our degree of control of the business development cycle, and to further enable our ability to grow rapidly.

 

Personal Care Ingredients

 

In addition to serving strategic partners in diverse markets and geographic locations, we will continue to devote significant resources to maintaining and growing our relationship with BASF Corporation (“BASF”), the largest customer in our personal care ingredients product group. This has been a successful relationship that we expect will contribute to our future growth. BASF, which describes itself as the world’s leading chemical company with annual revenue of approximately $65 billion, is a “globally leading supplier of sustainable high-performance ingredients for the personal care industry,” with recognized brands, significant revenue, and a broad sales network. BASF is primarily responsible for the business development cycle and maintains the direct customer relationships. We have a long-term exclusive relationship with BASF, primarily to provide nano-scale zinc oxide-based products made to specific specifications to be used as ingredients in personal care cosmetics, with sunscreens and daily wear products being the dominant applications. These materials differ significantly in their specifications from those used in the consumer products line. 

 

Research and Development

 

Most of our research and development over the past few years has been directly related to the development of Solésence consumer products. We endeavor to either meet specific customer needs or to develop solutions to address unmet or emerging needs where we believe our technologies will offer a distinct performance advantage. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional technologies platforms that have the capability to serve multiple beauty or life science markets; and 3) continuing to improve manufacturing operations to improve process reliability and reduce costs.

 

Our total research and development expense, which includes all expenses relating to our technology and advanced engineering groups was $3.8 million, during the years ended December 31, 2024 and 2023. This represents our share of these expenses only and does not take into account amounts spent by any of our customers in support of new product development. Our future success will depend in large part upon our ability to develop products that bring a high degree of value to our customers. Through the two-year period ended December 31, 2024, we had cumulative research and development expenses of approximately $7.6 million and $0.1 million cumulative capital expenditures on equipment and leasehold improvements.

 

Competitive Advantage

 

Through our Solésence consumer product line, our Active Stress Defense™ platform of proprietary technologies – which includes Kleair™ – offers unique skin health benefits through performance-related and aesthetic advantages in environmental protection skin health products, including in UVA/UVB, pollution and HEV (blue) light protection. These technologies expand access to healthy skin by improving both the product experience across the full range of skin tones while also leveraging a unique versatility that enables a variety of novel formats to reach the full range of product preferences and lifestyles. By combining our market awareness, proprietary dispersion capabilities and formulation know-how, our Solésence products enable our brand partners to expand the range of products within skin care and color cosmetics categories that can include sun and environmental protection, and consequently fill a unique market segment which drives the growing demand for our Solésence products.

 

Through our personal care ingredients product line, we believe that targeted collaborations with our long-standing customers will enable them to have a competitive advantage which will sustain and/or grow their market share in the sunscreen API market. Both the customer products and the personal care ingredients have been positively impacted by the growing interest among consumers for mineral-based sunscreens, which management sees as a validation of the Company strategy.

 

4 

 

 

Manufacturing Operations

 

We currently have manufacturing capacity based in three locations in the Chicago area. We are able to develop and supply engineered materials and bulk finished goods in quantities ranging from grams to metric tons. All facilities are registered under the ISO 9001, American National Standard, Quality Management System Requirements, ISO 22716 American National Standard, Environmental Management System Requirements, and ISO 14001, American National Standard, Environmental Management System Requirements. We are compliant with cGMP for products under U.S. Food and Drug Administration (“FDA”) regulation, applying to the manufacture of APIs and OTC Finished Dosage Form materials (primarily used in sun protection). We have registered some of the chemicals we ship to customers in Europe pursuant to the European Chemical Agency’s regulations issued to date pertaining to Registration Evaluation and Authorization of Chemicals (“REACH”). Currently, we have registered Zinc Oxide, Aluminum Oxide, Iron Oxide and Octyltrimethoxysilane under REACH. We maintain, by participation, support GMP site licenses related to import of our customer products in Canada and Australia.

 

Our operations employ a cellular, team-based manufacturing approach, where workers operate in work “cells,” under a lean manufacturing environment to continuously advance and improve production capabilities. We have also developed a highly flexible workforce that has been cross trained to allow it to be employed broadly across our manufacturing processes. Beginning in late 2019, we also began to employ a significant number of temporary operators to assist us in supporting the production of our Solésence customer products. Our manufacturing approach, targeted engineering actions, and capital investment have resulted in continuing process innovations and improvements that have reduced the variable manufacturing cost significantly over the past several years, while increasing our capacity to meet demand.

 

We are committed to a Lean Six Sigma manufacturing approach, to the extent possible given a certain measure of irregular demand, where we are able to reduce excess labor and manage the lowest practical inventory and supply levels in order to minimize working capital demands. This approach complements two of our major operational goals - (1) to increase output without adding unnecessarily to existing equipment and (2) to continually reduce production costs while consistently producing high quality products.

 

Intellectual Property and Proprietary Rights

 

We rely on a combination of patent, trademark, copyright, trade secret and other intellectual property laws, nondisclosure agreements and other protective measures to protect our intellectual property. In addition to obtaining patent and trademarks based on our inventions and products, we may also license certain third-party patents from time-to-time to expand our technology base.

 

As of the date of this filing, we own 10 U.S. patents and 5 pending U.S. patent applications. We also own 108 foreign patents and patent applications consisting of 68 issued or allowed foreign patents and 40 pending foreign patent applications. All of the pending and owned foreign patents are counterparts to domestic filings covering our platform of nanotechnologies and surface treatments.

 

Competition

 

Within each of our targeted markets and product applications, we face potential competition from contract manufacturers and developers, advanced materials and chemical companies, and suppliers of traditional materials. In many markets, the actual or potential competitors are larger and more diversified than we are; however, we believe we focus on market segments and opportunities where our materials and related technologies are superior to those of our competitors, often due to our abilities to produce highly engineered ingredients to meet specific performance requirements, develop advanced material solutions for customers’ specific applications, and in the case of consumer products line, finished products that impart the benefits of minerals-based products with superior tactile, visual, and performance characteristics.

 

With respect to traditional suppliers, we may compete against lower priced traditional materials for certain customer applications. In some product or process applications the benefits of using advanced materials do not always justify a process change or outweigh their frequently higher costs.

 

We believe that our material technologies and manufacturing platforms are strong. We believe we are well-positioned with our platform of integrated commercial materials technologies and track record of technology improvement and evolution.

 

Our Solésence consumer products faces competition from a wide variety of offerings in the field of skin care. Our Solésence products compete with existing solutions as well as new solutions from various sources, including other product developers and manufacturers who seek to serve skin care brands and integrated brands who also manufacture their own products in-house, and we must differentiate our value proposition in order to gain traction in this marketplace. The complexities of sunscreen regulation and the nuances of the development and manufacture of sunscreen products present a barrier for brands with integrated manufacturing in other skin care and cosmetics areas. Still, several Solésence consumer products customers have internal development and manufacturing capabilities that are similar to the capabilities of Solésence and can serve as indirect competition to our products and services. We believe that our Solésence consumer products technology and our expertise in the nuances of formulating products that contain UV protection, coupled with our expanding capability to produce novel formats, will allow us to become a competitive player in this market on a sustainable basis.

 

5 

 

 

Governmental Regulations, Including Climate Change

 

The manufacture and use of certain products that contain Active Pharmaceutical Ingredients are subject to governmental regulations. As a result, we are required to adhere to the cGMP requirements of the FDA and similar regulations that include testing, control and documentation requirements enforced by periodic inspections. We also comply with the European Chemical Agency’s regulations issued to date pertaining to the chemicals we have registered under REACH. In early 2022, we were granted site clearance by Australia’s TGA for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. TGA site clearance is legally required for brands to market Solésence-made products as primary sunscreens in Australia. Our initial focus will be on establishing a footprint with both new and existing Solésence brand partners, to enable the sale of our patented skin health finished products as primary sunscreens.

 

We are committed to environmental health and safety (“EH&S”). We believe we comply with all applicable exposure limit standards issued by the United States Department of Labor’s Occupational Health and Safety Administration (“OSHA”). Because nanotechnology remains an emerging and evolving science, there are no currently required, measurements or personal protective equipment available that are specific to nanoparticle safety. Accordingly, we rely on general chemical safety and process safety requirements to identify safe personal protective equipment and appropriate handling protocols. We believe that we have taken a leadership position on EH&S in our operations and have internal and external review and monitoring of our practices.

 

In addition, our facilities and operations are subject to the plant and laboratory safety requirements of various environmental and occupational safety and health laws. We believe we are in compliance with all such laws and regulations, and to date, those regulations have not materially restricted or impeded operations. Further, we believe our processes to be highly efficient, generating very low levels of waste and emissions. For this reason, we do not view issues surrounding climate change and any currently foreseeable related regulations as materially impacting our business and financial statements, beyond any inestimable impact on the macro-economic environment.

 

We have taken a responsible, proactive approach to EH&S by implementing appropriate procedures and processes to have our facilities registered under ISO 14001, American National Standard, Environmental Management System Requirements. We are also involved with leading industry groups that are defining nanomaterial standards and protocols. These currently include the ASTM International Committee on Nanotechnology, and the US TAG to ISO TC 229 Nanotechnology committee managed by the American National Standards Institute committee (ANSI). We also participate in FDA reviews relative to cosmetic and applicable drug applications. We have a full-time, advanced degreed professional, along with a supporting staff, who spend a significant amount of time managing governmental regulation compliance and EH&S. We believe that our Company has an exemplary safety record.

 

Employees

 

On December 31, 2024, we had a total of 98 full-time employees, 13 of whom hold advanced degrees. Additionally, we have a number of temporary, and temporary-to-permanent employees, typically 125 to 225 on a demand-driven basis, and a number of contractors with specific industry experience that have become a part of our talent pool. We have no collective bargaining agreements and believe that we have a strong relationship with our employees, whom management believes represent the strength of our Company.

 

Backlog

 

We do not believe that a backlog as of any particular date is indicative of future results. Our sales are primarily pursuant to purchase orders for delivery of our Solésence formulated products, personal care ingredients, and advanced materials. We have some agreements that give customers the right to purchase a specific quantity of ingredients during a specified time period. These agreements, however, do not obligate the customers to purchase any minimum quantity of such ingredients. The quantities actually purchased by the customer, as well as the shipment schedules, are frequently revised during the agreement term to reflect changes in the customer’s needs. For these reasons we do not believe that such agreements are meaningful for determining backlog amounts.

 

Business Segment and Geographical Information

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. See Note 13 to the accompanying Financial Statements for additional information.

 

6 

 

 

Key Customers

 

A limited number of key customers account for a substantial portion of our commercial revenue, and aside from our largest customer, we are seeing the composition of these key customers change with the growth we are experiencing within our consumers products line, which has grown to exceed personal care ingredients line significantly. For 2024, total consumer products revenue amounted to $44.4M or 85% of total revenue compared to $25.2M, or 68% for 2023. In particular, revenue from our three largest customers across all business areas included our largest customer in personal care applications (BASF) and two of our consumer products customers, which constituted approximately 13%, 32%, and 7%, respectively, of our 2024 total revenue.

 

As our consumer products continue to represent more of our total revenues, we expect to see a number of smaller (sub-10% of revenue) customers represent a more significant portion of our total revenue. We have experienced this in 2024 and 2023 and expect it to continue in 2025 and beyond.

 

While our agreements with BASF are long-term agreements, they may be terminated by BASF under certain circumstances with contractually required notice and do not provide any guarantees that BASF will buy our products. The loss of one of our largest customers or the failure to attract new customers could have a material adverse effect on our business, results of operations and financial condition. To reduce the impact of having a high concentration of sales to a limited number of customers, we have pursued new customers through our market focused business model, and particularly through our consumer products. To the extent we are successful in both adding a large number of customers through this model, and maintaining or expanding our existing partners, we believe we will be able to best manage the risks associated with customer concentration.

 

Forward-Looking Statements

 

We want to provide investors with more meaningful and useful information. As a result, this Annual Report on Form 10-K (the “Form 10-K”) contains certain “forward-looking statements”, as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance or achievements in 2025 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF which could trigger a requirement to sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including high purity zinc, and other items impacted by supply chain pressures; uncertain demand for, and acceptance of, our Solésence products, and our advanced materials; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations, especially any new governmental regulations focusing on the processing, handling, storage or sale of nanomaterials as it could impact our personal care ingredients business, that could be difficult to respond to or costly to comply with; business interruptions due to unexpected events or public health crises, including viral pandemics such as COVID-19; and the resolution of litigation or other legal proceedings in which we may become involved. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Form 10-K should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

 

Investor Information

 

We are subject to the informational requirements of the Exchange Act and, accordingly, file periodic reports, proxy statements and other information with the Securities and Exchange Commission (the “SEC”). Such reports, proxy statements and other information may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, N.E., Washington, DC 20549 or by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically.

 

Financial and other information may also be accessed at our website. The address is to ir.solesence.com. We make available, free of charge, copies of our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically with, or otherwise furnishing it to, the SEC, and intend to make all such reports and amendments to reports available free of charge on our website. We have included our website address throughout this Form 10-K as textual references only. The information contained on, or accessible through, our website is not incorporated into this Form 10-K.

 

7 

 

 

Item 1A. Risk Factors

 

Not required for a smaller reporting company.

 

Item 1B. Unresolved Staff Comments

 

Not required for a smaller reporting company.

 

Item 1C. Cybersecurity

 

Risk Assessment and Strategy

 

The Company regularly evaluates cybersecurity risk from computer viruses and more sophisticated and targeted cyber-related attacks such as ransomware, as well as cybersecurity failures resulting from human error and technological errors.

 

Our overall strategy in combatting known cybersecurity risks includes a variety of individual tactics, including:

 

●The use of antivirus software, virtual private networks, email security, as well as other software to prevent and detect data intrusions.
●The deployment of updates and patches as they are available and maintaining the current versions of major software to reduce the exposure to vulnerabilities.
●If necessary, the use of third-party security experts if and when an incident is detected.

 

We are not aware of having experienced any material cybersecurity incidents in 2024. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions.

 

Management Oversight

 

Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management, which then reports to the Board of Directors.

 

Board Oversight

 

The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks.

 

Item 2. Properties

 

We operate three facilities in the Chicago suburbs - a 36,000 square-foot production, research and headquarters facility in Romeoville, Illinois, a 20,000 square-foot production facility in Burr Ridge, Illinois and a 261,000 square-foot production and warehouse facility in Bolingbrook, Illinois.

 

Our manufacturing operations in Burr Ridge are registered under ISO 9001, and we believe that our manufacturing operations are within the cGMP requirements of the FDA for products that require such compliance. This facility is also registered under ISO 14001 which is the international standard for environmental management. The Burr Ridge site is registered with the FDA for API manufacturing.

 

The Romeoville facility houses our headquarters, advanced engineering, manufacturing (including particle coating, particle dispersion and pilot-scale manufacturing), and research and development with three applications development and formulating laboratories. The Romeoville facility has a quality control laboratory designed for the dual purposes of validating operations to cGMP and ISO standards and production process control. This laboratory is equipped to handle many routine analytical and in-process techniques that are currently required. All Romeoville manufacturing processes are registered under ISO 9001, ISO 22716 and ISO 14001, and we believe that the particle coating processes used for our ingredients and fully formulated sunscreens and cosmetic products for personal care are in compliance with the cGMP requirements of the FDA. The Romeoville site is registered with the FDA for API manufacturing, manufacturing, and packaging.

 

The Bolingbrook facility houses our warehousing operations, sunscreen lotions manufacturing, dispersion manufacturing, filling and assembly of our Solésence® products and additional quality control spaces. The Bolingbrook facility is registered with the FDA for OTC drug manufacturing and packaging, site is registered under ISO 9001, ISO 22716 and ISO 14001, and we believe that the particle coating processes used for our ingredients and fully formulated sunscreens and cosmetic products for personal care are in compliance with the cGMP requirements of the FDA. The Bolingbrook site is registered with the FDA for API manufacturing, manufacturing, and packaging.

 

8 

 

 

We lease our Romeoville, Burr Ridge and Bolingbrook facilities. The Romeoville lease term was extended to January 31, 2028, in August 2024. The Burr Ridge lease term was extended to September of 2025. During December 2021, we entered into a Standard Form Industrial Lease for a new facility in Bolingbrook, Illinois, which, among other things, will end in May of 2032, with options to extend this lease at market rent for each of three concurrent five-year periods.

 

With the addition of the Bolingbrook space in 2021, we believe that our leased facilities will provide sufficient capacity to fulfill current known customer demand as well as allow for the creation of substantial additional space to enable expansion of key production processes. We believe we will be able to expand certain operations, and consolidate others, to support additional growth in an economically efficient manner. We believe that our capital expenditures made in 2024, and projected for 2025, will support currently anticipated demand from existing and expected customers through 2025 and into 2026. Management continues to spend considerable time determining how best to optimize our facilities to maximize growth over the next few years. Our actual future capacity requirements will depend on many factors, including new and potential customer acceptance of our current and potential engineered materials, applications and products, both expected and currently unplanned growth from existing customers, continued progress in our research and development activities and product testing programs and the magnitude of these activities and programs.

 

Item 3. Legal Proceedings

 

As previously disclosed, in August 2022, BASF Corporation (“BASF”) filed a complaint against the Company (the “New Jersey Complaint”) in the Superior Court of New Jersey (“SCNJ”) alleging that the Company breached the Zinc Oxide Supply Agreement dated as of September 16, 1999 between the Company and BASF, as assignee, as amended through January 1, 2019 (the “Agreement”). The New Jersey Complaint specifically alleged that the Company had breached the exclusivity provision of the Agreement by selling zinc oxide to entities other than BASF, including sales to the Company’s subsidiary Solésence, LLC (“Solésence”), in markets designated as being in the field of use (the “Field”) under the Agreement. In February 2023, the Company answered the New Jersey Complaint, denying all wrongdoing and filed counterclaims, including a request for a declaration that contrary to BASF’s views, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide for uses in the Field nor does the exclusivity provision prohibit the Company’s sales through Solésence of products containing zinc oxide as an ingredient.

 

Following certain discovery, rulings on several motions, and the parties’ extensive negotiations, the Company and BASF entered into a Settlement Agreement and General Release on April 10, 2024 (the “Settlement Agreement”), providing for settlement of the New Jersey Complaint and resolution of the parties’ disputes. Under the Settlement Agreement, the Company and BASF agreed to enter into the Amendment (defined below) in exchange for (i) a mutual release of all claims related to the New Jersey Complaint and any claims based on similar facts or legal theories (collectively, the “Claims”), (ii) the filing of a Stipulation of Dismissal with the SCNJ voluntarily dismissing the New Jersey Complaint with prejudice, (iii) mutual covenants by the Company and BASF not to sue the other party for the Claims, (iv) the Company and BASF entering into the Modified Product MOU (defined below), (v) mutual indemnification as to certain claims arising out of the making, use, purchase, sale, or development of products in connection with the Modified Product MOU, and (vi) provisions regarding confidentiality of settlement terms and other customary settlement terms. The Stipulation of Dismissal was filed with the SCNJ on April 11, 2024, thereby concluding the New Jersey Complaint.

 

In connection with the Settlement Agreement, the Company and BASF entered into Amendment No. 5 (the “Amendment”) to the Agreement, and a Binding Memorandum of Understanding regarding the Company using its commercially reasonable efforts to develop a modified zinc oxide product for BASF’s exclusive purchase under the Agreement (the “Modified Product MOU”). The Amendment includes provisions (a) amending the exclusivity section of the Agreement to provide that (i) BASF has the exclusive right to use zinc oxide materials that the Company develops, makes, or sells to BASF as an ingredient for uses in the Field, and (ii) the Company or its affiliates, including Solésence, can supply and sell both certain finished products containing zinc oxide for use in the Field to customers anywhere in the world and certain zinc oxide dispersions that the Company developed or develops for a particular customer, and (b) amending the provisions of the Agreement concerning order forecasting and procedures, operational planning, inventory and capacity requirements, and periodic facility shutdown arrangements, to more effective serve each party’s business needs with respect to all product that BASF purchases from the Company under the Agreement.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

9 

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information; Holders; Dividends

 

Our common stock is traded under the symbol “NANX” on the OTCQB marketplace, operated by OTC Markets Group. The following table sets forth, for the periods indicated, the range of high and low sale prices for our common stock on the OTCQB marketplace:

 

   High   Low 
Fiscal year ended December 31, 2024:          
First Quarter  $0.98   $0.43 
Second Quarter   1.71    0.70 
Third Quarter   1.65    1.33 
Fourth Quarter   2.88    1.30 
Fiscal year ended December 31, 2023:          
First Quarter  $1.79   $1.08 
Second Quarter   1.45    0.50 
Third Quarter   1.40    0.88 
Fourth Quarter   1.00    0.55 

 

On March 28, 2025, the last reported sale price of our common stock was $2.09 per share, and there were 120 holders of record of our common stock.

 

We have never declared or paid any cash dividends on our common stock and do not currently anticipate paying any cash dividends or other distributions on our common stock in the foreseeable future. We intend instead to retain any future earnings for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements and such other factors deemed relevant by our Board of Directors. Our Business Loan Agreements with Beachcorp, LLC (“Beachcorp”), Strandler, LLC (“Strandler”), and Libertyville Bank and Trust Company (“Libertyville”), dated as of November 19, 2018, January 28, 2022, and December 21, 2021 respectively, require us to obtain the written consent of the lender prior to paying any cash dividends on our common stock.

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis should be read in conjunction with risks discussed in the financial statements and related notes thereto appearing elsewhere in this Form 10-K. When used in the following discussions, the words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and contingencies that could cause actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. See the “Forward Looking Statements” section in Part 1, Item 1, of this Form 10-K.

 

Overview

 

Solésence is a health-oriented, science-driven company, focused on various skin health and beauty markets. Our primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection enabled by our proprietary Active Pharmaceutical Ingredients (“APIs”), which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products. Additionally, we continue to sell products in legacy markets including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications— all of which currently fall into the advanced materials product category.

 

10 

 

 

Critical Accounting Estimates

 

Management also monitors the value of inventory for the effects of aging, obsolescence, and seasonality. Consistent with the provisions in FASB ASC 330-10-35, we adjust inventory valuation upon management’s determination that the potential for obsolete materials exist. The majority of the reserve is done by specific identification. Factors include inventory in quarantine, aging finished goods or obsolete materials as identified by management. In the application of this policy in 2024, management deemed a portion of inventory will likely experience such an impairment and elected to apply a $1,987,000 inventory reserve in anticipation. Some of the materials in question are nearing expiration and therefore more difficult to sell, some represent soon-to-be obsolete products, and some are raw materials that we no longer use regularly.

 

Certain assumptions are necessary to assess the impact of risks and uncertainties on the financial information, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. Any changes in those plans or assumptions could have a material impact on our liquidity and financial condition. While we have seen costs continue to increase on an inflationary basis as we enter 2025, it is our belief that we will be able to offset much of this cost as we gain greater production efficiencies and seek to increase our pricing where possible.

 

Results of Operations

 

Years Ended December 31, 2024 and 2023

 

Total revenue increased to $52,347,000 in 2024, compared to $37,297,000 in 2023. A substantial majority of our revenue for each year is from our largest customers, in particular, sales to our largest customer in skin care and sunscreen applications, finished skin health products marketed through our consumer products. Product revenue, the primary component of our total revenue, increased to $51,890,000 in 2024, compared to $36,641,000 in 2023. This increase was due to an increase in revenue from our consumer products partially offset by decreased personal care ingredients and advanced materials products.

 

Current Significant Customers

 

      For the years ended  
      December 31,  
Customer #   Product
Category		 2024     2023  
1   Consumer Products 32 %     17 %
2   Personal Care Ingredients 13 %     25 %
3   Consumer Products 7 %     15 %
    Total 52 %     57 %

 

Cost of revenue generally includes costs associated with commercial production and customer development arrangements. Cost of revenue increased to $36,159,000 in 2024, compared to $29,472,000 in 2023. The increase in cost of revenue was primarily driven by higher materials and direct labor costs related to the increased sales volume. Also contributing to the higher cost of revenue was increased costs associated with supply chain and maintenance activities costs due to the increased sales volume. We expect to continue new materials development and dispersion technologies for personal care applications and for our formulated Solésence products during 2025 and beyond, as part of our business model. At current revenue levels we have generated a positive gross margin, though margins can be impeded by the cyclicality of our demand, often leading to the Company not having enough revenue to efficiently absorb manufacturing overhead that is required to work with current customers and expected future customers. We believe that our current fixed manufacturing cost structure is sufficient to support higher levels of revenue volume. The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence products. We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow. We expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets and cost and wage inflation but may or may not realize gross margin percentage growth through 2025 and beyond, dependent upon the factors discussed above.

 

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new finished product formulations for skin care, new product applications for our skin care ingredients, advancement of our medical diagnostics ingredient knowledge, and the cost of enhancing our manufacturing processes. This includes legal fees related to intellectual property development, protection, and maintenance. As an example, we are currently focusing the bulk of our resources on developing new product formulations, and related new technologies, as we expand marketing and sales efforts relating to our Solésence products. This work has led to several new products and additional potential new products. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple skin health-related markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

11 

 

 

Research and development expense remained the same in 2024, totaling $3,837,000, the same as in 2023. In 2024 labor costs were higher than 2023 which were offset by lower legal and consulting costs in 2024 compared to 2023. We expect expenses for research and development to increase slightly in 2025 depending on growth in our Solésence line of products, and related technologies. This expense growth will be dependent upon the success we have in developing new products, which adds significantly to outside testing fees to both enhance product development and comply with regulatory requirements.

 

Selling, general and administrative expense decreased to $7,219,000 in 2024, compared to $7,534,000 in 2023. The net decrease was largely attributed to a decrease in legal costs. We expect 2025 expenses in this area to be slightly higher due to expanding parts of our administrative functions, including related staffing additions. The extent to which this increase occurs will be dependent upon growth.

 

Interest expense decreased to $670,000 in 2024, compared to $838,000 in 2023, due to lower interest rates in 2024 and decreased usage of the debt facilities. The interest expense for 2024 and 2023 related to interest paid relating to our revolving lines of credit for working capital funding and term loans supporting some of our equipment.

 

In Company-wide operations, we believe inflation has not had a material effect on our operations or financial position for 2024, although we have seen increases in our costs. We expect supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2025 and beyond. We will apply our best efforts to pass through cost increases to our customers. If we are unable to pass through any increases due to contractual limitations or conditions in our markets specifically, this could reduce margins and net income.

 

Liquidity and Capital Resources

 

Cash, cash proceeds and use of cash for 2024 and 2023 were:

 

   For the year ended December 31, 
   2024   2023 
Total cash  $1,409,000   $1,722,000 
Cash provided by (used in) operating activities   1,971,000    (2,006,000)
Net cash used in investing activities   (4,558,000)   (1,051,000)
Net cash provided by financing activities   2,274,000    2,593,000 

 

The $3,977,000 year-over-year increase in cash provided by operating activities for the year ended December 31, 2024 was mainly due to the Company earning $4,235,000 in net income in 2024 compared to $4,390,000 in net loss in 2023. Cash capital expenditures amounted to approximately $4,558,000 and $1,051,000 for the years ended December 31, 2024 and 2023, respectively. We did not dispose of or sell any assets during 2024 or 2023.

 

The Company maintains a credit agreement with Libertyville to support our obligations under our leased manufacturing and warehouse space in Bolingbrook, Illinois. As of December 31, 2024 there was no outstanding borrowings on this line of credit. This credit agreement has a maturity of December 22, 2025.

 

On January 28, 2022, to support the working capital demands created by the commercial growth of the Company and its wholly owned subsidiary, Solésence, LLC, the Company entered into (i) an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement, (ii) a Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, (iii) a Business Loan Agreement (the “New Revolving Loan Agreement” and together with the A&R Loan Agreement and the New Term Loan Agreement, the “Loan Agreements”) with Beachcorp, LLC, and (iv) three promissory notes in order to evidence the loans pursuant to the Loan Agreements (the “Notes”). Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors.

 

12 

 

 

The Loan Agreements changed the terms of both the Company’s asset-based revolving loan facility (the “A/R Revolver Facility”) and the secured advance (the “Term Loan”, which was assigned from Beachcorp, LLC to Strandler, LLC) under the Master Agreement and provide a new asset-based revolving loan facility based on inventory (the “Inventory Facility”). The maximum borrowing amount under the A/R Revolver Facility increases from $6,000,000 to $8,000,000, with a borrowing base consisting of qualified accounts receivable of the Company. The maximum borrowing amount under the Inventory Facility is $4,000,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The Loan Agreements also extended the date for which all principal and accrued interest under the A&R Revolver Facility and the Term Loan are due from March 31, 2023 and March 31, 2022, respectively, to March 31, 2024, which was also the maturity date for the Inventory Facility. The Loan Agreements reduce interest on outstanding borrowings under the A/R Revolver Facility and the Term Loan from the prime rate plus 2% and 5.25% per year, to a floating rate equal to the prime rate plus 0.75%, which is also the interest rate for borrowings under the Inventory Facility. The amount of the Term Loan remains $1,000,000. The A/R Revolver Facility, the Inventory Facility and the Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s revolving line of credit with Libertyville Bank & Trust.

 

On November 13, 2023 to support working capital demands the Company entered into (i) a new Promissory Note (“Bridge Note”) with Strandler, LLC, with a maximum borrowing amount of $2,000,000, interest rate at the prime rate plus 0.75%, and set to mature on May 13, 2024, and (ii) amendments to the Loan Agreements increasing the principal amount of the Inventory Facility to $5,200,000, increased the borrowing base to 55% of eligible inventory, up from 50% and extending the maturity date under the Loan Agreement to March 31, 2025. The Bridge Note was repaid in full in connection with the Purchase Agreement referred to below.

 

On March 1, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), between the Company and Strandler, LLC (“Strandler”).

 

Pursuant to the Purchase Agreement, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”).

 

Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock is outstanding, the Purchase Agreement also (i) prevented the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevented the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricted the Company’s ability to permit any lien or other encumbrance on Company assets.

 

At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from 60,000,000 to 95,000,000, each share of Series X Preferred Stock was convertible, at the option of the holder, into 1,000 shares of Common Stock at no additional cost. If the Company had not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock would have been redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $420 per share (each, a “Redemption”). If the Company had failed to fully pay any Redemption within five days of receiving notice, all unpaid amounts will have born interest at a rate of 10% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock would have been redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $420 per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.

 

Holders of Series X Preferred Stock (i) were not entitled to receive dividends, subject to customary anti-dilution protections, (ii) have no voting rights, and (iii)receive a liquidation preference of $400 per share. The Series X Preferred Stock ranks senior in right of payment to all securities designated as junior securities, including Common Stock.

 

On June 18, 2024, the Company held a special meeting of stockholders where the Certificate Amendment was approved. The Certificate Amendment was filed with the State of Delaware on June 19, 2024. On June 20, 2024, Strandler converted its 15,000 shares of Series X Preferred Stock to 15,000,000 shares of Common Stock.

 

In connection with the Company’s entry into the Purchase Agreement, the Company also entered into (i) a Second Amendment to Business Loan Agreement (the “Term Loan Agreement Amendment”) with Strandler, LLC, (ii) a Second Amendment to Business Loan Agreement (the “A&R Loan Agreement Amendment”) with Beachcorp, LLC, which is also an affiliate of our controlling shareholder, Bradford T. Whitmore (“Beachcorp”), and (iii) a Second Amendment to Business Loan Agreement with Beachcorp (the “Revolving Loan Agreement Amendment” and together with the Term Loan Agreement Amendment and the A&R Term Loan Agreement Amendment, the “Loan Agreement Amendments”). The Loan Agreement Amendments extend the maturity date under each respective loan agreement from March 31, 2025 to October 1, 2025. As of December 31, 2024, the Company’s A/R Revolver, Inventory Facility and New Term Loan matured on October 1, 2025. Since then, the Company’s related party debt holder for the A/R Revolver, Inventory Facility and New Term Loan has committed to refinancing the debt with a new maturity date after April 1, 2026.

 

13 

 

 

On December 31, 2024, the balance on the Term Loan was $1,000,000, the balance on the A/R Revolver Facility was $0, the balance on the Inventory Facility was $4,000,000. On December 31, 2023, the balance on the Term Loan was $1,000,000, the balance on the Bridge Load was $2,000,000, the balance on the A/R Revolver Facility was $2,810,000, and the balance on the Inventory Facility was $5,000,000.

 

For more information regarding the New Business Loan Agreement, see Note 3 to our Financial Statements referred to in Part II, Item 8 of this Annual Report on Form 10-K.

 

Our actual future capital requirements in 2025 and beyond will depend on many factors, including customer acceptance of our current and potential consumer products, APIs sold as ingredients in to the skin health markets, medical diagnostics ingredients, and other engineered materials, applications, and products, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, and the costs necessary to increase and expand our manufacturing capabilities and to market and sell these products and ingredients. Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, we expect that capital spending relating to currently known capital needs for 2025 will be between $6 million and $8 million, to be funded by profit from operations, our existing loans and lines of credit, and possible new financing. If those projects are delayed or ultimately prove unsuccessful, or if we fail to be able to support the additional cost of funding them in the near term, we expect our capital expenditures may fall below the lower end of the range. Similarly, substantial success in business development projects may cause the actual 2025 capital investment to exceed the top of this range.

 

We have federal net operating loss carryforwards for tax purposes of approximately $42 million on December 31, 2024 Because the Company may experience “ownership changes” within the meaning of the U.S. Internal Revenue Code (“IRC”) in connection with any future equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the IRC. If not utilized, $36 million of this loss carryforward will expire between 2025 and 2037. Given changes to the IRC, net operating loss carryforwards generated after January 1, 2018 do not expire, therefore, $6.8 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $18.2 million on December 31, 2024. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2030 and 2043.

 

As a result of the annual limitation and uncertainty as to the amount of future taxable income that will be earned prior to the expiration of the carryforward, we have concluded that it is likely that some portion of this carryforward will expire before ultimately becoming available to reduce income tax liabilities.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for a smaller reporting company.

 

Item 8. Financial Statements and Supplementary Data

 

The financial statements, with the report of independent auditors, listed in Item 15 appear on pages F-1 through F-21 of this Form 10-K.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures. We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer (which roles are currently filled by the same person), concluded that our disclosure controls and procedures were effective at reaching that level of reasonable assurance.

 

14 

 

 

Management’s Annual Report on Internal Control Over Financial Reporting. Management is responsible for the preparation, integrity and fair presentation of the financial statements and Notes to the financial statements. Management is also responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed under the supervision of the Company’s principal executive officer and principal financial officer in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that:

 

(i)Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of the Company; 
 (ii)Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
(iii)Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria established in Internal Control–Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

Based on our assessment and those criteria, our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer) (which roles are currently filled by the same person), believes that the Company maintained effective internal control over financial reporting as of December 31, 2024.

 

Changes in Internal Control over Financial Reporting. The Company’s management, including the Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Form 10-K.

 

Item 9B. Other Information

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

15 

 

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

DIRECTORS

 

Set forth below is certain information regarding the directors of the Company.

 

Name   Age   Position with Company   Director Since   Term Expires   Class
R. Janet Whitmore   70   Chair of the Board of Directors   2003   2025   I
Laura M. Beres   40   Director   2020   2025   I
                     

Mark E. Miller

  

61

  

Director

  

2023

  

2027

  

III

                     
Jess A. Jankowski   59   President, Chief Executive Officer, Chief Financial Officer, and Director   2009   2027   III

 

Ms. Whitmore joined the board in November 2003. She is a former director of Silverleaf Resorts, Inc., where she served as Chair of the Compensation Committee and as a member of the Audit Committee. She is also a former director of Epoch Biosciences, a supplier of proprietary products used to accelerate genomic analysis. Ms. Whitmore is Founder of Benton Consulting, LLC, which specializes in business development and processes. From 1976 through 1999, Ms. Whitmore held numerous engineering and finance positions at Mobil Corporation, including Mobil’s Chief Financial Analyst and Controller of Mobil’s Global Petrochemicals Division. Ms. Whitmore holds a B.S. degree in Chemical Engineering from Purdue University and an M.B.A. from Lewis University. We believe that Ms. Whitmore’s combination of global financial, engineering, and management expertise makes her a valuable member of our Board of Directors. Ms. Whitmore is the sister of Bradford T. Whitmore, and herself beneficially owned approximately 3% of the outstanding shares of our common stock as of October 20, 2023. Mr. Whitmore, together with his affiliate Grace Investments, LP., beneficially owned approximately 63% of the outstanding shares of our common stock as of October 20, 2023. He is also the manager of Beachcorp, LLC and Strandler, LLC. The Company has entered into loan agreements with both Beachcorp, LLC, and Strandler, LLC.

 

Ms. Beres has served as a director of the Company since October, 2020. She has spent her career in corporate strategy and operations in retail and consumer industries, transforming programs and building new organizational and market-facing capabilities. Ms. Beres currently serves as the VP Merchandising, Strategy & Growth at Ulta Beauty, having previously served as the VP, Enterprise Transformation. Previously, she has worked at Deloitte Consulting, advising primarily on growth and transformation strategies in large-scale, consumer-facing companies, with additional leadership roles in the CMO practice, developing and executing strategies on global accounts. Ms. Beres started her career working in the financial services, focused on small and middle market companies, with responsibilities including commercial lending and credit evaluation, and credit transaction negotiation. She earned her M.B.A. from The University of Chicago Booth School of Business and has a B.S. in Finance and B.A. in Oboe Performance from Butler University. Ms. Beres also serves on the Board of Directors for Youth Guidance, and has similarly served non-profit organizations on various Associate and Auxiliary Boards in Chicago. We believe that Ms. Beres’ broad strategic experience in CPG, and specific experience with cosmetics, along with her strong financial background makes her a valuable member of our Board of Directors.

 

Mr. Miller has served as a Director of the Company since July, 2023. He has spent most of his career in leadership and operations roles in chemical manufacturing companies in the personal care and pharmaceutical industries. Mr. Miller currently serves as Chief Executive Officer and Board Chair at MetiSense LLC. He also serves on the Board of Directors with Cupron, Inc. and Curie Co., two privately held organizations in advanced materials. Previously he was the President and Chief Operating Officer at Nagase Specialty Materials, where he led the North American organization, and he has worked at Business Performance Consultancy as a Principal and in Executive roles at Lonza and BASF. He earned his JD from the University of Illinois Chicago, M.B.A. from the University of Illinois Urbana-Champaign, and has a BBA in Business Administration from the University of Notre Dame. We believe that Mr. Miller’s broad strategic experience in personal care chemical manufacturing along with his strong executive leadership background makes him a valuable member of our Board of Directors.

 

Mr. Jankowski joined the Board in February 2009. He has served as the Company’s President and Chief Executive Officer since that time. Mr. Jankowski also served as the Company’s principal financial officer and principal accounting officer from November 2017 until March 2018, and again from April 2019 through the current time. After joining the Company in 1995, Mr. Jankowski held offices including Vice President of Finance, Chief Financial Officer, Secretary, Treasurer and Controller. Prior to joining the Company, he served as Controller for two building and public works contractors in the Chicago area, during which time he had significant business development responsibilities. He began his career working for Kemper Financial Services. Mr. Jankowski holds a B.S. from Northern Illinois University and an M.B.A. from Loyola University. He was appointed to serve on the board of directors of the Northern Illinois Technology Foundation, an economic development and technology transfer entity that is part of Northern Illinois University (2009-2018). Mr. Jankowski was also appointed to serve on the Due Diligence Team of the State’s Invest Illinois Venture Fund (2011-2015). He also served on the TechAmerica Midwest Board (2008-2012). Mr. Jankowski was also appointed to serve on the Romeoville Economic Development Commission (2004-2010). He has also served on the advisory board of NITECH (Formerly WESTEC), an Illinois Technology Enterprise Center focusing on the commercialization of advanced manufacturing technologies (2003-2008). Mr. Jankowski has served on the Advisory Board of the Nanobusiness Commercialization Association since 2009. We believe that Mr. Jankowski’s long-term and intimate experience with the Company’s operations and business development process, his financial and management expertise, and his extensive industry relationships, make him a valuable member of our Board of Directors.

 

16 

 

 

Meetings of the Board and Committees During the year ended December 31, 2024, the Board of Directors (“BOD”) held sixteen meetings. All directors attended all meetings of the BOD and related committee meetings in 2024 with the exception of one committee meeting where Ms. Beres was absent.

 

Committees of the Board of Directors -- The Board of Directors has established an Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee. Each operates in accordance with its charter (available on our website www.solesence.com under the “Investor Relations” section). The current members of the Audit and Finance Committee are Ms. Whitmore, Ms. Beres (Chair), and Mr. Miller. The members of the Compensation Committee are Ms. Whitmore (Chair), Ms. Beres, and Mr. Miller. The members of the Nominating and Corporate Governance Committee are Ms. Whitmore (Chair), Ms. Beres, and Mr. Miller.

 

The Audit and Finance Committee generally has responsibility for retaining the Company’s independent public auditors, reviewing the plan and scope of the accountants’ annual audit, reviewing the Company’s internal control functions and financial management policies, reviewing and approving all related party transactions, and reporting to the Board of Directors regarding all of the foregoing. The Audit and Finance Committee held six meetings during 2024. The Board of Directors has determined that Ms. Whitmore is an “audit committee financial expert” as described in applicable SEC rules. The Board of Directors has not determined affirmatively that Ms. Whitmore is independent under the Nasdaq Stock Market rules, but such rules are inapplicable to the Company because the Company is no longer listed on Nasdaq.

 

The Compensation Committee generally has responsibility for establishing executive officer and key employee compensation, reviewing, and establishing the Company’s executive compensation, evaluating our Outside Director compensation, and reporting to the Board of Directors regarding the foregoing. The Compensation Committee also has responsibility for administering the 2019 Equity Compensation Plan (the “2019 Equity Plan”), determining the number of options, if any, to be granted to the Company’s employees and consultants pursuant to the 2019 Equity Plan, and reporting to the Board of Directors regarding the foregoing. Regarding most compensation matters, including executive compensation, our management provides recommendations to the Compensation Committee; however, the Compensation Committee does not delegate any of its functions to others in setting compensation. The Compensation Committee does not currently utilize external consultants in executive or director compensation matters. The Compensation Committee held three meetings during 2024. Each member of the Compensation Committee is a “non-employee director” as defined in Rule 16b-3 under the Exchange Act and is an “Outside Director” as defined by the regulations under Section 162(m) of the Internal Revenue Code.

 

The Nominating and Corporate Governance Committee generally has responsibility for evaluating and nominating candidates to serve on the Board of Directors, and for establishing and reviewing our Corporate Governance Principles. The Nominating and Corporate Governance Committee held one meeting during 2024.

 

The Board of Directors considers its role in risk oversight to focus primarily on evaluating risk at the entity and strategic levels, with management primarily responsible for managing day-to-day risk factors and presenting summary materials for those positions to the Board of Directors. Consistent with this philosophy, the Board of Directors has no formal policy as to whether the roles of Chief Executive Officer and board Chair should be segregated or combined. The Board of Directors considers the circumstances of the Company and makes a determination as to the appropriate leadership structure for the Company at that time. As of the time of this filing, the positions of CEO and Board Chair are held by two individuals – Ms. Whitmore serves as Chair and Mr. Jankowski serves as CEO. Ms. Whitmore brings extensive experience in corporate leadership from her own working experience and from a number of boards on which she has served in the past, and Mr. Jankowski is expected to benefit from that experience. The Board of Directors believes this to be the most appropriate structure for the Company at this time. Under our Corporate Governance Principles, in the event that the Chair of the Board is not an Outside Director, the Board will elect a lead independent director, who will have the responsibility to schedule and prepare agendas for meetings of the Outside Directors, communicate with the CEO, disseminate information to the rest of the Board and raise issues with management on behalf of the Outside Directors when appropriate. The Board evaluates its leadership structure on an ongoing basis and may change it as circumstances warrant.

 

17 

 

 

The Board of Directors does not have a stated policy regarding diversity, although pursuant to our Corporate Governance Principles, diversity is one factor that the Nominating and Corporate Governance Committee considers when recommending directors for stockholder approval. The Board seeks experienced individuals for service who bring extensive experience in leadership, operations, finance, and engineering, particularly in areas directly applicable to the Company or its intended future endeavors.

 

EXECUTIVE OFFICERS

 

Set forth below is certain information regarding the executive officers of the Company as of the date of this Form 10-K who are not identified above as directors.

 

Name   Age   Position
Kevin Cureton   63   Chief Operating Officer

 

Mr. Cureton joined the Company in November 2012 as Vice President of Sales, Marketing and Business Development. Effective January 1, 2018, Mr. Cureton was named Chief Commercial Officer, and became the Company’s Chief Operating Officer in December 2019. His chemical industry experience has spanned more than twenty years, the majority of which has been in the personal care industry, including twelve years at AMCOL International Corporation, where he served as the founder and Managing Director of its skin care and dermatology technology business. Prior to AMCOL, he made significant contributions at Air Products, Borden, and other entities. Mr. Cureton holds a Bachelor of Science in chemical engineering from Carnegie Mellon University and an M.B.A. from the University of Chicago Booth School of Business.

 

The Board of Directors elects executive officers and such executive officers, subject to the terms of their employment agreements, serve at the discretion of the Board of Directors. Messrs. Jankowski and Cureton each have employment agreements with the Company. See Item 11 below. There are no family relationships among any of the directors or officers of the Company.

 

DELINQUENT SECTION 16(a) REPORTS

 

Section 16 of the Exchange Act requires the Company’s officers (as defined under Section 16), directors and persons who beneficially own greater than 10% of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Based solely on a review of the forms we have received, we believe that during 2024 all Section 16 filing requirements applicable to our officers, directors and 10% beneficial owners were complied with by such persons, with the exception of two late Form 4 filings by Ms. Whitmore.

 

CODE OF ETHICS

 

We have adopted a Code of Business Conduct and Ethics (“Code of Ethics”) that applies to, among others, our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Ethics is posted on our Internet website www.solesence.com under the “Investor Relations” section. In the event that we make any amendment to, or grant any waiver from, a provision of the Code of Ethics that requires disclosure under applicable SEC rules, we intend to disclose such amendment or waiver on our website.

 

INSIDER TRADING POLICY

 

Our insider trading policy includes provisions that prohibit officers, directors, advisory board members, employees and independent contractors, as well as each of those person’s spouse, minor child, any person living in their household from engaging in short sales, put or call options, hedging transactions, pledging, or other derivative transactions involving Solésence stock. The Company’s Insider Trading Policy is attached in Exhibit 19.

 

Item 11. Executive Compensation

 

SUMMARY COMPENSATION TABLE

 

The following table sets forth a summary of the compensation for each of our named executive officers in U.S. dollars for the years ended December 31, 2024 and 2023.

 

18 

 

 

Name and Principal Position   Year     Salary
($)		     Bonus
($) (1)		     Option
Awards
($) (2)		     All
Other Compensation
($) (3)		     Total
($)		  
Jess Jankowski     2024     $ 357,072     $ —     $ 39,738     $ 26,969     $ 423,779  
Chief Executive Officer     2023     $ 341,409     $ —     $ 5,521     $ 27,919     $ 374,849  
Kevin Cureton     2024     $ 309,256     $ —     $ 39,738     $ 21,299     $ 370,293  
Chief Operating Officer     2023     $ 294,492     $ —     $ 5,521     $ 22,704     $ 322,687  

 

(1) Any amounts earned during 2024 and 2023 would typically have been paid in early-to-mid 2025 and 2024, respectively. Bonus compensation is driven by Company performance against its goals as ultimately determined by the Compensation Committee of the Board of Directors (“Compensation Committee”). A set of Company-level objectives is created at the beginning of the year, focusing on total revenue, revenue growth, particular sources of revenue growth, business development achievements, cash flows and related targets, as well as a small discretionary component designed to capture items not specifically listed. Each measure has varying levels of achievement, which is reflected in the aggregate bonus measurement. The resulting bonus calculation is then applied to each individual’s bonus potential as a percentage of salary. Performance milestones were achieved in 2024 and related bonuses will be paid. Performance milestones were not achieved in 2023 and related bonuses were not paid.
(2) The amounts in this column represent the aggregate grant date fair value of awards granted in 2024 and 2023 in accordance with FASB ASC Topic 718. See Note 10 of the notes to our financial statements contained elsewhere in this Form 10-K for a discussion of all assumptions made by us in determining the FASB ASC Topic 718 values.
(3) The amounts in this column represent 401(k) match (total for executive officers of $14,305 during 2024 and $14,585 during 2023), and the value of the Company portion of the health and life insurance including employer HSA contributions. Health insurance benefits are the same for all employees. Life insurance is provided to all employees in the amount of the employee’s annual base salary, capped at a maximum of $150,000.
   

Employment Agreements

 

Effective as of August 12, 2009, we entered into an employment agreement with Jess Jankowski in connection with his services as President and Chief Executive Officer. No term has been assigned to Mr. Jankowski’s employment agreement.

 

Pursuant to the terms of his employment agreement, Mr. Jankowski will receive an annual base salary of not less than $275,000. In addition, Mr. Jankowski will be eligible for discretionary bonuses for services to be performed as an executive officer of the Company based on performance and achieving milestones approved by our Board of Directors (the “Board”).

 

Mr. Jankowski will be eligible for such stock options and other equity compensation as the Board deems appropriate, subject to the provisions of the 2019 Equity Compensation Plan. Mr. Jankowski will also be entitled to the employee benefits made available by us generally to all of our other executive officers, subject to the terms and conditions of our employee benefit plan in effect from time to time.

 

In the event Mr. Jankowski’s employment is terminated other than for “cause” (as such term is defined in the employment agreement), Mr. Jankowski will receive a sum equal to Mr. Jankowski’s base salary in effect at the time of termination for 52 full weeks after the effective date of termination, payable in proportionate amounts on our regular pay cycle for professional employees, provided that Mr. Jankowski signs, without subsequent revocation, a separation agreement and release in a form acceptable to us. In addition, all stock options granted to Mr. Jankowski prior to termination will become fully vested and exercisable in accordance with the applicable option grant agreement and the 2019 Equity Compensation. If he is terminated for cause, or if he resigns as an employee of the Company, Mr. Jankowski will not be entitled to any severance or other benefits accruing after the term of the employment agreement and such rights will be forfeited immediately upon the end of such term.

 

If, within two years after the occurrence of a change in control, as defined in his employment agreement, Mr. Jankowski’s employment is terminated other than for cause, his responsibilities or annual compensation are materially reduced without his prior consent, or we cease to be publicly held (each, a “Trigger”), then, subject to Mr. Jankowski signing, without subsequently revoking, a separation agreement and release in a form acceptable to us, Mr. Jankowski will receive a sum equal to his base salary for 104 full weeks after the date the Trigger occurs. In addition, all stock options granted to Mr. Jankowski prior to the Trigger will become fully vested and exercisable in accordance with the applicable option grant agreement and the 2019 Equity Compensation Plan.

 

Effective as of November 28, 2012, we entered into an employment agreement with Mr. Kevin Cureton providing for an annual base salary of not less than $190,000. No term has been assigned to Mr. Cureton’s employment agreement. If Mr. Cureton is terminated other than for “cause” (as such term is defined in Mr. Cureton’s employment agreement), then, subject to Mr. Cureton signing, without revoking, a separation agreement and release in a form acceptable to us, Mr. Cureton will receive severance benefits in an amount equal to Mr. Cureton’s base salary for 26 weeks. In addition, all stock options granted to Mr. Cureton prior to termination will become fully vested and exercisable in connection with the applicable option grant agreement and the 2019 Equity Compensation Plan. A signing bonus of $25,000 was paid upon Mr. Cureton’s acceptance of employment.

 

19 

 

 

OUTSTANDING EQUITY AWARDS AT YEAR-END

 

The following table sets forth information regarding each unexercised option held by each of our named executive officers as of December 31, 2024.

 

    Option Awards     Stock Awards  
Name   Number of Securities Underlying Unexercised Options (#) Exercisable     Number of Securities Underlying Unexercised Options (#) Unexercisable     Option Exercise Price ($)     Option Expiration Date     Number
of Shares of
Stock
That Have
Not
Vested
(#)		     Market Value of Shares of Stock That Have Not Vested ($)  
Jess Jankowski                                      
    69,000     -0-     $ 0.42     02/23/26              
    81,000     -0-     $ 0.68     02/21/27              
    90,000     -0-     $ 0.82     05/23/28              
    16,500     -0-     $ 0.51     05/22/29              
    90,000     -0-     $ 0.45     06/18/27              
    90,000     -0-     $ 4.17     12/28/28              
    48,000     24,000 (1)     $ 1.17     12/20/29              
    4,200     8,400 (2)    $ 0.61     12/27/30     —     —  
    -0-     22,500 (3)    $ 2.44     12/31/31     —     —  
                             
Kevin Cureton                                      
    43,500     -0-     $ 0.42     02/23/26              
    50,000     -0-     $ 0.68     02/21/27              
    80,000     -0-     $ 0.82     05/23/28              
    16,500     -0-     $ 0.51     05/22/29              
    90,000     -0-     $ 0.45     06/18/27              
    90,000     -0-     $ 4.17     12/28/28              
    48,000     24,000 (1)     $ 1.17     12/20/29              
    4,200     8,400 (2)     $ 0.61     12/27/30              
    -0-     22,500 (3)    $ 2.44     12/31/31     —     —  
(1) These grants expiring December 20, 2029 vest in three equal installments on December 20, 2023, 2024, and 2025.
(2) These grants expiring December 27, 2030 vest in three equal installments on December 27, 2024, 2025, and 2026.
(3) These grants expiring December 31, 2031 vest in three equal installments on December 31, 2025, 2026, and 2027.

 

POTENTIAL PAYMENT UPON TERMINATION OR CHANGE IN CONTROL

 

Severance Benefits. Please see discussion of severance benefits under “Employment Agreements” above.

 

Change in Control. Upon a change in control, the 2019 Equity Compensation Plan provides that: (1) vesting under all outstanding stock options will automatically accelerate and each option will become fully exercisable; (2) the restrictions and conditions on all outstanding restricted shares shall immediately lapse; and (3) the holders of performance shares will receive a payment in settlement of the performance shares, in an amount determined by the Compensation Committee, based on the target payment for the performance period and the portion of the performance period that precedes the change in control. If the Company is not the surviving entity, the successor is required to assume all unexercised options.

 

20 

 

 

Payments. The following table quantifies the estimated payments that would be made in each covered circumstance to the following named executive officers:

 

 Name  Termination By Company Without
Cause(1)(4)		   Change In
Control(2)(4)		   Involuntary
Termination In Connection With
or
Following a
Change In
Control(3)(4)		 
Jess Jankowski  $367,000   $36,000   $770,000 
Kevin Cureton  $160,000   $36,000   $196,000 

 

(1) This amount represents the severance benefits that would be received under the executive officer’s employment agreement as described had the executive officer been terminated by the Company without cause on December 31, 2023, including the value of any stock options that would have accelerated vesting in connection with such termination.
(2) This amount represents an estimate of the value that would have been received under the 2019 Equity Compensation Plan had a change in control occurred as of December 31, 2024, and the executive officers benefited from an acceleration of vesting in the 2019 Equity Compensation Plan awards, as described above.
(3)

This amount represents an estimate of the payments and value (including acceleration of vesting of equity-based awards) that would have been received by the executive officers had the executive officers been terminated by the Company without cause on December 31, 2024 in connection with a change in control on this date.

(4) In all three columns, for purposes of calculating the value of the acceleration of vesting of equity-based awards relating to a change in control on December 31, 2024, the closing price of our common stock as of December 31, 2024, was used. The amount represents the difference between the exercise price of any unvested options and $2.26.

 

DIRECTOR COMPENSATION

 

Upon first being elected to the Board of Directors, each director of the Company who is not an employee or consultant of the Company (an “Outside Director”) is granted stock options to purchase shares of common stock at the closing price as of the date of issuance (the fair market value). This initial option grant to an Outside Director typically vests over three years, though may accelerate upon termination from the Board of Directors.

 

In 2024, we paid quarterly compensation to the Chairman of the Board of Directors, for an annual total of $24,000. Our other two then Outside Directors, Ms. Beres and Mr Miller were each paid quarterly compensation for an annual total of $18,000. This compensation was made solely for services performed by each in their capacities as directors.

 

During the fourth quarter of 2024, we granted our Outside Directors stock options totaling 30,000 shares under the 2019 Equity Plan, as follows: the Chairman of the Board of Directors received stock options to purchase 12,000 shares of our common stock, while the other two of the then Outside Directors received stock options to purchase 9,000 shares of our common stock. Our current Outside Directors had the following shares of our common stock underlying stock options (both vested and unvested) outstanding as of December 31, 2024: Ms. Whitmore: 59,934 shares; Ms. Beres: 61,600 shares; and Mr. Miller: 31,600 shares.

 

In 2005, we adopted, and our stockholders approved, the 2005 Non-Employee Director Restricted Stock Plan (the “Director Restricted Stock Plan”) which reserved 150,000 shares of our common stock to be issued to Outside Directors in the form of restricted shares. In 2005, no awards were made under the Director Restricted Stock Plan. In 2005, we also adopted the Non-Employee Director Deferred Compensation Plan (the “Director Deferred Compensation Plan”) which permits an Outside Director to defer the receipt of director fees until separation from service or the Company undergoes a change in control. We amended the Director Restricted Stock Plan in 2005 to permit an Outside Director to defer receipt of restricted stock granted under it. The deferred restricted shares are accounted for under the Director Deferred Compensation Plan and issued upon separation from service or the Company’s change in control. Under the Director Deferred Compensation Plan, the deferred fees that would have been paid in cash are deemed invested in 5-year U.S. Treasury Bonds during the deferral period. The accumulated hypothetical earnings are paid following the Outside Director’s separation from service or the Company’s change in control. The deferred fees that would have been paid as restricted shares are deemed invested in our common stock during the deferral period. The Director Deferred Compensation Plan is an unfunded, nonqualified deferred compensation arrangement. In 2009, all Outside Directors elected to defer receipts of all of the restricted shares they became entitled to under the Director Restricted Stock Plan, which was consolidated into the 2010 Equity Plan. In November 2019, the 2010 Equity Plan was consolidated in to the 2019 Equity Compensation Plan.

 

21 

 

 

All Outside Directors are reimbursed for their reasonable out-of-pocket expenses incurred in attending board and committee meetings.

 

   2024 Outside Director Compensation 
Name  Fees Earned
or Paid in
Cash
($)		   Option Awards ($)(1)   Total ($) 
R. Janet Whitmore  $24,000   $21,193   $45,193 
Laura M. Beres  $18,000   $15,895   $33,895 
Mark E. Miller  $18,000   $15,895   $33,895 

 

(1) The amounts in this column represent the aggregate grant date fair value of awards granted in 2024 in accordance with FASB ASC Topic 718. See Note 10 of the notes to our financial statements contained elsewhere in this Form 10-K for a discussion of all assumptions made by us in determining the FASB ASC Topic 718 values.

 

It is not the Company’s practice to issue named executive officer or other employees option grants before or after the disclosure of material non-public information. The board of directors approve all option grants. For the last several years options have been granted one time a year in December to named executive officers and other employee. The only exception to this practice is when option grants are made to qualifying new hires on or near their hire date. It is not the board’s policy or practice to time the release of material non-public information and the issuance of option grants to affect the value of the named executives’ compensation.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLAN

 

The following table gives information about our common stock that may be issued upon the exercise of options and rights under our 2019 Equity Compensation Plan (the “2019 Equity Plan”) and our 2010 Equity Compensation Plan (the “2010 Equity Plan”) on December 31, 2024. The 2019 Equity Plan replaced the 2010 Equity Plan.

 

   (a)  

(b)

    (c) 
Plan Category   Number of securities to be issued upon exercise of outstanding options, warrants and rights    Weighted - average exercise price of outstanding options, warrants and rights   Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 
Plans Approved by Shareholders   3,212,000   $1.47    63,000 
Plans Not Approved by Shareholders   None   $—    None 

 

22 

 

 

SECURITY OWNERSHIP OF MANAGEMENT

AND PRINCIPAL STOCKHOLDERS

 

The following table sets forth, as of March 28, 2025 certain information with respect to the beneficial ownership of our common stock by (1) each person known by us to own beneficially more than 5% of the outstanding shares of common stock, (2) each of our directors, (3) each of our named executive officers and (4) all of our named executive officers and directors as a group. There were 70,103,279 shares of common stock outstanding as of March 28, 2025.

 

Name  Number of
Shares
Beneficially
Owned(1)		   Percent of
Shares
Beneficially
Owned		 
Bradford T. Whitmore   49,826,805(2)    71.08%
R. Janet Whitmore   2,082,009(3)    2.97%
Jess A. Jankowski   698,150(4)    * 
Kevin Cureton   614,412(5)    * 
Beres, Laura M   39,200(6)    * 
Miller, Mark E   7,533(7)    * 
All current executive officers and directors as a group (5 persons)   3,441,304(8)    4.84%

 

* Denotes beneficial ownership of less than one percent.

 

Unless otherwise indicated below, the person’s address is the same as the address for the Company.

 

(1) Beneficial ownership is determined in accordance with the rules of the SEC. Unless otherwise indicated below, the persons in the above table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them.
(2) Includes 25,358,879 shares of common stock held by Whitmore Holdings, LLC, 675,515 shares of common stock held by Grace Investments, LP, 23,684,270 shares of common stock held by Strandler, LLC and 108,141 shares held by Bradford T. Whitmore.  Mr. Whitmore is a manager of Whitmore Holdings, LLC.  In such capacities, Mr. Whitmore shares voting and investment power with respect to the shares of common stock held by Whitmore Holdings, LLC.  Mr. Whitmore is a manager of Strandler, LLC.  In such capacities, Mr. Whitmore shares voting and investment power with respect to the shares of common stock held by Strandler, LLC.  Mr. Whitmore is a general partner of Grace Investments, LP.  In such capacities, Mr. Whitmore shares voting and investment power with respect to the shares of common stock held by the Grace Investments, LP.  This information is based on information reported on a Form 4 filed on September 3, 2024 with the SEC. The address of the stockholder is 5215 Old Orchard Road Suite 620, Illinois 60077.
(3) Includes Ms. Whitmore’s 32,867 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 25, 2025.
(4) Includes Mr. Jankowski’s 488,700 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 25, 2025, as well as 1,000 shares held by his spouse.
(5) Includes Mr. Cureton’s 488,700 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 25, 2025.
(6)

Includes Ms. Beres’ 39,200 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 25, 2025.

(7)

Includes Mr. Miller’s 7,533 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 25, 2025.

(8) Includes all current executive officers and directors as a group’s 990,500 shares of common stock issuable upon exercise of options exercisable currently or within 60 days of March 25, 2025.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

We have engaged in a series of debt and equity transactions with Bradford T. Whitmore since January 1, 2023, as described above in Item 7. Together with his affiliates Grace Brothers, Ltd., Grace Investments, Ltd., Mr. Whitmore beneficially owned approximately 71% of the outstanding shares of our common stock as of March 28, 2025. Mr. Whitmore is the brother of R. Janet Whitmore, who has been the Chair of the Board of Directors since November 19, 2019 and one of our directors since 2003, and who is also a stockholder. Through his affiliates Beachcorp, LLC and Strandler, LLC, Mr. Whitmore is also a substantial lender to the Company under the Business Loan Agreement, dated November 16, 2018 (see Note 3) to our financial statements included in this Annual Report on Form 10-K).

 

23 

 

 

Director Independence. The Board of Directors has determined that the following Company directors are “independent” as that term is defined in the rules and regulations of the SEC and the Nasdaq Stock Market: Ms. Beres and Mr. Miller. Though we are not currently listed on Nasdaq, our Board of Directors used the Nasdaq listing standards in making its independence determinations. Under the Nasdaq Stock Market rules, the Company would qualify as a “controlled company” because of the direct and indirect ownership of Bradford T. Whitmore. As a controlled company, the Company would be exempt from the requirements under those rules to have a majority of independent directors, to have an independent compensation committee, or to have independent director oversight of director nominations.

 

The Board of Directors has established an Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee (the “Standing Committees”). Ms. Whitmore, Ms. Beres, and Mr. Miller are members of the Standing Committees, and Ms. Whitmore serves as Chair of each committee.

 

Item 14. Principal Accounting Fees and Services

 

Audit Fees. The aggregate amount billed by our principal accountant, RSM US LLP (“RSM”), for audit services performed for the fiscal years ended December 31, 2024 and 2023 was approximately $270,000 and $263,000 respectively. Audit services include the auditing of financial statements and quarterly reviews.

 

Audit Related Fees. There were approximately $26,000 in audit related fees billed by RSM for the years ended December 31, 2024 and 2023, which may include costs incurred for reviews of registration statements, assistance with Staff comment letters, and consultation on various accounting matters in support of our financial statements.

 

Tax Fees. There were no fees billed by our principal accountant for tax related services for the fiscal years ended December 31, 2024 and 2023.

 

All Other Fees. Other than those fees described above, during the fiscal years ended December 31, 2024 and 2023, there were no other fees billed for services performed by our principal accountant.

 

All of the fees described above were approved by our Audit and Finance Committee.

 

Audit and Finance Committee Pre-Approval Policies and Procedures. Our Audit and Finance Committee pre-approves the audit and non-audit services performed by RSM, our principal accountants, in order to assure that the provision of such services does not impair RSM’s independence. Unless a type of service to be provided by RSM has received general pre-approval, it will require specific pre-approval by the Audit and Finance Committee. In addition, any proposed services exceeding pre-approval cost levels or budgeted amounts will require specific pre-approval by the Audit and Finance Committee.

 

The term of any pre-approval is 12 months from the date of pre-approval, unless the Audit and Finance Committee specifically provides for a different period. The Audit and Finance Committee will periodically revise the list of pre-approved services, based on subsequent determinations, and has delegated pre-approval authority to the Chairman of the Audit and Finance Committee. In the event the Chairman exercises such delegated authority, he shall report such pre-approval decisions to the Audit and Finance Committee at its next scheduled meeting. The Audit and Finance Committee does not delegate its responsibilities to pre-approve services performed by the independent auditor to management.

 

24 

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) The following documents are filed as part of this Form 10-K:

 

  1. The following financial statements of the Company, with the report of independent registered public accounting firm, are filed as part of this Form 10-K:

 

Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2024 and 2023
Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023
Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2024 and 2023
Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023

 

Notes to Consolidated Financial Statements

 

  2. A list of exhibits required to be filed as part of this Form 10-K is set forth in the Exhibit Index beginning on page E-1 of this Form 10-K, and is incorporated herein by reference.

 

Item 16. Form 10-K Summary

 

NONE.

 

25 

 

SOLESENCE, INC

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
   
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 49) F-2
   
Consolidated Balance Sheets as of December 31, 2024 and 2023 F-4
   
Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 F-5
   
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023 F-6
   
Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F-7
   
Notes to the Consolidated Financial Statements F-8

 

F-1

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and the Board of Directors of Solesence, Inc.

 

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Solesence, Inc. and its subsidiaries, formerly known as Nanophase Technologies Corporation, (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

F-2

 

 

Inventory Excess and Obsolete Reserve

As described within Note 1 and Note 4 to the consolidated financial statements, the Company has recorded an allowance to reduce inventory relating to excess quantities or the obsolescence of certain products. As of December 31, 2024, the Company has reported inventories of approximately $20,267,000, net of an excess and obsolete reserve of $1,987,000. The Company monitors the value of inventory for the effects of aging, obsolescence, and seasonality, and recognizes a reserve equal to the value of inventory that will likely not be consumed in production or sold and therefore will experience an impairment. Such inventory may consist of materials nearing expiration, soon-to-be obsolete products or raw materials that are no longer regularly used.

 

We identified the valuation of the inventory excess and obsolete reserve as a critical audit matter because of the significant assumption and judgments made by management. Auditing management’s assumption and judgments regarding their expectations of inventory that will not be consumed in production or sold, and evaluating evidence obtained, involved a high degree of auditor judgment, subjectivity and increased audit effort.

 

Our audit procedures related to the Company’s evaluation of the excess and obsolete inventory reserve included the following primary procedures, among others:

 

·We reviewed the Company’s accounting policy to understand management’s estimation methodology and their significant assumption, assess consistency and identify changes from prior years.
·We performed corroborative inquiries with management and those in purchasing, operations, warehousing and production to understand the basis for the reserve.
·We evaluated the reasonableness of the significant assumption used by management including those related to identifying materials nearing expiration, soon-to-be obsolete products or raw materials that are no longer regularly used.
·We tested the completeness, accuracy and relevance of the underlying data used in management’s estimate of excess and obsolete inventory.
·We tested the calculations and application of management’s methodologies related to the valuation of excess and obsolete inventory.
·We performed a comparison of current year activity to the prior year reserve to assess the reasonableness of the Company's reserves and identify potential indicators of management bias that may be present.
·We obtained management's evaluation of the reasonableness of their significant assumption and reperformed calculations within to test for mathematical accuracy. We tested the completeness of the inventory subjected to their analysis. In addition, we tested the reliability of data underpinning management's analysis, including historical sales and usage data.

 

 

/s/ RSM US LLP

 

We have served as the Company's auditor since 2001.

 

Milwaukee, Wisconsin

March 31, 2025

 

F-3

 

 

SOLESENCE, INC.

CONSOLIDATED BALANCE SHEETS

 

             
   As of December 31, 
   2024   2023 
   (in thousands except share and
per share data)		 
ASSETS          
Current assets:          
Cash  $1,409   $1,722 
Trade accounts receivable   5,655    3,692 
Allowance for credit losses   (786)   (225)
Trade accounts receivable, net   4,869    3,467 
Inventories, net   20,267    10,031 
Prepaid expenses and other current assets   2,803    1,082 
Total current assets   29,348    16,302 
           
Equipment and leasehold improvements, net   12,734    8,668 
Operating leases, right of use   7,917    7,907 
Other assets, net   3    4 
Total assets  $50,002   $32,881 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Line of credit – accounts receivable, related party  $—   $2,810 
Line of credit – inventory, related party   4,000    — 
Current portion of term debt, related party   —    2,000 
Term debt, related party   1,000    — 
Current portion of operating lease obligations   1,260    1,297 
Accounts payable   9,093    6,260 
Deferred revenue   5,571    2,353 
Accrued expenses   4,849    869 
Total current liabilities   25,773    15,589 
           
Long-term portion of operating lease obligations   9,037    9,152 
Long-term line of credit – inventory, related party   —    5,000 
Long-term debt, related party   —    1,000 
Asset retirement obligations   246    238 
Total long-term liabilities   9,283    15,390 
           
Stockholders’ equity:          
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding   —    — 
Common stock, $.01 par value, 95,000,000 and 60,000,000 shares authorized; 70,103,279 and 49,627,254 shares issued and outstanding on December 31, 2024 and 2023, respectively   700    496 
Additional paid-in capital   114,674    106,069 
Accumulated deficit   (100,428)   (104,663)
Total stockholders’ equity   14,946    1,902 
 Total liabilities and stockholders’ equity  $50,002   $32,881 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-4

 

 

SOLESENCE, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

             
   Years ended December 31, 
   2024   2023 
   (in thousands except share and
per share data)		 
Revenue:        
Product revenue  $51,890   $36,641 
Other revenue   457    656 
Total revenue   52,347    37,297 
           
Operating expense:          
Cost of revenue   36,159    29,472 
Gross profit   16,188    7,825 
           
Research and development expense   3,837    3,837 
Selling, general and administrative expense   7,219    7,534 
Net income (loss) from operations   5,132    (3,546)
Interest expense   670    838 
Net income (loss) before provision for income taxes   4,462    (4,384)
Provision for income taxes   227    6 
           
Net income (loss)  $4,235   $(4,390)
           
Net income (loss) per share-basic  $0.07   $(0.09)
           
Weighted average number of basic common shares outstanding   62,350,459    49,556,305 
           
Net income (loss) per share-diluted  $0.07   $(0.09)
           
Weighted average number of diluted common shares outstanding   65,028,815    49,556,305 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-5

 

 

SOLESENCE INC.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 (in thousands except share data)

 

                                     
   Preferred Stock   Common Stock   Additional          
Description  Shares   Amount   Shares   Amount   Paid-in
Capital		  Accumulated
Deficit		  Total 
Balance on December 31, 2022   —   $—    49,320,680   $493   $105,226   $(100,070)  $5,649 
Cumulative effect of accounting changes related to expected credit losses   —    —    —    —    —    (203)   (203)
Issuances of shares and stock option exercises   —    —    306,574    3    151    —    154 
Stock-based compensation   —    —    —    —    773    —    773 
Rights offering expense   —    —    —    —    (81)   —    (81)
Net loss for the year ended December 31, 2023   —    —    —    —    —    (4,390)   (4,390)
Balance on December 31, 2023   —   $—    49,627,254   $496   $106,069   $(104,663)  $1,902 
Issuances of shares and stock option exercises   —    —    20,476,025    204    7,880    —    8,084 
Stock-based compensation   —    —    —    —    725    —    725 
Net income for the year ended December 31, 2024   —    —    —    —    —    4,235    4,235 
Balance on December 31, 2024   —   $—    70,103,279   $700   $114,674   $(100,428)  $14,946 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-6

 

 

SOLESENCE INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

           
   Years Ended December 31, 
   2024   2023 
   (in thousands) 
Operating activities:          
Net income (loss)  $4,235   $(4,390)
Adjustments to reconcile net income (loss) to cash provided by (used) in operating activities:          
Depreciation and amortization   928    742 
Share-based compensation   725    773 
Changes in assets and liabilities related to operations:          
Trade accounts receivable, net   (1,402)   1,064 
Inventories, net   (10,236)   (1,192)
Prepaid expenses and other assets   (1,721)   (216)
Accounts payable   2,399    (503)
Deferred revenue   3,218    165 
Accrued expenses   3,988    (146)
Net changes in right-of-use assets and lease liabilities – operating   (163)   1,697 
Net cash provided by (used in) operating activities   1,971    (2,006)
           
Investing activities:          
Acquisition of equipment and leasehold improvements   (4,558)   (1,051)
Net cash used in investing activities   (4,558)   (1,051)
           
Financing activities:          
Payments to line of credit – accounts receivable, related party   (2,810)   (1,472)
(Payments to) proceeds from line of credit - inventory, related party   (1,000)   2,000 
Payments to term loans, related party   (2,000)   (1,346)
Proceeds from term loans, related party   —    3,338 
Proceeds from issuance of mezzanine preferred stock   6,000    — 
Proceeds from exercise of stock options   2,084    73 
Net cash provided by financing activities   2,274    2,593 
Decrease in cash   (313)   (464)
Cash at beginning of period   1,722    2,186 
Cash at end of period  $1,409   $1,722 
           
Supplemental cash flow information:          
Cash paid for interest  $637   $752 
           
Supplemental non-cash investing and financing activity:          
Accounts payable incurred for the purchase of equipment and leasehold improvements  $434   $400 
Conversion of mezzanine preferred stock   6,000    — 
Right-of-use asset obtained in exchange for a lease liability   1,019    182 

 

(See accompanying Notes to Consolidated Financial Statements)

 

F-7

 

 

SOLESENCE, INC

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(In thousands, except share and per share data or as otherwise noted herein)

 

(1) Description of Business

 

Nanophase Technologies Corporation, now known as Solesence, Inc. (“Solésence,” “Company,” “we,” “our,” or “us”), is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence consumer products subsidiary”), is focused in various skin health- and beauty-markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our consumer products line.  Additionally, we continue to sell products in legacy markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives, all of which fall into the advanced materials product category. 

 

 We target markets, primarily related to skin health products and ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our Solésence® products to cosmetics and skin care brands, and our other materials to various end-use applications manufacturers.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Original Active Stress Defense ™ Technology — which has become the cornerstone of our new product development in consumer products line, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our consumer products line, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. 

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

The Company recorded a net profit and positive cash flow from operations in 2024.  In addition, the company reduced outstanding debt. While the Company’s debt currently matures in the next year, management has a commitment from its related party debt holder that the debt will be refinanced with a maturity date after April 1, 2026. Management believes that current liquidity and expected borrowing capacity are sufficient to fund operations and substantial doubt is not raised regarding the Company's ability to continue as a going concern.

 

(2) Summary of Significant Accounting Policies

 

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.

 

F-8

 

 

Cash

 

The Cash balance on December 31, 2024 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Solésence is to be the party initiating any transfers, whether to Solésence or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Solésence to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Solésence.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.

 

 Trade Accounts Receivable, Net

 

Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

    2024   2023
Balance, beginning   $ 225   $ 139
Current period provisions     564     95
Write offs     (3)     (9)
Balance, ending   $ 786   $ 225

 

 

Inventories, Net

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.

 

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.

 

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.

 

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $5,571 in deferred revenue reported in 2024, 99% related to prepayments received from certain customers per Company policy, and the remaining 1% related to prepayments from a product development agreement with a personal care ingredient customer.

 

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

F-9

 

 

Our financial instruments include cash, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on December 31, 2024 and 2023.

 

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2024 one customer earned a volume rebate of $35,000. In 2023 no volume rebates were recorded because the customers did not meet required volumes.

 

As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer. Revenue is recognized when the goods are shipped

 

The Company will for some customers arrange for the shipping of the finished goods. Revenues and costs associated with the shipment of the finished goods are recorded separately within product revenue and cost of revenue, respectively, on the consolidation statement of operations. With regard to revenue recognition, shipping activities that occur prior to the customers’ obtaining control of the goods are not a promised service to the customer, but rather activities to fulfill the Company’s promise to transfer the goods. As such, these activities are not deemed a performance obligation requiring allocation of the transaction price. Similarly, shipping activities that occur after the customers’ obtaining control of the goods are, as a matter of policy, also not a promised service to the customer, but rather an activity to fulfill the Company’s promise to transfer the good.

 

Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:

 

    Accounts Receivable   Contract Liabilities 
2022   $4,734    2,188 
2023    3,467    2,353 
2024    4,869    5,571 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $2,074 and $2,084 for the years ended December 31, 2024, and 2023, respectively.

 

 

 

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $457 and $656 for the years ended December 31, 2024 and 2023, respectively.

 

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.

 

Income Taxes

 

We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

F-10

 

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2024, and 2023, we had no liability for unrecognized tax benefits.

 

Earnings Per Share

 

Included in the computation of diluted earnings per share for the year ended December 31, 2024, was a total of 2,678,000 in potential shares of common stock. Options to purchase approximately 889,000 shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period. 

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2024   2023 
Numerator: (in Thousands)          
Net income (loss)  $4,235   $(4,390)
           
Denominator:          
Weighted average number of basic common shares outstanding   62,350,459    49,556,305 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,678,356    — 
Weighted average number of diluted common shares outstanding   65,028,815    49,556,305 
           
Basic earnings per common share:          
Net income (loss) per share – basic  $0.07   $(0.09)
Diluted earnings per common share:          
Net income (loss) per share – diluted  $0.07   $(0.09)

 

Recently Adopted Pronouncements

 

In November 2023 the FASB issued ASU 2023-07 “Improvements to Reportable Segment Disclosures”, which the Company adopted in 2024. The amendments in this Update improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses.

 

Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the Chief Operating Decision Maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this Update do not change or remove those disclosure requirements.

 

F-11

 

 

The amendments in this Update also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments.

 

This Update did not have a significant impact on the Company.

 

 Recently Issued Pronouncements

 

 On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. This new requirement will be effective for Solésence for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.

 

 

(3) Related Party Notes and Lines of Credit

 

Notes and lines of credit consist of the following:

 

       As of December 31, 
       2024   2023 
   Rate   Available  

Outstanding

Balance

   Available  

Outstanding

Balance

 
Libertyville Bank & Trust (1)  8.50%   $30   $—   $30   $— 
Libertyville Bank & Trust (2)  8.50%    500    —    500    — 
Beachcorp, LLC (3)   8.25%    5,604    —    3,298    2,810 
Beachcorp, LLC (4)   8.25%    5,200    4,000    5,200    5,000 
Strandler, LLC   (5)   8.25%    1,000    1,000    1,000    1,000 
Strandler, LLC  (6)  9.25%    —    —    2,000    2,000 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet.

 

2)On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to October 1, 2025.

 

4)On January 28, 2022, the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it was set to matured on March 31, 2024. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to October 1, 2025.

 

F-12

 

 

5)On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to October 1, 2025.

 

6)On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $2,000. The interest rate for the Bridge Note was at the prime rate plus 0.75%, and it was to mature on May 13, 2024. The Bridge Note was repaid in February 2024.

 

The Company classifies the line of credit – accounts receivable as current because we are required to pay back the borrowings as cash is received from our customers. The company’s remaining debt is presented within the Consolidated Balance Sheet as of December 31, 2024, and 2023 in accordance with the maturity dates in the financing agreements.

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust. The Company’s loan agreements with Strandler, LLC and Beachcorp, LLC currently are set to expire on October 1, 2025, which could become an operating risk if we are not able to refinance or extend the maturity dates.

 

Related party interest expense consists of the following:

 

   Twelve Months Ended December 31, 
   2024   2023 
Interest expense, related parties  $656   $770 

 

Accrued interest consists of the following:

 

   As of December 31, 
   2024   2023 
Accrued interest expense, related parties  $36   $81 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2024   2023 
Beachcorp, LLC  $4,000   $7,810 
Strandler, LLC   1,000    3,000 

 

 

(4) Inventories, net

 

Inventories consist of the following:

 

             
   As of December 31, 
   2024   2023 
Raw materials  $17,396   $8,524 
Finished goods   4,858    2,184 
Inventory reserve   (1,987)   (677)
      Total Inventories, net  $20,267   $10,031 

 

F-13

 

 

(5)

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements consist of the following: 

 

   As of December 31, 
   2024   2023 
Machinery and equipment  $23,551   $23,339 
Office equipment   1,014    1,014 
Office furniture   126    126 
Leasehold improvements   5,153    5,157 
Construction in progress   5,706    931 
    35,550    30,567 
Less: Accumulated depreciation and amortization   (22,816)   (21,899)
   $12,734   $8,668 

 

Depreciation expense was $918 and $732, for the years ended December 31, 2024 and 2023, respectively.

 

(6) Lease Commitments

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. The Company has one sublease of currently unused floorspace that is month-to-month.

 

The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

On September 1st of 2024 the facility located at 1319 Marquette Drive in Romeoville was extended through January 31, 2028. Additionally, on that same day, the facility located at 453 Commerce St in Burr Ridge was extended for one year. The present value of future lease payments associated with these extensions resulted in the addition of a ROU asset and lease liability totaling $1,019.

 

The office leases contain variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease and non-lease components for building leases.

 

Quantitative information regarding the Company’s leases is as follows:

 

         
   Twelve Months Ended December 31, 2024   Twelve Months Ended December 31, 2023 
Components of lease cost          
Operating lease cost components:          
Operating lease cost   1,944    1,881 
Variable lease cost   684    581 
Short-term lease cost   334    112 
Sub-lease income   (511)   (786)
 Total operating lease costs   2,451    1,788 
Total lease cost  $2,451   $1,788 

 

F-14

 

 

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $2,115   $172 
           
Lease liabilities arising from obtaining right-of-use assets  $1,019   $182 
Weighted-average remaining lease term-operating leases (in years)   6.8    7.9 
Weighted-average discount rate-operating leases   7.6%   7.1%

 

The future maturities of the Company’s operating leases as of December 31, 2024 are as follows:

 

2025   $1,975 
2026    1,909 
2027    1,965 
2028    1,587 
2029    1,591 
Thereafter    4,021 
Total payments   $13,048 
Less amounts representing interest    (2,752)
Total minimum payments required   $10,296 

 

The Company subleases a portion of a leased industrial building that is used primarily for the storage of furniture, equipment and displays used for retail sales. The arrangement is not with a related party.

 

Payments received by the Company for this sublease are comprised of two components, which include base rent and Common Area Maintenance (CAM) charges. While the base rent is fixed, the CAM charges are indexed directly to the Master Lease and are expected to be adjusted periodically as actual costs are incurred. However, the executed sublease agreement specifically itemizes these costs with a provision that informs the sublessee that the CAM charges will be adjusted (up or down) based on actual amounts once this information becomes known. As such, the nature of the charges is more closely representative of a fixed payment (an “in-substance fixed” charge) with the adjustments occurring simply to “true up” the listed CAM charges once actual charges from the head lessor become known. As sublessor, the Company has elected the practical expedient to not separate lease and nonlease components in disclosing future undiscounted cashflows and treats the combined components as a single lease component.

 

As sublessor, the Company is subletting to one tenant on a month-to-month arrangement.

 

(7) Accrued Expenses

 

Accrued expenses consist of the following:

 

             
   As of December 31, 
   2024   2023 
Accrued payroll and related expenses  $1,824   $255 
Accrued accounts payable   1,597    128 
Other   1,428    486 
 Total  $4,849   $869 

 

F-15

 

 

(8)Income Taxes

 

Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $227. Our current federal and deferred tax expenses are zero.

 

A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:

 

   2024   2023 
Income tax credit at statutory rates  $937   $(921)
Under accrual of income taxes   (1)   (3)
Nondeductible expenses   5    23 
Record tax credits   (116)    (118)
Permanent tax deduction stock options exercised   (27)   (63)
State income tax, net of federal benefits   179    (165)
Expiration of net operating losses and credits   332    1,492 
Effect of change in deferred tax rate   49    45 
Expiration of stock options   46    60 
Other   (39)    — 
Change in valuation allowance   (1,138)   (344)
   $227   $ 6 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

             
   As of December 31, 
   2024   2023 
Deferred tax liabilities:          
Excess tax depreciation  $(496)   (477)
ASC 842 operating lease asset   (1,938)   (1,975)
Total deferred tax liabilities   (2,434)   (2,452)
           
Deferred tax assets:          
Net operating loss carryforwards  $10,218   $12,020 
179 Carryforwards   —    245 
163(j) Business interest limitation carryforwards   —    302 
Inventory and other allowances   764    239 
Excess book amortization   60    60 
174 research and experimental expenditures   1,053    902 
Share-based compensation   788    530 
Tax credits   189    118 
ASC 842 operating lease liability   2,520    2,610 
Other accrued costs   293    13 
Total deferred tax assets   15,885    17,039 
           
Less:  valuation allowance   (13,451)   (14,587)
Deferred income taxes  $—   $— 

 

F-16

 

 

The valuation allowance decreased approximately $1.1 million and $0.3 million for the years ended December 31, 2024 and 2023, respectively (net of approximately $8.1 million and $7.1 million for the years ended December 31, 2024 and 2023, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2024, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.

 

We have federal net operating loss carryforwards for tax purposes of approximately $42 million on December 31, 2024. $36 million expire between 2025 and 2037. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $6.8 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $18.2 million on December 31, 2024. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.

 

(9)

Capital Stock

 

As of December 31, 2024, and 2023, we had 24,088 authorized but unissued shares of preferred stock.

 

Pursuant to the Securities Purchase Agreement executed on March 1, 2024, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”). Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock was outstanding, the Purchase Agreement also (i) prevented the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevented the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricted the Company’s ability to permit any lien or other encumbrance on Company assets.

 

At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from 60,000,000 to 95,000,000, each share of Series X Preferred Stock was convertible, at the option of the holder, into 1,000 shares of Common Stock at no additional cost. If the Company had not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock would have been redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $420 per share (each, a “Redemption”). If the Company failed to fully pay any Redemption within five days of receiving notice, all unpaid amounts would bear interest at a rate of 10% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock would have been redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $420 per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.

 

Holders of Series X Preferred Stock (i) were not entitled to receive dividends, subject to customary anti-dilution protections, (ii) had no voting rights, and (iii) would have received a liquidation preference of $400 per share. The Series X Preferred Stock ranked senior in right of payment to all securities designated as junior securities, including Common Stock.

 

ASC 815-15-25-17D provides guidance for assessing host contracts in the form of preferred shares, in which 25-17D(b) states that an investor’s ability to “convert a preferred share into a fixed number of common shares generally is viewed as an equity-like characteristic”. Because conversion of the Series X Preferred Shares were at the discretion of the Holder, conversion was in a fixed number of shares, dividends are not typically paid and cash settlement would only occur in the unlikely event of change in control, the host contract had the characteristics of, and was classified as, an equity instrument, and the embedded derivatives and host contract were considered clearly and closely related. As such, the embedded derivative did not require bifurcation and the Series X Preferred Shares were reported as mezzanine equity on the balance sheet during the period when these instruments were issued and outstanding.

 

Issuance costs associated with issuance of the Series X Preferred Stock were immaterial.

 

F-17

 

 

On June 18, 2024, the Company held a special meeting of stockholders where the Certificate Amendment was approved. The Certificate Amendment was filed with the State of Delaware on June 19, 2024. On June 20, 2024, Strandler converted its 15,000 shares of Series X Preferred Stock to 15,000,000 shares of Common Stock.

 

(10) Stock Options and Stock Grants

 

We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 expire seven years from the date of grant. Future options to be granted under the 2019 Plan will expire seven years from the date of grant.

 

Employee Stock Options

 

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

             
  

Years ended

December 31,

 
   2024   2023 
Share-based compensation expense  $725   $773 
Remaining unrecognized compensation expense   1,057    1,118 
Remaining weighted average-period, expense recognition (years)   2.4    1.8 

 

We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of 10 years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. 

 

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended December 31, 
   2024   2023 
Weighted-average risk-free interest rates:   4.3%   3.8%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   4    4 
           
Weighted-average expected stock price volatility:   91%   93%
           
Weighted-average fair value of the options granted:  $1.74   $0.50 

 

F-18

 

 

Additional disclosures for options granted for all years presented:

 

   Years Ended December 31, 
   2024   2023 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   8%   8%

 

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:

 

           Weighted     
       Weighted   Average   Aggregate 
       Average   Remaining   Intrinsic 
   Shares   Exercise Price   Contractual   Value 
Options  (Rounded)   per Share   Term (Years)   (000s) 
Outstanding on January 1, 2024   3,525,966   $1.22    4.2   $160 
                     
Granted   388,000   $2.40           
Exercised   (455,995)  $0.52           
Forfeited or expired   (246,232)  $1.13           
                     
Outstanding on December 31, 2024   3,211,739   $1.47    4.4   $3,961 
Exercisable on December 31, 2024   2,206,666   $1.46    3.6   $2,984 
                     
Shares available for grant   62,900                

 

The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 on the last business day for the year ended December 31, 2024.

 

             
  

Years ended

December 31,

 
   2024   2023 
Shares exercised   455,995    294,074 
Total intrinsic value  $370   $195 
Cash received  $239   $154 

 

Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2024 and 2023.

 

(11) 401(k) Profit-Sharing Plan

 

We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. Contributions made in 2024 and 2023 aggregated to $206 and $191, respectively.

 

(12) Significant Customers

 

We had three significant customers for the year ended December 31, 2024.

 

F-19

 

 

Revenues from these three customers, as a percentage of total Company revenue, was approximately:

 

       For the years ended 
       December 31, 
Customer #   Product Category  2024   2023 
1   Consumer Products   32%   17%
2   Personal Care Ingredients   13%   25%
3   Consumer Products   7%   15%
    Total   52%   57%


 

 Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:

 

       As of
December 31,		 
Customer #   Product Category  2024   2023 
1   Consumer Products  $2,366   $1,288 
2   Personal Care Ingredients   160    — 
3   Consumer Products   309    864 
    Total  $2,835   $2,152 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our second largest customer, that have contingencies outlined which could potentially result in the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event could result in the loss of some of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.

 

(13) Business Segmentation and Geographical Distribution

 

The Company operates as a single business segment, in which the factors used to make this determination include differences in products, services, geographical areas, regulatory environment, and other such criteria considered for the appropriateness of aggregation. The types of products and services for which the sole reportable segment, which is the same as the Company as a whole, offered by the company is discussed in Note 1. Since the Company operates as a single segment, there were no intra-entity sales or transfers.

 

The role of Chief Operating Decision Maker for the Company is comprised of a committee that includes the Chief Executive and Chief Operating Officers. The Chief Operating Decision Maker assesses performance for the single segment and decides how to allocate resources based on net income that also is reported on the income statement as net income. The measure of segment assets is reported on the balance sheet as total assets. The accounting policies of the sole segment are the same as those described in the summary of significant accounting policies in Note 2.

 

F-20

 

 

The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:

 

             
   As of December 31, 
   2024   2023 
Total revenue  $52,347   $37,297 
           
Employee costs   12,933    10,811 
Contractors and professional services   7,815    6,588 
Materials and supplies   15,559    14,669 
Depreciation   928    742 
Interest expense   670    838 
Other income   (2)   (4)
Tax expense   318    101 
Facilities   3,413    2,870 
Shipping   1,193    760 
Testing   917    1,078 
IT services   1,091    1,060 
Insurance   785    721 
Manufacturing other expense   992    604 
Selling, general and administrative other expense   1,500    849 
Total Expense   48,112    41,687 
           
Net Income (loss)  $4,235   $(4,390)

 

Revenue from international sources approximated $1,825 and $2,918 for the years ended December 31, 2024 and 2023, respectively. As part of our revenue from international sources, we recognized approximately $366 and $1,664 in product revenue from German companies, in the aggregate, for the years ended December 31, 2024 and 2023, respectively.

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, personal care ingredients, advanced materials and consumer products. The revenues for 2024 and 2023 by category are as follows:

 

  

For the years ended

December 31

 
Product Category  2024   2023 
Consumer Products  $44,373   $25,211 
Personal Care Ingredients   6,827    9,277 
Advanced Materials   1,147    2,809 
Total Sales  $52,347   $37,297 

 

(14) Subsequent Event

 

On March 7, 2025, the Company announced its rebranding as Solesence, Inc., marking a new chapter in its commitment to innovation, self-expression, and inclusivity in skin health. The company’s stock will continue to trade under the NANX ticker symbol. Its corporate website transitioned to solesence.com, historic Company financials and disclosures are now available at ir.solesence.com. Nanophase Technologies Corporation changed its legal name to Solesence, Inc. by amending its certificate of incorporation with the state of Delaware on March 10, 2025.

 

As of December 31, 2024, the Company’s A/R Revolver, Inventory Facility and New Term Loan mature on October 1, 2025. Since then, the Company’s related party debt holder for the A/R Revolver, Inventory Facility and New Term Loan has committed to refinancing the debt with a new maturity date after April 1, 2026.

 

F-21

 

 

EXHIBIT INDEX

 

Exhibit
Number		  
   
2.1 Plan and Agreement of Merger dated as of November 25, 1997 by and between the Company and its Illinois predecessor, incorporated by reference to Exhibit 2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 (the “1997 10-K”), SEC File No. 000-22333.
   
3(i).1 Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the 1997 10-K, SEC File No. 000-22333.
   
3(i).2 First Amendment to the Certificate of Incorporation of the Company dated July 27, 2006, incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed July 27, 2006, SEC File No. 000-22333.
   
3(i).3 Second Amendment to the Certificate of Incorporation of the Company dated August 23, 2010, incorporated by reference to Exhibit A of the Company’s Definitive Proxy Statement on Schedule 14A filed July 9, 2010, SEC File No. 000-22333.
   
3(i).4 Third Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 29, 2016.
   
3(i).5 Fourth Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 22, 2019.
   
3(i).6 Fifth Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3(i).6 to the Company’s Annual Report on Form 10-K filed March 28, 2024.
   
3(i).7 Sixth Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed January 16, 2025.
   
3(i).8 Seventh Amendment to the Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 12, 2025.
   
3(ii).1 By-Laws of the Company, incorporated by reference to Exhibit 3.2 to the 1997 10-K, SEC File No. 000-22333.
   
4.1 Specimen stock certificate representing common stock, incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1/A filed November 4, 1997 (File No. 333-36937) (the “Form S-1/A”).
   
4.2 Form of Warrants, incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1 filed October 1, 1997 (File No. 333-36937) (the “IPO S-1”).
   
4.3 Certificate of Designations of Series A Junior Participating Preferred Stock, incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1998, SEC File No. 000-22333.
   
4.4 Stock Purchase Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Holdings, Inc., incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.
   
4.5 Registration Rights Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Holdings, Inc., incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000-22333.
   
4.6 Common Stock Purchase Agreement, dated February 10, 2016, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed February 10, 2016.
   
4.7 Common Stock Purchase Agreement, dated December 19, 2017, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed December 21, 2017.

 

E-1

 

 

4.8 Common Stock Purchase Agreement, dated May 13, 2019, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed May 15, 2019
   
4.9 Securities Purchase Agreement, dated November 13, 2019, between the Company and Bradford T. Whitmore, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.
   
4.10 Commercial Security Agreement, dated November 20, 2019, between the Company, Solésence, LLC and Bradford T. Whitmore, incorporated by reference to Exhibit 4.2 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2019.
   
4.11 Certification of Designation of Series X Preferred Stock, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 5, 2024, EC File No. 000-22333.
   
10.1 Industrial Building Lease dated September 15, 2004 between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004 (the “2004 10-K”), SEC File No. 000- 22333.
   
10.2 Industrial Building Lease Agreement between Centerpoint Properties Trust (formerly CP Financing Trust) and the Company, dated June 15, 2000, incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2000 (the “2000 10-K”), SEC File No. 000-22333.
   
10.3 Lease Amendment effective October 1, 2005 between the Company and Centerpoint Properties Trust, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed October 20, 2005, SEC File No. 000-22333.
   
10.4 Second Amendment to Industrial Lease Agreement, dated as of November 13, 2014 between the Company and MLRP 1319 Marquette LLC, successor-in-interest to Centerpoint Properties Trust, incorporated by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10- K for the year ended December 31, 2014.
   
10.5 Third Amendment to Industrial Lease Agreement, entered into on October 17, 2016 and effective October 1, 2016, by and between the Company and 1319 Marquette, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 19, 2016.
   
10.6 Mutual Cooperation Agreement entered into on January 17, 2012, by and among the Company, C.I. Kasei Co., Ltd. and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 20, 2012, SEC File No. 000-22333.
   
10.7 Trademark Ownership Assignment Agreement, dated March 31, 2012, between the Company and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 4, 2012, SEC File No 000-22333.
   
10.8 Memorandum on the Payment of Royalty, dated March 31, 2012, between the Company and CIK NanoTek Corporation, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed April 4, 2012, SEC File No 000-22333.
   
10.9 Supply Agreement between the Company and Schering-Plough HealthCare Products, Inc. dated as of March 15, 1997, incorporated by reference to Exhibit 10.17 to the Form S-1/A.
   
10.10* Zinc Oxide Supply Agreement dated as of September 16, 1999 between the Company and BASF Corporation, as assignee, incorporated by reference to Exhibit 10.22 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1999, SEC File No. 000-22333.
   
10.11* Amendment No. 1 to Zinc Oxide Supply Agreement dated as of January, 2001 between the Company and BASF Corporation, incorporated by reference to Exhibit 10.24 to the 2000 10-K, SEC File No. 000-22333.
   
10.12 Amendment No. 2. to Zinc Oxide Supply Agreement dated as of March 17, 2003 between the Company and BASF Corporation, incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2002 (the “2002 10-K”), SEC File No. 000-22333.

 

E-2

 

 

10.13* Amendment No. 3 to Zinc Oxide Supply Agreement entered into on December 12, 2012, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 6, 2012, SEC File No. 000-22333.
   
10.14* Amendment No. 4 to Zinc Oxide Supply Agreement, dated as of January 1, 2019 and entered into on March 11, 2019, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed May 15, 2019. 
   
10.15* Amendment No. 5 effective as of April 10, 2024, to Zinc Oxide Supply Agreement, dated as of September 16, 1999, between the Company and BASF Corporation, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed April 11, 2024. 
   
10.16 Z-COTE HP-2 Brand Supply Agreement dated May 15, 2006 between the Company and BASF Corporation, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed June 20, 2006, SEC File No. 000-22333.
   
10.17* Amended and Restated Cooperation Agreement dated August 25, 2006 between the Company and Rohm and Haas Electronic Materials CMP Inc., incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed August 28, 2006, SEC File No. 000- 22333.
   
10.18 Supply Agreement effective as of March 23, 2009, between the Company and Rohm and Haas Electronic Materials CMP Inc., incorporated by reference to Exhibit 10.56 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, SEC File No. 000-22333.
   
10.19* Distributor Agreement dated October 24, 2005 between Johnson Matthey Catalog Company, Inc., d/b/a ALFA AESAR and the Company, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed November 1, 2005, SEC File No. 000-22333.
   
10.20* Supply Agreement dated March 3, 2006 between Roche Diagnostics GmbH and the Company, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed March 9, 2006, SEC File No. 000-22333.
   
10.21* First Amendment to the Supply Agreement entered into on November 19, 2014 between the Company and Roche Diagnostics GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 25, 2014.
   
10.22* Second Amendment to the Supply Agreement, entered into on November 21, 2016, between the Company and Roche Diagnostics GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 28, 2016.
   
10.23* Third Amendment to the Supply Agreement, entered into on February 3, 2023, between the Company and Roche Diagnostics GmbH
   
10.24 Joint Development Agreement dated March 23, 2004 between the Company and Altana Chemie AG, incorporated by reference to Exhibit 10.29 to the 2003 10-K, SEC File No. 000-22333.
   
10.25* Agreement dated July 7, 2008 between the Company and Altana Chemie GmbH, incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed July 18, 2008, SEC File No. 000-22333.
   
10.26* Settlement and Termination Agreement, dated August 20, 2010, between the Company and Altana Chemie GmbH, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 25, 2010, SEC File No. 000-22333.
   
10.27* Supply Agreement, dated as of March 31, 2016, between the Company and Ester Solutions Company, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 6, 2016.
   
10.28 First Amendment to Supply Agreement, dated May 21, 2018, by and between Nanophase Technologies Corporation and Hallstar Ester Solutions Corporation (formerly known as Ester Solutions Company), incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 25, 2018.
   
10.29 Joint Development Agreement, dated as of July 31, 2019, between the Company and Sumitomo Corporation of Americas, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 2, 2019.

 

E-3

 

 

10.30 Joint Development & Supply Agreement, dated December 12, 2016, by and between Solésence, LLC and Colorescience Inc., incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2018.
   
10.31 Amended and Restated Joint Development & Supply Agreement, executed by Solésence, LLC on May 18, 2018, by and between Solésence, LLC and Colorescience Inc., incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2018.
   
10.32 Promissory Note, dated March 4, 2015, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 10, 2015.
   
10.33 Commercial Security Agreement, dated March 4, 2015, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed March 10, 2015.
   
10.34 Change in Terms Agreement, dated March 4, 2016, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed March 10, 2016.
   
10.35 Change in Terms Agreement, dated February 14, 2017, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
   
10.36 Promissory Note, executed by the Company on March 26, 2018, granted by the Company in favor of Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
   
10.37 Commercial Security Agreement, executed by the Company on March 26, 2018, between the Company and Libertyville Bank and Trust Company, incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
   
10.38 Business Loan Agreement, executed by the Company on March 22, 2019, between the Company and Libertyville Bank and Trust Company, incorporated by reference to the Exhibit 10.32 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
   
10.39 Change in Terms Agreement, executed by the Company on March 22, 2019, between the Company and Libertyville Bank and Trust Company, incorporated by reference to the Exhibit 10.33 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
   
10.40 Business Loan Agreement, dated November 16, 2018, between the Company and Beachcorp, LLC, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.
   
10.41 Promissory Note, dated November 19, 2018, made by the Company and payable to the order of Beachcorp, LLC to evidence a term loan in the original principal amount of up to $500,000, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.
   
10.42 Promissory Note, dated November 19, 2018, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $2,000,000, incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed November 19, 2018.
   
10.43 First Amendment to Business Loan Agreement, dated March 23, 2020, between the Company and Beachcorp, LLC, incorporated by reference to the Company’s Annual Report on Form 10-K filed March 30, 2020.
   
10.44 Fourth Amendment to Business Loan Agreement, dated April 21, 2021, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 21, 2021.
   
10.45 Business Loan Agreement, dated January 28, 2022, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 2, 2022.
   
10.46 Business Loan Agreement, dated January 28, 2022, between the Company and Strandler, LLC, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed February 2, 2022.

 

E-4

 

 

10.47 Amended and Restated Business Loan Agreement, dated January 28, 2022, between the Company and Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed February 2, 2022.
   
10.48 Replacement Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $8,000,000, incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed February 2, 2022.
   
10.49 Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Strandler, LLC to evidence a term loan in the original principal amount of up to $1,000,000, incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed February 2, 2022.
   
10.50 Promissory Note, dated January 28, 2022, made by the Company and payable to the order of Beachcorp, LLC to evidence revolving borrowings in a principal amount of up to $4,000,000, incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed February 2, 2022.
   
10.51 First Amendment to Amended and Restated Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.52 Replacement Promissory Note with Beachcorp,LLC, incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.53 First Amendment to Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.54 First Amendment to Business Loan Agreement with Strandler, LLC, incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.55 Promissory Note with Strandler, LLC, incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, SEC File No. 000-22333.
   
10.56 Securities Purchase Agreement with Strandler, LLC, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 5, 2024, SEC File No. 000-22333.
   
10.57 Second Amendment to Business Loan Agreement with Strandler, LLC, incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 5, 2024, SEC File No. 000-22333.
   
10.58 Second Amendment to Amended and Restated Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed March 5, 2024, SEC File No. 000-22333.
   
10.59 Second Admendment to Business Loan Agreement with Beachcorp, LLC, incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed March 5, 2024, SEC File No. 000-22333.
   
10.60 Employment Agreement effective August 12, 2009 between the Company and Jess Jankowski, incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, SEC File No. 000-22333. +
   
10.61 Employment Agreement dated November 28, 2012, between the Company and Kevin Cureton, incorporated by reference to Exhibit 10.36 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, SEC File No. 000-22333. +
   
10.62 Nanophase Technologies Corporation 2004 Equity Compensation Plan (“2004 Equity Plan”), incorporated by reference to Exhibit 4 to the Company’s Registration Statement on Form S-8 (File No. 333-119466). +
   
10.63 2008 Long-Term Cash Incentive Plan, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed July 25, 2008, SEC File No. 000-22333.+
   
10.64 Nanophase Technologies Corporation 2010 Equity Compensation Plan, as amended, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 29, 2016.+

 

E-5

 

 

10.65 Form of Stock Option Award Agreement under the 2010 Equity Compensation Plan, incorporated by reference to Exhibit 10.47 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.+
   
10.66 Nanophase Technologies Corporation 2019 Equity Compensation Plan, incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 22, 2019.+
   
10.67 Building Lease, dated as of September 15, 2010, between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.50 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
   
10.68 Building Lease, dated as of March 13, 2017, between the Company and the Village of Burr Ridge, incorporated by reference to Exhibit 10.51 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
   
10.69* Know-How License Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed June 29, 2017.
   
10.70 Technology Development Agreement, executed by the Company on June 26, 2017, between the Company and Eminess Technologies, Inc., incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed June 29, 2017.
   
10.71* Exclusive Supply Agreement, effective April 1, 2021, between Solésence, LLC and Ilia Beauty, Inc., incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed June 14, 2021.
   
10.72* Lease, effective December 1, 2021, between the Company and FR JH 10, LLC, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed December 9, 2021.
   
19 Solésence Insider Trading Policy
   
21.1 Subsidiary of the Company.
   
23.1 Consent of RSM US LLP. (filed herewith)
   
31.1 Certification of the Chief Executive Officer (principal executive officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act. (filed herewith)
   
31.2 Certification of the Chief Financial Officer (principal financial officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act. (filed herewith)
   
32 Certification of the Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) pursuant to 18 U.S.C. Section 1350. (filed herewith)
   
101 The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Cash Flows, (4) the Statements of Stockholders’ Equity, and (5) the Notes to the Financial Statements.
   
* Confidentiality previously granted for portions of this agreement.
   
+ Indicates management contracts or compensatory plans or arrangements.

 

E-6

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 31st day of March, 2025.

 

  SOLESENCE INC.
       
    By: /s/ Jess A. Jankowski
      Jess A. Jankowski
      President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on the 31st day of March, 2025.

 

Signature   Title
     
/s/ Jess A. Jankowski   President, Chief Executive Officer (principal executive officer,
Jess A. Jankowski   principal financial officer, and principal accounting officer) and Director
     
/s/ R. Janet Whitmore   Chair of the Board of Directors
R. Janet Whitmore    
     
/s/ Laura M. Beres   Director
Laura M. Beres    
     
/s/ Mark E. Miller   Director
Mark E. Miller    

 

 

 EX-19 2 ex19.htm SOLESENCE INSIDER TRADING POLICY
 

Solesence, Inc. 10-K

 

Exhibit 19

 

 

Solésence, Inc.

1319 Marquette Drive

Romeoville, Illinois 60446

 

 

TO: All Directors, Advisory Board Members, Officers and Employees of Solésence
   
FROM: Insider Trading Compliance Officer, Jess Jankowski
   
DATE: March 7, 2025
   
RE: Amended Policy on Insider Trading
   

In the course of employment or other relationship with Solésence, Inc. (“Solésence” or the “Company”), directors, advisory board members, officers, employees, and independent contractors may come into possession of confidential and highly sensitive information concerning the Company, its suppliers, customers, investors or other persons or companies with whom Solésence does business. This confidential and sensitive information may have a potential for affecting the market price of securities issued either by Solésence or the other involved companies.

 

Federal securities laws, under some circumstances, impose considerable civil and criminal penalties on persons who improperly obtain or use material, non-public information in connection with a purchase or sale of securities. In addition to civil damages of up to three times the profit gained or loss avoided, an individual could be subject to imprisonment of up to 20 years and criminal penalties of up to $5,000,000 for violations, plus prejudgment interest and private party damages. Recent federal legislation has given the Securities and Exchange Commission (“SEC”) and courts greater powers in imposing penalties for violations of the insider trading provisions of the federal securities laws. The SEC and governmental prosecutors have been vigorously enforcing these insider trading laws against both institutions and individuals.

 

Violations adversely affect the Company’s reputation. Furthermore, if the Company fails to take appropriate steps to prevent insider trading, the Company and its directors, officers and other supervisory personnel may be subject to “controlling person” liability and potential civil and criminal penalties. In light of the importance of preserving Solésence’s reputation for maintaining the highest legal, business and ethical standards, as well as the detrimental impact on employees and Solésence for failures to comply with applicable laws, the Company is hereby providing specific guidance concerning the propriety of various personal transactions, and has developed specific procedures in certain cases to attempt reasonably to ensure that neither Solésence nor its directors, advisory board members, officers and employees violate insider trading laws.

 

With this in mind, all directors, advisory board members, officers and employees of Solésence have been presented with a copy of this memorandum. We are asking you to read this memorandum and thoroughly understand its contents. Once you are sure you have a complete understanding of its meaning, we are asking that you sign the attached Insider Trading Compliance Statement.

 

 

 

 

Explanation of the Law

 

The federal securities laws and regulations prohibit the purchase or sale of a security at a time when the person trading in that security possesses material, non-public information concerning the issuer of the security, or the market for the security, which has not yet become a matter of general public knowledge and which has been obtained or is being used in breach of a duty to maintain the information in confidence. Communication of nonpublic information to a third party, under circumstances where improper trading can or may be anticipated, is also prohibited. These prohibitions apply to any security, including derivative securities such as put and call options, options to acquire common stock including company-granted stock options, warrants, convertible debentures, preferred stock and debt securities such as bonds and notes -- not just common stock.

 

“Material, non-public information” includes information that is not available to the public at large which could affect the market price of the security and to which a reasonable investor would attach importance in deciding whether to buy, sell, or retain the security. Common examples of information that will frequently be regarded as material are: (1) significant acquisitions; (2) matters involving significant new products, patent approvals and/or licensing agreements; (3) matters relating to new financing; (4) gain or loss of a substantial supplier or customer; (5) negotiating or signing a significant contract; (6) financial results or financial condition or projections by a corporation’s officers or directors of future financial results or financial condition; (7) news of a pending or proposed merger or acquisition, or a tender offer or exchange offer; (8) information about a major joint venture; (9) news of a significant sale of assets; (10) changes in dividend policies or the declaration of a stock split or the offering of additional securities; (11) impending bankruptcy or financial liquidity problems; (12) changes in management; (13) significant litigation; (14) significant regulatory exposure due to actual or threatened action by state or federal regulators; (15) major restructuring actions or asset impairments; (16) changes in auditors; or (17) discovery of an error in the Company’s financial statements or notification from an independent auditor that the Company may no longer rely on a previously issued audit report or completed interim review. It should be noted that either positive or negative information may be material.

 

Information is considered to be available to the public only when it has been released to the public through appropriate channels (for example, by means of a press release or a public statement from one of Solésence’s senior officers) and enough time has elapsed to permit the investment market to absorb and evaluate the information. Publicly released information will normally be regarded as absorbed and evaluated within two days after its disclosure.

 

Company Policy

 

1.    Applicability.

 

This policy applies to all officers, directors, advisory board members, employees, and independent contractors of the Company, as well as each of those person’s spouse, minor children, any person living in their household (collectively, “Covered Persons”). It is also the Company’s policy that the Company will not engage in transactions in the Company’s securities while aware of material, non-public information, except as otherwise set forth herein.

 

2.    No Trading On Material, Non-Public Information.

 

Any Covered Person who has material, non-public information relating to Solésence or any other company, including any of the Company’s major suppliers, customers or joint venture partners, (i) may not transact in the securities of Solésence or such other company, (ii) pass along the information to others or recommend to anyone to transact in the securities of Solésence or such other company (so called “tipping”), or (iii) permit any person whose decisions are directed, influenced or controlled by such Covered Person, anyone acting on his or her behalf, or anyone to whom he or she has disclosed the material non-public information, to transact in such securities. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are no exception. Even the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.

 

 

 

 

A reasonable time should be allowed to elapse (at least two business days) before trading in the security to allow for public dissemination and evaluation of the information after public disclosure through appropriate channels. Generally, it is expected that you will be less likely to be in possession of material, non-public information during the 30-day period beginning two days after the release of either quarterly or annual financial results. However, even during these periods, you are subject to the above prohibitions if you possess material, non-public information.

 

3.    Prior Approval Required for All Persons.

 

Since everyone is likely to have access to material, non-public information, it is Solésence’s policy that Covered Persons must not transact in the Company’s securities or the securities of any other company with whom the Company does a significant amount of business, whether or not the Covered Person possesses specific material, non-public information, unless the written permission from the Company’s Insider Trading Compliance Officer (the “Compliance Officer”) is first received. Written permission will be given for a specified period but will continue to be subject to the above prohibitions if such person possesses material, non-public information.

 

3. Other Trading Restrictions.

 

In addition, it is Solésence’s policy that Covered Persons shall not engage in any of the following activities with respect to the Company’s securities:

 

a.Transacting in Solésence’s securities during the period beginning on the twenty-fifth day of the last month of a calendar quarter (i.e., March 25, June 25, September 25, and December 25) through and including the third business day following the press release of such quarter’s earnings or prior year’s earnings in the case of the fourth quarter.

 

b.Transacting in Solésence’s securities during any other ad-hoc blackout period as may be declared from time to time by the Compliance Officer.

 

c.Transacting in Solésence’s securities on a short-term basis. Any security purchased must be held for a minimum of six months before sale, unless the stock is subject to forced sale (e.g., as a consequence of a merger or acquisition).

 

d.Holding Solésence securities in a margin account or pledging them as collateral for a loan that may be sold without your consent by the broker if you fail to meet a margin call or by the lender in foreclosure if you default on the loan.

 

e.Short sales.

 

 

 

 

f.Buying or selling put options or call options on Solésence’s securities, or entering into hedging transactions with respect to Solésence’s securities such as “costless collars,” “prepaid variable forwards,” “equity swaps” or similar transactions intended to preserve value.

 

g.Engaging in limit orders, standing orders or other pre-arranged transactions that execute automatically, except for “same-day” limit orders and approved 10b5-1 plans that are not otherwise subject to limitations.

 

4. Rule 10b5-1 Sales or Trading Plans.

 

Transactions in Solésence’s securities by persons subject to this Policy that are made pursuant to a 10b5-1 sales or trading plan that has been approved in advance and in writing by the Compliance Officer are generally not subject to the prohibition on trading on the basis of material non-public information or the restrictions contained in this Policy relating to blackout periods and the preclearance approval process. Rule 10b5-1 provides an “affirmative defense” in those instances, although not an absolute safe harbor, from insider trading liability under the federal securities laws provided that the trading plans meet certain requirements. In every instance, a 10b5-1 plan must be entered into in good faith during a permitted trading period and when the person is not aware of material non-public information. Once the plan is adopted, and for as long as it continues in effect, the person must not exercise any further influence over how, when or whether to trade the securities subject to the plan.

 

Persons subject to this Policy should discuss their proposed 10b5-1 plans with the Compliance Officer to determine the restrictions expected relative to plan design. These expectations may change for new plan requests as time advances and regulations change. At a minimum, plans must specify the amount, pricing and timing of the transactions (including arrangements to set these terms by formula) in advance, or alternatively, delegate discretion on those matters to an independent party. Once a person’s 10b5-1 plan is approved and put into place, all proposed modifications of the plan must also be submitted to the Compliance Officer for approval prior to their implementation, and must be made when you are not aware of material non-public information and during a permitted trading period. In effect, any modification of a 10b5-1 plan is treated as if the existing 10b5-1 plan has been terminated and a new 10b5-1 plan has been put in place, subject to approval by the Compliance Officer or the Chair of the Compensation Committee of the Solésence Board of Directors.

 

Nothing in this Policy prohibits a person subject to this Policy from terminating a 10b5-1 plan in accordance with applicable law and regulation. However, such persons should be aware that modifications to, or terminations of, 10b5-1 plans may be viewed as exercises of insider control that could affect the determination of whether an insider entered into a 10b5-1 plan in good faith and is therefore entitled to affirmative defenses under the plan. Consequently, it is recommended that persons subject to this Policy consult with their personal legal advisors before making plan changes.

 

Rule 10b5-1 requires Covered Persons to wait for a mandatory cooling-off period after adoption before trading can commence: (1) Officers and directors must wait for the later of (a) 90 days after adoption or modification and (b) two business days after the disclosure of the Company’s financial results for the fiscal quarter in which the 10b5-1 plan was adopted or modified (not to exceed 120 days); and (2) all other Covered Persons must wait 30 days after adoption of modification.

 

Insiders seeking to establish a 10b5-1 plan should contact the Company’s legal counsel. Solésence’s acceptance of a 10b5-1 plan does not mean that the plan automatically meets the requirements of applicable law or that persons adopting such plans will be insulated from insider trading liability. It is the responsibility of each person to ensure compliance with insider trading laws and regulations, including Rule 10b5-1.

 

 

 

 

Appointment and Duties of the Compliance Officer

 

The Company has appointed the Company’s Chief Financial Officer as the Compliance Officer. The Compliance Officer may assign certain of the related duties to another Company employee from time to time.

 

The appointment of a Compliance Officer does not shift responsibilities under this Policy away from the individual. The individual remains solely responsible for compliance with this Policy. The duties of the Compliance Officer are strictly for the Company’s benefit. Neither the Compliance Officer nor any of the Company’s employed or retained attorneys shall be deemed to represent individual employees or other persons subject to this Policy.

 

 

 

 

Solésence, Inc.

1319 Marquette Drive

Romeoville, Illinois 60446

 

Acknowledgment

 

I have carefully reviewed the Solésence, Inc. Policy on Insider Trading, as amended through March 7, 2025, and understand all of its provisions. I certify that to the best of my knowledge I have complied with these policies since such date (or during my term of employment, or tenure as a director or advisory board member, if after such date) and that I will continue to adhere to these policies and procedures in the future.

 

I realize that failure to observe and comply with all of the provisions contained in the memorandum may subject me to sanctions including disciplinary action, up to and including discharge, as well as civil liability and criminal penalties under applicable law.

 

Signature:     Date:  
         
Print Name:        
         
Title:        

 

 

 EX-21 3 ex21-1.htm SUBSIDIARY OF THE COMPANY
 

Solesence, Inc. 10-K

 

Exhibit 21.1

 

SUBSIDIARY OF SOLESENCE INC.

 

(as of December 31, 2024)

 

  Name Jurisdiction of Formation
     
  Solésence, LLC Delaware

 

 

 EX-23.1 4 ex23-1.htm CONSENT OF RSM US LLP,
 

Solesence, Inc. 10-K

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements (No. 333-53445, No. 333-74170, No. 333-119466, No. 333-150765, No. 333-187649, and No. 333-255357) on Form S-8 and Registration Statements (No. 333-90326, No. 333-116224, No. 333-140461, and No. 333-163363) on Form S-3 of Solesence, Inc., formerly known as Nanophase Technologies Corporation, of our report dated March 31, 2025, relating to the consolidated financial statements of Solesence, Inc., appearing in this Annual Report on Form 10-K of Solesence, Inc. for the year ended December 31, 2024.

 

/s/ RSM US LLP

 

Milwaukee, Wisconsin

March 31, 2025

 

 

 EX-31.1 5 ex31-1.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
 

Solesence, Inc. 10-K

 

Exhibit 31.1

 

Certification of the Chief Executive Officer
Pursuant to

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess A. Jankowski, certify that:

 

1.        I have reviewed this annual report on Form 10-K of Solesence, Inc,;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)      Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2025    
     
  /s/  JESS A. JANKOWSKI  
    Jess A. Jankowski
    President and Chief Executive Officer
    (Principal Executive Officer)

 

 

 EX-31.2 6 ex31-2.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
 

Solesence, Inc. 10-K

 

 Exhibit 31.2

 

Certification of the Chief Financial Officer
Pursuant to 

Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess Jankowski, certify that:

 

1.        I have reviewed this annual report on Form 10-K of Solesence, Inc.;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)        Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a)        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)        Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2025    
     
  /s/ JESS A. JANKOWSKI  
    Jess A. Jankowski
    President, Chief Executive Officer, and Chief Financial Officer
   

(Principal Financial Officer)

 

 

 EX-32 7 ex32.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
 

Solesence, Inc. 10-K

 

Exhibit 32

 

Certification Pursuant to 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with this annual report of Solesence, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1.             The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.             The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 31, 2025    
     
  /s/ JESS A. JANKOWSKI  
    Jess A. Jankowski
    President, Chief Executive Officer, and Chief Financial Officer

 

 

 EX-101.SCH 8 nanx-20241231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 999014 - Disclosure - Risk Assessment and Strategy link:presentationLink link:calculationLink link:definitionLink 999015 - Disclosure - Management Oversight link:presentationLink link:calculationLink link:definitionLink 999016 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 999017 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 999018 - Disclosure - Related Party Notes and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 999019 - Disclosure - Inventories, net link:presentationLink link:calculationLink link:definitionLink 999020 - Disclosure - Equipment and Leasehold Improvements link:presentationLink link:calculationLink link:definitionLink 999021 - Disclosure - Lease Commitments link:presentationLink link:calculationLink link:definitionLink 999022 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 999023 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 999024 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 999025 - Disclosure - Stock Options and Stock Grants link:presentationLink link:calculationLink link:definitionLink 999026 - Disclosure - 401(k) Profit-Sharing Plan link:presentationLink link:calculationLink link:definitionLink 999027 - Disclosure - Significant Customers link:presentationLink link:calculationLink link:definitionLink 999028 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 999029 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 999030 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 999031 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 999032 - Disclosure - Related Party Notes and Lines of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 999033 - Disclosure - Inventories, net (Tables) link:presentationLink link:calculationLink link:definitionLink 999034 - Disclosure - Equipment and Leasehold Improvements (Tables) link:presentationLink link:calculationLink link:definitionLink 999035 - Disclosure - Lease Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 999036 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 999037 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 999038 - Disclosure - Stock Options and Stock Grants (Tables) link:presentationLink link:calculationLink link:definitionLink 999039 - Disclosure - Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 999040 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 999041 - Disclosure - We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. (Details) link:presentationLink link:calculationLink link:definitionLink 999042 - Disclosure - Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 999043 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows (Details) link:presentationLink link:calculationLink link:definitionLink 999044 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999045 - Disclosure - Notes and lines of credit consist of the following (Details) link:presentationLink link:calculationLink link:definitionLink 999046 - Disclosure - Related party interest expense consists of the following (Details) link:presentationLink link:calculationLink link:definitionLink 999047 - Disclosure - Inventories consist of the following (Details) link:presentationLink link:calculationLink link:definitionLink 999048 - Disclosure - Equipment and leasehold improvements consist of the following (Details) link:presentationLink link:calculationLink link:definitionLink 999049 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999050 - Disclosure - Quantitative information regarding the Company’s leases is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 999051 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: (Details) link:presentationLink link:calculationLink link:definitionLink 999052 - Disclosure - The future maturities of the Company’s operating leases as of December 31, 2024 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 999053 - Disclosure - Lease Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999054 - Disclosure - Accrued expenses consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 999055 - Disclosure - A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 999056 - Disclosure - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) link:presentationLink link:calculationLink link:definitionLink 999057 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999058 - Disclosure - Capital Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999059 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) link:presentationLink link:calculationLink link:definitionLink 999060 - Disclosure - The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) link:presentationLink link:calculationLink link:definitionLink 999061 - Disclosure - Additional disclosures for options granted for all years presented: (Details) link:presentationLink link:calculationLink link:definitionLink 999062 - Disclosure - The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: (Details) link:presentationLink link:calculationLink link:definitionLink 999063 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 (Details) link:presentationLink link:calculationLink link:definitionLink 999064 - Disclosure - Stock Options and Stock Grants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999065 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999066 - Disclosure - Revenues from these three customers, as a percentage of total Company revenue, was approximately: (Details) link:presentationLink link:calculationLink link:definitionLink 999067 - Disclosure - Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: (Details) link:presentationLink link:calculationLink link:definitionLink 999068 - Disclosure - Significant Customers (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999069 - Disclosure - The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 999070 - Disclosure - The revenues for 2024 and 2023 by category are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 999071 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999072 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 nanx-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 nanx-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 nanx-20241231_lab.xml XBRL LABEL FILE Product and Service [Axis] Product [Member] Product and Service, Other [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Leasehold Improvements [Member] Other Capitalized Property Plant and Equipment [Member] Related Party Transaction [Axis] Prepayments From Certain Customers Per Company Policy [Member] Prepayments From Product Development Agreement With A Personal Care Ingredient Customer [Member] Timing of Transfer of Good or Service [Axis] Transferred over Time [Member] Credit Facility [Axis] Libertyville Bank and Trust [Member] Libertyville Bank and Trust One [Member] Beachcorp, LLC [Member] Beachcorp, LLC One [Member] Strandler, LLC [Member] Strandler LLC One [Member] Letter of Credit [Member] Short-Term Debt, Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Business Loan Agreement [Member] Revolving Credit Facility [Member] Counterparty Name [Axis] Inventory Facility [Member] Replacement Promissory Note [Member] Term Loan [Member] Bridge Note [Member] Related and Nonrelated Parties [Axis] Related Party [Member] Machinery and Equipment [Member] Office Equipment [Member] Furniture and Fixtures [Member] Construction in Progress [Member] Tax Period [Axis] Expiring 2025 to 2037 [Member] Income Tax Jurisdiction [Axis] Domestic Tax Jurisdiction [Member] Tax Year 2018 [Member] State and Local Jurisdiction [Member] Class of Stock [Axis] Series X Preferred Stock [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Plan Name [Axis] Prior to 2019 Plan [Member] 2019 Plan [Member] 2010 Plan [Member] Customer [Axis] Customer One [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer Two [Member] Customer Three [Member] Customers One Through Three [Member] Supply Commitment [Axis] Supply Commitment [Member] Nature of Expense [Axis] Employee Costs [Member] Contractors And Professional Services [Member] Materials And Supplies [Member] Depreciation [Member] Interest Expense [Member] Other Income [Member] Tax Expense [Member] Facilities [Member] Shipping [Member] Testing [Member] I T Services [Member] Insurance [Member] Manufacturing Other Expense [Member] Selling General And Administrative Other Expense [Member] Geographical [Axis] Non-US [Member] Consumer Products [Member] Personal Care ingredients [Member] Advanced Materials [Member] Lender Name [Axis] A/R Revolver, Inventory Facility and New Term Loan [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable Allowance for credit losses Trade accounts receivable, net Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right of use Other assets, net Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Line of credit – accounts receivable, related party Line of credit – inventory, related party Current portion of term debt, related party Term debt, related party Current portion of operating lease obligations Accounts payable Deferred revenue Accrued expenses Total current liabilities Long-term portion of operating lease obligations Long-term line of credit – inventory, related party Long-term debt, related party Asset retirement obligations Total long-term liabilities Stockholders’ equity: Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding Common stock, $.01 par value, 95,000,000 and 60,000,000 shares authorized; 70,103,279 and 49,627,254 shares issued and outstanding on December 31, 2024 and 2023, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity  Total liabilities and stockholders’ equity Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, outstanding Preferred stock, issued Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Operating expense: Cost of revenue Gross profit Research and development expense Selling, general and administrative expense Net income (loss) from operations Interest expense Net income (loss) before provision for income taxes Provision for income taxes Net income (loss) Net income (loss) per share-basic Weighted average number of basic common shares outstanding Net income (loss) per share-diluted Weighted average number of diluted common shares outstanding Beginning balance Beginning balance (in shares) Cumulative effect of accounting changes related to expected credit losses Issuances of shares and stock option exercises Issuances of shares and stock option exercises (in shares) Stock-based compensation Rights offering expense Net income Ending balance Ending balance (in shares) Statement of Cash Flows [Abstract] Operating activities: Net income (loss) Adjustments to reconcile net income (loss) to cash provided by (used) in operating activities: Depreciation and amortization Share-based compensation Changes in assets and liabilities related to operations: Trade accounts receivable, net Inventories, net Prepaid expenses and other assets Accounts payable Deferred revenue Accrued expenses Net changes in right-of-use assets and lease liabilities – operating Net cash provided by (used in) operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Payments to line of credit – accounts receivable, related party (Payments to) proceeds from line of credit - inventory, related party Payments to term loans, related party Proceeds from term loans, related party Proceeds from issuance of mezzanine preferred stock Proceeds from exercise of stock options Net cash provided by financing activities Decrease in cash Cash at beginning of period Cash at end of period Supplemental cash flow information: Cash paid for interest Supplemental non-cash investing and financing activity: Accounts payable incurred for the purchase of equipment and leasehold improvements Conversion of mezzanine preferred stock Right-of-use asset obtained in exchange for a lease liability Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration No Insider Trading [Flag] Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] Risk Assessment and Strategy Management Oversight Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] Related Party Notes and Lines of Credit Inventory Disclosure [Abstract] Inventories, net Property, Plant and Equipment [Abstract] Equipment and Leasehold Improvements Commitments and Contingencies Disclosure [Abstract] Lease Commitments Payables and Accruals [Abstract] Accrued Expenses Income Tax Disclosure [Abstract] Income Taxes Equity [Abstract] Capital Stock Share-Based Payment Arrangement [Abstract] Stock Options and Stock Grants Retirement Benefits [Abstract] 401(k) Profit-Sharing Plan Risks and Uncertainties [Abstract] Significant Customers Segment Reporting [Abstract] Business Segmentation and Geographical Distribution Subsequent Events [Abstract] Subsequent Event Use of Estimates and Risks and Uncertainties Cash Trade Accounts Receivable, Net Inventories, Net Equipment and Leasehold Improvements Long Lived Assets Deferred Revenue Financial Instruments Product Revenue Other Revenue Research and Development Expenses Income Taxes Earnings Per Share Recently Adopted Pronouncements Recently Issued Pronouncements We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows Notes and lines of credit consist of the following Related party interest expense consists of the following Inventories consist of the following Equipment and leasehold improvements consist of the following Quantitative information regarding the Company’s leases is as follows: Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: The future maturities of the Company’s operating leases as of December 31, 2024 are as follows: Accrued expenses consist of the following: A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following: We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: Additional disclosures for options granted for all years presented: The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 Revenues from these three customers, as a percentage of total Company revenue, was approximately: Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: The revenues for 2024 and 2023 by category are as follows: Balance, beginning Current period provisions Write offs Balance, ending Accounts receivable, net Contract liabilities Numerator: (in Thousands) Denominator: Weighted average additional shares assuming conversion of in-the-money stock options to common shares Weighted average number of diluted common shares outstanding Basic earnings per common share: Net income (loss) per share – basic Diluted earnings per common share: Net income (loss) per share – diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Equipment leasehold improvements and leased assets useful life Deferred revenue Percentage of Prepayments Volume rebate Revenue recognized in the reporting period included in contract liability balance at beginning of period Revenue Potential common stock included in computation of diluted earnings per share Anti-dilutive pptions excluded from computation of earnings per share Line of Credit Facility [Table] Line of Credit Facility [Line Items] Related Party Transaction, Rate Line of Credit Facility, Current Borrowing Capacity Long-Term Line of Credit Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Description of Variable Rate Basis Debt Instrument, Basis Spread on Variable Rate Line of Credit Facility, Expiration Date Line of Credit Percentage of Eligible inventory Interest expense Accrued interest expense Related Party Transaction, Amounts of Transaction Raw materials Finished goods Inventory reserve       Total Inventories, net Property plant and equipment,gross Less: Accumulated depreciation and amortization Property, Plant and Equipment, Net, Total Depreciation expense Components of lease cost Operating lease cost components: Operating lease cost Variable lease cost Short-term lease cost Sub-lease income  Total operating lease costs Total lease cost Operating cash outflow from operating leases Lease liabilities arising from obtaining right-of-use assets Weighted-average remaining lease term-operating leases (in years) Weighted-average discount rate-operating leases 2025 2026 2027 2028 2029 Thereafter Total payments Less amounts representing interest Total minimum payments required Accrued payroll and related expenses Accrued accounts payable Other  Total Income tax credit at statutory rates Under accrual of income taxes Nondeductible expenses Record tax credits Permanent tax deduction stock options exercised State income tax, net of federal benefits Expiration of net operating losses and credits Effect of change in deferred tax rate Expiration of stock options Other Change in valuation allowance   Deferred tax liabilities: Excess tax depreciation ASC 842 operating lease asset Total deferred tax liabilities Deferred tax assets: Net operating loss carryforwards 179 Carryforwards 163(j) Business interest limitation carryforwards Inventory and other allowances Excess book amortization 174 research and experimental expenditures Share-based compensation Tax credits ASC 842 operating lease liability Other accrued costs Total deferred tax assets Less:  valuation allowance Deferred income taxes Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Income tax provision Increase (decrease) in valuation allowance Valuation allowance, net operating loss carryforwards and credits Net operating loss carryforwards Operating loss carryforwards expiration period start Operating loss carryforwards expiration period end Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock, shares authorized Number of shares issued Price per share Consideration from sale of shares Common stock, authorized for conversion of preferred stock Convertible Preferred Stock, Shares Issued upon Conversion Conversion price Interest rate Liquidation preference Shares converted Shares issued upon conversion Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based compensation expense Remaining unrecognized compensation expense Remaining weighted average-period, expense recognition (years) Weighted-average risk-free interest rates Dividend yield Weighted-average expected life (years) of the option Weighted-average expected stock price volatility Weighted-average fair value of the options granted Vesting period (years) of shares granted in period Contractual life (years) of shares granted in period Estimated forfeitures Shares Outstanding, Beginning Shares Outstanding, Beginning, (per share) Weighted Average Remaining Contractual Term, Outstanding, end Shares Outstanding, Beginning (Intrinsic value) Granted Granted (per share) Exercised Exercised (per share) Forfeited or expired Forfeited or expired (per share) Shares Outstanding, Ending Shares Outstanding, Ending, (per share) Shares Outstanding, Ending (Intrinsic value) Shares Exercisable Shares Exercisable, (per share) Shares Exercisable (years) Shares Exercisable (Intrinsic value) Shares available for grant Closing stock share price Shares exercised Total intrinsic value Cash received Expiration period Defined contribution plan, cost Concentration Risk [Table] Concentration Risk [Line Items] Revenue from customers Total Supply Commitment [Table] Supply Commitment [Line Items] Equipment sale - net book value Equipment sale- original book value Interim Period, Costs Not Allocable [Table] Interim Period, Costs Not Allocable [Line Items] Total Expense Segment Reporting, Revenue from External Customer, Product and Service [Table] Revenue from External Customer [Line Items] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues Subsequent Event [Table] Subsequent Event [Line Items] Expiration date The element represents advanced materials member. The element represents customer one member. The element represents customer three member. The element represents customer two member. The element represents equipment sale original book value of equipment and upgrades. The element represents personal care ingredients member. The element represents line of credit percentage of eligible inventory. The element represents equipment sale net book value equipment. The element represents business loan agreement member. The element represents beachcorp l l c member. The element represents libertyville bank and trust member. The element represents libertyville bank and trust one member. Beachcorp, LLC One. The element represents strandler l l c member. Inventory Facility. Bridge Note. The element represents percentage of prepayments. The element represents other revenue policy text block. The element represents recently issued pronouncements policies text block. The element represents operating lease cost components abstract. The element represents summary of supplemental cash flow information related to leases table text block. The element represents nondeductible expenses. The element represents overunder accrual of income taxes. The element represents operating loss carryforwards expiration year start. The element represents operating loss carryforwards expiration year end. The element represents additional disclosures for options granted table text block. The element represents share based compensation arrangement by share based payment award award contractual life. The element represents share based compensation arrangement by share based payment award fair value assumptions fortfeiture rate. The element represents stock options recognized table text block. The element represents contract with customer account receivables table text block. The element represents expiration of nol credits. The element represents strandler l l c one member. The element represents term loan member. Replacement Promissory Note [Member] Series X Preferred Stock [Member] If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at specified rate per annum. The maximum number of common shares permitted to be issued by an entity's charter and bylaws for conversion of preferred stock. Volume rebates recognized as a reduction in revenue. Customers One Through Three [Member] Total operating lease costs. The element represents lines of credit inventory current. The element represents tax credits. The element represents consumer products member. The element represents asc842 operating lease asset. The element represents asc842 operating lease liability. The element represents employee costs member. The element represents contractors and professional services member. The element represents materials and supplies member. The element represents depreciation member. The element represents tax expense member. The element represents facilities member. The element represents shipping member. The element represents testing member. The element represents i t services member. The element represents insurance member. The element represents manufacturing other expense member. The element represents selling general and administrative other expense member. The element represents prepayments from certain customers per company policy member. The element represents prepayments from product development agreement with a personal care ingredient customer member. Indicates no disclosure of Rule 10b5-1 plan. Expiring 2025 to 2037. Carrying amount of accrued accounts payable. Prior to 2019 Plan. 2019 Plan. 2010 Plan. A/R Revolver, Inventory Facility and New Term Loan. Accounts Receivable, Allowance for Credit Loss, Current Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Deferred Revenue Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Long-Term Lines of Credit Repayments of Other Long-Term Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Inventory Disclosure [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Accounts Receivable, Allowance for Credit Loss, Writeoff Deferred Income Interest Expense, Operating and Nonoperating Inventory Valuation Reserves Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Sublease Income Lease Costs Operating Lease, Cost Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Effective Income Tax Rate Reconciliation, Tax Credit, Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred Tax Liabilities, Property, Plant and Equipment Asc842 Operating Lease Asset Deferred Tax Liabilities, Gross Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Operating Loss Carryforwards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price EX-101.PRE 12 nanx-20241231_pre.xml XBRL PRESENTATION FILE GRAPHIC 13 ex19001.jpg GRAPHIC begin 644 ex19001.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 28, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 000-22333    
Entity Registrant Name NANOPHASE TECHNOLOGIES CORPORATION    
Entity Central Index Key 0000883107    
Entity Tax Identification Number 36-3687863    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1319 Marquette Drive    
Entity Address, City or Town Romeoville    
Entity Address, State or Province IL    
Entity Address, Postal Zip Code 60446    
City Area Code (630)    
Local Phone Number 771-6708    
Title of 12(b) Security Common Stock, par value $.01 per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 27,254,231
Entity Common Stock, Shares Outstanding   70,103,279  
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 49    
Auditor Name RSM US LLP    
Auditor Location Milwaukee, Wisconsin    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 1,409 $ 1,722
Trade accounts receivable 5,655 3,692
Allowance for credit losses (786) (225)
Trade accounts receivable, net 4,869 3,467
Inventories, net 20,267 10,031
Prepaid expenses and other current assets 2,803 1,082
Total current assets 29,348 16,302
Equipment and leasehold improvements, net 12,734 8,668
Operating leases, right of use 7,917 7,907
Other assets, net 3 4
Total assets 50,002 32,881
Current liabilities:    
Line of credit – accounts receivable, related party 2,810
Line of credit – inventory, related party 4,000
Current portion of term debt, related party 2,000
Term debt, related party 1,000
Current portion of operating lease obligations 1,260 1,297
Accounts payable 9,093 6,260
Deferred revenue 5,571 2,353
Accrued expenses 4,849 869
Total current liabilities 25,773 15,589
Long-term portion of operating lease obligations 9,037 9,152
Long-term line of credit – inventory, related party 5,000
Long-term debt, related party 1,000
Asset retirement obligations 246 238
Total long-term liabilities 9,283 15,390
Stockholders’ equity:    
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding
Common stock, $.01 par value, 95,000,000 and 60,000,000 shares authorized; 70,103,279 and 49,627,254 shares issued and outstanding on December 31, 2024 and 2023, respectively 700 496
Additional paid-in capital 114,674 106,069
Accumulated deficit (100,428) (104,663)
Total stockholders’ equity 14,946 1,902
 Total liabilities and stockholders’ equity $ 50,002 $ 32,881
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized 24,088 24,088
Preferred stock, outstanding 0 0
Preferred stock, issued 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized 95,000,000 60,000,000
Common stock, issued 70,103,279 49,627,254
Common stock, outstanding 70,103,279 49,627,254
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue:    
Total revenue $ 52,347 $ 37,297
Operating expense:    
Cost of revenue 36,159 29,472
Gross profit 16,188 7,825
Research and development expense 3,837 3,837
Selling, general and administrative expense 7,219 7,534
Net income (loss) from operations 5,132 (3,546)
Interest expense 670 838
Net income (loss) before provision for income taxes 4,462 (4,384)
Provision for income taxes 227 6
Net income (loss) $ 4,235 $ (4,390)
Net income (loss) per share-basic $ 0.07 $ (0.09)
Weighted average number of basic common shares outstanding 62,350,459 49,556,305
Net income (loss) per share-diluted $ 0.07 $ (0.09)
Weighted average number of diluted common shares outstanding 65,028,815 49,556,305
Product [Member]    
Revenue:    
Total revenue $ 51,890 $ 36,641
Product and Service, Other [Member]    
Revenue:    
Total revenue $ 457 $ 656
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance at Dec. 31, 2022 $ 493 $ 105,226 $ (100,070) $ 5,649
Beginning balance (in shares) at Dec. 31, 2022 49,320,680      
Cumulative effect of accounting changes related to expected credit losses (203) (203)
Issuances of shares and stock option exercises $ 3 151 154
Issuances of shares and stock option exercises (in shares)   306,574      
Stock-based compensation 773 773
Rights offering expense (81) (81)
Net income (4,390) (4,390)
Ending balance at Dec. 31, 2023 $ 496 106,069 (104,663) 1,902
Ending balance (in shares) at Dec. 31, 2023 49,627,254      
Issuances of shares and stock option exercises $ 204 7,880 8,084
Issuances of shares and stock option exercises (in shares)   20,476,025      
Stock-based compensation 725 725
Net income 4,235 4,235
Ending balance at Dec. 31, 2024 $ 700 $ 114,674 $ (100,428) $ 14,946
Ending balance (in shares) at Dec. 31, 2024 70,103,279      
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating activities:    
Net income (loss) $ 4,235 $ (4,390)
Adjustments to reconcile net income (loss) to cash provided by (used) in operating activities:    
Depreciation and amortization 928 742
Share-based compensation 725 773
Changes in assets and liabilities related to operations:    
Trade accounts receivable, net (1,402) 1,064
Inventories, net (10,236) (1,192)
Prepaid expenses and other assets (1,721) (216)
Accounts payable 2,399 (503)
Deferred revenue 3,218 165
Accrued expenses 3,988 (146)
Net changes in right-of-use assets and lease liabilities – operating (163) 1,697
Net cash provided by (used in) operating activities 1,971 (2,006)
Investing activities:    
Acquisition of equipment and leasehold improvements (4,558) (1,051)
Net cash used in investing activities (4,558) (1,051)
Financing activities:    
Payments to line of credit – accounts receivable, related party (2,810) (1,472)
(Payments to) proceeds from line of credit - inventory, related party (1,000) 2,000
Payments to term loans, related party (2,000) (1,346)
Proceeds from term loans, related party 3,338
Proceeds from issuance of mezzanine preferred stock 6,000
Proceeds from exercise of stock options 2,084 73
Net cash provided by financing activities 2,274 2,593
Decrease in cash (313) (464)
Cash at beginning of period 1,722 2,186
Cash at end of period 1,409 1,722
Supplemental cash flow information:    
Cash paid for interest 637 752
Supplemental non-cash investing and financing activity:    
Accounts payable incurred for the purchase of equipment and leasehold improvements 434 400
Conversion of mezzanine preferred stock 6,000
Right-of-use asset obtained in exchange for a lease liability $ 1,019 $ 182
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure [Table]    
Net Income (Loss) $ 4,235 $ (4,390)
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 12 Months Ended
Dec. 31, 2024
Insider Trading Arrangements [Line Items]  
No Insider Trading [Flag] true
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

Risk Assessment and Strategy

 

The Company regularly evaluates cybersecurity risk from computer viruses and more sophisticated and targeted cyber-related attacks such as ransomware, as well as cybersecurity failures resulting from human error and technological errors.

 

Our overall strategy in combatting known cybersecurity risks includes a variety of individual tactics, including:

 

●The use of antivirus software, virtual private networks, email security, as well as other software to prevent and detect data intrusions.
●The deployment of updates and patches as they are available and maintaining the current versions of major software to reduce the exposure to vulnerabilities.
●If necessary, the use of third-party security experts if and when an incident is detected.

 

We are not aware of having experienced any material cybersecurity incidents in 2024. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions.

 
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] We are not aware of having experienced any material cybersecurity incidents in 2024. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions.
Cybersecurity Risk Board of Directors Oversight [Text Block]

Management Oversight

 

Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management, which then reports to the Board of Directors.

 

Board Oversight

 

The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks.

 
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks.
Cybersecurity Risk Role of Management [Text Block] Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management, which then reports to the Board of Directors.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Risk Assessment and Strategy
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
Risk Assessment and Strategy

Risk Assessment and Strategy

 

The Company regularly evaluates cybersecurity risk from computer viruses and more sophisticated and targeted cyber-related attacks such as ransomware, as well as cybersecurity failures resulting from human error and technological errors.

 

Our overall strategy in combatting known cybersecurity risks includes a variety of individual tactics, including:

 

●The use of antivirus software, virtual private networks, email security, as well as other software to prevent and detect data intrusions.
●The deployment of updates and patches as they are available and maintaining the current versions of major software to reduce the exposure to vulnerabilities.
●If necessary, the use of third-party security experts if and when an incident is detected.

 

We are not aware of having experienced any material cybersecurity incidents in 2024. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions.

 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Management Oversight
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
Management Oversight

Management Oversight

 

Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management, which then reports to the Board of Directors.

 

Board Oversight

 

The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks.

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Description of Business
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

 

(1) Description of Business

 

Nanophase Technologies Corporation, now known as Solesence, Inc. (“Solésence,” “Company,” “we,” “our,” or “us”), is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence consumer products subsidiary”), is focused in various skin health- and beauty-markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our consumer products line.  Additionally, we continue to sell products in legacy markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives, all of which fall into the advanced materials product category. 

 

 We target markets, primarily related to skin health products and ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our Solésence® products to cosmetics and skin care brands, and our other materials to various end-use applications manufacturers.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Original Active Stress Defense ™ Technology — which has become the cornerstone of our new product development in consumer products line, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our consumer products line, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. 

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

The Company recorded a net profit and positive cash flow from operations in 2024.  In addition, the company reduced outstanding debt. While the Company’s debt currently matures in the next year, management has a commitment from its related party debt holder that the debt will be refinanced with a maturity date after April 1, 2026. Management believes that current liquidity and expected borrowing capacity are sufficient to fund operations and substantial doubt is not raised regarding the Company's ability to continue as a going concern.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

 

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.

 

Cash

 

The Cash balance on December 31, 2024 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Solésence is to be the party initiating any transfers, whether to Solésence or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Solésence to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Solésence.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.

 

 Trade Accounts Receivable, Net

 

Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

    2024   2023
Balance, beginning   $ 225   $ 139
Current period provisions     564     95
Write offs     (3)     (9)
Balance, ending   $ 786   $ 225

 

 

Inventories, Net

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.

 

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.

 

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.

 

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $5,571 in deferred revenue reported in 2024, 99% related to prepayments received from certain customers per Company policy, and the remaining 1% related to prepayments from a product development agreement with a personal care ingredient customer.

 

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

 

Our financial instruments include cash, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on December 31, 2024 and 2023.

 

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2024 one customer earned a volume rebate of $35,000. In 2023 no volume rebates were recorded because the customers did not meet required volumes.

 

As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer. Revenue is recognized when the goods are shipped

 

The Company will for some customers arrange for the shipping of the finished goods. Revenues and costs associated with the shipment of the finished goods are recorded separately within product revenue and cost of revenue, respectively, on the consolidation statement of operations. With regard to revenue recognition, shipping activities that occur prior to the customers’ obtaining control of the goods are not a promised service to the customer, but rather activities to fulfill the Company’s promise to transfer the goods. As such, these activities are not deemed a performance obligation requiring allocation of the transaction price. Similarly, shipping activities that occur after the customers’ obtaining control of the goods are, as a matter of policy, also not a promised service to the customer, but rather an activity to fulfill the Company’s promise to transfer the good.

 

Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:

 

    Accounts Receivable   Contract Liabilities 
2022   $4,734    2,188 
2023    3,467    2,353 
2024    4,869    5,571 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $2,074 and $2,084 for the years ended December 31, 2024, and 2023, respectively.

 

 

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $457 and $656 for the years ended December 31, 2024 and 2023, respectively.

 

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.

 

Income Taxes

 

We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2024, and 2023, we had no liability for unrecognized tax benefits.

 

Earnings Per Share

 

Included in the computation of diluted earnings per share for the year ended December 31, 2024, was a total of 2,678,000 in potential shares of common stock. Options to purchase approximately 889,000 shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period. 

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2024   2023 
Numerator: (in Thousands)          
Net income (loss)  $4,235   $(4,390)
           
Denominator:          
Weighted average number of basic common shares outstanding   62,350,459    49,556,305 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,678,356    — 
Weighted average number of diluted common shares outstanding   65,028,815    49,556,305 
           
Basic earnings per common share:          
Net income (loss) per share – basic  $0.07   $(0.09)
Diluted earnings per common share:          
Net income (loss) per share – diluted  $0.07   $(0.09)

 

Recently Adopted Pronouncements

 

In November 2023 the FASB issued ASU 2023-07 “Improvements to Reportable Segment Disclosures”, which the Company adopted in 2024. The amendments in this Update improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses.

 

Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the Chief Operating Decision Maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this Update do not change or remove those disclosure requirements.

 

The amendments in this Update also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments.

 

This Update did not have a significant impact on the Company.

 

 Recently Issued Pronouncements

 

 On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. This new requirement will be effective for Solésence for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Related Party Notes and Lines of Credit
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Related Party Notes and Lines of Credit

 

(3) Related Party Notes and Lines of Credit

 

Notes and lines of credit consist of the following:

 

       As of December 31, 
       2024   2023 
   Rate   Available  

Outstanding

Balance

   Available  

Outstanding

Balance

 
Libertyville Bank & Trust (1)  8.50%   $30   $—   $30   $— 
Libertyville Bank & Trust (2)  8.50%    500    —    500    — 
Beachcorp, LLC (3)   8.25%    5,604    —    3,298    2,810 
Beachcorp, LLC (4)   8.25%    5,200    4,000    5,200    5,000 
Strandler, LLC   (5)   8.25%    1,000    1,000    1,000    1,000 
Strandler, LLC  (6)  9.25%    —    —    2,000    2,000 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet.

 

2)On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to October 1, 2025.

 

4)On January 28, 2022, the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it was set to matured on March 31, 2024. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to October 1, 2025.

 

 

5)On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to October 1, 2025.

 

6)On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $2,000. The interest rate for the Bridge Note was at the prime rate plus 0.75%, and it was to mature on May 13, 2024. The Bridge Note was repaid in February 2024.

 

The Company classifies the line of credit – accounts receivable as current because we are required to pay back the borrowings as cash is received from our customers. The company’s remaining debt is presented within the Consolidated Balance Sheet as of December 31, 2024, and 2023 in accordance with the maturity dates in the financing agreements.

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust. The Company’s loan agreements with Strandler, LLC and Beachcorp, LLC currently are set to expire on October 1, 2025, which could become an operating risk if we are not able to refinance or extend the maturity dates.

 

Related party interest expense consists of the following:

 

   Twelve Months Ended December 31, 
   2024   2023 
Interest expense, related parties  $656   $770 

 

Accrued interest consists of the following:

 

   As of December 31, 
   2024   2023 
Accrued interest expense, related parties  $36   $81 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2024   2023 
Beachcorp, LLC  $4,000   $7,810 
Strandler, LLC   1,000    3,000 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories, net
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories, net

 

(4) Inventories, net

 

Inventories consist of the following:

 

             
   As of December 31, 
   2024   2023 
Raw materials  $17,396   $8,524 
Finished goods   4,858    2,184 
Inventory reserve   (1,987)   (677)
      Total Inventories, net  $20,267   $10,031 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Equipment and Leasehold Improvements
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Equipment and Leasehold Improvements

 

(5)

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements consist of the following: 

 

   As of December 31, 
   2024   2023 
Machinery and equipment  $23,551   $23,339 
Office equipment   1,014    1,014 
Office furniture   126    126 
Leasehold improvements   5,153    5,157 
Construction in progress   5,706    931 
    35,550    30,567 
Less: Accumulated depreciation and amortization   (22,816)   (21,899)
   $12,734   $8,668 

 

Depreciation expense was $918 and $732, for the years ended December 31, 2024 and 2023, respectively.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Lease Commitments
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Lease Commitments

(6) Lease Commitments

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. The Company has one sublease of currently unused floorspace that is month-to-month.

 

The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

On September 1st of 2024 the facility located at 1319 Marquette Drive in Romeoville was extended through January 31, 2028. Additionally, on that same day, the facility located at 453 Commerce St in Burr Ridge was extended for one year. The present value of future lease payments associated with these extensions resulted in the addition of a ROU asset and lease liability totaling $1,019.

 

The office leases contain variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease and non-lease components for building leases.

 

Quantitative information regarding the Company’s leases is as follows:

 

         
   Twelve Months Ended December 31, 2024   Twelve Months Ended December 31, 2023 
Components of lease cost          
Operating lease cost components:          
Operating lease cost   1,944    1,881 
Variable lease cost   684    581 
Short-term lease cost   334    112 
Sub-lease income   (511)   (786)
 Total operating lease costs   2,451    1,788 
Total lease cost  $2,451   $1,788 

 

 

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $2,115   $172 
           
Lease liabilities arising from obtaining right-of-use assets  $1,019   $182 
Weighted-average remaining lease term-operating leases (in years)   6.8    7.9 
Weighted-average discount rate-operating leases   7.6%   7.1%

 

The future maturities of the Company’s operating leases as of December 31, 2024 are as follows:

 

2025   $1,975 
2026    1,909 
2027    1,965 
2028    1,587 
2029    1,591 
Thereafter    4,021 
Total payments   $13,048 
Less amounts representing interest    (2,752)
Total minimum payments required   $10,296 

 

The Company subleases a portion of a leased industrial building that is used primarily for the storage of furniture, equipment and displays used for retail sales. The arrangement is not with a related party.

 

Payments received by the Company for this sublease are comprised of two components, which include base rent and Common Area Maintenance (CAM) charges. While the base rent is fixed, the CAM charges are indexed directly to the Master Lease and are expected to be adjusted periodically as actual costs are incurred. However, the executed sublease agreement specifically itemizes these costs with a provision that informs the sublessee that the CAM charges will be adjusted (up or down) based on actual amounts once this information becomes known. As such, the nature of the charges is more closely representative of a fixed payment (an “in-substance fixed” charge) with the adjustments occurring simply to “true up” the listed CAM charges once actual charges from the head lessor become known. As sublessor, the Company has elected the practical expedient to not separate lease and nonlease components in disclosing future undiscounted cashflows and treats the combined components as a single lease component.

 

As sublessor, the Company is subletting to one tenant on a month-to-month arrangement.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
Accrued Expenses

 

(7) Accrued Expenses

 

Accrued expenses consist of the following:

 

             
   As of December 31, 
   2024   2023 
Accrued payroll and related expenses  $1,824   $255 
Accrued accounts payable   1,597    128 
Other   1,428    486 
 Total  $4,849   $869 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes

 

(8)Income Taxes

 

Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $227. Our current federal and deferred tax expenses are zero.

 

A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:

 

   2024   2023 
Income tax credit at statutory rates  $937   $(921)
Under accrual of income taxes   (1)   (3)
Nondeductible expenses   5    23 
Record tax credits   (116)    (118)
Permanent tax deduction stock options exercised   (27)   (63)
State income tax, net of federal benefits   179    (165)
Expiration of net operating losses and credits   332    1,492 
Effect of change in deferred tax rate   49    45 
Expiration of stock options   46    60 
Other   (39)    — 
Change in valuation allowance   (1,138)   (344)
   $227   $ 6 

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

             
   As of December 31, 
   2024   2023 
Deferred tax liabilities:          
Excess tax depreciation  $(496)   (477)
ASC 842 operating lease asset   (1,938)   (1,975)
Total deferred tax liabilities   (2,434)   (2,452)
           
Deferred tax assets:          
Net operating loss carryforwards  $10,218   $12,020 
179 Carryforwards   —    245 
163(j) Business interest limitation carryforwards   —    302 
Inventory and other allowances   764    239 
Excess book amortization   60    60 
174 research and experimental expenditures   1,053    902 
Share-based compensation   788    530 
Tax credits   189    118 
ASC 842 operating lease liability   2,520    2,610 
Other accrued costs   293    13 
Total deferred tax assets   15,885    17,039 
           
Less:  valuation allowance   (13,451)   (14,587)
Deferred income taxes  $—   $— 

 

 

The valuation allowance decreased approximately $1.1 million and $0.3 million for the years ended December 31, 2024 and 2023, respectively (net of approximately $8.1 million and $7.1 million for the years ended December 31, 2024 and 2023, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2024, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.

 

We have federal net operating loss carryforwards for tax purposes of approximately $42 million on December 31, 2024. $36 million expire between 2025 and 2037. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $6.8 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $18.2 million on December 31, 2024. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Capital Stock
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Capital Stock

 

(9)

Capital Stock

 

As of December 31, 2024, and 2023, we had 24,088 authorized but unissued shares of preferred stock.

 

Pursuant to the Securities Purchase Agreement executed on March 1, 2024, the Company issued to Strandler 15,000 shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $400, for total consideration of $6,000,000, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”). Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock was outstanding, the Purchase Agreement also (i) prevented the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevented the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricted the Company’s ability to permit any lien or other encumbrance on Company assets.

 

At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from 60,000,000 to 95,000,000, each share of Series X Preferred Stock was convertible, at the option of the holder, into 1,000 shares of Common Stock at no additional cost. If the Company had not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock would have been redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $420 per share (each, a “Redemption”). If the Company failed to fully pay any Redemption within five days of receiving notice, all unpaid amounts would bear interest at a rate of 10% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock would have been redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $420 per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.

 

Holders of Series X Preferred Stock (i) were not entitled to receive dividends, subject to customary anti-dilution protections, (ii) had no voting rights, and (iii) would have received a liquidation preference of $400 per share. The Series X Preferred Stock ranked senior in right of payment to all securities designated as junior securities, including Common Stock.

 

ASC 815-15-25-17D provides guidance for assessing host contracts in the form of preferred shares, in which 25-17D(b) states that an investor’s ability to “convert a preferred share into a fixed number of common shares generally is viewed as an equity-like characteristic”. Because conversion of the Series X Preferred Shares were at the discretion of the Holder, conversion was in a fixed number of shares, dividends are not typically paid and cash settlement would only occur in the unlikely event of change in control, the host contract had the characteristics of, and was classified as, an equity instrument, and the embedded derivatives and host contract were considered clearly and closely related. As such, the embedded derivative did not require bifurcation and the Series X Preferred Shares were reported as mezzanine equity on the balance sheet during the period when these instruments were issued and outstanding.

 

Issuance costs associated with issuance of the Series X Preferred Stock were immaterial.

 

On June 18, 2024, the Company held a special meeting of stockholders where the Certificate Amendment was approved. The Certificate Amendment was filed with the State of Delaware on June 19, 2024. On June 20, 2024, Strandler converted its 15,000 shares of Series X Preferred Stock to 15,000,000 shares of Common Stock.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Stock Options and Stock Grants
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock Options and Stock Grants

 

(10) Stock Options and Stock Grants

 

We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 expire seven years from the date of grant. Future options to be granted under the 2019 Plan will expire seven years from the date of grant.

 

Employee Stock Options

 

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

             
  

Years ended

December 31,

 
   2024   2023 
Share-based compensation expense  $725   $773 
Remaining unrecognized compensation expense   1,057    1,118 
Remaining weighted average-period, expense recognition (years)   2.4    1.8 

 

We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of 10 years as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. 

 

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended December 31, 
   2024   2023 
Weighted-average risk-free interest rates:   4.3%   3.8%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   4    4 
           
Weighted-average expected stock price volatility:   91%   93%
           
Weighted-average fair value of the options granted:  $1.74   $0.50 

 

Additional disclosures for options granted for all years presented:

 

   Years Ended December 31, 
   2024   2023 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   8%   8%

 

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:

 

           Weighted     
       Weighted   Average   Aggregate 
       Average   Remaining   Intrinsic 
   Shares   Exercise Price   Contractual   Value 
Options  (Rounded)   per Share   Term (Years)   (000s) 
Outstanding on January 1, 2024   3,525,966   $1.22    4.2   $160 
                     
Granted   388,000   $2.40           
Exercised   (455,995)  $0.52           
Forfeited or expired   (246,232)  $1.13           
                     
Outstanding on December 31, 2024   3,211,739   $1.47    4.4   $3,961 
Exercisable on December 31, 2024   2,206,666   $1.46    3.6   $2,984 
                     
Shares available for grant   62,900                

 

The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 on the last business day for the year ended December 31, 2024.

 

             
  

Years ended

December 31,

 
   2024   2023 
Shares exercised   455,995    294,074 
Total intrinsic value  $370   $195 
Cash received  $239   $154 

 

Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2024 and 2023.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.25.1
401(k) Profit-Sharing Plan
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
401(k) Profit-Sharing Plan

 

(11) 401(k) Profit-Sharing Plan

 

We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. Contributions made in 2024 and 2023 aggregated to $206 and $191, respectively.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Customers
 12 Months Ended
Dec. 31, 2024
Risks and Uncertainties [Abstract]  
Significant Customers

 

(12) Significant Customers

 

We had three significant customers for the year ended December 31, 2024.

 

Revenues from these three customers, as a percentage of total Company revenue, was approximately:

 

       For the years ended 
       December 31, 
Customer #   Product Category  2024   2023 
1   Consumer Products   32%   17%
2   Personal Care Ingredients   13%   25%
3   Consumer Products   7%   15%
    Total   52%   57%


 

 Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:

 

       As of
December 31,		 
Customer #   Product Category  2024   2023 
1   Consumer Products  $2,366   $1,288 
2   Personal Care Ingredients   160    — 
3   Consumer Products   309    864 
    Total  $2,835   $2,152 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our second largest customer, that have contingencies outlined which could potentially result in the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event could result in the loss of some of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Business Segmentation and Geographical Distribution
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Business Segmentation and Geographical Distribution

 

(13) Business Segmentation and Geographical Distribution

 

The Company operates as a single business segment, in which the factors used to make this determination include differences in products, services, geographical areas, regulatory environment, and other such criteria considered for the appropriateness of aggregation. The types of products and services for which the sole reportable segment, which is the same as the Company as a whole, offered by the company is discussed in Note 1. Since the Company operates as a single segment, there were no intra-entity sales or transfers.

 

The role of Chief Operating Decision Maker for the Company is comprised of a committee that includes the Chief Executive and Chief Operating Officers. The Chief Operating Decision Maker assesses performance for the single segment and decides how to allocate resources based on net income that also is reported on the income statement as net income. The measure of segment assets is reported on the balance sheet as total assets. The accounting policies of the sole segment are the same as those described in the summary of significant accounting policies in Note 2.

 

The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:

 

             
   As of December 31, 
   2024   2023 
Total revenue  $52,347   $37,297 
           
Employee costs   12,933    10,811 
Contractors and professional services   7,815    6,588 
Materials and supplies   15,559    14,669 
Depreciation   928    742 
Interest expense   670    838 
Other income   (2)   (4)
Tax expense   318    101 
Facilities   3,413    2,870 
Shipping   1,193    760 
Testing   917    1,078 
IT services   1,091    1,060 
Insurance   785    721 
Manufacturing other expense   992    604 
Selling, general and administrative other expense   1,500    849 
Total Expense   48,112    41,687 
           
Net Income (loss)  $4,235   $(4,390)

 

Revenue from international sources approximated $1,825 and $2,918 for the years ended December 31, 2024 and 2023, respectively. As part of our revenue from international sources, we recognized approximately $366 and $1,664 in product revenue from German companies, in the aggregate, for the years ended December 31, 2024 and 2023, respectively.

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, personal care ingredients, advanced materials and consumer products. The revenues for 2024 and 2023 by category are as follows:

 

  

For the years ended

December 31

 
Product Category  2024   2023 
Consumer Products  $44,373   $25,211 
Personal Care Ingredients   6,827    9,277 
Advanced Materials   1,147    2,809 
Total Sales  $52,347   $37,297 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Event
 12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Event

 

(14) Subsequent Event

 

On March 7, 2025, the Company announced its rebranding as Solesence, Inc., marking a new chapter in its commitment to innovation, self-expression, and inclusivity in skin health. The company’s stock will continue to trade under the NANX ticker symbol. Its corporate website transitioned to solesence.com, historic Company financials and disclosures are now available at ir.solesence.com. Nanophase Technologies Corporation changed its legal name to Solesence, Inc. by amending its certificate of incorporation with the state of Delaware on March 10, 2025.

 

As of December 31, 2024, the Company’s A/R Revolver, Inventory Facility and New Term Loan mature on October 1, 2025. Since then, the Company’s related party debt holder for the A/R Revolver, Inventory Facility and New Term Loan has committed to refinancing the debt with a new maturity date after April 1, 2026.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Use of Estimates and Risks and Uncertainties

Use of Estimates and Risks and Uncertainties

 

The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.
Cash

Cash

 

The Cash balance on December 31, 2024 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Solésence is to be the party initiating any transfers, whether to Solésence or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Solésence to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Solésence.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.
Trade Accounts Receivable, Net

 Trade Accounts Receivable, Net

 

Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

    2024   2023
Balance, beginning   $ 225   $ 139
Current period provisions     564     95
Write offs     (3)     (9)
Balance, ending   $ 786   $ 225

 
Inventories, Net

Inventories, Net

 

Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.
Equipment and Leasehold Improvements

Equipment and Leasehold Improvements

 

Equipment is stated at cost and is being depreciated over its estimated useful life (3-20 years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (3-7 years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (7-10 years) using the straight-line method.
Long Lived Assets

Long Lived Assets

 

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.
Deferred Revenue

Deferred Revenue

 

The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $5,571 in deferred revenue reported in 2024, 99% related to prepayments received from certain customers per Company policy, and the remaining 1% related to prepayments from a product development agreement with a personal care ingredient customer.
Financial Instruments

Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

 

Our financial instruments include cash, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on December 31, 2024 and 2023.
Product Revenue

Product Revenue

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2024 one customer earned a volume rebate of $35,000. In 2023 no volume rebates were recorded because the customers did not meet required volumes.

 

As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer. Revenue is recognized when the goods are shipped

 

The Company will for some customers arrange for the shipping of the finished goods. Revenues and costs associated with the shipment of the finished goods are recorded separately within product revenue and cost of revenue, respectively, on the consolidation statement of operations. With regard to revenue recognition, shipping activities that occur prior to the customers’ obtaining control of the goods are not a promised service to the customer, but rather activities to fulfill the Company’s promise to transfer the goods. As such, these activities are not deemed a performance obligation requiring allocation of the transaction price. Similarly, shipping activities that occur after the customers’ obtaining control of the goods are, as a matter of policy, also not a promised service to the customer, but rather an activity to fulfill the Company’s promise to transfer the good.

 

Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:

 

    Accounts Receivable   Contract Liabilities 
2022   $4,734    2,188 
2023    3,467    2,353 
2024    4,869    5,571 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $2,074 and $2,084 for the years ended December 31, 2024, and 2023, respectively.
Other Revenue

Other Revenue

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $457 and $656 for the years ended December 31, 2024 and 2023, respectively.
Research and Development Expenses

Research and Development Expenses

 

Research and development expenses are recognized as expense when incurred.
Income Taxes

Income Taxes

 

We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2024, and 2023, we had no liability for unrecognized tax benefits.
Earnings Per Share

Earnings Per Share

 

Included in the computation of diluted earnings per share for the year ended December 31, 2024, was a total of 2,678,000 in potential shares of common stock. Options to purchase approximately 889,000 shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period. 

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2024   2023 
Numerator: (in Thousands)          
Net income (loss)  $4,235   $(4,390)
           
Denominator:          
Weighted average number of basic common shares outstanding   62,350,459    49,556,305 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,678,356    — 
Weighted average number of diluted common shares outstanding   65,028,815    49,556,305 
           
Basic earnings per common share:          
Net income (loss) per share – basic  $0.07   $(0.09)
Diluted earnings per common share:          
Net income (loss) per share – diluted  $0.07   $(0.09)
Recently Adopted Pronouncements

Recently Adopted Pronouncements

 

In November 2023 the FASB issued ASU 2023-07 “Improvements to Reportable Segment Disclosures”, which the Company adopted in 2024. The amendments in this Update improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses.

 

Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the Chief Operating Decision Maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this Update do not change or remove those disclosure requirements.

 

The amendments in this Update also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments.

 

This Update did not have a significant impact on the Company.
Recently Issued Pronouncements

 Recently Issued Pronouncements

 

 On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. This new requirement will be effective for Solésence for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment.

Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.

 

    2024   2023
Balance, beginning   $ 225   $ 139
Current period provisions     564     95
Write offs     (3)     (9)
Balance, ending   $ 786   $ 225
Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:

Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:

 

    Accounts Receivable   Contract Liabilities 
2022   $4,734    2,188 
2023    3,467    2,353 
2024    4,869    5,571 
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

 

             
   Years Ended December 31, 
   2024   2023 
Numerator: (in Thousands)          
Net income (loss)  $4,235   $(4,390)
           
Denominator:          
Weighted average number of basic common shares outstanding   62,350,459    49,556,305 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   2,678,356    — 
Weighted average number of diluted common shares outstanding   65,028,815    49,556,305 
           
Basic earnings per common share:          
Net income (loss) per share – basic  $0.07   $(0.09)
Diluted earnings per common share:          
Net income (loss) per share – diluted  $0.07   $(0.09)
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Related Party Notes and Lines of Credit (Tables)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Notes and lines of credit consist of the following

Notes and lines of credit consist of the following:

 

       As of December 31, 
       2024   2023 
   Rate   Available  

Outstanding

Balance

   Available  

Outstanding

Balance

 
Libertyville Bank & Trust (1)  8.50%   $30   $—   $30   $— 
Libertyville Bank & Trust (2)  8.50%    500    —    500    — 
Beachcorp, LLC (3)   8.25%    5,604    —    3,298    2,810 
Beachcorp, LLC (4)   8.25%    5,200    4,000    5,200    5,000 
Strandler, LLC   (5)   8.25%    1,000    1,000    1,000    1,000 
Strandler, LLC  (6)  9.25%    —    —    2,000    2,000 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet.

 

2)On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to October 1, 2025.

 

4)On January 28, 2022, the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it was set to matured on March 31, 2024. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to October 1, 2025.

 

 

5)On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to October 1, 2025.

 

6)On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $2,000. The interest rate for the Bridge Note was at the prime rate plus 0.75%, and it was to mature on May 13, 2024. The Bridge Note was repaid in February 2024.
Related party interest expense consists of the following

Related party interest expense consists of the following:

 

   Twelve Months Ended December 31, 
   2024   2023 
Interest expense, related parties  $656   $770 

 

Accrued interest consists of the following:

 

   As of December 31, 
   2024   2023 
Accrued interest expense, related parties  $36   $81 

 

Outstanding balances associated with related parties are as follows:

 

   As of December 31, 
   2024   2023 
Beachcorp, LLC  $4,000   $7,810 
Strandler, LLC   1,000    3,000 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories, net (Tables)
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories consist of the following

Inventories consist of the following:

 

             
   As of December 31, 
   2024   2023 
Raw materials  $17,396   $8,524 
Finished goods   4,858    2,184 
Inventory reserve   (1,987)   (677)
      Total Inventories, net  $20,267   $10,031 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Equipment and Leasehold Improvements (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Equipment and leasehold improvements consist of the following

Equipment and leasehold improvements consist of the following: 

 

   As of December 31, 
   2024   2023 
Machinery and equipment  $23,551   $23,339 
Office equipment   1,014    1,014 
Office furniture   126    126 
Leasehold improvements   5,153    5,157 
Construction in progress   5,706    931 
    35,550    30,567 
Less: Accumulated depreciation and amortization   (22,816)   (21,899)
   $12,734   $8,668 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Lease Commitments (Tables)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Quantitative information regarding the Company’s leases is as follows:

Quantitative information regarding the Company’s leases is as follows:

 

         
   Twelve Months Ended December 31, 2024   Twelve Months Ended December 31, 2023 
Components of lease cost          
Operating lease cost components:          
Operating lease cost   1,944    1,881 
Variable lease cost   684    581 
Short-term lease cost   334    112 
Sub-lease income   (511)   (786)
 Total operating lease costs   2,451    1,788 
Total lease cost  $2,451   $1,788 
Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:

Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $2,115   $172 
           
Lease liabilities arising from obtaining right-of-use assets  $1,019   $182 
Weighted-average remaining lease term-operating leases (in years)   6.8    7.9 
Weighted-average discount rate-operating leases   7.6%   7.1%
The future maturities of the Company’s operating leases as of December 31, 2024 are as follows:

The future maturities of the Company’s operating leases as of December 31, 2024 are as follows:

 

2025   $1,975 
2026    1,909 
2027    1,965 
2028    1,587 
2029    1,591 
Thereafter    4,021 
Total payments   $13,048 
Less amounts representing interest    (2,752)
Total minimum payments required   $10,296 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
Accrued expenses consist of the following:

Accrued expenses consist of the following:

 

             
   As of December 31, 
   2024   2023 
Accrued payroll and related expenses  $1,824   $255 
Accrued accounts payable   1,597    128 
Other   1,428    486 
 Total  $4,849   $869 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:

A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:

 

   2024   2023 
Income tax credit at statutory rates  $937   $(921)
Under accrual of income taxes   (1)   (3)
Nondeductible expenses   5    23 
Record tax credits   (116)    (118)
Permanent tax deduction stock options exercised   (27)   (63)
State income tax, net of federal benefits   179    (165)
Expiration of net operating losses and credits   332    1,492 
Effect of change in deferred tax rate   49    45 
Expiration of stock options   46    60 
Other   (39)    — 
Change in valuation allowance   (1,138)   (344)
   $227   $ 6 
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:

 

             
   As of December 31, 
   2024   2023 
Deferred tax liabilities:          
Excess tax depreciation  $(496)   (477)
ASC 842 operating lease asset   (1,938)   (1,975)
Total deferred tax liabilities   (2,434)   (2,452)
           
Deferred tax assets:          
Net operating loss carryforwards  $10,218   $12,020 
179 Carryforwards   —    245 
163(j) Business interest limitation carryforwards   —    302 
Inventory and other allowances   764    239 
Excess book amortization   60    60 
174 research and experimental expenditures   1,053    902 
Share-based compensation   788    530 
Tax credits   189    118 
ASC 842 operating lease liability   2,520    2,610 
Other accrued costs   293    13 
Total deferred tax assets   15,885    17,039 
           
Less:  valuation allowance   (13,451)   (14,587)
Deferred income taxes  $—   $— 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Stock Options and Stock Grants (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.

We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. 

 

             
  

Years ended

December 31,

 
   2024   2023 
Share-based compensation expense  $725   $773 
Remaining unrecognized compensation expense   1,057    1,118 
Remaining weighted average-period, expense recognition (years)   2.4    1.8 
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:

 

   Years Ended December 31, 
   2024   2023 
Weighted-average risk-free interest rates:   4.3%   3.8%
           
Dividend yield:   0%   0%
           
Weighted-average expected life (years) of the option:   4    4 
           
Weighted-average expected stock price volatility:   91%   93%
           
Weighted-average fair value of the options granted:  $1.74   $0.50 
Additional disclosures for options granted for all years presented:

Additional disclosures for options granted for all years presented:

 

   Years Ended December 31, 
   2024   2023 
Vesting period (years) of shares granted in period   3    3 
           
Contractual life (years) of shares granted in period   7    7 
           
Estimated forfeitures   8%   8%
The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:

The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:

 

           Weighted     
       Weighted   Average   Aggregate 
       Average   Remaining   Intrinsic 
   Shares   Exercise Price   Contractual   Value 
Options  (Rounded)   per Share   Term (Years)   (000s) 
Outstanding on January 1, 2024   3,525,966   $1.22    4.2   $160 
                     
Granted   388,000   $2.40           
Exercised   (455,995)  $0.52           
Forfeited or expired   (246,232)  $1.13           
                     
Outstanding on December 31, 2024   3,211,739   $1.47    4.4   $3,961 
Exercisable on December 31, 2024   2,206,666   $1.46    3.6   $2,984 
                     
Shares available for grant   62,900                
The aggregate intrinsic value in the table above is based on our closing stock price of $2.26

The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 on the last business day for the year ended December 31, 2024.

 

             
  

Years ended

December 31,

 
   2024   2023 
Shares exercised   455,995    294,074 
Total intrinsic value  $370   $195 
Cash received  $239   $154 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Customers (Tables)
 12 Months Ended
Dec. 31, 2024
Risks and Uncertainties [Abstract]  
Revenues from these three customers, as a percentage of total Company revenue, was approximately:

We had three significant customers for the year ended December 31, 2024.

 

Revenues from these three customers, as a percentage of total Company revenue, was approximately:

 

       For the years ended 
       December 31, 
Customer #   Product Category  2024   2023 
1   Consumer Products   32%   17%
2   Personal Care Ingredients   13%   25%
3   Consumer Products   7%   15%
    Total   52%   57%
Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:

 Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:

 

       As of
December 31,		 
Customer #   Product Category  2024   2023 
1   Consumer Products  $2,366   $1,288 
2   Personal Care Ingredients   160    — 
3   Consumer Products   309    864 
    Total  $2,835   $2,152 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Business Segmentation and Geographical Distribution (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:

The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:

 

             
   As of December 31, 
   2024   2023 
Total revenue  $52,347   $37,297 
           
Employee costs   12,933    10,811 
Contractors and professional services   7,815    6,588 
Materials and supplies   15,559    14,669 
Depreciation   928    742 
Interest expense   670    838 
Other income   (2)   (4)
Tax expense   318    101 
Facilities   3,413    2,870 
Shipping   1,193    760 
Testing   917    1,078 
IT services   1,091    1,060 
Insurance   785    721 
Manufacturing other expense   992    604 
Selling, general and administrative other expense   1,500    849 
Total Expense   48,112    41,687 
           
Net Income (loss)  $4,235   $(4,390)
The revenues for 2024 and 2023 by category are as follows:

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, personal care ingredients, advanced materials and consumer products. The revenues for 2024 and 2023 by category are as follows:

 

  

For the years ended

December 31

 
Product Category  2024   2023 
Consumer Products  $44,373   $25,211 
Personal Care Ingredients   6,827    9,277 
Advanced Materials   1,147    2,809 
Total Sales  $52,347   $37,297 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.25.1
We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Balance, beginning $ 225 $ 139
Current period provisions 564 95
Write offs (3) (9)
Balance, ending $ 786 $ 225
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]      
Accounts receivable, net $ 4,869 $ 3,467 $ 4,734
Contract liabilities $ 5,571 $ 2,353 $ 2,188
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Numerator: (in Thousands)    
Net income (loss) $ 4,235 $ (4,390)
Denominator:    
Weighted average number of basic common shares outstanding 62,350,459 49,556,305
Weighted average additional shares assuming conversion of in-the-money stock options to common shares 2,678,356
Weighted average number of diluted common shares outstanding 65,028,815 49,556,305
Basic earnings per common share:    
Net income (loss) per share – basic $ 0.07 $ (0.09)
Diluted earnings per common share:    
Net income (loss) per share – diluted $ 0.07 $ (0.09)
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Deferred revenue $ 5,571,000  
Volume rebate 35,000  
Revenue recognized in the reporting period included in contract liability balance at beginning of period 2,074,000 $ 2,084,000
Revenue $ 52,347,000 $ 37,297,000
Potential common stock included in computation of diluted earnings per share 2,678,000  
Anti-dilutive pptions excluded from computation of earnings per share   889,000
Transferred over Time [Member]    
Property, Plant and Equipment [Line Items]    
Revenue $ 457,000 $ 656,000
Prepayments From Certain Customers Per Company Policy [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of Prepayments 99.00%  
Prepayments From Product Development Agreement With A Personal Care Ingredient Customer [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of Prepayments 1.00%  
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 20 years  
Leasehold Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 3 years  
Leasehold Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 7 years  
Other Capitalized Property Plant and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 7 years  
Other Capitalized Property Plant and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Equipment leasehold improvements and leased assets useful life 10 years  
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Notes and lines of credit consist of the following (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended 36 Months Ended
Mar. 01, 2024
Nov. 13, 2023
Jan. 28, 2022
Jul. 31, 2014
Dec. 31, 2024
Dec. 31, 2024
Dec. 30, 2024
Dec. 31, 2023
Jan. 26, 2022
Letter of Credit [Member]                  
Line of Credit Facility [Line Items]                  
Debt Instrument, Description of Variable Rate Basis       prime rate   prime rate      
Debt Instrument, Basis Spread on Variable Rate       1.00%   1.00%      
Libertyville Bank and Trust [Member]                  
Line of Credit Facility [Line Items]                  
Related Party Transaction, Rate [1]         8.50%        
Line of Credit Facility, Current Borrowing Capacity [1]         $ 30 $ 30   $ 30  
Long-Term Line of Credit [1]            
Libertyville Bank and Trust One [Member]                  
Line of Credit Facility [Line Items]                  
Related Party Transaction, Rate [2]         8.50%        
Line of Credit Facility, Current Borrowing Capacity [2]         $ 500 500   500  
Long-Term Line of Credit [2]            
Beachcorp, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Related Party Transaction, Rate [3]         8.25%        
Line of Credit Facility, Current Borrowing Capacity [3]         $ 5,604 5,604   3,298  
Long-Term Line of Credit [3]           2,810  
Beachcorp, LLC One [Member]                  
Line of Credit Facility [Line Items]                  
Related Party Transaction, Rate [4]         8.25%        
Line of Credit Facility, Current Borrowing Capacity [4]         $ 5,200 5,200   5,200  
Long-Term Line of Credit [4]             $ 4,000 5,000  
Strandler, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Related Party Transaction, Rate [5]         8.25%        
Line of Credit Facility, Current Borrowing Capacity [5]         $ 1,000 1,000   1,000  
Long-Term Line of Credit [5]         $ 1,000 1,000   1,000  
Strandler LLC One [Member]                  
Line of Credit Facility [Line Items]                  
Related Party Transaction, Rate [6]         9.25%        
Line of Credit Facility, Current Borrowing Capacity [6]         $ 0 0   2,000  
Long-Term Line of Credit [6]         $ 0 $ 0   $ 2,000  
Letter of Credit [Member]                  
Line of Credit Facility [Line Items]                  
Line of Credit Facility, Maximum Borrowing Capacity       $ 30          
Revolving Credit Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Line of Credit Facility, Maximum Borrowing Capacity     $ 8,000           $ 6,000
Debt Instrument, Description of Variable Rate Basis   prime rate prime rate            
Debt Instrument, Basis Spread on Variable Rate     0.75%            
Line of Credit Facility, Expiration Date Oct. 01, 2025   Mar. 31, 2024            
Inventory Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Line of Credit Facility, Maximum Borrowing Capacity     $ 4,000            
Debt Instrument, Description of Variable Rate Basis     prime rate            
Debt Instrument, Basis Spread on Variable Rate     0.75%            
Line of Credit Facility, Expiration Date     Mar. 31, 2024            
Line of Credit Percentage of Eligible inventory     50.00%            
Replacement Promissory Note [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Line of Credit Facility, Maximum Borrowing Capacity   $ 5,200              
Debt Instrument, Basis Spread on Variable Rate   0.75%              
Line of Credit Facility, Expiration Date Oct. 01, 2025                
Line of Credit Percentage of Eligible inventory   55.00%              
Term Loan [Member] | Strandler, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Debt Instrument, Description of Variable Rate Basis     prime rate            
Debt Instrument, Basis Spread on Variable Rate     0.75%            
Line of Credit Facility, Expiration Date Oct. 01, 2025                
Bridge Note [Member] | Strandler, LLC [Member]                  
Line of Credit Facility [Line Items]                  
Line of Credit Facility, Maximum Borrowing Capacity   $ 2,000              
Debt Instrument, Description of Variable Rate Basis   prime rate              
Debt Instrument, Basis Spread on Variable Rate   0.75%              
Line of Credit Facility, Expiration Date   May 13, 2024              
[1] Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet.
[2] On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.
[3] On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to October 1, 2025.
[4] On January 28, 2022, the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it was set to matured on March 31, 2024. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to October 1, 2025.
[5] On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to October 1, 2025.
[6] On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $2,000. The interest rate for the Bridge Note was at the prime rate plus 0.75%, and it was to mature on May 13, 2024. The Bridge Note was repaid in February 2024.
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Related party interest expense consists of the following (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Beachcorp, LLC [Member]    
Line of Credit Facility [Line Items]    
Related Party Transaction, Amounts of Transaction $ 4,000 $ 7,810
Strandler, LLC [Member]    
Line of Credit Facility [Line Items]    
Related Party Transaction, Amounts of Transaction 1,000 3,000
Related Party [Member]    
Line of Credit Facility [Line Items]    
Interest expense 656 770
Accrued interest expense $ 36 $ 81
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories consist of the following (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 17,396 $ 8,524
Finished goods 4,858 2,184
Inventory reserve (1,987) (677)
      Total Inventories, net $ 20,267 $ 10,031
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Equipment and leasehold improvements consist of the following (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross $ 35,550 $ 30,567
Less: Accumulated depreciation and amortization (22,816) (21,899)
Property, Plant and Equipment, Net, Total 12,734 8,668
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 23,551 23,339
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 1,014 1,014
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 126 126
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross 5,153 5,157
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment,gross $ 5,706 $ 931
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Equipment and Leasehold Improvements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 918 $ 732
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Quantitative information regarding the Company’s leases is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating lease cost components:    
Operating lease cost $ 1,944 $ 1,881
Variable lease cost 684 581
Short-term lease cost 334 112
Sub-lease income (511) (786)
 Total operating lease costs 2,451 1,788
Total lease cost $ 2,451 $ 1,788
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Operating cash outflow from operating leases $ 2,115 $ 172
Lease liabilities arising from obtaining right-of-use assets $ 1,019 $ 182
Weighted-average remaining lease term-operating leases (in years) 6 years 9 months 18 days 7 years 10 months 24 days
Weighted-average discount rate-operating leases 7.60% 7.10%
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.25.1
The future maturities of the Company’s operating leases as of December 31, 2024 are as follows: (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2025 $ 1,975
2026 1,909
2027 1,965
2028 1,587
2029 1,591
Thereafter 4,021
Total payments 13,048
Less amounts representing interest (2,752)
Total minimum payments required $ 10,296
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Lease Commitments (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Lease liabilities arising from obtaining right-of-use assets $ 1,019 $ 182
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued expenses consist of the following: (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued payroll and related expenses $ 1,824 $ 255
Accrued accounts payable 1,597 128
Other 1,428 486
 Total $ 4,849 $ 869
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.25.1
A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Income tax credit at statutory rates $ 937 $ (921)
Under accrual of income taxes (1) (3)
Nondeductible expenses 5 23
Record tax credits (116) (118)
Permanent tax deduction stock options exercised (27) (63)
State income tax, net of federal benefits 179 (165)
Expiration of net operating losses and credits 332 1,492
Effect of change in deferred tax rate 49 45
Expiration of stock options 46 60
Other (39)
Change in valuation allowance (1,138) (344)
  $ 227 $ 6
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax liabilities:    
Excess tax depreciation $ (496) $ (477)
ASC 842 operating lease asset (1,938) (1,975)
Total deferred tax liabilities (2,434) (2,452)
Deferred tax assets:    
Net operating loss carryforwards 10,218 12,020
179 Carryforwards 245
163(j) Business interest limitation carryforwards 302
Inventory and other allowances 764 239
Excess book amortization 60 60
174 research and experimental expenditures 1,053 902
Share-based compensation 788 530
Tax credits 189 118
ASC 842 operating lease liability 2,520 2,610
Other accrued costs 293 13
Total deferred tax assets 15,885 17,039
Less:  valuation allowance (13,451) (14,587)
Deferred income taxes
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating Loss Carryforwards [Line Items]    
Income tax provision $ 227 $ 6
Increase (decrease) in valuation allowance 1,100 300
Valuation allowance, net operating loss carryforwards and credits 8,100 $ 7,100
Net operating loss carryforwards $ 42,000  
Domestic Tax Jurisdiction [Member]    
Operating Loss Carryforwards [Line Items]    
Operating loss carryforwards expiration period start 2025  
Operating loss carryforwards expiration period end 2037  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 18,200  
Operating loss carryforwards expiration period start 2029  
Operating loss carryforwards expiration period end 2039  
Expiring 2025 to 2037 [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 36,000  
Tax Year 2018 [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carryforwards $ 6,800  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Capital Stock (Details Narrative) - USD ($)
 12 Months Ended
Jun. 20, 2024
Mar. 01, 2024
Dec. 31, 2024
Dec. 31, 2023
Class of Stock [Line Items]        
Preferred stock, shares authorized     24,088 24,088
Consideration from sale of shares     $ 6,000,000
Common stock, par value (in dollars per share)   $ 0.01 $ 0.01 $ 0.01
Common stock, authorized   60,000,000 95,000,000 60,000,000
Convertible Preferred Stock, Shares Issued upon Conversion     1,000  
Conversion price   $ 420    
Common Stock [Member]        
Class of Stock [Line Items]        
Number of shares issued     20,476,025 306,574
Shares issued upon conversion 15,000,000      
Series X Preferred Stock [Member]        
Class of Stock [Line Items]        
Number of shares issued   15,000    
Price per share   $ 400    
Consideration from sale of shares   $ 6,000,000    
Common stock, authorized for conversion of preferred stock   95,000,000    
Conversion price   $ 420    
Interest rate   10.00%    
Liquidation preference   $ 400    
Shares converted 15,000      
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.25.1
We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Share-based compensation expense $ 725 $ 773
Remaining unrecognized compensation expense $ 1,057 $ 1,118
Remaining weighted average-period, expense recognition (years) 2 years 4 months 24 days 1 year 9 months 18 days
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.25.1
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Weighted-average risk-free interest rates 4.30% 3.80%
Dividend yield 0.00% 0.00%
Weighted-average expected life (years) of the option 4 years 4 years
Weighted-average expected stock price volatility 91.00% 93.00%
Weighted-average fair value of the options granted $ 1.74 $ 0.50
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Additional disclosures for options granted for all years presented: (Details) - Share-Based Payment Arrangement, Option [Member]
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period (years) of shares granted in period 3 years 3 years
Contractual life (years) of shares granted in period 7 years 7 years
Estimated forfeitures 8.00% 8.00%
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.25.1
The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Shares Outstanding, Beginning 3,525,966  
Shares Outstanding, Beginning, (per share) $ 1.22  
Weighted Average Remaining Contractual Term, Outstanding, end 4 years 4 months 24 days 4 years 2 months 12 days
Shares Outstanding, Beginning (Intrinsic value) $ 160  
Granted 388,000  
Granted (per share) $ 2.40  
Exercised (455,995)  
Exercised (per share) $ 0.52  
Forfeited or expired (246,232)  
Forfeited or expired (per share) $ 1.13  
Shares Outstanding, Ending 3,211,739 3,525,966
Shares Outstanding, Ending, (per share) $ 1.47 $ 1.22
Shares Outstanding, Ending (Intrinsic value) $ 3,961 $ 160
Shares Exercisable 2,206,666  
Shares Exercisable, (per share) $ 1.46  
Shares Exercisable (years) 3 years 7 months 6 days  
Shares Exercisable (Intrinsic value) $ 2,984  
Shares available for grant 62,900  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.25.1
The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Shares exercised 455,995  
Cash received $ 2,084 $ 73
Share-Based Payment Arrangement, Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Closing stock share price $ 2.26  
Shares exercised 455,995 294,074
Total intrinsic value $ 370 $ 195
Cash received $ 239 $ 154
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Stock Options and Stock Grants (Details Narrative) - Share-Based Payment Arrangement, Option [Member]
 12 Months Ended
Dec. 31, 2024
Prior to 2019 Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Expiration period 7 years
2019 Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Expiration period 7 years
2010 Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Expiration period 10 years
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.25.1
401(k) Profit-Sharing Plan (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Retirement Benefits [Abstract]    
Defined contribution plan, cost $ 206 $ 191
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Revenues from these three customers, as a percentage of total Company revenue, was approximately: (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Customer One [Member]    
Concentration Risk [Line Items]    
Revenue from customers 32.00% 17.00%
Customer Two [Member]    
Concentration Risk [Line Items]    
Revenue from customers 13.00% 25.00%
Customer Three [Member]    
Concentration Risk [Line Items]    
Revenue from customers 7.00% 15.00%
Customers One Through Three [Member]    
Concentration Risk [Line Items]    
Revenue from customers 52.00% 57.00%
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.25.1
Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Total $ 2,835 $ 2,152
Customer One [Member]    
Total 2,366 1,288
Customer Two [Member]    
Total 160
Customer Three [Member]    
Total $ 309 $ 864
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Customers (Details Narrative) - Supply Commitment [Member]
Dec. 31, 2024
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Equipment sale- original book value 30.00%
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.25.1
The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Interim Period, Costs Not Allocable [Line Items]    
Total revenue $ 52,347 $ 37,297
Total Expense 48,112 41,687
Net income 4,235 (4,390)
Employee Costs [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 12,933 10,811
Contractors And Professional Services [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 7,815 6,588
Materials And Supplies [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 15,559 14,669
Depreciation [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 928 742
Interest Expense [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 670 838
Other Income [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense (2) (4)
Tax Expense [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 318 101
Facilities [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 3,413 2,870
Shipping [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 1,193 760
Testing [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 917 1,078
I T Services [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 1,091 1,060
Insurance [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 785 721
Manufacturing Other Expense [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense 992 604
Selling General And Administrative Other Expense [Member]    
Interim Period, Costs Not Allocable [Line Items]    
Total Expense $ 1,500 $ 849
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.25.1
The revenues for 2024 and 2023 by category are as follows: (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue from External Customer [Line Items]    
Total revenue $ 52,347 $ 37,297
Consumer Products [Member]    
Revenue from External Customer [Line Items]    
Total revenue 44,373 25,211
Personal Care ingredients [Member]    
Revenue from External Customer [Line Items]    
Total revenue 6,827 9,277
Advanced Materials [Member]    
Revenue from External Customer [Line Items]    
Total revenue $ 1,147 $ 2,809
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.25.1
Business Segmentation and Geographical Distribution (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Product [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 366 $ 1,664
Non-US [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Revenues $ 1,825 $ 2,918
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Event (Details Narrative) - A/R Revolver, Inventory Facility and New Term Loan [Member]
 3 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Subsequent Event [Line Items]    
Expiration date Oct. 01, 2025  
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Expiration date   Apr. 01, 2026
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

?8S"GF2A0$ I)1#E&=-!@?D//-6-TX7_ MJ#+7#ESN?RY)8F[Q KQ/-&96?<,*VJ]LU_\#4$L#!!0 ( #9O?UI90B.3 M>P( '\% 9 >&PO=V]R:W-H965TM#@:+=Y6'8@V+3ME!9\B0E;O]^DNVXV99F>[%$ MBCP\-'4T;X1\4B6BAN>*<;5P2JWK2\]3:8D54>>B1FY.9M[Y[FWNPG:R%>++&;;9P M?$L(&:;:(A"S;/$*&;- AL;/'M,92MK$_?T._:;MW?2R)@JO!/M&,UTNG)D# M&>9DP_2#:#YAW\_8XJ6"J?8+31<;A0ZD&Z5%U2<;!A7EW4J>^_^PES#SWT@( M^X2PY=T5:EE>$TV2N10-2!MMT.RF;;7--N0HMT-YU-*<4I.GDUN^1:Z%I*A< MX*CGGC:H]LQ+>X15AQ"^@1"$<">X+A5\Y!EFOP-XAL[ *=QQ6H5'$:\Q/8$8)2B46W22]^^"B?_A"-UXH!L?0_^OD1Q%.,SO-#Z#/Z'W'9 *(S6E0>2@ M2X1<,*-8RHO14EF?F0I6:Y1V,B,[&3N>:/1 &G,?-4I*F((3"*9N=#$QFYD[ M#N/1#>74W,X,"B$R!;$[&\\@=(-9/'H=2\\13@/W8C:%,SB=3,TR^BPT87^3 M/C&5W7 RM=5\UX\"./37O3U15"B+5OJVRPW7G3X&[_"Z+#M1O89W3],=D07E M"ACF)M4_GXX=D)W<.T.+NI786F@CV'9;FA<2I0TPY[D0>F?8 L.;F_P"4$L# M!!0 ( #9O?UKF&MJ5Z@( &X& 9 >&PO=V]R:W-H965TYCVX, E6 6; MVJ9I]^MW#0E-I32:]@#XX]SC M_4N;.^:RI@HN1/F39;J8V2.;9)#3IM1W8OL5=OG$AB\5I6K?9-MA(UPQ;906 MU2X8^Q7CW9<^[_;A(&#DO1,0[ *"5G>W4*ORDFHZGTJQ)=*@D&U;C)FM">49N !,L1)F1ZZJ6X@G,C)JZ&E#?=L2X[ MUN =5C\@MX+K0I$KGD'VEL!%B;W.8*]S&9QDO(3TG(2^0P(OB$[PA7W>8Z )*+ M$J\^XQMKH^\G\T9RIAL)Q \2\U@WQ\7&CA^'[7MH7:!P+9O.+Q@G"-M@ M"0UHZ"5D'/I6&*,6CX2>$R=#Y%1J0A9IVE1-235D: A8])31SG(P$5H)J=F? M;N!3$#@C/R%GV/*=T7A,SJP!JG.&883YC9PD&>'^'%# ,]JO FM+%1F,_1$9 M#,/@V#ER#SR@ KEIG<[4HN&ZLX-^M#?31>&PO=V]R:W-H965T&Z0_\[ZPY=UM*I>U-\U9G/;T:KD2]D+"<@=&+.4GZ>7MM35;88D::+1@ M5?DVA-,5.>716YQJW/.WORJH).Y-66H/6WMW/?6 I<-IVD)\#!#).Q!Q(AY, MY7,G?JXRE1T"3"%/+U32"?4Q^2[B)Y5.Q'D\%LDLF7\'[[Q7\ISQSM_!&Z@G M9)5!WFT$9H)U(06^U4)LQ&O*)T F4"^QN=JK'82JMRTP" M[<*F5W\VNB;.$W&OK$?5(!A_1(@64%=IT61*F H?*TH#-YF:,MH);U 7*F0^ M#KRR2 _I%8,%N:4_ABPR.-PJ@I@,U0?64U-(6^R$>I9% RP7T7WF(0N6OV-# M%:43@_:WN:J(V4Y :=R0SE1R#:ATKZ5Z43:%Y<:=4DX,X0=*[-$CNMK85B$Z M/Y0YEXY-XYIU( &?M+' ]&#>5 TY:E,88X,/? ZCP(LE9>R9-V>\")AD%]-4 M7EA6/5PUMG.M3/FTW6R0ZU;T0GJ%J7W%3GZ:!CTL3<1OU7B4=5>E6MPC@70X_$LOF390\QU6"F4@M&C M9VDUO-#%0RUW(>BWN4YSHG(:* AG-"0->U$HRA?ER$,H"+*B,";W(NA+T@R. M)3\92(I8E*1F150@9\\E(GUKC6 <\:^]2NW M+I AS!NO"_V_$-OR6>J"M:JI5.D4P.H%%M70C8@A[!JY'Y2.2/S*5&?!!)2] MB!@BVZ?O1/RSD:B-7E*OA*"AZU,<(CFD9=)C*=7Y$%%"P 5ZO;N* MOFQ5 9AA=Q"H[<&!77T7?X7J/+K?"PXO=&SJNE 4NQ1$TN64TMMH MX!]4D4*VP7+,&7VV[92T"*UW?$'!0N:^BO@Q6)[X43@SABRI"/1U.>ORM@13 MM%"2<>^@ G9%X'JTV:$?6 -,B*2$V%A3ONTC9($X7I %EDGTZVLTI)AV1!YN MKRG;Z='2$'9F-F?4=:1SRCLV(I4)_*Z2Z"O/:2H[D\]@^43EMVPO[VOLV1MY M3J FF^Y47$Q68CFY?(MT4#_?0BPG%^)O^([Q3:F^:3S-'/!?8UFIZ'@G?&L< MR3EPQ'M6'>0?-MF"X\OE@AXN:#F[I.62EA>\N\)RL5K2\I*6EW$$\5#I-C"% MF(]G2=Q&:%\_@7D^GLU7<(QS?4A8Q8,/SU;[#G"2C)>+I,\&]#==-N4>R])( M0-40H+-Q[O@8N/(9P9]S@@7.*(C\"M,AZS MNT?U[W.QEM;O)N+S7M54H:[VA;]3,DBF7=1W,O-ZHZ:U<.@1YWX>.G*6 M",;&#$/6@28T7Z#8$-V#=!0J(4M) B*FEM2UKS6VL__"46049;7)J&L!0+J# MUA@%+J$]3L0O9HMIP09AP#EM"&!OI">K0L%Q8*4W+:;&A(!>R<-57VY;S]36 M/&O^0QF"A MH&,,8%A5#17ST6O^M+HH#/4Z:FD:!S&RK4_&ZT7N;0; M]E+ 4+-PXEN%RQ-QY\ \S8.:%94#U96"CCM/;!03^*.BBMT^U4*CYHQ@QW5Y M)4XPA5$%268?='4&Y9SG(& J/H@_M/"GP3H\6[!V'*V12=*9NWDT]KCP!SK<#2._'M#4?[N_$.9 MZ!22CV;/H@]*#$%O9B!4]2S\_>-F$BHR1MNVDJ/ 4*_:< ?E\1\YY4.\M%-6 M-H2CAWDOVY//%7."!K01,]9ZSFF7DWKP\HS.?;?>M!4#)7"JX%^MW^Q)^S)PUN9![@-LS"TV>#J;+)DFN5)0*<;XSQW0,QZ%\WW?X?4$L#!!0 ( #9O?UH5[D(+=0( M 'L% 9 >&PO=V]R:W-H965T(!EX:+O34JXQIQ[ZO\PH;IB]DBX).2JD:9BA4*U^W"EGA0 WW MHR 8^0VKA9=-7&ZALHE<&UX+7"C0ZZ9A:CM'+C=3+_3VB8=Z51F;\+-)RU;X MB.9KNU 4^3U+43W?Y'OZE[A.X3^22#*<- MR!),A5!*3KZMQ6H\F&F;I.%@LT1E!S2P [)3B@=[GI9M%4'2[7PFB+M7.BHN'5)811.OA,$A3%291"DHX&7Z1AG.#)>9I< MT9J.KN#8!_J ZJW>!D:VSUU(:,JO;5O0ZHK(%=%Y*:?:!O:!_;[/?4$L#!!0 ( #9O M?UJ?O?I[H@4 '$, 9 >&PO=V]R:W-H965T=H[C^87*9_W!_Y4 MM+&=L6!/%EI_Y\F'_+07LD%44.880>+GCBZI*!@(9OS88O;V*EFP.]ZAO_>^ MPY>%M'2IBV\J=^O3WK0GFD8IRI. MRHTSV%6043802=07<1BG+^ E>_\2CY?\TC]QI6Q6:-L8$G^=+ZPS M8,3?3_G<(J9/(W*5S&TM,SKMH0PLF3OJG;U^%8W#MR_8F^[M35]"_V4^7I8^ MGKX1703QN3&B0FFK=M')^Z V^DYQ3?5YM6AR5:W$0KLUZ&8,54[(*F=B$V9Y M'Y572$>Y<%I\'=P,Q))R,K+PIZS#5@><+$"M.!)Q/!'G$,UTE:E"25^!>AD\ M'A4+JFBI'..Z-0E9Z@:ZL5TWK&[Q(&1=%P]L'>^_WZKM(!A6#G$DU0(.'8K$ MWCN!Z8%E0MI +P4(1N6"S)YDWA$,$K9<6L@5Z%1V'OA-W@@^/.K,$!,8+9WW MO7':/'@[V.E9,L'W\2R.Q)O@*PK"H.EDIH'54'Q@RS&.B.,$YSYIKIP&S6E1 MD*![=%N+ R,!O5\0/Y-W]+)@-&;1*)I"^)K0F"K.&9_9XL!WM(WLN] U3RQ MR63*(JC'2 N$QZSXYJ?<]3U18.@NP=L$61%-9E X'D'HW7VMS"Z;K4!-O( L M<1HXS CGSMHDB4743V=Q\&ZY1!]FH6PMJQ4KWG/L,9GI3*2CGY0<^I*.Q3@, M/H,1!O&;P9O7KZ9Q%+\-+O>X=[)H6G')J9151K"_'R53'_0TA2,M18_$&(38 M6M%-4("[@2\.3SUVDTTD[X-EHQR5M3:XQ42NL(JRR8@YZ#9$E1?*I#&>O"VQ MO91$@%P;(=3$ H7A%%G/U*6J8*="V T!F0,:U(VI]2ZDCS5B1<.Y/.2WV!T> MB!NUJM1297);3IH)XO5K=(/\*7=Q#M>L]?EA16T-P(9Y<.XENU73*8RK;@8[ M+LV10P3$;FF)/IEM>P#J(YUY!J<3<#$XO[D4TS3NTHAPR;:AXJS-VJQA,&$" MWFJ'&.7/Z 7!^VF2L@ &HQ@"!R:V"9@'G_Y'W#9?B.E&FIR+.0K[,6H,@[@? MQF' 17!Y<&9+/!&#LM$X.?[GC;AH+#HRT%3E0 H$M%"EUBRD\R!N)H9? M4!PRWUE0E+C^4-']<)2(&53?K*6AW_A=DWNRH/NTF)/I5(R2,+CM-)]H.A-H M/,\F;9>)!Q'W1W&([W&T*U;?";T2"Z1XEH@H>2J;VQJ)1OWI=(36TP_A^1_P M>_Y,72=(M.^F4=H?32?=E!]0_&@?\L?1+;C^!&J0$USV,<$=9/2]PO./B@=F MPR 2X2 14_Q.\/E&8BWO:-\TT2N"%YG%9=NM5]\7?E*"T!XE8RXQ7 ,A;I7Q M8(K@#V)>FO'2[*FGQK#S#"S)K/QCEVL;3:-]$>Y7]^_I\_89^7B\?8Q_E&:E MT&X+6D(T'$Q&/6':!VX[<;KVCTH\'/!$]<,U_A.0X0/87VKM=A-6L/^7&PO=V]R:W-H965TS^LSCV?,\=JZ&U\Q![JM3>-/!E4([?OQ MV!<5U\J/;,L-=A;6U2I@Z99CWSI6952JS7B:YP?C6NEF<'HED%^3 ^/6[5DJ\Y_-Y>.:S&6RNEKKGQVC;D M>'$R.)N\/Y^)?!3X0_/:/W@GR61N[8TL+LN302X!L>$BB 6%QXHOV!@QA#"^ M]C8'6Y>B^/!]8_WGF#MRF2O/%];\J&1'4NDE/==OC\$#A,']&8=HK3&/8FI1FT$IQLIRG5PV-70"Z<7JM5!&;H.MK@Y'@>8E(UQT:N?)_7I,^J3 M*7VV3:@\?6Q*+A\;&".6;4#334#GTQP%>WO;!/>BO;UG M['W\VNEP1W^?S7UPX, _3R693,R>-B'GXKUO5<$G Q#?LUOQX/3UJ\E!?O1" M@+-M@+.7K/^X B^K[[S;S7H3631!9Y[L@H CUW-V@F4F6 Y)-:6@NC>D-5.E ML)@-\\-#NNJ<[U03*%@*%=,U%YW30;.7K:("Z>ELZ9AQ&$/&M]@.7!+.U&>% M;>J+-8S*%[9N57-'VOL.0C"):.'9()3)_C#/XBH?Y1,Z"R1* ><] MAKEPMDXKB0G/(>F&UI4UG%DG[ZUR84@+:]!6=+-\Y+MU:%K.W-%"&]E3./V( MO93X:4R,=HS]8U-%.Q8J('^1:-=_O;UTD" M:XJW]/AD3C?RIK&TLD&0==+T M?*(6MK&_MITILTK!5>^R)$5&XQB6JK)%0,%)_6?O#WRI.:@#WH'\.GY G\KL"%3_W< 94@I$.X6 MG^Y)4*1:]P18J M \M2##(4,SA(Y_5[,B2'D0G(3J1*[<'36(%>+_%I^, BK56$\OM$-C!NZ4-8 M9T*R<-?B;$A2K=)E9$*A?$6> [@7CUSD!/H%9&R!WK*I5M=(POC**Q$3O"K5 M+ 7-5%IK4E-Y5.Q(0?GZ&"@/.!(1)8G"@"HXM1'AX3W$,(TYT$E825@,2:,L M,;XPSIU>*;DG^+CYV&]$$RL/! 3DPK"2+A-3-A97C;O,L0&IRI%T8=\5U? Y M!T"RC(?426 P/-<+--MT1#:!_:"RCM&'0B)1S=^^J0;#(>L3M0GCN3+Q]*0K M7HG&WC=+=$AM 5;%4=#S VAZ^WT/EVAPG\-Q:4IHC^C2R[PH! P/62!M"RUI MX_(2JJ@FVR_Q,S:KY 2W0:FA,B/ZM:%?NH9I3;TD^ M2W?#>_%TP\:T7J+&9'@!U7ST=G^0&OAF$6P;;XIS&S -XFN%BSX[$<#^PF(: M] MQL/W7X?0_4$L#!!0 ( #9O?UJ?KN\US08 "$0 9 >&PO=V]R M:W-H965T[.P^Q*9EU6#QUJHK,Z5;I>[.2 MTM)#5=;FK+>R=CT?#$RVDI4P?;66-7Y9*%T)BT>]')BUEB)W1E4Y2*)H/*A$ M4??.3]V[&WU^JAI;%K6\T62:JA+Z\5*6:GO6BWO=BT_%#\="V6\E;: M?ZUO-)X&.Y2\J&1M"E63EHNSWD4\OQSR?#?A2R&W9F],O),[I>[YX>?\K!>Q M0[*4F64$@:^-O))ER4!PX\\6L[=;D@WWQQWZ#V[OV,N=,/)*E5^+W*[.>M,> MY7(AFM)^4MN?9+N?$>-EJC3ND[9^[C#M4=88JZK6&!Y41>V_Q4/+PY[!-'K# M(&D-$N>W7\AY^5%8<7ZJU98TSP8:#]Q6G36<*VH.RJW5^+6 G3V_M2J[I]_7 M3)$A4>?DW_RH16W-Z7OK7CE=#RY!*1S.E&/$)@EBXTMKN4 M;OSOBSMC-=3RGT.[]]C#P]B<07.S%ID\ZR%%C-0;V3O__IMX''UXQ_/ASO/A M>^C_(%;OXQW%T3&]#TI?):W$1A*8D1J,%;55@7$SU-KGU5)+QYR!=.V*,JDM MB@&IQ:+ V(0DJW6I'J7T\'FAD9%*FSY]7DG:QS*TY%6QS%H72I-59#%%Y.U2 M:L'/01+%,[K^LRGL(UVI"O7)"/?[32EJ.F*3[[^9)DGTPT6>U+C*: MQ-.0#BC,A $HV:Z*# 3MNXRE,994&)2X3"WKXB]8J;I\!#B*IX.Z_/>1,P#G#B9,&MWM(!SWXEB;)B#\G:?!);\G8[20$R='GZ! 5G%K*P M#2CITW4WTR$$>\M PIYEY39'N2B@8K3Z>YPM-) H6W&5-9U#SA,?!M^*%'9&T[)Z4T MN'J2X"L>WS2*+-)PUGGB,$"?5&HZ6\T5V1 M8A15%DCH/?&VLL]L2K8>._B+K! M#8):ORD-1\DHG(W'3C])@J1(>#B.@A_;"*33:0@LO$63B8+.0T1[.(+I;$3' M7G5)\(,/"A[0!IY5;]C8(K859\4)#H#3DO[;D<#>ERW]7NBA>T5:5MD^XT MRHG ]Q'VTY)8KW62F2KD&H%=%&ZLXT5#^B[M5P4.&$MM*I>].0MJN[^$8T9 M[Q*J92)X'45>GMGH'SK^#_:N;9742W8)^'VAE.T>>('= M?P7._P902P,$% @ -F]_6D_#U01U @ ;04 !D !X;"]W;W)K&ULE51=;],P%'W?K[@*"&T2-!_MQAAMI'4#P<.D:A7L M ?'@)K>)-BX=7Z:$\5]H.^R8 M=LP:8U75)U-<<=G]V6M_#GL)U]&1A*1/2+SN;B.O\IY9EDZU:D$[-+&Y@2_5 M9Y,X+MVE+*VF54YY-IU$\?GS!2RT6G/[85DRS64!"\'D-+3$[U!AUG/-.Z[D M"%>:8_TL0DK!!7;)3-T].,MYC-H)Q_!Z2*)FE(4Y2J22#?RZ71FKZ77\/E1QQSH.9#K06>U F=J@3S$- MG1F3EC,AMD ?P*H6:HMHH"T55*Z=D#=(1 [N6'B&9.&7IC]],X([>BF:KQKG M34,O.D?@TM\S,)F[P1A846@LF,7\S"IX2Y-7$'^*#QUMN&>!"G7AC6Y(<2-M MYX9A=N@EMYV%_L*[1O3 =,%)D\ UI4:CCY&ULI5=;;]LV%'[7KSAPUZ$%#%_DW)8; MD+3KUH<"0=*N#\,>:.G8)D*)*DG%\;_?=TA9<3HW&+872S3/^<[](W6^MN[> MKY@#/5:F]A>#50C-Z7CLBQ57RH]LPS5V%M95*F#IEF/?.%9E5*K,.)],CL:5 MTO7@\CS^=^,NSVT;C*[YQI%OJTJYS34;N[X83 ?;/V[U:.6?,?A M2W/CL!KW**6NN/;:UN1X<3&XFIY>'XA\%/A#\]KOO)-$,K?V7A8?RXO!1!QB MPT40!(7' []C8P0(;GSK, >]25'& BM8'6W7*\*#2=7JJQRX/.PHGDQ\HY)U" M'OU.AJ*7[U50E^?.KLF)--#D)88:M>&RY& M-)L.*9_D!R_@S?I 9Q%O]@.\6^WO/:FZI"]UP2Z@7X-F3W]>S7UP:(Z_]D6= M, _V8\K G/I&%7PQP$1X=@\\N/SYU?1H]QP\X2:H\T)(7T4\.NX#I@WLDN*-B@#+VS5:/J#68\H@QI+:)-X^RCQMRQV9QF M'W;\\,F1;->1;!L5O:(;9\NV0*#075JWB4[*SRR;PE@- H)<)^5IEM-KFA[3 MZRRG&WAJ:_%).::/]=)QJ>&OI^D,4ODAI&9[,(X%0C8_QX@.!?)0_KPJ"MN* MOH.S^D'-#8-%C$(/]LG]3\E2_P3>F[@K#]W_D9V?*!_.CH[PG [SDY.733_&QOEF:37^CDZ*!+DB"?S [CK V MSHRF,0@:MKB*MM8ZK.CZZNX#[+C&.A5)_HV8SR=GLA%?IV=OAV1;'$-<6 R_ M46[)/O2I'J( *E T!X&@ZR77!8@AZTZPDM8K7:RPV9J2&AM@72MCI%T]J)]T M'1O3*Q.KU*1@Q1G^UNI&O.W'HJ]>L'&Y]0(@(0T7-H#PH$O."@5JT6&#X!>8 M2TFQ;%=R5.\JQXP?G_E=TS5SZ4?T>:51_C84D,.IL2%;(,6D%[1F6BAM>L". M$J7EXDF/_LRKGDN(AZ MPP31JZUC4N?(GC7E]TG)4!=&E9&>*69K-HF/CXL]N-F:T8K03_$)R\?6B(=_ MG]6"I9K2-\^]B*63-V0.$FIN'V26N'//6(^9M5#;H<@M645;@,O47!LI%DRA M@QC]R'OEL>^X,3@T4N>E[I+!A9V^FVJAV\"N$FZ-TE67]AKC[CWN3SL!"%!6 M;'/9M*Y8X:)21M]0/X2#C6K/! MM%3QO!_1E9!166K)GC+2M5JF6\9';82>8A.5*?!YJX'9=W9*,$HS!W]MQ'D, M.#(GM*A2)KJZ/1TM?7S1%ZR5]PQ"0 9+701HEQF"E9GOZ>*IZMOX1S@2*PTV MD*GW\)$C(R>'=J?5; M3[]GL2<22VGT+5IA-_G/*08-$J&\3#.>$N(]0RVHQ2(66PB+N&J,W3 HK$S] M)LQG*XW+ BOT*,AM)&0[9Z-A++6A8/6*),2NJ' 0+E!+T )SL-E3GW-%Z(+BWFQ&]!OX/,43T^PD\8E/=A,0YZ^2*S75 M-@AT/#HE^]IQU]F1L?R]-@;)?_)^N;60^:"7E8*D4<+LHAY-"'?%-"?_/6G0 M,LY$T%?K1_ON;N.=*S;:9QD_)#S%,SC=MOM_^V^5JW1%?Q)/'SJ?< 1I-(7A M!50GHV-\&KCT\9 6P3;QP@[.0:_&UQ6^M]B) /87%J=0MQ #_1?AI&:!@ HPX !D !X;"]W;W)K&ULK5=M;]NV%OZN7T'X#D,+:+'U8LOND@")VV[YT#9HLNW#L ^T1,M$ M)5$CJ3C>K[_/(279:=-+Y7^HO9"6'98UTUYF*RL[9] M,YV:?"=J;LY4*QKL;)6NN<6K+J>FU8(7[E!=3>/9;#&MN6PFE^=N[59?GJO. M5K(1MYJ9KJZY/ER+2NTO)M%D6/@LRYVEA>GE>;HJ+R8P B4KDEC1P_'L0:U%5 MI @P_NYU3D:3=/#T>=#^WOD.7S;KRKA?MO>R\WC"\LY85?>'@:"6C?_/'WL>3@XL9]\Y$/<'8H?;&W(HWW++ M+\^UVC--TM!&#\Y5=QK@9$-!N;,:NQ+G[.5U9[!B#+L3);BVW'/5%.P7H4K- MVYW,><7>2F.UW'2T>SZU,$S'IWEOY-H;B;]C)(K9!]78G6'OFD(43Q5,@7B$ M'0^PK^,7-;X5^1E+HI#%LSA]05\RTI X?L\^B5=K*IF1_7FW@,I+F MK^?\]=K2Y[51(;TQ+<_%Q0258H1^$)/+'_\3+68_OX U';&F+VG_MT+VHI'G M77@5):_9_V&>W>\$6ZNZY=85@A=QNA19-+@PI:K4JNMR: MD)$C$JLA*T_ !AS]#&M:E%W%8>G 1/,@M6H\%G). 0!!0X*5[#MG\>B';\[G2,H'(I==:6BL(+[=#"O14..7O M'D7>4?-W@?S*(/NTW8+V'E;P]>Y7<#B8HC\& 3<1B:-*P1CCPJA:!AJQX&690>,+;,2=G M/;DUTKG3CM\1#6!;\YS"#:^<&_XC@)O *HL"]@>\/I[GJFL<(:VJ9"Y]_H[Y M.1K1XJMT5 ;5* Q*9@.+TEOLOP ,ZF-$'0R^BT=\*!EJ M+;XRO^5"L+XF3BN3Q#@5/8<0'-.!IT27#O(J/%@V@Z MP7Y@\SA,T@P/21;&JRQX5[>5.@@J<(-@1W&X2A(6S<)E% 5KU;B!1HV4_"2& MD,Q@#SK'[I-!=LX6X7RY##YPU^/XZB2;0$Y"AX MSW-924L6DS"-$A:'RVP6W.UDVU(F1F&T2EBVF 7WL$0KJRC#ZBQ;!C?W1X^P MLHKH%Y(W#>K"13I;SED61_"QZ6B\=)HT^"X_(%FM8K:8I<$=/AJQ2T.C0>95 MC@Y>8.S0D..NM3P]&87S&1Q.5WW(WO7KZ3*,\#641N%BF04?D9@W/145DO8U M(IF&<3+'_U=IF*QFX.=S'^VM5C6U5J']L,/8&GJ(&SJ/$M^HJ+$?8'P9S\'6 M"D0FBP7>%XN4?>ITW\5Q^-A%@^_.8.]E55$^PA"K5%/^5,'78F@FE+N^. I\ MMF(>^_+^K9&TJ MBX9C;_+P35F^[WO\07"4CZ#/V-,B#6Y[S.M!P;%HUP.07L90E!'=+,%#/ ]C MU.;MX-Z:#-\[

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

ED:H[1D]"$P5]/]<1D=L/)U&;S73\*X-!/]_:&HT)9M"O 5KGANIN3 MP3ILF64W7&_NW8JZ([*@7 '#W(3ZY].Q [(;^T[1HFY';2VT&=Q6+,VF1&D= MS'TNA-XI-L&P>Y/?4$L#!!0 ( #9O?UIX( [DWP( %H& 9 >&PO M=V]R:W-H965TQ)$#Z M&%:@Q8)VC\.P@V+3L5!9C($C]BC+ASJ?M MV5+-I[(QG E8*J*;JJ+JY1RXW,SR!/Y_6= WW8+[52X4[OT?) M605",RF(@F+F+L+)^<#JMPK?&6STGDQL)"LI'^SF.I^Y@24$'#)C$2A^GN " M.+= 2.-QB^GV+JWAOKQ#_]3&CK&LJ(8+R7^PW)0S=^22' K:<',G-Y]A&T]B M\3+)=;N23:>;1B[)&FUDM35&!A43W9<^;_.P9S *WC"(M@91R[MSU+*\I(;. MITINB++:B&:%-M36&LDQ88MR;Q3>,K0S\ZO'AM689$.HR,D-8("EY#FYKFHE MG\#>:/+A*UUQT*=3WZ!+:^AG6_CS#CYZ SZ,R*T4IM3D2N20_PW@(]>><+0C M?!X=1;R$[(S$H4>B(!H$W*S\5*&X5/ MY]>AV#ODP6%DVTX37=,,9B[VBP;U!.[\_;LP#3X>X3WH>0^.H?]3.-X7CNT7 M+I/8/=H061!3 BDDQR9D8GTHF*/N#@?S7QRA$DZ1$RM)V21 M94W5<&H@Q_& R,!Y@ M?",O34?DT%/Q]_J] K5NIYK-="-,U_K]:3\X%]V\>%7OINXM56LF-!:O0-/@ M;)BX1'63K-L86;?38R4-SJ)6+''X@[(*>%](:78;ZZ#_.YG_ 5!+ P04 M" V;W]:2AUM[ST$ !6"P &0 'AL+W=O=7+)@+;$ 2+Y)(RI$$^-*B!1+4C=WDH>C#BAQ*BY!<9G=I MQ7_?F25-JS:M!D'[0NYEYLS,SMG96>ZE^J)W (9]*XM*K]R=,?69Y^ET!R77 M$UE#A3NY5"4W.%5;3]<*>&:5RL(+?3_R2BXJ=[VT:]=JO92-*40%UXKIIBRY MNK^ 0NY7;N ^+'P4VYVA!6^]K/D6;L#\45\KG'D]2B9*J+20%5.0K]SSX.PB M(GDK\$G 7A^,&46RD?(+37[-5JY/#D$!J2$$CK\[N(2B("!TXVN'Z?8F2?%P M_(#^LXT=8]EP#9>R^"PRLUNYB@GEF_!PR)7C3I6<0GZ2\M,.Z:+'"%[""D'V0 ME=EI]E.50?9/ \=Z[T+'[R["(\B7D$Z8=-@Q$(_G!W!F_;13BW>] 6\PSAY ME6'%U(T"]N?Y1AN%E/EKZ!A:([-A(W2-SG3-4UBY>$\T MJ#MPUV]?!9'_[D@(LSZ$V3'T]>\-1Y\-)S(S4;77LKTA6ZXRC(:9G;@[G:)N$#HWS6;<+HL*30([F0L*Z@AL\?",'\XE_99-_#UQI!B^DD^XB96R0D3_BH_,_^NC8:4LP MLE=SD5D,7LJ&N(9Y+1H"$97%+=$H%A7R\9&'!=)'%,)@X3FDFXT 'T][T+F2 MY5,J:)OH()A3HN/0>?\4C2$S-8FWVAN#+S--%;U/8YF/&Y3G6H/1EBM^L*!_ M$CJ?[1,&V9C?H+YT@9EE8Z'(:J M\!PBGD3L#7X#]N8(;:.>MM%12MSBF>>-H3J.#&A4>RQX\D-5Z)DOW(H.Y%_! MO]7.HVX-U\Y!7YW_V%=BK.7+:!'/:1+1T%_0,*9A9%<3',Z3F(8+&BX"!]W# M5B_'Q+/9R ^#KNS4_+Y]1!%S.O)G"=)0Z_X"*+ !VK<5+P%J Q:HDW 4S\.^ MQ&$S(\JF?,12\+41"J\-@OJC995?;]O2K?=-XWO9* MC^)MQ_F!JZVHZ"'*4=6?Q%AI5-O%M1,C:]LY;:3!/LP.=]CX@B(!W,^E- \3 M,M"WTNN_ 5!+ P04 " V;W]:J>"#U7H" ")!0 &0 'AL+W=O5]9M!-FTY6N\1_NM76I:!3VEJ!N4IE82 M-)8S-H\FB\3%^X#O-6[-P1Q<)BNE'MWB2S%CH3.$ G/K")R&)[Q&(1R(;/S> M,5E_I!,>SO?T3SYWRF7%#5XK\:,N;#5C*8,"2[X1]DYM/^,NGY'CY4H8_PO; M+C89,L@WQJIF)R8'32V[D3_O[N% D(:O".*=(/:^NX.\RQMN>3;5:@O:11/- M37RJ7DWF:NF*"R )\Y%P9^SE?&:OI[_#J6H)@_H)6?;V M330./YSPF_1^DU/TOCBX+TZNJ!N,!56"K1!*):BI:KF>''-^DGW<^?\?.)@; MMTD5PF:%VE5IX*KD2C4<[#DM?]$D\?>M47![R#Z#Z#PEQ1G$HU$OX7FN-M(: MIW7%HJ#1U25$<3KX2A8TK9,XA20=#QZ4Y8+DR7F:7-&8CJ_@V*T'!^W1H%[[ M1\#E1N=TG=+O]N_,O&NOO^'=(W7+];J6!@26) TO+D<,=-?XW<*JUC?;2EEJ M73^MZ*U$[0+H>ZF4W2_< ?WKF_T!4$L#!!0 ( #9O?UKQ^;JU2P4 *,- M 9 >&PO=V]R:W-H965T'6][6E]L4CK7 M[YSSD3K;://%KHF<>"CRTI[WU\Y5I\.A3==42/M:5U3BS5*;0CILS6IH*T,R M\TI%/HR"8#PLI"K[\S/_[,;,SW3M^%2]-H)3)1?EUAF\5=!S\_=EJ@L2 M=_*!K#BYDXN<[*NSH8-I%ABFK9G+QDSTC)DP$A]TZ=96O"TSRO8-#!%3%UBT M#>PR.FKQFM+7(@X'(@JBY(B]N$LT]O;B?TQ47"N;YMK6AL2O%POK#%KCMT,Y M-Q:3PQ9Y7$YM)5,Z[V,>+)E[ZL^_>Q&.@S='XDVZ>)-CUN<7:/E4EZG*E?3] MJY="-3DXY+"@DI;*":>%6Y.0A:Y+)_"ZJAUE8O$H9%7ECZI<^??O*",C\UT+ M1CIB=2!A80[S3:(R^E[Y><-V1QB](2U'@*I0L2#354;(,N-%+)276>H< MX/=D%H7B5>\S9LF N%)3(^J]!N!IA8@XB2'W4?/0U2 XC*^@!S"VAR';^L&(Y9-0RG4+XAD%M)P(UE6CO('=23?A&ZXHV%43*IL@#U))JP\I@= MWSJ&[RFJ@2AQCB#098MT6R KPLD,#LMHK5,0/4"4N \,,.+?1 MQG$DPD$RBWIOETMP.2NE:UFNV#$3,!E(/A4SF8ED]#C^A(PSP MFR&;[UY,HS!ZT[OJ[-[+O&[4)9=2EBDA_D$83SWH28)$7HHHXFJ-Q9%Y'W7S M/CHZ[]?;1/9JC".*SR_?O8P49TD>!C^.CHI*&QRF(E-X:@AAF$7XM;M2K54J6RG4C-/>;]Z]H\U6TO78RZ5=:7F!TU8X08#M+)43P/T\E! MD'O? ,B];P'DWL57'+]#8->[D[:3TBEF#8#8ECX =MIR-7@LF7FF22;@C-[% M[968)M'NN!,N5 U4/%VS9KJPF#!1W&D'C+)G_(*(!DFR$V!3CM M??R*8)IZ =.--!F3;A@,(G A%M$@B((>D]75GDQ+$"("M83C^.3W5^*RMF@Y M6%.E0U, T%P5RC6IIP>UXR#".7"/$C'E+=JV$H\B&HRB +_C<$NJ_L3R3BPL M1;-8A/&A:K8S$HX&T^D(1\0@0.8_(N_39_@W1J']J1&PO=V]R:W-H965TR#;8KB/7SN^-R1].E.Z3NSYMS"?29S<]996[N9]OLF6?., MF9[:\!S?+)7.F,5'O>J;C>8L=4:9[(>^/^QG3.2=V:GKN]*S4U58*7)^I<$4 M6<;TPSF7:G?6"3K[CFNQ6EOJZ,].-VS%;[C]?7.E\:E?HZ0BX[D1*@?-EV>= M>3 ]']-X-^"#X#MST ;R9*'4'3V\3<\Z/A'BDB>6$!C^;/D%EY* D,9?%6:G MGI(,#]M[]-?.=_1EP0R_4/*C2.WZK#/N0,J7K)#V6NU^Y94_ \)+E#3N&W;5 M6+\#26&LRBIC9)")O/QE]U4,LMFIUKM0--H1*.&<]59 M(SF1TZ+<6(UO!=K9V8U5R1V\WU"(#+ \A;+GC6:Y-7!TRQ:2F^/3OL7)R*2? M5,#G)7#X!' 0PCN5V[6!5WG*T\\!^LBRIAKNJ9Z'K8B7/.E!%'0A],.X!2^J M78\<7O24ZVNF^TV1:>7>')EO<\C[@0YYGSC3V$^:!50J833'+@MXHQA^_-_#;Y#ZLY3YLE?L\35TJ,0FI,(E4IL#H?;!&3AMA@?2^7/\G#4$'W)Z:MH(JLP"+JC:.(LXA&RHJH4(=%@3\"M;J-UV W] M87=8^10/L3Q3,^Q.QO$^SFS+A'00I "7<##$$7YKV1O7J33^UU1B^V6G/:-< MY*KZ8EJ3GDI]LH7:NF-6>01"ATB.5+0H.H=E'NO#B[ 7#IN2I97.T\G2P-'[ M;HY ))]]]*-CXUY0>SV%D[CKCV+O5EG4_9?A0QV,2(W!9.!=,+.F(QO'VVA* M4Y>2&<2-J]@_N-IE7*_K-NZBN% 6KYVNN<9[/M&ULK59=3]LP%'WOK[@*8]JDBGRUI8.V4H&A\8!4\3$>ICVXR6UCD=B9 M[5+Z[W?MI*'32H387N*O>X_/B8]S,UI+]:@S1 //12[TV,N,*4]\7R<9%DP? MR1(%K2RD*IBAH5KZNE3(4I=4Y'X4! ._8%QXDY&;FZG)2*Y,S@7.%.A543"U M.<-Z&TG;O@R,W;"GXQ*ML1;-/?E3-'(;U!27J#07 I0N!A[T_#DK&_C M7K9"[EHQU>FFSL#3U(<<%6N;F1ZV]8ZW$$$YEK]X1U'1MXD*RTD46= M3 P*+JJ6/=?OX2T)49T0.=[51H[E!3-L,E)R#] I>&,&U%";3 M\%6DF/X)X!.YAF&T97@6M2)>8'($<=B%*(AZ+7AQHSAV>/$K>#=9DG^!V2@\(&4MK%OK%0YV&$= 'PW*%#3(% M:,T =)18S%$UQWD$>[1U_JNVSN4.#UT1Z>P2Z6QM#PD+EC.R?7,\[[(2 M^QOXK;9J9;S_'L';=+S#-F_4T9EJROT'GWR J!L/!M2&W6@X;'?+(("/!\,H MC$[W^B4.OL!PT*OM8I&'<=^U(7EGGVO\G>I 4$M7 S4XZ56A:&:;,CNMJLM+ M>%6CKYE:C7P54-H#6%U*:[&PO=V]R:W-H M965TBAYH:6P12Y$J2<5Q?WV'E.2D;3;= @5ZL4EJ'M\,YQO.Q5[I3Z9&M/#8 M"&DN)[6U[?ET:LH:&V;.5(N2OFR5;IBEK=Y-3:N155ZI$=,DBN;3AG$Y65[X MLSN]O%"=%5SBG0;3-0W3AVL4:G\YB2?CP0>^JZT[F"XO6K;#-=J/[9VFW?1H MI>(-2L.5!(W;R\E5?'X]<_)>X">.>_-L#2Z2C5*?W.:FNIQ$#A *+*VSP.CO M 5MS)2OX'M5.L[;F M)1/PAANK^:;S7T_NV4:@.;V86D+@[$S+P=MU[RWYC+767ZTDLG-9J@;!*L ')CIF MR99J6B8/0,8\VV6)7IQ+V-?,PIX=G#P30I5.GB)2G2[1G,&:[R3?4JE0ZLR0 M0GRDSD'^0]+F90U,DSN";!CY9<:O28[;@]LQDE("0R]&^ZTB-WMS_E+2_W5: M@O\_+<%_FY;@RH#:NNO&9D,1$04"1P''@S2X5Y9(J_$!98?P-EC8_398@Z!&6/;+H:YA0; MY"0[@WDX*XK@EL+6G(E>WG1M*SB)Q+-P-EM G(7S^8*N@"A0\K[!+)("\BP) M;B1IHCEF!>9Y!$5:!.\I#7J\C9,$3N$D@]/@GCT>1=.X(,AQ\(Z57'#K/*9A M%J>0A$4>!>N:MZVC1!S&BQ3R>13%6%,S3*+PWF1!S]28=X,J1!4M*=TDUF8I#/Z M/\G"=!'!Z2O]9';L)[-_),Y0,Z[0M.^I/@975+ Y@*OOG=*'+R'IJ[Y>[HSO M.PVJYZR2AHJS:34W&#"@1VHG$#;C:S62R2=8"$<%XAP()7??"DHSG1J#5-H. M:,_+BEY66Q-I'<$^2NY.UO3>.9[^C&-H_'?TED;NT+TA:P(NB>&VUD09-^DX M3E1=:8]:CLX$W'B.E,XI =98<0))GUCUX(JI(N7G3"DIRJZAC0:>^L5J!#+(&%=@5%AY2HMD%B;4%N[& M\%;.\-0$BB2'19CD>7 U1OK4$XA_U'N(E-%8Y6M&X\/?VQ*\5,/39[,- M(=SY"<[51B=M/^8<3X]#XE4_&SV)]Q/F+=,[3G4E<$NJT5E.):K[J:W?6-7Z M26FC+,U=?EG3H(O:"=#WK5)VW#@'Q]%Y^0=02P,$% @ -F]_6G0O%YLU M P 20@ !D !X;"]W;W)K&ULK59-C],P$/TK MHX 02,NF3=H4EC;2M@N" ]**!?: .+C)M+%P[& [[>Z_9^RDH=NF%0FTLAR M[U2*,!H,DK!D7 ;IU*_=ZG2J:BNXQ%L-IBY+IA_G*-1V%@R#W<(7OBZL6PC3 M:<76>(?V6W6K:19V*#DO41JN)&A.6[,W!A?)4JE?;O(I MGP4#1P@%9M8A,/IL<(%".""B\;O%#+HCG>/^>(?^P<=.L2R9P842]SRWQ2QX M$T".*U8+^T5M/V(;S]CA94H8_PO;UG800%8;J\K6F1B47#9?]M#F8<]AF)QP MB%J'Z-!A=,(A;AUB'VC#S(=UPRQ+IUIM03MK0G,#GQOO3=%PZ52\LYIV.?G9 M]!XI:(N:H!%L@< $"J1RS58K>JEP)RT MR%0MK0$F<8$X$.%FJ-#954E./E81=; ULY2K3J("V &MJ2J M^SJWS)+Q[GS2*P<2WQ'-:JV)BS^3$:>,5\S9EBS3"C,E54)NW)$;GR6W:.^_>UDJATJK#7>UM?<.-U#)WOGC9'3 \=CF M[;B?8M)13,Y2O-?<(KWN52^GY.B\U_$!I1Z3$UF;=)0F_R8IROR$GI,CK29O MD@-BQS;[FC?,PKVJ7*)>^V9EP+^FIAITJTT_G%,_]'WC8)WZY+5O#^%?F*;) M?F::+J8!@2N"'%Q.B)%N&E&ULK55=;YLP%/TK%JNF5NH* ?*QC""U0=/V,"EJU^UAVH.! MFV#5V)GM).V_W[4A*&EIE8>^8%_[GL,]!W.=[*1ZT!6 (8\U%WKF5<:LI[ZO MBPIJJJ_D&@3N+*6JJ<%0K7R]5D!+!ZJY'P;!R*\I$UZ:N+6%2A.Y,9P)6"BB M-W5-U=,-<+F;>0-OOW#+5I6Q"WZ:K.D*[L# M3+/8YKN$7PQV^F!.K))#C?LW]UVE%+3C7,)?_-2E/-O(E'2EC2#3>WECZ\,!8!"_ @A;0'@J(&H!T:F N 4XJ_U&BO,AHX:FB9([ MHFPVLMF),].A43X3]K/?&86[#'$FG4MA%)J/YG$J"M $CQ(Q%9 GH$H3$"64 M)(,"ZAP4B0:7) S"V#VC2T)%:6-+6&K]2*55QU%?3 YZ?#HQYX=CH\/(;[ M:'KG?-@Y'SJ^Z!6^ZZ*0&V&86)&%Y*Q@Z/V?ZUR[S_&WSYV&+^[GL_UAJM>T M@)F'#4"#VH*7?OPP& 5?^KQZ3[+LGB8;$/"3Z5,0OWCT2*!L NXOI33[P/:P[HY+_P-02P,$% M @ -F]_6FOOBY[- P 80T !D !X;"]W;W)K&ULK5=MC]HX$/XK5EI5NU+9O ?8 E)9>KK[T&K5[5X_F\00:QT[9SO0_OL; M.R$;()O>]D "',?S>)YY[/%XMA?R2>6$:/2C8%S-G5SK\M9U59J3 JL;41(. M;S9"%EC#H]RZJI0$9]:H8&[@>8E;8,J=QS,-?V=SQC$>$D50;" Q_.W)'&#-(X,<_#:C3SFD,N^T# M^A^6/)!98T7N!/M.,YW/G8F#,K+!%=-?Q?Y/TA"*#5XJF+*_:-^,]1R45DJ+ MHC$&#PK*ZW_\HPE$Q\!/7C (&H/@U"!ZP2!L#$)+M/;,TEIAC1AC6"P MF!2Z6A&-*5/7:(0>'U;HZNTU>HO>D>P8P(4 ME$,#E%H-!_CP(OB'H< MNOOOYN& .V$K:FCQPA?POE0%D5@+>8NNNJ&Z[HM5#17U0YDLNH91T-H2^^0-*C'!8J05=,J'ZV-41L(4R*VRVB M((QG[J[+XGS0* JG7COJR+VX=2\>%&5%N( -;&7I\RR^I X7 CLBFK1$DT$= MOMO4"5L>[V 5;@GB5;&&3=^FA4,NJ?U\8#2-XR3TXG[=QBV=\>OHX"RC)L]A=J" %9R"X#\PXS!(-4F0\A&DQA%P M)3^;S"E*8ZFZ*=9"]#$?GQ$*DO$DC),3XH/N]VN-!F2>M'&9_*[,AYS_*J$G MYT+'7C"9^*>[\WS@L-#3EM!T<(,N[>(\.J>Z!'HW[?22F_9"8$?D?>^Y$/!> MESX[)_6[-Y/ ]S_4^[?WP*VQQQU1O!MO[!U]_!,A>XQ&8#7ME]'OE#3^<*;M M*SE^*64#>B$M+X5V'(+@.03!_Q:SV:6]L0A^1\YSHSXYW4ZQ"F7*UM;P"O2I MN*XKKK:WOBAK.OY M^D&+TI;$:Z&AP+;-'.Y 1)H!\'XCA#X\F G:6]7B7U!+ P04 " V;W]: MXS.7?QH& 2)@ &0 'AL+W=O=)*=6XCIA*J/T"6LZ2S#F?NYX. MR.[XRNB]K/Q&FLJ2\Q_ZX#JXZ-FZ1S2DOM(0!/YMZ9R&H4:"?OPL0'O[-G5@ M]?,/)!9$DGG//S& K6YZ(UZ** KDH;JEM__00M" XWG\U!F?]%]<:_= M0WXJ%8^*8.A!Q.+\/WDHA*@$.-Z1 %P$X*QHK% M:[3@(?,9E>C-%56$A1+]280@6OVWZ#WZ%WOSZ=F(IZ(W&M/RBYC&QZKC40?XH &=0 +:.RYX$$7],^0Z[Q"V<;^A0_.7A[N&[KA[ M:=T,SSV"MQ!0;$+MWJ%%J#4E<8 ^_$Q9 E6@T/=/<#NZ5C22?S>)EV/WF[%U M<9_+A/CTH@?5*ZG8TM[TMU\V)MJSR,+;V2QV#/8V#D\96':42!Q9*H1A)YN%24%;T_!,U*XS4< ./@<:OT?&!06([719Q(NLG*'E&5IXQVH@^UA_U ?[R 5 ML#VJW5>C/MQ3'[Z$>E//AH?)A]W^\+!KAS>Z0SP>'NW;:-^WD;%O"ZY@1F D M!*6C"-8VF/7]'T^&($I21;*5#V0.6)@JN$*)T,I+K3N2&R(:"8X.I?>&HT-^ MQEZ^,C7'>PW&1@UF(,#[C!:L*RA)-%.)Z$,AP4KPZ*D(+R-O;/;4>71\H.1H M-#XZ_HY=+L*VD?UG06)93)-\"W0^@U5"WV]HM*2B<7DP Y[*JRVT.OV*!W$Z M7"D+\+:D: FM+@4NI<"OG:>*R.K\TQ\T3%,-]WD#[WB6EG[&,?H$&"::D)T> M$XD^ZH*R5( Q](PW.@GJ@K>=/(/,<:5?+5/AN/GV9U%\;)*9V3 M8[9.![D/HQVDX(FNH&!#GH_Q;"THS7Y]8VJ#9KH<)(]A89_#ZH2N8[@>,'W] ML6+,U6'LTLDIT1):7<#2?SG#+JO#Z.Y.EJ(EM+H4I=USGO%[)U7'J*$Z;.=I M=73AW9S2O#EF]U89R"*?T;_HAL4L2B-SBK=JS]I"J[]]*%TBPT295$B*D1-(-#^$Q)DH$F-M\#M7:9)<"1*2D<":5=)6&\(RY:G0_ MSS3HHAT\#S15T-P<^5HI2D>'S8ZNN3;(P[.U8<8].2%:0JNK4'I'W.7+,-RJ M3VP+K2Y%Z1.Q^858![5A;A#;AN+HPBCBTBABLU'\M%?@NJK B:N(N9&3TZ,+ MIXE+IXF]+BNE5<_8%EI=BM(S8O-+NPXJQ=R@:17IPC/BTC-BLV=\0:&\9$EI MR286DG1A.G%I.O&XRT)IU7FVA5;_T%0Z3]?\_K#]0GFFP>'Q0C%'OE:*TGFZ M9B/XE]KH=U D88J$V2>.QSQI3I/35AISXR=_ENO"F;JE,W5QEQ\H6[6G;:'5 MI:A\JC6_VNR@@,P-F@JH"WOJEO;4-;O%_U% +UB!S(V?G#5=N%>W=*_NH,L" M:M6UMH56EZ)TK:[Y_6@'!61NT#$\U)A#3]7"JNRNB:A89YN.),HVR.2;4_9G M\XU-E\[Y/-O_\^3\S#F?9=M\K!(FWRUU0\2:Q1($6@&D?3:$P13Y!J3\0/$D MV\.SY$KQ*/NYH22@0M\ UU>]/VT@> MQ_%_9<15ISV)A=A. NU1I"WUCQEO=ZMV=^\!V@R4D\YI),E^=O]VZ*XO;-X6$^N8EG M47Z0WL;S\IJK-)M%17DQNS[,;[,XNEPTFDT/[<%@?#B+DOG>Z?LS* M2X=/RF4RB^=YDLY%%E^]W?O%>A,>+1HL;O%7$C_D2S^+ZJY;3#>T,"I&SBK#88;&@SK!L/5!J,-#49U@]&V M#<9U@_&V]^&H;G"T;8/CNL'QMG?Z==W@];8-K,'W9VZP=9.G)_MQTCW.DL44 M>Q\5T>E)ECZ(K+I]Z54_+.;IHGTYLY)Y55*?BZR\-BG;%:>_I46B4D67R:%F*1EW>1%]9OB)A97Z;0LOV1^+7YZ'Q=1,LW_)7X6?WY^+WYZ M]2_Q2B1S\<=->I>75'YR6)1#JSHXG-3#\!Z'86\8AB4^I//B)A?N_#*^;&GO M=[2WNX# ##AC W!8/JA/CZS]_9$]LXWBAR@[$ -K7]@#>]@RH/?FYK^E]P?" M-+?;GH^.YG?3 ^$L!F^U#=XW-W\?3[XW;[WOP6AM#LC9( MS"4QC\1\$@M(3)*8(K$0PK3:&#W5QLAXL'@?7Q1"SO,BNRO7/<6^>!_GDRRY M72Q?RIKY*\J2Z&(:BT]1$8MW4?D*KZU4C)WT+142L>,%5NV_W)\.#@;6R>']\F0G>PRVZ5&2/2H2"R%,F]5'3[/ZR+P62,H7 M_L6W^V0ZK?YZS[\L5NY_9'>Y>5E@5/O.91)S2"?+@F.R-DC,)3&/Q'P2"TA,DI@BL1#"M-IX_50;KXW'C4_QM'R51/,\6D0:^YM>_KPS@^=6:RT9&_6M)1)S2ZV_'#H>#9;_ MM_+J*" '($E,D5@(85K)6(,F&1ETO-AJ/:#LB[.[+"O7%.)=FF6/DK9XC82'97:HL>0ZE&?[4LY MH&6>[>G\^N<_XFPF]'G?.J7-U*8I;6S5>TJ3FHMJ'JKYS]%$:P(*01*]?XH: M5D@-2Z\@NZD@^]F+\]_+DC(MT,UT[]H@-1?5/%3S42U -8EJ"M5"2M-+I8FT M+6V^UUA6;C MJ.:BFH=J?JWU6[RC0Y"HIE MI#2]?)HLW#+GIM0"WMS+II)",W149MV4.O7NMXF5T:3KUF[B=0O-UU'-134/U7Q4"U!-HII"M9#2 M]#)I@G8+3]H[Q'.GO:[0K!W57%3S4,VWVO-V>[2ZQ$ S=E13J!92FOXIN29F MMW](S-[1RX8J,K?J6T6HYJ*:AVJ^O1YHC\:#X4H-U;<:&V\ET9&IECX=^_7Q MRD*=ZE.?\TW8;G-A>P>U:6*C83NJN:CFH9K_'*UUH4Y!$KU_JM:6R\,^ME;W ML:@^]?)HDG3;G*2OK,*[PG.SUGNNH^$YJGFHYJ-:@&H2U12JA92F5T<3GMN[ M"<]M-#Q'-1?5/%3S42U -8EJ"M5"2M/+I G/;3P\[Q#/A^UUA8;GJ.:BFH=J MOMT>GJ^MQ-%>):HI5 LI3:^8)B^W?TA>WM'+IBI"\W)46B M&PY6I[:J;[7REI&U MA%XFTWB;=M3KS+GZ/YY33.NA-OL]1[)J.)-ZIYJ.:C M6H!J$M44JH64IE=&DWC;NTF\;33Q1C47U3Q4\U$M0#6):@K50DK3RZ1)O&T\ M\>X0ST?M=84FWJCFHIJ':KZ]9>*-]BI13:%:2&GZ^3R;Q-OY(8EW1R\;JLC< MJF\5H9J+:AZJ^?U6$AV9VJK/D.I3G_--XNUPB7<'M6EB MHXDWJKFHYJ&:7VM=$WL]-VZ;V&A6O56?(=6G/K&;K-HQ9]5/Z^>MHFHSUGN2 MHE$UJGFHYJ-:@&H2U12JA92F%\?2JJOE.:U3]>FT)C?8J44VA M6DAI>L4T4;7S0Z+JCEXV51$:5:.:BVH>JOG.>E2]MLQ8SXS7UAAH2-W2H=VR MQMA%2.TT(;7#A=0=U*8IC8;4J.:BFH=JOK,>!*]-ZN 3Y$7Y/9W6R[-<"9N9?>58/&RJCF MU9KI+,0^VF. :A+5%*J%E*9_(UX3*0_-8>^G^#Z=WB^F^NI!HWY=)?XGWMWE M9;,\%[^FT5S\L&U5Q4\U#-1[4 U22J*50+*4VO ML"; 'EH[>5$V1&-I5'-1S4,U']4"5).HIE MI#2]3)HX?-AU$G3D19FYE]Y5 M@^;DM;;\,NIX;7_%0_OT42U -8EJ"M7"EN=JO/Q' T6OVSC^;.J!:@FD0UA6HAI>FET*33PV>FT^[7VZ3\(UH=)=YO*@(S M_?ND.!!B8.T+80^J]Q^T3'PT4.X8SXIDTH?K0F$9B&U-HQHYJ;JV9STKA MH7WZJ!:@FD0UA6HAI>G5T&3G0W-V3FU@H=DYJKD=CT#'CA;Z"6Q4"U!-HII" MM9#2M"(9-:'ZR!RJOWQ'R]Q!W_I -;?6.G>TT%Y]5 M03:*:0K60TO12:-+O M4QG4TH?>H5^C],*.:6VO'VI%B[3"!YMVH%J":1#6%:B&E MZ870Y.(C$INNHYJ*:AVH^J@6H)E%-H5I(:7J9-!G\ MZ)D9?+_]7G,OO:MFFY-UNVB?'JKYJ!:@FD0UA6HAI>G5T.3O(W/^#FQEH:EZ MK75M/KEHKQZJ^:@6H)I$-85J(:7II=#DY:..3YZ_9"O+3&_QYBRST/MU$YJ3 MHYJ/:@&J2513J!92FEX>34X^ZI63/VLO"\W(:VUE]VGM0(%^OAS5?%0+4$VB MFD*UD-+T2F@R\I$Y(7X\X4ZU0[6T+_5Y^Z_+,/.]RP -QU'-0S4?U0)4DZBF M4"VD-*U8=)CF6[NH/>1 LW%49MX^8>^E=-=NU -4DJBE4"RE-KX8F,Q^;@VUJTPK]R'G' MF,WGNT*'XJ&:CVH!JDE44Z@64II>)$UR/C8GY\"F%1JZS07CU4\U$M M0#6):@K50DK32Z&)SL?//#7[-IM6:&S>,= /T3=A.9L_W^>BH_%0S4>U -4D MJBE4"RE-*XZC*BC7?]-D@D<=WVAL_?TYF4]BH>ZFW\JI: WWQ4,L;J+[6,RB M9%Z4_\67(A(7T?S+STF>WY67ID_?H#-YK+*K-!-WMZ)(Q2MG()J7/\+2+[P: M[Y>+!O'J>/'/TE6#@Z-1N;[))C>+S[Q6)2%^GQ3I1=G-X^61>#5S.+N.S^+I-!>3]&Y> M5)LC2[\567Q5/D?6FW?VWN'Z[X\&;U3YY+9=8Y776-4UATT7IR>WT75W;O7)67*1%D?U5FA;? M+U0=/*39E\5=.OT_4$L#!!0 ( #9O?UKQY@XP2 , - , 9 >&PO M=V]R:W-H965TM M4BNA/K8/U3Z8Y$*L)G%F&VC__6PGA(1'MDKI%["=>X_/N;X.A\&:LA<> 0CT MFL0I'QJ1$-FE:?(@@@3SVHQ)TQ$\":UX9(R5E1NF+FMR$0\-2C""&0"@(++]6 M,($X5DB2QY\"U"CW5(G5\0;]6HN78F:8PX3&OT@HHJ'1-U (<[R,Q3U=_X!" M4%?A!33F^A.MBUC+0,&2"YH4R9)!0M+\&[\6A:@DV-Z1!*=(<'83.D<2W"+! MU4)S9EK6%1;8'S"Z1DQ%2S0UT+71V5(-2=4Q/@@FGQ*9)_Q[B+& $&68B3=$ M4@$,N$#P*ON$ PJH/# N.*)S)") @< DYE_05_3T<(5.3[Z@ M$PF 'B.ZY#@-^< 4DJ#:Q@P*,N. MV&E$O(+@'+GV&7(LIW. T.3_T]T&.FY9;5?C=8[@C0$'44!9=H9N;R?H^0Z2 M&;#?ARK5"*0N]R7/< !#0]Y>#FP%AO_YD^U9WPZI; FLIKE3:NYH=/>(YELY M5^TS81 2@:YQ0&(B>^U9/[@1D/"#!>BT68"6P&H%Z)8%Z#8>^N:*3?45>V0X MY5B_P\[0**'+-+]=E?5#UW]X&U=A[)7NO MD;TZ5FGL?TK*]-@O0$EBM /VR /V/;]E\"Z_2 MC?9^R^X'N=6@&ON+DOW%.]@W=6PCSGL/K"6PFF3;VOZ.6Q_2LP5L2S5H"ZU> MA(J9L1M/_F;'OQP4;.^UG-?U=MKR0%"O=Z0M;6=+SVFD-PH"MI2-N6NS#M)T M]E[F[A[+_9B^O4/2K'C#!-A"6V8NC9V\Q;F/*E=S6SY6MEQYRYUU:=='VJ2: M6YCQ%'?*TH M87 OD%P7!1:OUT!Y-;5<:SOP0%:Y,@-V')5X!0M03^6]T#V[8TE) 4P2SI" M;&I=N9>ST,37 =\(5++71L;)DO-GT[E+IY9C! &%1!D&K'\;F &EADC+^-5R M6MV2!MAO;]EO:N_:RQ)+F''ZG:0JGUH3"Z60X355#[RZA=9/8/@23F7]1543 M._8LE*REXD4+U@H*PIH_?FGWH0=P1^\ O!;@?13@MP"_-MHHJVW-L<)Q)'B% MA(G6;*91[TV-UFX(,UE<**%GB<:I^(YM@"DN"$B4<)T8+.T--BCHZ/3M 1(@P]YGPM,4ME9"LMQE#:2;OP=;.P]\["^>(L_Q1@/PV@VP>OVP>OYO/_L@^O:$YD0KE<"T _KI92"7W2 M?@[Y:PA'PX3F]EW*$B^/=[[S[A]CC!USI M(Z5 $$P',]G @QINRL(F=L?^11C9F[Z%_:A)8%*[&9 VZJ2-#DJ[(8SHPYVB M%>?#IZS!A[U51Y-@LB-M/\AS)^]("SIIP4%I?TY,FY$A=<'>PF?NQ62\(V\@ M*AR/A^6%G;SP7X_,X>\C5YBB7ETX10S4D+EP+^'Z,H:[YO:C7,?QW1UW=J^$ MF>?C*Q8KPB2BD&F<&ULM5A='$BPBP3[I0E.D>!D MA>;,LK(NB22S"6=;Q'6T0M,7F399MJJ&QGH8[R17;ZG*D[._?Z8T4<,B$8F7 M* 2E2,#"):)1PMD&]!N!?*:&34C$5D@&@%8L5*-/XS5Z>PF2T%"\0^_1U[M+ M]/;-._0&T1A]"5@J%**8F%*QU+]E^@6CCSDC^P"C2_#/D8//D&W9@Y;T^P,SSF M^!JRG#Y>(86(2EDJD3[=J/"T;6$2'QO*S7''K1C MZREZ(1+BP]10$UA-!J>4P>E"+V5 2:D"/*EPMN9, MM(YTCNEFF'I!VP6O'#LOCA"=>*89\R] 16DV%4RC ZP5HQVNM&6RT6 MN-&S;5&.+4!K"ZV%F^OLW6AT]FXGXM$#UA-:O?[*)6'OE+W;JV/J"ZTN1>69<*<7>6WO M#O?:TL6NTVS>UJ@#.PM<^1O<;7#F:C\L>9H?1*C=KBIAK:1YIG\[,8\>M)[0 MZ@I4A@F/3]F_O7JHOM#JQP.5B;([GR8EB[++ ,@2N Y0[U>,R:<; M?<94GBG.?@-02P,$% @ -F]_6OG+_0-Q @ QP4 !D !X;"]W;W)K M&ULK51=3]LP%/TK5H8FD!C.1_D82R/1EFE(8ZI@ M; _3'MSDMK%P[& [+?S[73MI**Q%>]A+XX][3LXYZ;WI2NE[4P)8\E@):89! M:6U]3JG)2ZB8.5(U2+R9*UTQBUN]H*;6P H/J@2-P_"$5HS+($O]V51GJ6JL MX!*FFIBFJIA^&H%0JV$0!>N#&[XHK3N@65JS!=R"O:NG&G>T9REX!=)P)8F& M^3"XB,[' U?O"WYP6)F--7%.9DK=N\U5,0Q")P@$Y-8Q,'PL80Q"."*4\=!Q M!OTK'7!SO6;_[+VCEQDS,%;B)R]L.0S. E+ G#7"WJC5%^C\'#N^7 GC?\FJ MJPT#DC?&JJH#HX**R_;)'KL<-@#1R0Y W 'BUX#!#D#2 1)OM%7F;4V895FJ MU8IH5XUL;N&S\6ATPZ7[BK=6XRU'G,TN'QI>XU>QA,F"? 5,I%2B(%=5K=42 MW(TA^Q.PC M#OC&MF+YDAU\4XU-I^W3(9D*UB7]G/NOBYFQ&O_.O[=%US(/MC.[%C\W-71C9ZH0"_\J# D5XVT[3^I/VVGT0BGD>_: M5^<;1'7T4I-7YC:F&SEAE"]BPO)U5VB\F3XH\!4$HEU,1&AY;$H M=VB->4SH&LD$T(QE.:9O%V>!ZPQN!$I!E4X@(A 6:,52=1C$"%W.06*2BBO4 M04^+.;H\OT+G2A4])JP0F,9B;$L%K9>VHPIP6@*Z)P =%]TQ*A.!/M,8XO<" MMG);6W9WEJ=NJ^(@<\H^>=T/N> U/14-, =!S7 V7MM)@.^-MU7 MJ(4+*LO7;SU;-OBI:O"F$1[,J\9_:_J=_4>F_&JXPWQ-J.XO*R79O1XH)%YV MXG(@66Z:V9))U1K-9:(^7H#K '5_Q9C<#?0"]>=0^!M02P,$% @ -F]_ M6NVZP!M5 P W @ !D !X;"]W;W)K&ULK5;; M;N,V$/V5@;HH$F =71S;26H+2.P6+;"+!IMN]Z'H RV-+&))424I>_/W'5*R M:CNRT0+U@T52,X=SSI SFN^4_FI*1 O?I*C,(BBMK1_"T&0E2F9N5(T5O2F4 MELS25&]"4VMDN7>2(DRB:!I*QJL@G?NU9YW.56,%K_!9@VFD9/KU"87:+8(X MV"]\XIO2NH4PG==L@R]H/]?/FF9ACY)SB97AJ@*-Q2)XC!^6,V?O#7[GN#,' M8W!,UDI]=9-?\D40N8!08&8= J/'%I2,0](Y)*<.TS,.X\YA[(FVD7E:*V99.M=J!]I9$YH;>&V\-['A ME &F(%" M"3)U3PVV1'A%I@U@E9/M"C.4:]0PCM]#$B6WP*K<#<8/<+5"R[@PUS""SR\K MN'IW#>]H1_BM5(TA.S,/+5%S 8991^.II9&&8-VD,?D;8A1?'_"8\#H[@R/:<]C>I''%U\?,1^Q+8F]0:H2 MLHOQV297D9:=8AQ=$> MB@K46Z@C86:],+/_)DQ.=U,UE052 M\H,B1#N\']0;JBFV@V/4GJL%5T?_0[ M27)XT"@DZHWOGP9\?&UI[%?;%OU$+=JWLI-U:MV/OF.%_\"T??\CTQM>&:)7 M$&1T,Z-CI]M>VDZLJGT[6BM+SX47%14X53,7=D(H+DQJDHW\+S(K2BKG71LUFY%.N:M*ED-MX+(MJJH>+V& MDJ\FCN^\+=RQ^4+I!3<=-W0.]Z >FUN!,[?WDK,*:LEX3004$^?*O[CVC8$Y M\9/!2FZ,B0YEQOF3GGS+)XZG%4$)F=(N*#Z6< -EJ3VACN>U4Z=G:L/-\9OW M+R9X#&9&)=SP\A?+U6+B) [)H:!MJ>[XZBNL PJUOXR7TOR2U?JLYY"LE8I7 M:V-44+&Z>]*7=2(V#()@AT&P-@B,[@YD5$ZIHNE8\!41^C1ZTP,3JK%&<:S6 M;^5>"=QE:*?2AP60HE6M /2*#Z882,(+HG#CAE<-K5]/CI+ CR]QN0%!%:OG MI 3,A"34')U"!M4,!!GXGTC@!4-"T1WN%;S$MRXOR.D4%&6E/"/'A-7D8<%; M2>M]WI#7;H1=;Y.^?Q?DI.C\\^NG$Q!7T>@CX/@?$[V.$7 M0ZV8PL]-851UCJ'7.E"H,YV/*9-9R:7.TN^KF50"/Z8_-O$=9&B'Z J[D W- M8.)@"4D02W#2DR,_\B[WA##H0QCL\YYB1D*;ILXJ-%:Z2)>I/XKQY-+"&O:L MX2%69&-U5M$'EC>RL\*>%1YBQ396:&%%.^**>E9TB)786-$V*TQB.RON6?$A MULC&BBVLD6]G)3TKV>72@0-F*R11QZP0[BJ">.]A.YHB5IZ*NI*1MU MM!WGP!LF=JSOO36"IOHJZ7_9Y#^!5!+ P04 M " V;W]: C8/#X0" #H!0 &0 'AL+W=O6M*V.DD=:6"22&IHW!!\0'-[DTUOP2;*<= M_YZSDX9N:B<^\"7VV?<\=_?$=]E&Z0=3 UCR*+@TTZ"VMKD(0U/4(*@Y50U( MO*F4%M2BJ5>A:330TH,$#Y,HFH2",AGDF3^[T7FF6LN9A!M-3"L$U;]GP-5F M&L3!]N"6K6KK#L(\:^@*[L#>-S<:K7!@*9D :9B21$,U#2[CB_G8^7N';PPV M9F=/7"5+I1Z<\:F8C]/6<.;Y"<>._9-/Y3M* %*VQ2O1@S$ P MV:WTL==A!Q!/#@"2'I \!XP/ -(>D/I"N\Q\60MJ:9YIM2':>2.;VWAM/!JK M8=+]Q3NK\98ASN:? 34@A.;_#D]?2"<=!$T]7WJ ;U=*E BEE9;)%Z#$>]!B_Q-X_,,[HDG%FG094,X.*D$HK0=02'YMTIG8--U+5J$5_:@S8 MO<^KBW;FH[D1M<[C*'Z7A>O=@O#3U='N-,T O3*SQ)#"M5*V[V^X;0; M5S,<5[ZMGYWC&+OTW1O^I>EFX#75*R8-X5 A973Z%C/2W5SI#*L:WYI+9;'1 M_;;&40S:.>!]I93=&B[ ,-SS/U!+ P04 " V;W]:J>ECR94" (!P M&0 'AL+W=O]4#J#)?<%+M7!RK:N9ZZHDAX*J]T2AR M"\I*)Y[;L;6,YZ+6G)6PED3514'EPQ5P<5@X8^=QX)KMT1UL0-]6 M:XD]MV-)60&E8J(D$K*%+2,3;P-^,#BH7IL8)ULA[DSG:[IP1D80<$BT M8:#XV\,2.#=$*.-/R^ET2QI@O_W(_MEZ1R];JF I^$^6ZGSA3!V20D9KKJ_% MX0NT?D+#EPBN[)<UTJ)HP:B@8&7SI_=M'GJ L-%7<:(FS#'$ZODP264-*X![WA0)% M$H$54IJ(C.@<2"8X%IJ5NQDY78&FC*LS\I'<;E;D].2,G!!6DIM6'X%R3GQQQ^(-_*" ?CR[7#_*=S%1'39\+IL>);/?X%O M31_HEF,6T VQJ:%?\U]FXK5/1!8M5M#B1PJGO;8R@!#6MH6#%YIG$@R)L.:PP[ MC>&K&K_C&9)#@L+CM8+>8HV@XZ!@&@T+BCI!T;]NH1NA*1_2&AW5+I@&%\^T M'@=-HXMG6MW>/67>B&]4[EBI"(<,4:/S"<)E<^\V'2TJ>W5MA<:+T#9S?*I MF@"&PO=V]R:W-H965TZ>[AVM7O;/E1]<&!(K 5,;9-D_WW'AA!"'-2K^I)@F!F^&0\SX]F> MBU>Y!5#DD*6YG#M;I8H[UY71%C(J;WD!.3Y)N,BHPJ78N+(00&.CE*6N/QB$ M;D99[BQFYMZC6,QXJ5*6PZ,@LLPR*MZ6D/+]W/&3XNS;J-._4BNWKH_7/QGET9DTEK'CZ!XO5=NY,'!)# M0LM4/?']%Z@=,H 13Z7Y)?M:=N"0J)2*9[4R$F0LK_[IH0Y$2\$+KRCXM8+? M51A>40AJA< X6I$9MQZHHHN9X'LBM#1:TQ] MB'@>L911$U>>$)9'/ .BZ(&L(8>$*:(X45L@-.-EK@@^+DH%,5F_$5H4Z1O+ M-^;Y9XA!T+1M05 %6CWE4J(Y3#P@A> [9A(!ERUAD(1*3? $61K$"3P/A)_ MX \)S6-]$1!F9!*>8@+*._+^ 11EJ?Q ;LC+\P-Y_^X#>8J8[*L8N)?B8GGDV\\5UM)/N4QQ.<&7 QP$V7_&.6EWVL1_;EM?+$ MK?Z]>M"#$S2;'AA[P15[7ZN(?\?M>6 RPJTI<5?^O%]+)?"[^LL6LLKBT&Y1 M%YL[6= (Y@Y6$PEB!\[BYY^\.'% MNT<=NDL)_PK=N*$;]](]88T3<6O/K61C2^"\L -G%9K8\28-WJ07[Q&P(>6 ME543UG'$ZHC5/WHEO- +B4$%$3'9+4@5^^02R^]FIT4FO!+8:4,^[25_5KJ\ MGS+R(\EQ], D3>I.4#<0:[RG%SS>>-IAOI2Y\<*1'=H;G)K>H!?[TZ%@HNEW M!KD ?0/[F&Y4NA%AP^G)E?H%;; @\#OP%B%O./6OT+=:MM=/GR0X!&GR:$OS MC8Z_GEQ (&[3/LG8O\'XGV6UE9._Y*A^QU:9,+!%CJ:=VII7G]/6S5YL*-I606:Z@F)YI$] M$X:V,A9,NAY9Q(+A\$J83QW-ZVUI/S@M+&MK[;;J7Q0WBU#8X71;8W(&8F-. M#Q*G69QIJUFNN5N=4);ZA*+'[,Y]/+G&UL MK5C;;N,V$/T50ET4";")1-ULI[:!C=.B"_02K+/M,R-1-KL2J9*4G?3K=R@Y MLFQ12@KDQ1:IF>&9"^>0FN^%_*:VE&KT5.1<+9RMUN6-ZZID2PNBKD5).;S) MA"R(AJ'NY>+N>BTCGC]%XB514%D<^W-!?[ MA8.=EXDO;+/59L)=SDNRH6NJOY;W$D9N:R5E!>6*"8XDS1;.)WRSPC.C4$O\ MQ>A>=9Z1<>51B&]F\#E=.)Y!1'.::&."P-^.KFB>&TN X]^#4:==TRAVGU^L M_U([#\X\$D57(O^;I7J[<*8.2FE&JEQ_$?M?Z<&AR-A+1*[J7[0_R'H.2BJE M17%0!@0%X\T_>3H$HJ. PP$%_Z#@OU4A."@$M:,-LMJM.Z+)J#+Y,7%&>DL1AUJ"642S M#*84$AG2M"B%A*RCE,&LI#P!I4>J]Y3R6BDA4CXSOD&D$!5OM(A2%)X(3U'. MR"/+F6:@!J6(,L8)3QC)866PK(UF6#TL+ZHI$GPB;OHXHYJPG)UB:[0U_4=NOAPB3[ 6_2P%96"I=7< MU1!G$RTW.<3TMHFI/QC3Y!H%^"/R/3^TJ*_>KAZ\"F?QW-UU?;$)32:MT G&L,48 MCF+\M%ZA:>@C:,J2U$6?4VA)S4ZQ(6W,Q5T0>!9,SZ!:I2:1'6O48HU&L3X( M#=LS':@E&]BH#\,/@_ ,K%4J\NU@XQ9L_/:2;_J.M=KC]ZSV=S)VXO"D=7@R MFIT_H$EWJDA Y=.QP!OU\#/? 6\*H'A#OP+X5R*2PZ&/&*ZW[1<@/9@-@.V<8_)9>;PZ+YI0 YX?_!IO]P5070>R=HQR5.05Y9&$\ M2G=0\R$RB20RV=9!I4^P8?]8JR+X2# 8!'OL/CA&SJ2'1YGN]^@.=TT5-_\[DA>-231ME0K[#YS7>$@C/ Y;IM<&$T'3J?X MR')XG.:LET,KTO?BLGP\3*P[%U/8-_(YHK?#+0H MZUORH]!PYZX?MY2D5!H!>)\)H5\&YN+=?FA9?@=02P,$% @ -F]_6F6' MW@A+! J18 !D !X;"]W;W)K&ULM5AK;]LV M%/TKA%8,"=!%(FW+C]D&$J?#,B1MT+0=AF(?&.G:%BJ)&DD_^N]'2K)D13+; M"/(76P_><\^Y(B\/.-TQ_DVL 23:1V$L9M9:RF1BV\);0T3%%4L@5F^6C$=4 MJEN^LD7"@?II4!3:Q'%<.Z)!;,VGZ;-'/I^RC0R#&!XY$ILHHOS[#81L-[.P M=7CP,5BMI7Y@SZ<)7<$3R,_)(U=W=H'B!Q'$(F QXK"<6==XLB!$!Z0CO@2P M$T?72$MY9NR;OKGS9Y:C&4$(GM005/UM80%AJ)$4C_]R4*O(J0./KP_H?Z3B ME9AG*F#!PK\#7ZYGULA"/BSI)I0?V>Y/R 4--)['0I'^HETVUG4MY&V$9%$> MK!A$09S]TWU>B*, ?"J Y 'D94#_1$ O#^BE0C-FJ:Q;*NE\RMD.<3U:H>F+ MM#9IM%(3Q/HS/DFNW@8J3L[O8H]%@#[1/0AT<0N2!J% [RGG5-?W$OV&/C_= MHHLWE^@-"F+T:GNLE2D1.I,$$/+)9K@=[%/OA5 %OQ M+LB3 _D;8D2\!>\*]?!;1!S2;R"T^/GPGH%.KZAE+\7KG<#[D("N6KQ"]TP( MM%!%_*X6VHYR7Z"O]VHTNI,0B7^;:I=!]YNA]6*>B(1Z,+/4:A7 MV#-?_T% MN\[O3;H[ JM4H5]4H6]"/\PH2?]!$.<-VC^A@[#@O M.-<']8[&5%B[!6O7R/I+G=Y;%*L>SXH9%^H9YU5FG%JE2> ]FX6-T:SU%= MC%O[ $-\2LVP4#,TJGG_ ^)-9(F%##S= M2M%?&QX(/\AVJJ\/$#T#;USU1LS7KOJ.P"KRQX7\\?EZW[C+*G0$5JD"=LKM MU#%.@P^F%0G[).#90E;# N8C(2F7C5NI.8W:L09-XLUA;=4?F0GWCCQ9 M+O\<#@^7%@^/SMC<.O5Z7:%5*U&Z/6RT4>V:V[C6W'INW<2;,[=41DH#1\S. M2MOW?X!R-;7QR#BUS4"O_:!=H55EE\Z-X/--;=*1\\HK<0X?1TH?1\P^KLW4 MSB$K!Q6CVLPV)WZM,/OHT"\"ODK/0A57MHEE=H16/,W.6V_P9)$>2[YX?HTG MU^GIHUW"9(>X#Y2O@EB@$)8*TKD:*H$\.Q?-;B1+TJ/%9R8EB]++-5 ?N!Z@ MWB\9DX<;G: XG9[_#U!+ P04 " V;W]:9(-4S3\% #Q(@ &0 'AL M+W=OEWU)%'<[JG M["O?$B+0]S3)^,S9"I'?N2Y?;4F*>8_F))-7-I2E6,A#]NKRG!&\+HW2Q T\ M;^2F.,Z<^;0\]\SF4UJ(),[(,T.\2%/,_GD@"=W/'-]Y._$Y?MT*=<*=3W/\ M2I9$?,F?F3QR:\HZ3DG&8YHA1C8SY]Z_BX*^,BA;_!Z3/3_XC-2CO%#Z51T\ MKF>.I^Z()&0E% ++?SNR($FB2/(^OE50I_:I# \_O]$_E \O'^8%<[*@R1_Q M6FQGSL1!:[+!12(^T_VOI'J@H>*M:,++OVBOVPYO';0JN*!I92SO((TS_1]_ MKX0X,/ '9PR"RB"XUJ!?&?2/#49G# :5P>!:#\/*H'QT5S][*5R(!9Y/&=TC MIEI+FOI0JE]:2[WB3'64I6#R:BSMQ'R!\UC@!"T%77U%-R$1.$XX^H09PRJ$ M[]#/Z,LR1#<_OINZ0CI49NZJ@H<:'IR!^P%ZHIG8?]8\M)N'9-5#_?/FT?7F?8L8_3IV M_9+7/Q>[!'..Z*8*WE\?Y77T*$C*_VZYN0<-&[3#5$*ZXSE>D9DC,PXG;$>< M^4\_^"/OES:=(6$A)"P"@AD1&=01&=CH\V>9Y0AC9(VX"LE[Q+=8>D&X$%O* MXG^/WP$=&"NS:V @8:&&C4J8&G)V\V#@3293=W>H^*56AI3#6LJA53#:,IXC@AJKMK4=N4M"*[*@D)"S5L>*#1R"M_CK3\'TZ1I>..:K5' M%]1.4RESU6MSS- .)P5!-W&&UC1),.,H)TQ+WS82/%CY7:77L/&!6E[/\TVI MPFL:11<:&6*-:['&'<2RO]M64E=9QB-KP=MC:W:X@&A)-:HDF ME][>'6$B?I%O;),4EUJQI4Z*CYP7\F212RUU>S7[;!/1ZJNKB)"P<'*BGW\J M,I!'(Q"W=2!NKPA$.:W/6;PB;?):"5WEO3U)=(/@N'M".HR 8(:ZOM=,G[UK MKRJ"T$)060=',B!P4-#[DK+BB0<4%DA:"TB(HFAF7 MH(E+8'U3/A7JW6CF;R@N\W]K3*RDSC&!I(45S9CM>H/QR N&1VF_I67?&PW' M@_:AU6_*/M]:P\R7A_KI\7-E'3\KGC%,MR@:*;J36GGVVN[ M)6&Q5/W/X_F,/>N#UG:@M!"4%D'1S.@TU:(_!,WZH)4B*"T$I450-#,N35WI MVPO++ED?M(2L:" MEGZ,OQ7Q6J=SG3A(=J8K@U:E%^HZX0:E15 TK;)[\-5^2MAKN:="B5AD0G]M7I_5^S9"_RXJMS<XTSCA*RD4BO-Y9]DNG]%?I T+S<0/!"A:!I^7%+L)P$ MJ0;R^H92\7:@'-2[7.;_ 5!+ P04 " V;W]:J+J">B8# !4" &0 M 'AL+W=O%-QV[M5DW'"WQ-;^?--#8,AN6N/0<%4S$\?"9*N#:8Z1]M!I?G]]O/MW7I0NCVJ(W??LF&';?MYGSG\B>6-6OK>H?8J^L*F]NVXUO"[YD'#A&6T.W MTU$X&/O;9DPM>T:]>L\3J8-:ZN"@U#NT-9N+-6Q$XR-\K>K!/XJ"[F#T3';+ MIB X;]<]K'4/7ZF[<"67-+,M*NH@ISDJ+N-.75ZJL%PHQSMD2I^TA7+XO! < M$OJ0E5]YV(>8[=H*Q?PP4^"8X-V>*#AO(2H]\1L%.D.U=GU+4W(VPI1UI%XM M6^.,6J-K(<_6J65>ND[A_Z4I^^T-4VLN-*2X(LKNV8C2I,H>5DZ,S%T;6$I# M3<4-$VK[J.P&>K^2TNPG]H#ZC\3T#U!+ P04 " V;W]:5;J2+4\# ^ M"0 &0 'AL+W=ON'EQE27OJ^3' NFA[+"DF8RJ0IFJ*O6OJX4LM0Y%<(/ M@V#B%XR77CQW8[HQ 6B&C\:#&];DGK>-A^0'_KM).6%=-X+<57GII\XX=MGHN+%XBA79?V+6V@0=)K8TL6F=B4/"R^;/[-@X'#J/)(PYAZQ"> M.HP?<8A:A\@);9@Y63?,L'BNY Z4M28TVW"Q<=ZDAI" M)9O!79)+0;[2V4*E>&+!"YFBH,54.Z%AK5AI",>.,2%@CTQILD>-=OP2GM^@ M85SH%S" I^"#SAE-SGU#RBU_/VE5+AN5X2,J1R%\D*7)-;PI4TR/ 7P*61>W M\"%NR_ LX@TF0XA&+R$,PG$/H>L_=X_.T(FZ-$8.+WH$[\X&9K!D-BNW;$_' MS,"5HO"NT;6_7:UL1A/SO2]X#?:X']O6D4M=L007GDN-VJ(7/WLRF@2O^X3_ M)["C,(R[,(S/H<=?W:G%=,"VJ*@(@>)Z,\@4TJ:F'44+&G#[NB\*#?0K!VV+ MWS8.AL&8LK,]E-=K%%QWOB[.\;_B6IUBFL.G]07(S!W]YDSW43^_RK@Y]7T[Z1\."FWV?R.GOT1^^&IVDJ-.* M2K:H\3@U7;GMH]^L,3U@-AI.QR?T?S<*AAC_@FE>%A^86G.2(S CR& XI9VOFMNZZ1A9N0MO M)0U=GZZ9TP,'E36@^4Q*\]"Q"W1/IO@G4$L#!!0 ( #9O?UKU%D="VP( M .\' 9 >&PO=V]R:W-H965TM(9HH'G7!1ZY&7&E /?UTF&.=,=66)!*PNI[#0\<-WIO#%;)7,HG.[E)1UY@ M$T*!B;$,C/[6.$4A+!&E\;OF])HC+7!_O&/_XK23ECG3.)7B)T]--O(N/4AQ MP5;"W,G-5ZSUG%N^1 KM?F%3[PT\2%;:R+P&4P8Y+ZI_]ES[L ?H]@\ PAH0 MO@7T#@"B&A YH55F3M85,RP>*KD!97<3FQTX;QR:U/#"WN*]4;3*"6?B<9IR MZR<3D'*="*E7"C70\P!9V@4-2\4*@ZF+,2%@BTQIH#>CT<8'<'*%AG&A3^$, M[C.F\&Q"QJ8P8UNZ;P-C10Q+M.-/\-VQPN,MYG-4OX:^(14V%S^I,YY4&8<' M,NZ&<"L+DVFX+E),7Q/X)+_Q(-QY, F/,EYATH&H^PG"(.RU)#3]=WAT))VH MN9+(\44'^/8MG,JO''#]U^\+G-G/]$]LJJ7F-5[QA[_(#:\&())2HN4SAQ3_,4 MY *T->?E[?*BWM-FQ_$SHNK!MTE_!_"5S/-&YOE1IBF]=T4%;T5?J> +?*_0 MXZ=<'!;Z#N KH?U&:/\HTS5=)Y7FJM@LD!M;C-J45#27CL8VJG4<=(++H;_> MS_HOFZH,_;W:F:-:NI:B(9&KPE0EI(E676M"7142 4NB#+H7)"=JFHOU<3(TE7HN314[]TPHXZ,RFZ@]8649C>Q!S0]/OX# M4$L#!!0 ( #9O?UJU(JYPP@0 &P4 9 >&PO=V]R:W-H965T6:>&7MF\.C ^'>QH52BMRB,Q;BUD7([ MM"RQW-"(B#;;TAB^K!B/B(17OK;$EE/B:Z$HM+!M>U9$@K@U&>FY1SX9L9T, M@Y@^A"%,5)4%HQ]5R]?_''+5A;1D"ZE@B#PV-,Y#4.% M!';\DX*V,IU*L#@^H?^JR0.9!1%TSL)O@2\WXU:_A7RZ(KM0/K'#[S0EU%5X M2Q8*_8L.Z5J[A98[(5F4"H,%41 G3_*6.J(@@+OO".!4 %\KX*8"KB::6*9I MW1-))B/.#HBKU8"F!MHW6AK8!+$*X[/D\#4 .3EYV5"T8B%$,XC72))%2-.0 M!O]2@21\9MO&Z.:>2A*$XC.Z0Z_/]^CFTV?T"5E(; @'U"!&KW$@ MQ2U,POAEPW8"-(F1)8&X,M]:IB1G"4G\#DD'HZ\LEAN!'I0MYP 6>"QS&SZY M;8:-B,"FG3&I,6A^O;AK,,?-HNAJ//<=O&?EL;L9;&$WU M^*_I0D@.$?R[SGD)=J<>6^61H=B2)1VW(%$(RO>T-?GY)\>S?ZDC_C^!G;FA MD[FA8T)/W"#0'SLI).P4V(6W:$;701S#L(YY N=I.)7P]A.WB[L#SQM9^R(I MH]J&I+H9J6YS4K?H9@MG2I^8SW4,$^Q>@:'3QKA$SVA 0WI>1L\STONF$RWL MV^F>ZI#*_#@F?D"#+5)'.?-++?-)K'G)T\P7<$D A7:(]"7?U<4\4=(MQ]^Q2 MV(U&- Q[/Z/8-U+\#9*3+*?BQ/1^]5#V^[9=MMZ(W]#Z06;]X!KK+QV^0>7P MX7:G1,.HJ"$-Q\ZKOVTD\O!&^3(0]8%(98N1N.MTNX-!M\3!K*0IB4(+XUQ' MXE(\4IQB0.QVMYP-S=J:LL$Y&VQD ]WIB@9J=T&?1=^VT%?51P=7HX,['G8K M?(SZFO+)6Q/'6/)K^5P,E%M3MARW3.Q']!I.WFPX'^\V'O2SEE)-KX$=I^<. MRJPN-R7G!N>-A//Q3N(A?5X*2%T?T>F53;_0;9S;G7<(CKG2OF_W=;4PA2\6 M0W?@.67CJZN*)?/<]KR2.U>5\C1%J;]7M1;V*C''V/:\2B-JUM9TR^=%VS%7 M[2J;RSNG7[=S*KQ^1#5W\G+NF.MYE1>ZT=U=/24SF)LVAKU38^B]VV&:D1K2 MQGGUQ^;J7T?[F@.5PA:/"A[TRYV-67E3[AOA(._QL$"ND*(.UV#X+&DZNMY$6RK;X=6C I6:2'&TI\RM4" M^+YB3)Y>E(+L@G'R'U!+ P04 " V;W]:5(%\:7D# #9"P &0 'AL M+W=O;<>9;2!V M5K3 @@5-LGXH]H&6SI(0251)VD[^_8Z4HLB*HG5M@'ZQ2>KNX3T/C\>;[;FX MDPFB@OL\*^3<2I0JSVQ;A@GF3)[P$@OZLN$B9XJF(K9E*9!%QBG/;,]QQG;. MTL):S,S:E5C,^%9E:8%7 N0VSYEX6&+&]W/+M1X7/J=QHO2"O9B5+,9K5+?E ME:"9W:!$:8Z%3'D! C=SZ]P]6[G&P5C\G>)>ML:@J:PYO].33]'<2;-+^QK6\>"<"L5SVMGBB!/B^J?W=="M!S<\0L.7NW@=1V" M%QS\VL$W1*O(#*T+IMAB)O@>A+8F-#TPVAAO8I,6^ABOE:"O*?FIQ4V"P.)8 M8,P40EHHD=(1A;!CV5;/09&!8NN,S-9\1TO2R!8!G0'?"@@S+M,B!HHTO(-2 MI"$"W\"1=^*-X>T%*I9F\AV\A]OK"WA[] Z.P :9,(%2P]\6J9+'M$CCFX1O M)2LB.;,54=,!VF%-8UG1\%Z@X7IPR0N52/BCB# Z!+!)DT88[U&8I3>(>('A M"?CN,7B.%_0$M/I^=W\@'+\Y)]_@^2_@76O%WB^-\BN>TRV6S-R#5"HMBA MM7CSFSMV?N\3YY7 #J0*&JF"(?1**@EXCR),93<9*K(5PM@@Z$JW6P2CT70Z MFMF[-HW!C7Z0QJBA,1JDL6(RH4(9(I6Y7@Z5^ZC%P7-.@PZ#YT83OS$YB&O< MQ#7^;WF[&?:4A,?P5VD2\^LEYFL4O;DVN,/_S;57 CL08]*(,?G%UW+RFE*] M$MB!5*>-5*?#^7SP4)@7H'HN^EA74)-V;M-[TLGMP?U^D,VT83/]Z2(S_;XB M\]S,FP;.).B_IJ[S]+([@R'><,6R[I/>^[0ZSXJ$/W$Z4?88N2TJAS&VN@_W MYXI<[7]0Y?QI-[;G1NZHJY_=:I)R%+'I'26$?%NHJBUH5JO^=*G[4]UD==:I M;STWW9K]!%,UO9=,Q*0U9+@A2.=D0A&)JH^L)HJ7IA5;ISH#9IN?O$O4$L#!!0 ( #9O?UIY.21AN@( .<) 9 >&PO M=V]R:W-H965TY9S-?8RK8L3WU=)AHRH U$@-SL+(1G19BJ7OBHDDM09L=R/@F#@,T*Y%X_< MVE3&(['2.>4XE:!6C!&YGF NRK$7>IN%:[K,M%WPXU%!ECA#_;V82C/S&Y24 M,N2*"@X2%V/O-#R9A,[ G?A!L52M,5@I0R'7N!980Y)MI"$/.ZPS/, M/RN0;WF3FO8'F_0/SKQ1LR<*#P3^4^:ZFSL'7F0XH*L(G(E7M"69\-/$A62@M6&QL&C/+J3>YK1[0,PL$6@Z@VB!SOZB+'\IQH$H^D M*$':TP;-#IQ49VW(46ZC,M/2[%)CI^.9%LDM?"NLBQ00GD*U\DD2KA6\.T=- M:*[@*Y&26 >^AWV8943B_L0X(X4I69L@:3@U^WR)=KQ7X\'-%;(YRE\C7QNJ M]D(_J6E-*EK1%EIA!%>"ZTS!!4\Q_1O -QH;H=%&Z"3J1#S'Y !ZX1Y$0=3O MP.LUCNLYO/X6O*FD0H(6!B\\AFE.NN5V@ME/[T05),&Q9[XMA?(.O?CMFW 0 M?.B@VF^H]AUZ;UN,6^$Z$\Q\T(JX^+1B!O/UXV$MB4SAYHN!A$N-3#VJKO\" MZ@X;=8>=@;BX+ZBL]!1H@I(^1K ;8@AK)%)UD!DT9 :=2/^6#)T83W37L&$X M?.5D&+Z NJ-&W='SDZ$;8GOG XU@?\L ML%7?PN=GQ X,$\:M.>&W:B]#N70=AH)$K+BNRG"SVG0QIU7M?CA>M4!71"ZI MJ<(Y+HQI<# T?RU9=1751(O"5?*YT*8O<,/,=&(H[0&SOQ!";R;V@J:WB_\ M4$L#!!0 ( #9O?UH']HDH&PO=V]R:W-H965T FE\:: M8P?;:<=_S]E)0S?:B0=>8OM\WW?W77R7;J5ZT!6 (8\U%WKL5<8T-[ZO\PIJ MJB]E P)O2JEJ:O"HUKYN%-#"@6KN1T$P\FO*A)>ESC9762I;PYF N2*ZK6NJ M?DV R^W8"[V=8<'6E;$&/TL;NH8EF/MFKO#D#RP%JT%H)@514(Z]V_!FFEA_ MY_"5P5;O[8E5LI+RP1X^%6,OL D!A]Q8!HK+!J; N27"-'[VG-X0T@+W]SOV M#TX[:EE1#5/)O['"5&/OC4<**&G+S4)N/T*OY\KRY9)K]R7;SO:B/K M'HP9U$QT*WWLZ[ '"$=' %$/B)X#DB. N ?$3FB7F9,UHX9FJ9);HJPWLMF- MJXU#HQHF[%]<&H6W#'$F2X+P].&,S)4LF;E85E0QL29S3@4YG8&AC&ORF2I% M;;7/R 6Y7\[(ZR)]*307KR$CN6LD1+07+\P8JM6M>P#;ZI4U9J2Z:=$=C&QEE&9W ML &&D9W]!E!+ P04 " V;W]:;KI14%@# #Z#@ &0 'AL+W=OS0'(N^L*NV1A1.Z M%6E"X)$AOLTRS%YGD-)B:KG6?F&1;&*A%NQPDN,-/('XF3\R.;-KE%62 >$) M)8C!>FI]#S>HW_1Y"69)>8PI^GO9"7BJ36RT K6>)N*!2V^0D6HK_ B MFG)]145EZU@HVG)!L\I91I EI/S'+U4BCAS!KHF5D MFM8=%CB<,%H@IJPEFAKHW&AOR28AJHQ/@LF[B?03X0)V0+; T9K1#(D8.,@K M Z@>#HS?(,P11CFP"(B0M45TC005.$5SFN68O,IZ:I0;5"C3/&?T)9$IAO1U MC-[=@84I'HL 8UK5<)/P9_7F ; GLKS2K@D(S(%$LU76X.;&% M)*U"MZ.*X*PDZ)TAZ'KH@1(1<_29K!+!EMNJ4>?N4S;Q.Q#N(>LAW;Y#G M>$%+0//+W?V..A:4$.37(W!-;@/JJYCPP)>PL3NF15DA&J)O"JW)_^A@XQH29@74%)TS=!H_]T2H MK4[N&:6ZWB%J[R*M7SA!:,PF'$XWK&Y>NT=.-*;0F M_\/YQNT\0EPCW:!%A?W37;[=ZG2;MX^Z"/F\C6ZN.(KHEHCR=%ROE@W<3#5P MJ@LY69>-W2?=SM@'F+(K?,!LDQ".4EA+2*&PO=V]R:W-H965TLFEJI*U\) M91E!:A--W4.UJA_;P[0'A]P$J\9FMA/:?S^;4)2OHK3J"]APS\DY]P3;227D MH\H1-3P5C*NADVM=#EQ793D61)V)$KEY,Q.R(-I,Y=Q5I40RK4$%

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 163 302 1 true 71 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://nanophase.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 9 false false R10.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 10 false false R11.htm 999014 - Disclosure - Risk Assessment and Strategy Sheet http://nanophase.com/role/RiskAssessmentAndStrategy Risk Assessment and Strategy Notes 11 false false R12.htm 999015 - Disclosure - Management Oversight Sheet http://nanophase.com/role/ManagementOversight Management Oversight Notes 12 false false R13.htm 999016 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 13 false false R14.htm 999017 - Disclosure - Summary of Significant Accounting Policies Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 14 false false R15.htm 999018 - Disclosure - Related Party Notes and Lines of Credit Notes http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit Related Party Notes and Lines of Credit Notes 15 false false R16.htm 999019 - Disclosure - Inventories, net Sheet http://nanophase.com/role/InventoriesNet Inventories, net Notes 16 false false R17.htm 999020 - Disclosure - Equipment and Leasehold Improvements Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovements Equipment and Leasehold Improvements Notes 17 false false R18.htm 999021 - Disclosure - Lease Commitments Sheet http://nanophase.com/role/LeaseCommitments Lease Commitments Notes 18 false false R19.htm 999022 - Disclosure - Accrued Expenses Sheet http://nanophase.com/role/AccruedExpenses Accrued Expenses Notes 19 false false R20.htm 999023 - Disclosure - Income Taxes Sheet http://nanophase.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 999024 - Disclosure - Capital Stock Sheet http://nanophase.com/role/CapitalStock Capital Stock Notes 21 false false R22.htm 999025 - Disclosure - Stock Options and Stock Grants Sheet http://nanophase.com/role/StockOptionsAndStockGrants Stock Options and Stock Grants Notes 22 false false R23.htm 999026 - Disclosure - 401(k) Profit-Sharing Plan Sheet http://nanophase.com/role/KProfit-sharingPlan 401(k) Profit-Sharing Plan Notes 23 false false R24.htm 999027 - Disclosure - Significant Customers Sheet http://nanophase.com/role/SignificantCustomers Significant Customers Notes 24 false false R25.htm 999028 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 25 false false R26.htm 999029 - Disclosure - Subsequent Event Sheet http://nanophase.com/role/SubsequentEvent Subsequent Event Notes 26 false false R27.htm 999030 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://nanophase.com/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 999031 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://nanophase.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 999032 - Disclosure - Related Party Notes and Lines of Credit (Tables) Notes http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables Related Party Notes and Lines of Credit (Tables) Tables http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit 29 false false R30.htm 999033 - Disclosure - Inventories, net (Tables) Sheet http://nanophase.com/role/InventoriesNetTables Inventories, net (Tables) Tables http://nanophase.com/role/InventoriesNet 30 false false R31.htm 999034 - Disclosure - Equipment and Leasehold Improvements (Tables) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables Equipment and Leasehold Improvements (Tables) Tables http://nanophase.com/role/EquipmentAndLeaseholdImprovements 31 false false R32.htm 999035 - Disclosure - Lease Commitments (Tables) Sheet http://nanophase.com/role/LeaseCommitmentsTables Lease Commitments (Tables) Tables http://nanophase.com/role/LeaseCommitments 32 false false R33.htm 999036 - Disclosure - Accrued Expenses (Tables) Sheet http://nanophase.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://nanophase.com/role/AccruedExpenses 33 false false R34.htm 999037 - Disclosure - Income Taxes (Tables) Sheet http://nanophase.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://nanophase.com/role/IncomeTaxes 34 false false R35.htm 999038 - Disclosure - Stock Options and Stock Grants (Tables) Sheet http://nanophase.com/role/StockOptionsAndStockGrantsTables Stock Options and Stock Grants (Tables) Tables http://nanophase.com/role/StockOptionsAndStockGrants 35 false false R36.htm 999039 - Disclosure - Significant Customers (Tables) Sheet http://nanophase.com/role/SignificantCustomersTables Significant Customers (Tables) Tables http://nanophase.com/role/SignificantCustomers 36 false false R37.htm 999040 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 37 false false R38.htm 999041 - Disclosure - We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. (Details) Sheet http://nanophase.com/role/WeDetermineAllowanceForCreditLossesByIdentifyingTroubledAccountsAndByUsingHistoricalExperienceAppliedToAgingOfAccountsAsWellAsExpectedLossesBasedOnCurrentAndAnticipatedMacroeconomicEnvironment.Details We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. (Details) Details 38 false false R39.htm 999042 - Disclosure - Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: (Details) Sheet http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120242023And2022AreAsFollowsDetails Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: (Details) Details 39 false false R40.htm 999043 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows (Details) Sheet http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows (Details) Details 40 false false R41.htm 999044 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables 41 false false R42.htm 999045 - Disclosure - Notes and lines of credit consist of the following (Details) Notes http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails Notes and lines of credit consist of the following (Details) Details 42 false false R43.htm 999046 - Disclosure - Related party interest expense consists of the following (Details) Sheet http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails Related party interest expense consists of the following (Details) Details 43 false false R44.htm 999047 - Disclosure - Inventories consist of the following (Details) Sheet http://nanophase.com/role/InventoriesConsistOfFollowingDetails Inventories consist of the following (Details) Details 44 false false R45.htm 999048 - Disclosure - Equipment and leasehold improvements consist of the following (Details) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails Equipment and leasehold improvements consist of the following (Details) Details 45 false false R46.htm 999049 - Disclosure - Equipment and Leasehold Improvements (Details Narrative) Sheet http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative Equipment and Leasehold Improvements (Details Narrative) Details http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables 46 false false R47.htm 999050 - Disclosure - Quantitative information regarding the Company???s leases is as follows: (Details) Sheet http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails Quantitative information regarding the Company???s leases is as follows: (Details) Details 47 false false R48.htm 999051 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: (Details) Sheet http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312024And2023Details Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: (Details) Details 48 false false R49.htm 999052 - Disclosure - The future maturities of the Company???s operating leases as of December 31, 2024 are as follows: (Details) Sheet http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails The future maturities of the Company???s operating leases as of December 31, 2024 are as follows: (Details) Details 49 false false R50.htm 999053 - Disclosure - Lease Commitments (Details Narrative) Sheet http://nanophase.com/role/LeaseCommitmentsDetailsNarrative Lease Commitments (Details Narrative) Details http://nanophase.com/role/LeaseCommitmentsTables 50 false false R51.htm 999054 - Disclosure - Accrued expenses consist of the following: (Details) Sheet http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails Accrued expenses consist of the following: (Details) Details 51 false false R52.htm 999055 - Disclosure - A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: (Details) Sheet http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: (Details) Details 52 false false R53.htm 999056 - Disclosure - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) Sheet http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details) Details 53 false false R54.htm 999057 - Disclosure - Income Taxes (Details Narrative) Sheet http://nanophase.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://nanophase.com/role/IncomeTaxesTables 54 false false R55.htm 999058 - Disclosure - Capital Stock (Details Narrative) Sheet http://nanophase.com/role/CapitalStockDetailsNarrative Capital Stock (Details Narrative) Details http://nanophase.com/role/CapitalStock 55 false false R56.htm 999059 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) Sheet http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details) Details 56 false false R57.htm 999060 - Disclosure - The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) Sheet http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details) Details 57 false false R58.htm 999061 - Disclosure - Additional disclosures for options granted for all years presented: (Details) Sheet http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails Additional disclosures for options granted for all years presented: (Details) Details 58 false false R59.htm 999062 - Disclosure - The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: (Details) Sheet http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: (Details) Details 59 false false R60.htm 999063 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 (Details) Sheet http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 (Details) Details 60 false false R61.htm 999064 - Disclosure - Stock Options and Stock Grants (Details Narrative) Sheet http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative Stock Options and Stock Grants (Details Narrative) Details http://nanophase.com/role/StockOptionsAndStockGrantsTables 61 false false R62.htm 999065 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative) Sheet http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative 401(k) Profit-Sharing Plan (Details Narrative) Details http://nanophase.com/role/KProfit-sharingPlan 62 false false R63.htm 999066 - Disclosure - Revenues from these three customers, as a percentage of total Company revenue, was approximately: (Details) Sheet http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails Revenues from these three customers, as a percentage of total Company revenue, was approximately: (Details) Details 63 false false R64.htm 999067 - Disclosure - Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: (Details) Sheet http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: (Details) Details 64 false false R65.htm 999068 - Disclosure - Significant Customers (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersDetailsNarrative Significant Customers (Details Narrative) Details http://nanophase.com/role/SignificantCustomersTables 65 false false R66.htm 999069 - Disclosure - The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: (Details) Sheet http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: (Details) Details 66 false false R67.htm 999070 - Disclosure - The revenues for 2024 and 2023 by category are as follows: (Details) Sheet http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails The revenues for 2024 and 2023 by category are as follows: (Details) Details 67 false false R68.htm 999071 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 68 false false R69.htm 999072 - Disclosure - Subsequent Event (Details Narrative) Sheet http://nanophase.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://nanophase.com/role/SubsequentEvent 69 false false All Reports Book All Reports nanx-20241231.xsd nanx-20241231_cal.xml nanx-20241231_def.xml nanx-20241231_lab.xml nanx-20241231_pre.xml solesence_10k-123124.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "solesence_10k-123124.htm": { "nsprefix": "nanx", "nsuri": "http://nanophase.com/20241231", "dts": { "schema": { "local": [ "nanx-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "nanx-20241231_cal.xml" ] }, "definitionLink": { "local": [ "nanx-20241231_def.xml" ] }, "labelLink": { "local": [ "nanx-20241231_lab.xml" ] }, "presentationLink": { "local": [ "nanx-20241231_pre.xml" ] }, "inline": { "local": [ "solesence_10k-123124.htm" ] } }, "keyStandard": 275, "keyCustom": 27, "axisStandard": 24, "axisCustom": 0, "memberStandard": 30, "memberCustom": 38, "hidden": { "total": 56, "http://fasb.org/us-gaap/2024": 50, "http://xbrl.sec.gov/dei/2024": 5, "http://nanophase.com/20241231": 1 }, "contextCount": 163, "entityCount": 1, "segmentCount": 71, "elementCount": 607, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 614, "http://xbrl.sec.gov/dei/2024": 34, "http://xbrl.sec.gov/cyd/2024": 6, "http://xbrl.sec.gov/ecd/2024": 1 }, "report": { "R1": { "role": "http://nanophase.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R2": { "role": "http://nanophase.com/role/ConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R3": { "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R4": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R5": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R6": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "nanx:NoInsiderTradingFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "nanx:NoInsiderTradingFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementThirdPartyEngagedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R11": { "role": "http://nanophase.com/role/RiskAssessmentAndStrategy", "longName": "999014 - Disclosure - Risk Assessment and Strategy", "shortName": "Risk Assessment and Strategy", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://nanophase.com/role/ManagementOversight", "longName": "999015 - Disclosure - Management Oversight", "shortName": "Management Oversight", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://nanophase.com/role/DescriptionOfBusiness", "longName": "999016 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R14": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPolicies", "longName": "999017 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R15": { "role": "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit", "longName": "999018 - Disclosure - Related Party Notes and Lines of Credit", "shortName": "Related Party Notes and Lines of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R16": { "role": "http://nanophase.com/role/InventoriesNet", "longName": "999019 - Disclosure - Inventories, net", "shortName": "Inventories, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R17": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovements", "longName": "999020 - Disclosure - Equipment and Leasehold Improvements", "shortName": "Equipment and Leasehold Improvements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R18": { "role": "http://nanophase.com/role/LeaseCommitments", "longName": "999021 - Disclosure - Lease Commitments", "shortName": "Lease Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R19": { "role": "http://nanophase.com/role/AccruedExpenses", "longName": "999022 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R20": { "role": "http://nanophase.com/role/IncomeTaxes", "longName": "999023 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R21": { "role": "http://nanophase.com/role/CapitalStock", "longName": "999024 - Disclosure - Capital Stock", "shortName": "Capital Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R22": { "role": "http://nanophase.com/role/StockOptionsAndStockGrants", "longName": "999025 - Disclosure - Stock Options and Stock Grants", "shortName": "Stock Options and Stock Grants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R23": { "role": "http://nanophase.com/role/KProfit-sharingPlan", "longName": "999026 - Disclosure - 401(k) Profit-Sharing Plan", "shortName": "401(k) Profit-Sharing Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R24": { "role": "http://nanophase.com/role/SignificantCustomers", "longName": "999027 - Disclosure - Significant Customers", "shortName": "Significant Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R25": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution", "longName": "999028 - Disclosure - Business Segmentation and Geographical Distribution", "shortName": "Business Segmentation and Geographical Distribution", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R26": { "role": "http://nanophase.com/role/SubsequentEvent", "longName": "999029 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R27": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "999030 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R28": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "999031 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R29": { "role": "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables", "longName": "999032 - Disclosure - Related Party Notes and Lines of Credit (Tables)", "shortName": "Related Party Notes and Lines of Credit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R30": { "role": "http://nanophase.com/role/InventoriesNetTables", "longName": "999033 - Disclosure - Inventories, net (Tables)", "shortName": "Inventories, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R31": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables", "longName": "999034 - Disclosure - Equipment and Leasehold Improvements (Tables)", "shortName": "Equipment and Leasehold Improvements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R32": { "role": "http://nanophase.com/role/LeaseCommitmentsTables", "longName": "999035 - Disclosure - Lease Commitments (Tables)", "shortName": "Lease Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R33": { "role": "http://nanophase.com/role/AccruedExpensesTables", "longName": "999036 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R34": { "role": "http://nanophase.com/role/IncomeTaxesTables", "longName": "999037 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R35": { "role": "http://nanophase.com/role/StockOptionsAndStockGrantsTables", "longName": "999038 - Disclosure - Stock Options and Stock Grants (Tables)", "shortName": "Stock Options and Stock Grants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R36": { "role": "http://nanophase.com/role/SignificantCustomersTables", "longName": "999039 - Disclosure - Significant Customers (Tables)", "shortName": "Significant Customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R37": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables", "longName": "999040 - Disclosure - Business Segmentation and Geographical Distribution (Tables)", "shortName": "Business Segmentation and Geographical Distribution (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R38": { "role": "http://nanophase.com/role/WeDetermineAllowanceForCreditLossesByIdentifyingTroubledAccountsAndByUsingHistoricalExperienceAppliedToAgingOfAccountsAsWellAsExpectedLossesBasedOnCurrentAndAnticipatedMacroeconomicEnvironment.Details", "longName": "999041 - Disclosure - We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. (Details)", "shortName": "We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R39": { "role": "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120242023And2022AreAsFollowsDetails", "longName": "999042 - Disclosure - Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: (Details)", "shortName": "Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R40": { "role": "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "longName": "999043 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows (Details)", "shortName": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R41": { "role": "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "999044 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R42": { "role": "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "longName": "999045 - Disclosure - Notes and lines of credit consist of the following (Details)", "shortName": "Notes and lines of credit consist of the following (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2014-07-012014-07-31_us-gaap_LetterOfCreditMember", "name": "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "link:footnote", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2014-07-012014-07-31_us-gaap_LetterOfCreditMember", "name": "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "link:footnote", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R43": { "role": "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails", "longName": "999046 - Disclosure - Related party interest expense consists of the following (Details)", "shortName": "Related party interest expense consists of the following (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_custom_BeachcorpLLCMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_BeachcorpLLCMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R44": { "role": "http://nanophase.com/role/InventoriesConsistOfFollowingDetails", "longName": "999047 - Disclosure - Inventories consist of the following (Details)", "shortName": "Inventories consist of the following (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R45": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "longName": "999048 - Disclosure - Equipment and leasehold improvements consist of the following (Details)", "shortName": "Equipment and leasehold improvements consist of the following (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R46": { "role": "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative", "longName": "999049 - Disclosure - Equipment and Leasehold Improvements (Details Narrative)", "shortName": "Equipment and Leasehold Improvements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R47": { "role": "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails", "longName": "999050 - Disclosure - Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "shortName": "Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R48": { "role": "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312024And2023Details", "longName": "999051 - Disclosure - Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: (Details)", "shortName": "Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R49": { "role": "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails", "longName": "999052 - Disclosure - The future maturities of the Company\u2019s operating leases as of December 31, 2024 are as follows: (Details)", "shortName": "The future maturities of the Company\u2019s operating leases as of December 31, 2024 are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R50": { "role": "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative", "longName": "999053 - Disclosure - Lease Commitments (Details Narrative)", "shortName": "Lease Commitments (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails", "longName": "999054 - Disclosure - Accrued expenses consist of the following: (Details)", "shortName": "Accrued expenses consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R52": { "role": "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails", "longName": "999055 - Disclosure - A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: (Details)", "shortName": "A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R53": { "role": "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails", "longName": "999056 - Disclosure - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details)", "shortName": "Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R54": { "role": "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "longName": "999057 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R55": { "role": "http://nanophase.com/role/CapitalStockDetailsNarrative", "longName": "999058 - Disclosure - Capital Stock (Details Narrative)", "shortName": "Capital Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-01", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R56": { "role": "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details", "longName": "999059 - Disclosure - We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details)", "shortName": "We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:StockOptionPlanExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:StockOptionPlanExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R57": { "role": "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails", "longName": "999060 - Disclosure - The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details)", "shortName": "The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R58": { "role": "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "longName": "999061 - Disclosure - Additional disclosures for options granted for all years presented: (Details)", "shortName": "Additional disclosures for options granted for all years presented: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "nanx:AdditionalDisclosuresForOptionsGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "nanx:AdditionalDisclosuresForOptionsGrantedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R59": { "role": "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details", "longName": "999062 - Disclosure - The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: (Details)", "shortName": "The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R60": { "role": "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "longName": "999063 - Disclosure - The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 (Details)", "shortName": "The aggregate intrinsic value in the table above is based on our closing stock price of $2.26 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "nanx:StockOptionsRecognizedTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R61": { "role": "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "longName": "999064 - Disclosure - Stock Options and Stock Grants (Details Narrative)", "shortName": "Stock Options and Stock Grants (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember_custom_PriorTo2019PlanMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember_custom_PriorTo2019PlanMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R62": { "role": "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative", "longName": "999065 - Disclosure - 401(k) Profit-Sharing Plan (Details Narrative)", "shortName": "401(k) Profit-Sharing Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R63": { "role": "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails", "longName": "999066 - Disclosure - Revenues from these three customers, as a percentage of total Company revenue, was approximately: (Details)", "shortName": "Revenues from these three customers, as a percentage of total Company revenue, was approximately: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R64": { "role": "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "longName": "999067 - Disclosure - Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: (Details)", "shortName": "Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R65": { "role": "http://nanophase.com/role/SignificantCustomersDetailsNarrative", "longName": "999068 - Disclosure - Significant Customers (Details Narrative)", "shortName": "Significant Customers (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_SupplyCommitmentMember", "name": "nanx:EquipmentSaleNetBookValueEquipment", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_SupplyCommitmentMember", "name": "nanx:EquipmentSaleNetBookValueEquipment", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R66": { "role": "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails", "longName": "999069 - Disclosure - The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: (Details)", "shortName": "The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R67": { "role": "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails", "longName": "999070 - Disclosure - The revenues for 2024 and 2023 by category are as follows: (Details)", "shortName": "The revenues for 2024 and 2023 by category are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_ConsumerProductsMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "unique": true } }, "R68": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "longName": "999071 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative)", "shortName": "Business Segmentation and Geographical Distribution (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_ProductMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_ProductMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } }, "R69": { "role": "http://nanophase.com/role/SubsequentEventDetailsNarrative", "longName": "999072 - Disclosure - Subsequent Event (Details Narrative)", "shortName": "Subsequent Event (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "From2024-12-292024-12-31_custom_ARRevolverInventoryFacilityAndNewTermLoanMember", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-12-292024-12-31_custom_ARRevolverInventoryFacilityAndNewTermLoanMember", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "solesence_10k-123124.htm", "first": true, "unique": true } } }, "tag": { "nanx_ARRevolverInventoryFacilityAndNewTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ARRevolverInventoryFacilityAndNewTermLoanMember", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "A/R Revolver, Inventory Facility and New Term Loan [Member]", "documentation": "A/R Revolver, Inventory Facility and New Term Loan." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r52", "r55", "r59", "r892" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r52", "r678" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment.", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r849" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r152", "r240", "r646" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120242023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Trade accounts receivable, net", "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r844" ] }, "nanx_AccruedAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "AccruedAccountsPayable", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Accrued accounts payable", "documentation": "Carrying amount of accrued accounts payable." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 }, "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails", "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r55" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r37", "r146", "r512" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r766" ] }, "nanx_AdditionalDisclosuresForOptionsGrantedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20241231", "localname": "AdditionalDisclosuresForOptionsGrantedTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "Additional disclosures for options granted for all years presented:", "documentation": "The element represents additional disclosures for options granted table text block." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r66", "r678", "r950" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r543", "r833", "r834", "r835", "r836", "r901", "r951" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r772" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r772" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r772" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r772" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r47", "r48", "r335" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Rights offering expense", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r7", "r102" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to cash provided by (used) in operating activities:" } } }, "auth_ref": [] }, "nanx_AdvancedMaterialsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "AdvancedMaterialsMember", "presentation": [ "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Advanced Materials [Member]", "documentation": "The element represents advanced materials member." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r733", "r744", "r758", "r784" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r736", "r747", "r761", "r787" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r772" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r779" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r737", "r748", "r762", "r779", "r788", "r792", "r800" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/WeDetermineAllowanceForCreditLossesByIdentifyingTroubledAccountsAndByUsingHistoricalExperienceAppliedToAgingOfAccountsAsWellAsExpectedLossesBasedOnCurrentAndAnticipatedMacroeconomicEnvironment.Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for credit losses", "periodStartLabel": "Balance, beginning", "periodEndLabel": "Balance, ending", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r153", "r241", "r245" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://nanophase.com/role/WeDetermineAllowanceForCreditLossesByIdentifyingTroubledAccountsAndByUsingHistoricalExperienceAppliedToAgingOfAccountsAsWellAsExpectedLossesBasedOnCurrentAndAnticipatedMacroeconomicEnvironment.Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Write offs", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r247" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r740" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive pptions excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r414" ] }, "nanx_Asc842OperatingLeaseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "Asc842OperatingLeaseAsset", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "ASC 842 operating lease asset", "documentation": "The element represents asc842 operating lease asset.", "label": "Asc842 Operating Lease Asset" } } }, "auth_ref": [] }, "nanx_Asc842OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "Asc842OperatingLeaseLiability", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "ASC 842 operating lease liability", "documentation": "The element represents asc842 operating lease liability." } } }, "auth_ref": [] }, "us-gaap_AssetRetirementObligationsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetRetirementObligationsNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Asset retirement obligations", "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r853" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r109", "r121", "r148", "r175", "r209", "r217", "r228", "r231", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r415", "r417", "r430", "r504", "r579", "r657", "r658", "r678", "r705", "r859", "r860", "r908" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r141", "r156", "r175", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r415", "r417", "r430", "r678", "r859", "r860", "r908" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r740" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r717", "r719", "r740" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r717", "r719", "r740" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r717", "r719", "r740" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r795" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r796" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r791" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r791" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r791" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r791" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r791" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r791" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r793" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r792" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r792" ] }, "nanx_BeachcorpLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "BeachcorpLLCMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC [Member]", "documentation": "The element represents beachcorp l l c member." } } }, "auth_ref": [] }, "nanx_BeachcorpLLCOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "BeachcorpLLCOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC One [Member]", "documentation": "Beachcorp, LLC One." } } }, "auth_ref": [] }, "nanx_BridgeNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "BridgeNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Bridge Note [Member]", "documentation": "Bridge Note." } } }, "auth_ref": [] }, "nanx_BusinessLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "BusinessLoanAgreementMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Business Loan Agreement [Member]", "documentation": "The element represents business loan agreement member." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable incurred for the purchase of equipment and leasehold improvements", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r18", "r19", "r20" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r144", "r644" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r84", "r171" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Decrease in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r84" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental non-cash investing and financing activity:" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r770" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r138", "r149", "r150", "r151", "r175", "r197", "r201", "r203", "r205", "r211", "r212", "r242", "r263", "r265", "r266", "r267", "r270", "r271", "r285", "r286", "r290", "r293", "r301", "r430", "r537", "r538", "r539", "r540", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r567", "r588", "r605", "r620", "r621", "r622", "r623", "r624", "r817", "r830", "r837" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r149", "r150", "r151", "r211", "r285", "r286", "r288", "r290", "r293", "r299", "r301", "r537", "r538", "r539", "r540", "r663", "r817", "r830" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r771" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r771" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitments" ], "lang": { "en-us": { "role": { "label": "Lease Commitments", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r695", "r696", "r697", "r699", "r700", "r701", "r702", "r833", "r834", "r836", "r901", "r949", "r951" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r65" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r65", "r567" ] }, "nanx_CommonStockSharesAuthorizedForConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://nanophase.com/20241231", "localname": "CommonStockSharesAuthorizedForConversionOfPreferredStock", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized for conversion of preferred stock", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws for conversion of preferred stock." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r65" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r65", "r567", "r585", "r951", "r952" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value, 95,000,000 and 60,000,000 shares authorized; 70,103,279 and 49,627,254 shares issued and outstanding on December 31, 2024 and 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r65", "r507", "r678" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r776" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r775" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r777" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r774" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r25", "r26", "r49", "r50", "r238", "r627" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r25", "r26", "r49", "r50", "r238", "r534", "r627" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r25", "r26", "r49", "r50", "r238", "r627", "r821" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomers" ], "lang": { "en-us": { "role": { "label": "Significant Customers", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r627" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from customers", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r25", "r26", "r49", "r50", "r238" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r24", "r25", "r26", "r27", "r49", "r108", "r627" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r25", "r26", "r49", "r50", "r238", "r627" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "nanx_ConsumerProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ConsumerProductsMember", "presentation": [ "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Consumer Products [Member]", "documentation": "The element represents consumer products member." } } }, "auth_ref": [] }, "nanx_ContractWithCustomerAccountReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ContractWithCustomerAccountReceivablesTableTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersTables" ], "lang": { "en-us": { "role": { "label": "Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:", "documentation": "The element represents contract with customer account receivables table text block." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r863" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ContractBalancesForYearsEndedDecember3120242023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r303", "r304", "r316" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue recognized in the reporting period included in contract liability balance at beginning of period", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "crdr": "debit", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current." } } }, "auth_ref": [ "r303", "r305", "r316" ] }, "nanx_ContractorsAndProfessionalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ContractorsAndProfessionalServicesMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Contractors And Professional Services [Member]", "documentation": "The element represents contractors and professional services member." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of mezzanine preferred stock", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r18", "r19", "r20" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r18", "r19", "r20" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued upon conversion", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r18", "r19", "r20" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r13", "r42", "r64", "r100", "r296" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r76", "r77", "r469" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Total Expense", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r81" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r179", "r180", "r273", "r288", "r460", "r466", "r503", "r647", "r649" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r262", "r857" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r262", "r857", "r858" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r89", "r238" ] }, "nanx_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "CustomerOneMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "The element represents customer one member." } } }, "auth_ref": [] }, "nanx_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "CustomerThreeMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "The element represents customer three member." } } }, "auth_ref": [] }, "nanx_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "CustomerTwoMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "The element represents customer two member." } } }, "auth_ref": [] }, "nanx_CustomersOneThroughThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "CustomersOneThroughThreeMember", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Customers One Through Three [Member]", "documentation": "Customers One Through Three [Member]" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r727", "r810" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://nanophase.com/role/ManagementOversight", "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]", "verboseLabel": "Management Oversight" } } }, "auth_ref": [ "r727", "r810" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r729", "r812" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r729", "r812" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://nanophase.com/role/RiskAssessmentAndStrategy", "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]", "verboseLabel": "Risk Assessment and Strategy" } } }, "auth_ref": [ "r722", "r805" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r723", "r806" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r723", "r806" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r721", "r804" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r724", "r807" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r726", "r809" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r726", "r809" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r727", "r810" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r728", "r811" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r725", "r808" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCredit" ], "lang": { "en-us": { "role": { "label": "Related Party Notes and Lines of Credit", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r96", "r173", "r252", "r253", "r254", "r255", "r256", "r261", "r262", "r272", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r439" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Description of Variable Rate Basis", "documentation": "Description of reference rate used for variable rate of debt instrument." } } }, "auth_ref": [] }, "us-gaap_DeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncome", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Deferred Income", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r818", "r919", "r946" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r61", "r62", "r111", "r392" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r823" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Excess book amortization", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r393" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Inventory and other allowances", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income taxes", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r897" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "179 Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "163(j) Business interest limitation carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "174 research and experimental expenditures", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Other accrued costs", "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less:\u00a0\u00a0valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r394" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Excess tax depreciation", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r900" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r331" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r36" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r209", "r221", "r231", "r657", "r658" ] }, "nanx_DepreciationMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "DepreciationMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation [Member]", "documentation": "The element represents depreciation member." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables" ], "lang": { "en-us": { "role": { "label": "The revenues for 2024 and 2023 by category are as follows:", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r864" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrants" ], "lang": { "en-us": { "role": { "label": "Stock Options and Stock Grants", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r333", "r338", "r365", "r366", "r368", "r670" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r719" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r717", "r719", "r740" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r717", "r719", "r740", "r780" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r718" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r706" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r719" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r719" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r765" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r709" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r377" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Net income (loss) per share-basic", "verboseLabel": "Net income (loss) per share \u2013 basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r164", "r186", "r187", "r188", "r189", "r190", "r191", "r195", "r197", "r203", "r204", "r205", "r208", "r410", "r413", "r427", "r428", "r500", "r517", "r652" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Basic earnings per common share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Net income (loss) per share-diluted", "verboseLabel": "Net income (loss) per share \u2013 diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r164", "r186", "r187", "r188", "r189", "r190", "r191", "r197", "r203", "r204", "r205", "r208", "r410", "r413", "r427", "r428", "r500", "r517", "r652" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Diluted earnings per common share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r21", "r22", "r207" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Permanent tax deduction stock options exercised", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r819", "r893", "r894" ] }, "nanx_EmployeeCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "EmployeeCostsMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Employee Costs [Member]", "documentation": "The element represents employee costs member." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Accrued payroll and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r55" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "periodEndLabel": "Remaining unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r367" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Remaining weighted average-period, expense recognition (years)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r367" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r712" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r708" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r708" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r816" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r708" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r813" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r740" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r708" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r708" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r708" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r708" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r814" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "nanx_EquipmentSaleNetBookValueEquipment": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20241231", "localname": "EquipmentSaleNetBookValueEquipment", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment sale - net book value", "documentation": "The element represents equipment sale net book value equipment." } } }, "auth_ref": [] }, "nanx_EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20241231", "localname": "EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment sale- original book value", "documentation": "The element represents equipment sale original book value of equipment and upgrades." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r139", "r160", "r161", "r162", "r181", "r182", "r183", "r185", "r190", "r192", "r194", "r210", "r243", "r244", "r251", "r302", "r400", "r401", "r407", "r408", "r409", "r411", "r412", "r413", "r419", "r420", "r421", "r422", "r423", "r424", "r426", "r431", "r432", "r433", "r434", "r435", "r436", "r440", "r441", "r456", "r516", "r528", "r529", "r530", "r543", "r605" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r773" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r733", "r744", "r758", "r784" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r730", "r741", "r755", "r781" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r779" ] }, "nanx_ExpirationOfNolCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ExpirationOfNolCredits", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Expiration of net operating losses and credits", "documentation": "The element represents expiration of nol credits." } } }, "auth_ref": [] }, "nanx_Expiring2025To2037Member": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "Expiring2025To2037Member", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiring 2025 to 2037 [Member]", "documentation": "Expiring 2025 to 2037." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "nanx_FacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "FacilitiesMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Facilities [Member]", "documentation": "The element represents facilities member." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r6" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r737", "r748", "r762", "r788" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r737", "r748", "r762", "r788" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r737", "r748", "r762", "r788" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r737", "r748", "r762", "r788" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r737", "r748", "r762", "r788" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r74", "r78", "r120", "r175", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r430", "r653", "r657", "r839", "r840", "r841", "r842", "r843", "r859" ] }, "nanx_ITServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ITServicesMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "I T Services [Member]", "documentation": "The element represents i t services member." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r94" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r75", "r116", "r120", "r501", "r514", "r653", "r657", "r839", "r840", "r841", "r842", "r843" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r170", "r377", "r378", "r388", "r397", "r672", "r899" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r170", "r377", "r378", "r388", "r397", "r672", "r899" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r176", "r372", "r377", "r385", "r386", "r387", "r389", "r396", "r402", "r404", "r405", "r406", "r542", "r672" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/IncomeTaxesDetailsNarrative", "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "totalLabel": "", "verboseLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r125", "r135", "r193", "r194", "r209", "r222", "r231", "r376", "r377", "r403", "r518", "r672" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r159", "r374", "r375", "r389", "r390", "r395", "r399", "r536" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r383", "r672", "r893" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Effect of change in deferred tax rate", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r373", "r377", "r381", "r672" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Income tax credit at statutory rates", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r377", "r672" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Expiration of stock options", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r672", "r893", "r895" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r672", "r893", "r894" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "State income tax, net of federal benefits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r380", "r672", "r893" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Record tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r382", "r384", "r893" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r640" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities related to operations:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net changes in right-of-use assets and lease liabilities \u2013 operating", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r822", "r829" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average additional shares assuming conversion of in-the-money stock options to common shares", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r198", "r199", "r200", "r205", "r337" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r737", "r748", "r762", "r779", "r788", "r792", "r800" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r798" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r720", "r803" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r720", "r803" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r720", "r803" ] }, "nanx_InsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "InsuranceMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Insurance [Member]", "documentation": "The element represents insurance member." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r209", "r217", "r220", "r223", "r231", "r438", "r657", "r658" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r11" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r220", "r828" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r166", "r168", "r169" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Accrued interest expense", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r112", "r917" ] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": [ "r23" ] }, "us-gaap_InterimPeriodCostsNotAllocableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterimPeriodCostsNotAllocableLineItems", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Interim Period, Costs Not Allocable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InterimPeriodCostsNotAllocableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterimPeriodCostsNotAllocableTable", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Interim Period, Costs Not Allocable [Table]", "documentation": "Disclosure of information about cost and expense incurred during interim period that cannot be readily identified with activity or benefit of other interim period and charged to interim period in which it incurred. Includes, but is not limited to, nature and amount of cost." } } }, "auth_ref": [ "r23" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/InventoriesNet" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories, net", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r248" ] }, "nanx_InventoryFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "InventoryFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Facility [Member]", "documentation": "Inventory Facility." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r824" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total Inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r155", "r645", "r678" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventories, Net", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r126", "r143", "r154", "r248", "r249", "r250", "r468", "r650" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r825" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory reserve", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r91", "r826" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r445", "r677" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Components of lease cost" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "Quantitative information regarding the Company\u2019s leases is as follows:", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r905" ] }, "nanx_LeaseCostsOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "LeaseCostsOperating", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease costs", "documentation": "Total operating lease costs.", "label": "Lease Costs Operating" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r93", "r454" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "The future maturities of the Company\u2019s operating leases as of December 31, 2024 are as follows:", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r906" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312024And2023Details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term-operating leases (in years)", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r455", "r904" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r70", "r115", "r509", "r678", "r832", "r848", "r903" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r56", "r142", "r175", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r416", "r417", "r418", "r430", "r678", "r859", "r908", "r909" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r12", "r58", "r59", "r60", "r63", "r175", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r416", "r417", "r418", "r430", "r859", "r908", "r909" ] }, "nanx_LibertyvilleBankAndTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "LibertyvilleBankAndTrustMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Libertyville Bank and Trust [Member]", "documentation": "The element represents libertyville bank and trust member." } } }, "auth_ref": [] }, "nanx_LibertyvilleBankAndTrustOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "LibertyvilleBankAndTrustOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Libertyville Bank and Trust One [Member]", "documentation": "The element represents libertyville bank and trust one member." } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r12", "r113", "r918" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r53", "r57", "r831", "r857", "r858" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r53", "r57" ] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Expiration Date", "verboseLabel": "Expiration date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r53", "r57" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r53", "r57", "r831", "r857" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r262", "r831", "r857" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r53", "r57" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r53", "r57", "r262", "r831", "r857" ] }, "nanx_LineOfCreditPercentageOfEligibleInventory": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20241231", "localname": "LineOfCreditPercentageOfEligibleInventory", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Percentage of Eligible inventory", "documentation": "The element represents line of credit percentage of eligible inventory." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Line of credit \u2013 accounts receivable, related party", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r54", "r110" ] }, "nanx_LinesOfCreditInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "LinesOfCreditInventoryCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Line of credit \u2013 inventory, related party", "documentation": "The element represents lines of credit inventory current." } } }, "auth_ref": [] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of term debt, related party", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r55" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term line of credit \u2013 inventory, related party", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r12", "r38", "r39" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r238", "r666", "r688", "r692", "r864", "r919", "r920", "r921", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r947", "r948" ] }, "nanx_ManufacturingOtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ManufacturingOtherExpenseMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Manufacturing Other Expense [Member]", "documentation": "The element represents manufacturing other expense member." } } }, "auth_ref": [] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r751", "r752" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r751", "r753" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r751", "r754" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r751", "r754" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r751", "r754" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r751", "r754" ] }, "nanx_MaterialsAndSuppliesMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "MaterialsAndSuppliesMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Materials And Supplies [Member]", "documentation": "The element represents materials and supplies member." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r332", "r369", "r429", "r467", "r526", "r527", "r533", "r558", "r559", "r611", "r613", "r615", "r616", "r618", "r637", "r638", "r662", "r663", "r669", "r673", "r674", "r675", "r676", "r689", "r861", "r910", "r911", "r912", "r913", "r914", "r915" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r771" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r771" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r332", "r369", "r429", "r467", "r526", "r527", "r533", "r558", "r559", "r611", "r613", "r615", "r616", "r618", "r637", "r638", "r662", "r663", "r669", "r673", "r674", "r675", "r689", "r861", "r910", "r911", "r912", "r913", "r914", "r915" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r791" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r799" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "auth_ref": [ "r238", "r666", "r688", "r692", "r864", "r919", "r920", "r921", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r947", "r948" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r772" ] }, "us-gaap_NatureOfExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfExpenseAxis", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Nature of Expense [Axis]", "documentation": "Information by type of cost or expense." } } }, "auth_ref": [ "r23" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://nanophase.com/role/DescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r127", "r136" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r167" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r84", "r85", "r86" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails", "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "label": "Net income", "verboseLabel": "Net income (loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r79", "r86", "r117", "r140", "r157", "r158", "r162", "r175", "r184", "r186", "r187", "r188", "r189", "r190", "r193", "r194", "r202", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r410", "r413", "r428", "r430", "r515", "r587", "r603", "r604", "r703", "r859" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Numerator: (in Thousands)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Adopted Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "nanx_NoInsiderTradingFlag": { "xbrltype": "booleanItemType", "nsuri": "http://nanophase.com/20241231", "localname": "NoInsiderTradingFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "No Insider Trading [Flag]", "documentation": "Indicates no disclosure of Rule 10b5-1 plan." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r771" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r769" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r768" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r799" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r799" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r953", "r954", "r955", "r956" ] }, "nanx_NondeductibleExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "NondeductibleExpenses", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Nondeductible expenses", "documentation": "The element represents nondeductible expenses." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r120", "r653", "r839", "r840", "r841", "r842", "r843" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r446", "r677" ] }, "nanx_OperatingLeaseCostComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20241231", "localname": "OperatingLeaseCostComponentsAbstract", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost components:", "documentation": "The element represents operating lease cost components abstract." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysOperatingLeasesAsOfDecember312024AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Total minimum payments required", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r443" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r443" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term portion of operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r443" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312024And2023Details" ], "lang": { "en-us": { "role": { "label": "Operating cash outflow from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r444", "r450" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating leases, right of use", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r442" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312024And2023Details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate-operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r452", "r677" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r398" ] }, "nanx_OperatingLossCarryforwardsExpirationYearEnd": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20241231", "localname": "OperatingLossCarryforwardsExpirationYearEnd", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards expiration period end", "documentation": "The element represents operating loss carryforwards expiration year end." } } }, "auth_ref": [] }, "nanx_OperatingLossCarryforwardsExpirationYearStart": { "xbrltype": "stringItemType", "nsuri": "http://nanophase.com/20241231", "localname": "OperatingLossCarryforwardsExpirationYearStart", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards expiration period start", "documentation": "The element represents operating loss carryforwards expiration year start." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r398" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r398" ] }, "nanx_Options2010PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "Options2010PlanMember", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2010 Plan [Member]", "documentation": "2010 Plan." } } }, "auth_ref": [] }, "nanx_Options2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "Options2019PlanMember", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2019 Plan [Member]", "documentation": "2019 Plan." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/AccruedExpensesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r55" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets, net", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r147" ] }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Capitalized Property Plant and Equipment [Member]", "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized." } } }, "auth_ref": [ "r93" ] }, "us-gaap_OtherIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Other Income [Member]", "documentation": "Primary financial statement caption encompassing other revenue." } } }, "auth_ref": [ "r107" ] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Term debt, related party", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r54", "r55", "r566" ] }, "us-gaap_OtherLongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term debt, related party", "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r12", "r566" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r771" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r719" ] }, "nanx_OtherRevenuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20241231", "localname": "OtherRevenuePolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Other Revenue", "documentation": "The element represents other revenue policy text block." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r735", "r746", "r760", "r786" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r738", "r749", "r763", "r789" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r738", "r749", "r763", "r789" ] }, "nanx_OverunderAccrualOfIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "OverunderAccrualOfIncomeTaxes", "crdr": "debit", "calculation": { "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ReconciliationOfIncomeTaxBenefitToAmountComputedByApplyingFederalIncomeTaxRateToLossBeforeProvisionForIncomeTaxesAsOfDecember312024And2023IsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Under accrual of income taxes", "documentation": "The element represents overunder accrual of income taxes." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r767" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of equipment and leasehold improvements", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r82" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r770" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r770" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/KProfit-sharingPlan" ], "lang": { "en-us": { "role": { "label": "401(k) Profit-Sharing Plan", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r668" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r769" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r772" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r768" ] }, "nanx_PercentageOfPrepayments": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20241231", "localname": "PercentageOfPrepayments", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of Prepayments", "documentation": "The element represents percentage of prepayments." } } }, "auth_ref": [] }, "nanx_PersonalCareIngredientsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "PersonalCareIngredientsMember", "presentation": [ "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Personal Care ingredients [Member]", "documentation": "The element represents personal care ingredients member." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r769" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r713" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r715" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r287" ] }, "nanx_PreferredStockConvertibleInterestRateForUnpaidRedemption": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20241231", "localname": "PreferredStockConvertibleInterestRateForUnpaidRedemption", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "If the Company fails to fully pay any Redemption within five days of receiving notice, all unpaid amounts will bear interest at specified rate per annum." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liquidation preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r42", "r43", "r64", "r830", "r862" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r695", "r696", "r699", "r700", "r701", "r702", "r949", "r951" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r64", "r285" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r64", "r567" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r64", "r285" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r64", "r567", "r585", "r951", "r952" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r64", "r506", "r678" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r827" ] }, "nanx_PrepaymentsFromCertainCustomersPerCompanyPolicyMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "PrepaymentsFromCertainCustomersPerCompanyPolicyMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prepayments From Certain Customers Per Company Policy [Member]", "documentation": "The element represents prepayments from certain customers per company policy member." } } }, "auth_ref": [] }, "nanx_PrepaymentsFromProductDevelopmentAgreementWithAPersonalCareIngredientCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "PrepaymentsFromProductDevelopmentAgreementWithAPersonalCareIngredientCustomerMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prepayments From Product Development Agreement With A Personal Care Ingredient Customer [Member]", "documentation": "The element represents prepayments from product development agreement with a personal care ingredient customer member." } } }, "auth_ref": [] }, "nanx_PriorTo2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "PriorTo2019PlanMember", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prior to 2019 Plan [Member]", "documentation": "Prior to 2019 Plan." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of mezzanine preferred stock", "verboseLabel": "Consideration from sale of shares", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from term loans, related party", "documentation": "Amount of cash inflow from issuance of long-term debt classified as other." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Payments to) proceeds from line of credit - inventory, related party", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options", "verboseLabel": "Cash received", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r10" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r865" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r664" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r234", "r469", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r642", "r664", "r687", "r689", "r690", "r693", "r694", "r855", "r856", "r864", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r947", "r948" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "auth_ref": [ "r234", "r469", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r642", "r664", "r687", "r689", "r690", "r693", "r694", "r855", "r856", "r864", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r947", "r948" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r454" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovements" ], "lang": { "en-us": { "role": { "label": "Equipment and Leasehold Improvements", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r92", "r130", "r133", "r134" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment,gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r93", "r145", "r513" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Equipment and leasehold improvements, net", "totalLabel": "Property, Plant and Equipment, Net, Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r454", "r502", "r513", "r678" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Equipment and Leasehold Improvements", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r130", "r133", "r511" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsTables" ], "lang": { "en-us": { "role": { "label": "Equipment and leasehold improvements consist of the following", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r93", "r454" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment leasehold improvements and leased assets useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://nanophase.com/role/WeDetermineAllowanceForCreditLossesByIdentifyingTroubledAccountsAndByUsingHistoricalExperienceAppliedToAgingOfAccountsAsWellAsExpectedLossesBasedOnCurrentAndAnticipatedMacroeconomicEnvironment.Details" ], "lang": { "en-us": { "role": { "label": "Current period provisions", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r165", "r246" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r767" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r767" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r319", "r332", "r361", "r362", "r363", "r369", "r429", "r464", "r465", "r467", "r526", "r527", "r533", "r558", "r559", "r611", "r613", "r615", "r616", "r618", "r637", "r638", "r662", "r663", "r669", "r673", "r674", "r675", "r676", "r689", "r697", "r854", "r861", "r902", "r911", "r912", "r913", "r914", "r915" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r257", "r258", "r259", "r260", "r319", "r332", "r361", "r362", "r363", "r369", "r429", "r464", "r465", "r467", "r526", "r527", "r533", "r558", "r559", "r611", "r613", "r615", "r616", "r618", "r637", "r638", "r662", "r663", "r669", "r673", "r674", "r675", "r676", "r689", "r697", "r854", "r861", "r902", "r911", "r912", "r913", "r914", "r915" ] }, "nanx_RecentlyIssuedPronouncementsPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20241231", "localname": "RecentlyIssuedPronouncementsPoliciesTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Pronouncements", "documentation": "The element represents recently issued pronouncements policies text block." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r730", "r741", "r755", "r781" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r239", "r323", "r457", "r458", "r505", "r510", "r561", "r562", "r563", "r564", "r565", "r584", "r586", "r610" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r177", "r178", "r457", "r458", "r459", "r460", "r505", "r510", "r561", "r562", "r563", "r564", "r565", "r584", "r586", "r610" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r51", "r457" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r457", "r458", "r907" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r239", "r323", "r457", "r458", "r505", "r510", "r561", "r562", "r563", "r564", "r565", "r584", "r586", "r610", "r907" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to line of credit \u2013 accounts receivable, related party", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r83" ] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to term loans, related party", "label": "Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r83" ] }, "nanx_ReplacementPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ReplacementPromissoryNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Replacement Promissory Note [Member]", "documentation": "Replacement Promissory Note [Member]" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "auth_ref": [ "r179", "r180", "r273", "r288", "r460", "r466", "r503", "r648", "r649" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r371", "r639", "r657", "r916" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r370" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r731", "r742", "r756", "r782" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r732", "r743", "r757", "r783" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r739", "r750", "r764", "r790" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r67", "r102", "r508", "r531", "r532", "r541", "r568", "r678" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r139", "r181", "r182", "r183", "r185", "r190", "r192", "r194", "r243", "r244", "r251", "r400", "r401", "r407", "r408", "r409", "r411", "r412", "r413", "r419", "r421", "r422", "r424", "r426", "r440", "r441", "r528", "r530", "r543", "r951" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total revenue", "verboseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r118", "r119", "r209", "r218", "r219", "r227", "r231", "r234", "r236", "r238", "r314", "r315", "r469" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r137", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r641" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Product Revenue", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r589", "r641", "r651" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r118", "r119", "r163", "r175", "r209", "r218", "r219", "r227", "r231", "r234", "r236", "r238", "r242", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r430", "r501", "r657", "r859" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows", "http://nanophase.com/role/LeaseCommitmentsDetailsNarrative", "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForYearsEndedDecember312024And2023Details" ], "lang": { "en-us": { "role": { "label": "Right-of-use asset obtained in exchange for a lease liability", "verboseLabel": "Lease liabilities arising from obtaining right-of-use assets", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r451", "r677" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r799" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r799" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://nanophase.com/role/RevenuesFromTheseThreeCustomersAsPercentageOfTotalCompanyRevenueWasApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r238", "r820" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://nanophase.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Accrued expenses consist of the following:", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://nanophase.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r897" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r838" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://nanophase.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r379", "r672", "r893" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://nanophase.com/role/RevenuesFor2024And2023ByCategoryAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://nanophase.com/role/InventoriesNetTables" ], "lang": { "en-us": { "role": { "label": "Inventories consist of the following", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r14", "r71", "r72", "r73" ] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables" ], "lang": { "en-us": { "role": { "label": "Notes and lines of credit consist of the following", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r53", "r57" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://nanophase.com/role/EquipmentAndLeaseholdImprovementsConsistOfFollowingDetails", "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5", "r454" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://nanophase.com/role/RelatedPartyNotesAndLinesOfCreditTables" ], "lang": { "en-us": { "role": { "label": "Related party interest expense consists of the following", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r35", "r74" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables" ], "lang": { "en-us": { "role": { "label": "The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r334", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r103" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r106" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r40", "r41", "r42", "r43", "r44", "r45", "r97", "r99", "r101", "r102", "r149", "r150", "r151", "r211", "r285", "r286", "r288", "r290", "r293", "r299", "r301", "r537", "r538", "r539", "r540", "r663", "r817", "r830" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersTables" ], "lang": { "en-us": { "role": { "label": "Revenues from these three customers, as a percentage of total Company revenue, was approximately:", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r24", "r25", "r26", "r27", "r49", "r108" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r707" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r711" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r710" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r716" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "auth_ref": [ "r236", "r237", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r555", "r556", "r557", "r612", "r614", "r617", "r619", "r626", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r643", "r665", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r691", "r697", "r864", "r919", "r920", "r921", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r947", "r948" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution" ], "lang": { "en-us": { "role": { "label": "Business Segmentation and Geographical Distribution", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r121", "r209", "r213", "r214", "r215", "r216", "r217", "r224", "r225", "r226", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r238", "r654", "r655", "r656", "r657", "r659", "r660", "r661" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r80" ] }, "nanx_SellingGeneralAndAdministrativeOtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "SellingGeneralAndAdministrativeOtherExpenseMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Selling General And Administrative Other Expense [Member]", "documentation": "The element represents selling general and administrative other expense member." } } }, "auth_ref": [] }, "nanx_SeriesXPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "SeriesXPreferredStockMember", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series X Preferred Stock [Member]", "documentation": "Series X Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Contractual life (years) of shares granted in period", "documentation": "The element represents share based compensation arrangement by share based payment award award contractual life." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Vesting period (years) of shares granted in period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r670" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r362" ] }, "nanx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Estimated forfeitures", "documentation": "The element represents share based compensation arrangement by share based payment award fair value assumptions fortfeiture rate." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average risk-free interest rates", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average expected stock price volatility", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r361" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r334", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "periodEndLabel": "Shares Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r344" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "periodEndLabel": "Shares Exercisable, (per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r344" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details" ], "lang": { "en-us": { "role": { "label": "Total intrinsic value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r357" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited or expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r872" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Forfeited or expired (per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r872" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r346" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average fair value of the options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Outstanding, Beginning (Intrinsic value)", "periodEndLabel": "Shares Outstanding, Ending (Intrinsic value)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Outstanding, Beginning", "periodEndLabel": "Shares Outstanding, Ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r342", "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Outstanding, Beginning, (per share)", "periodEndLabel": "Shares Outstanding, Ending, (per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r342", "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://nanophase.com/role/AdditionalDisclosuresForOptionsGrantedForAllYearsPresentedDetails", "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative", "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Exercised (per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r347" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Granted (per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r346" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details" ], "lang": { "en-us": { "role": { "label": "Closing stock share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r671" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://nanophase.com/role/FollowingTableIllustratesVariousAssumptionsUsedToCalculateBlack-scholesOptionPricingModelForOptionsGrantedForAllYearsPresentedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average expected life (years) of the option", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r360" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Shares Exercisable (Intrinsic value)", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r46" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Shares Exercisable (years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r46" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Term, Outstanding, end", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r104" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "nanx_ShippingMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "ShippingMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Shipping [Member]", "documentation": "The element represents shipping member." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r54", "r850", "r851", "r852" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r52", "r850", "r851", "r852" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r447", "r677" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r87", "r172" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r714" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r377" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r138", "r149", "r150", "r151", "r175", "r197", "r201", "r203", "r205", "r211", "r212", "r242", "r263", "r265", "r266", "r267", "r270", "r271", "r285", "r286", "r290", "r293", "r301", "r430", "r537", "r538", "r539", "r540", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r567", "r588", "r605", "r620", "r621", "r622", "r623", "r624", "r817", "r830", "r837" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r65", "r68", "r69", "r139", "r160", "r161", "r162", "r181", "r182", "r183", "r185", "r190", "r192", "r194", "r210", "r243", "r244", "r251", "r302", "r400", "r401", "r407", "r408", "r409", "r411", "r412", "r413", "r419", "r420", "r421", "r422", "r423", "r424", "r426", "r431", "r432", "r433", "r434", "r435", "r436", "r440", "r441", "r456", "r516", "r528", "r529", "r530", "r543", "r605" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r236", "r237", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r555", "r556", "r557", "r612", "r614", "r617", "r619", "r626", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r643", "r665", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r691", "r697", "r864", "r919", "r920", "r921", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r947", "r948" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r181", "r182", "r183", "r210", "r441", "r469", "r535", "r554", "r560", "r561", "r562", "r563", "r564", "r565", "r567", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r582", "r583", "r584", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r605", "r698" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersAsPercentageOfTotalCompanyAccountsReceivableWasApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r181", "r182", "r183", "r210", "r239", "r441", "r469", "r535", "r554", "r560", "r561", "r562", "r563", "r564", "r565", "r567", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r582", "r583", "r584", "r586", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r605", "r698" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r734", "r745", "r759", "r785" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://nanophase.com/role/CapitalStockDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuances of shares and stock option exercises (in shares)", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r64", "r65", "r102", "r537", "r605", "r621" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://nanophase.com/role/AggregateIntrinsicValueInTableAboveIsBasedOnOurClosingStockPriceOf2.26Details", "http://nanophase.com/role/FollowingTableSummarizesOptionActivityForOurEmployeesAndDirectorsDuringYearEndedDecember312024Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "Shares exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r64", "r65", "r102", "r347" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuances of shares and stock option exercises", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r64", "r65", "r102", "r543", "r605", "r621", "r704" ] }, "us-gaap_StockOptionPlanExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionPlanExpense", "crdr": "debit", "presentation": [ "http://nanophase.com/role/WeFollowAscTopic718Share-basedPaymentsInWhichCompensationExpenseIsRecognizedOnlyForShare-basedPaymentsExpectedToVest.Details" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Amount of noncash expense for option under share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "nanx_StockOptionsRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20241231", "localname": "StockOptionsRecognizedTableTextBlock", "presentation": [ "http://nanophase.com/role/StockOptionsAndStockGrantsTables" ], "lang": { "en-us": { "role": { "label": "The aggregate intrinsic value in the table above is based on our closing stock price of $2.26", "documentation": "The element represents stock options recognized table text block." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets", "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r65", "r68", "r69", "r90", "r569", "r585", "r606", "r607", "r678", "r705", "r832", "r848", "r903", "r951" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/CapitalStock" ], "lang": { "en-us": { "role": { "label": "Capital Stock", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r98", "r174", "r284", "r286", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r298", "r300", "r302", "r425", "r608", "r609", "r625" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cumulative effect of accounting changes related to expected credit losses", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "nanx_StrandlerLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "StrandlerLLCMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/RelatedPartyInterestExpenseConsistsOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Strandler, LLC [Member]", "documentation": "The element represents strandler l l c member." } } }, "auth_ref": [] }, "nanx_StrandlerLLCOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "StrandlerLLCOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Strandler LLC One [Member]", "documentation": "The element represents strandler l l c one member." } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Sub-lease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r449", "r677" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://nanophase.com/role/SubsequentEventDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r437", "r462" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://nanophase.com/role/SubsequentEvent" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r461", "r463" ] }, "nanx_SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nanophase.com/20241231", "localname": "SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://nanophase.com/role/LeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:", "documentation": "The element represents summary of supplemental cash flow information related to leases table text block." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentArrangementMember", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r60", "r114" ] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentAxis", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer." } } }, "auth_ref": [ "r60", "r114" ] }, "us-gaap_SupplyCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentLineItems", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentMember", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Member]", "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments." } } }, "auth_ref": [ "r60", "r114" ] }, "us-gaap_SupplyCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentTable", "presentation": [ "http://nanophase.com/role/SignificantCustomersDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Table]", "documentation": "Disclosure of information about supply arrangement in which resource is committed to supply product or service or both, to customer. Includes, but is not limited to, identification of committed product and service, purchasing party, price, effect on price for failing to deliver required quantity, cancellation right, and termination provision." } } }, "auth_ref": [ "r60", "r114" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r778" ] }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardValuationAllowance", "crdr": "credit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Valuation allowance, net operating loss carryforwards and credits", "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r898" ] }, "nanx_TaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "TaxCredits", "crdr": "debit", "calculation": { "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/DeferredIncomeTaxesReflectNetTaxEffectsOfTemporaryDifferencesBetweenCarryingAmountsOfAssetsAndLiabilitiesForFinancialReportingPurposesAndAmountsUsedForIncomeTaxPurposes.SignificantComponentsOfOurDeferredIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Tax credits", "documentation": "The element represents tax credits." } } }, "auth_ref": [] }, "nanx_TaxExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "TaxExpenseMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Tax Expense [Member]", "documentation": "The element represents tax expense member." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r896" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "auth_ref": [ "r896" ] }, "us-gaap_TaxYear2018Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxYear2018Member", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Year 2018 [Member]", "documentation": "Identified as tax year 2018." } } }, "auth_ref": [ "r896" ] }, "nanx_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "TermLoanMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan [Member]", "documentation": "The element represents term loan member." } } }, "auth_ref": [] }, "nanx_TestingMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20241231", "localname": "TestingMember", "presentation": [ "http://nanophase.com/role/ChiefOperatingDecisionMakerUsesGrossProfitAndNetIncomeToEvaluateCompanyPerformanceAndInWhatWayToAllocateResources.SignificantSegmentExpensesWhichAreSameAsEntityAsWholeAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Testing [Member]", "documentation": "The element represents testing member." } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r667", "r864" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r667", "r864" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r770" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r777" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Trade Accounts Receivable, Net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r122", "r123", "r124", "r845", "r846", "r847" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r667" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r801" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r802" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r802" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r800" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r800" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r801" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r414" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r797" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates and Risks and Uncertainties", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r28", "r29", "r30", "r128", "r129", "r131", "r132" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://nanophase.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase (decrease) in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r391" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "parentTag": "nanx_LeaseCostsOperating", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r448", "r677" ] }, "nanx_VolumeRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20241231", "localname": "VolumeRebates", "crdr": "debit", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volume rebate", "documentation": "Volume rebates recognized as a reduction in revenue." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://nanophase.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Potential common stock included in computation of diluted earnings per share", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r838" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of diluted common shares outstanding", "totalLabel": "Weighted average number of diluted common shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r196", "r205" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperations", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of basic common shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r195", "r205" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r815" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r817": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 92 0001999371-25-003471-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001999371-25-003471-xbrl.zip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solesence_10k-123124_htm.xml IDEA: XBRL DOCUMENT 0000883107 2024-01-01 2024-12-31 0000883107 2024-06-30 0000883107 2025-03-28 0000883107 2024-12-31 0000883107 2023-12-31 0000883107 2023-01-01 2023-12-31 0000883107 us-gaap:ProductMember 2024-01-01 2024-12-31 0000883107 us-gaap:ProductMember 2023-01-01 2023-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-12-31 0000883107 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000883107 us-gaap:PreferredStockMember 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-12-31 0000883107 2022-12-31 0000883107 us-gaap:PreferredStockMember 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-12-31 0000883107 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000883107 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000883107 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0000883107 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000883107 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000883107 us-gaap:PreferredStockMember 2024-12-31 0000883107 us-gaap:CommonStockMember 2024-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000883107 us-gaap:RetainedEarningsMember 2024-12-31 0000883107 srt:MinimumMember us-gaap:EquipmentMember 2024-12-31 0000883107 srt:MaximumMember us-gaap:EquipmentMember 2024-12-31 0000883107 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2024-12-31 0000883107 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2024-12-31 0000883107 srt:MinimumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2024-12-31 0000883107 srt:MaximumMember us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2024-12-31 0000883107 nanx:PrepaymentsFromCertainCustomersPerCompanyPolicyMember 2024-12-31 0000883107 nanx:PrepaymentsFromProductDevelopmentAgreementWithAPersonalCareIngredientCustomerMember 2024-12-31 0000883107 us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000883107 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2024-01-01 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2024-01-01 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2024-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2024-01-01 2024-12-31 0000883107 nanx:BeachcorpLLCMember 2024-12-31 0000883107 nanx:BeachcorpLLCMember 2023-12-31 0000883107 nanx:BeachcorpLLCOneMember 2024-01-01 2024-12-31 0000883107 nanx:BeachcorpLLCOneMember 2024-12-31 0000883107 nanx:BeachcorpLLCOneMember 2024-12-30 0000883107 nanx:BeachcorpLLCOneMember 2023-12-31 0000883107 nanx:StrandlerLLCMember 2024-01-01 2024-12-31 0000883107 nanx:StrandlerLLCMember 2024-12-31 0000883107 nanx:StrandlerLLCMember 2023-12-31 0000883107 nanx:StrandlerLLCOneMember 2024-01-01 2024-12-31 0000883107 nanx:StrandlerLLCOneMember 2024-12-31 0000883107 nanx:StrandlerLLCOneMember 2023-12-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2014-07-01 2014-07-31 0000883107 us-gaap:LetterOfCreditMember 2021-12-21 2024-12-31 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-26 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2024-02-29 2024-03-01 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:ReplacementPromissoryNoteMember nanx:BusinessLoanAgreementMember 2023-11-13 0000883107 nanx:BeachcorpLLCMember nanx:ReplacementPromissoryNoteMember nanx:BusinessLoanAgreementMember 2023-11-12 2023-11-13 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2023-11-12 2023-11-13 0000883107 nanx:BeachcorpLLCMember nanx:ReplacementPromissoryNoteMember nanx:BusinessLoanAgreementMember 2024-02-29 2024-03-01 0000883107 nanx:StrandlerLLCMember nanx:TermLoanMember 2022-01-27 2022-01-28 0000883107 nanx:StrandlerLLCMember nanx:TermLoanMember 2024-02-29 2024-03-01 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember 2023-11-12 2023-11-13 0000883107 us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0000883107 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000883107 us-gaap:RelatedPartyMember 2024-12-31 0000883107 us-gaap:RelatedPartyMember 2023-12-31 0000883107 nanx:BeachcorpLLCMember 2023-01-01 2023-12-31 0000883107 nanx:StrandlerLLCMember 2023-01-01 2023-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2024-12-31 0000883107 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000883107 us-gaap:OfficeEquipmentMember 2024-12-31 0000883107 us-gaap:OfficeEquipmentMember 2023-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2024-12-31 0000883107 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2024-12-31 0000883107 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000883107 us-gaap:ConstructionInProgressMember 2024-12-31 0000883107 us-gaap:ConstructionInProgressMember 2023-12-31 0000883107 nanx:Expiring2025To2037Member 2024-12-31 0000883107 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0000883107 us-gaap:TaxYear2018Member 2024-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0000883107 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-12-31 0000883107 nanx:SeriesXPreferredStockMember 2024-02-29 2024-03-01 0000883107 nanx:SeriesXPreferredStockMember 2024-03-01 0000883107 2024-03-01 0000883107 nanx:SeriesXPreferredStockMember 2024-06-18 2024-06-20 0000883107 us-gaap:CommonStockMember 2024-06-18 2024-06-20 0000883107 us-gaap:EmployeeStockOptionMember nanx:PriorTo2019PlanMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember nanx:Options2019PlanMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember nanx:Options2010PlanMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2024-12-31 0000883107 us-gaap:EmployeeStockOptionMember 2023-12-31 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000883107 nanx:CustomerOneMember 2024-12-31 0000883107 nanx:CustomerOneMember 2023-12-31 0000883107 nanx:CustomerTwoMember 2024-12-31 0000883107 nanx:CustomerTwoMember 2023-12-31 0000883107 nanx:CustomerThreeMember 2024-12-31 0000883107 nanx:CustomerThreeMember 2023-12-31 0000883107 us-gaap:SupplyCommitmentMember 2024-12-31 0000883107 nanx:EmployeeCostsMember 2024-01-01 2024-12-31 0000883107 nanx:EmployeeCostsMember 2023-01-01 2023-12-31 0000883107 nanx:ContractorsAndProfessionalServicesMember 2024-01-01 2024-12-31 0000883107 nanx:ContractorsAndProfessionalServicesMember 2023-01-01 2023-12-31 0000883107 nanx:MaterialsAndSuppliesMember 2024-01-01 2024-12-31 0000883107 nanx:MaterialsAndSuppliesMember 2023-01-01 2023-12-31 0000883107 nanx:DepreciationMember 2024-01-01 2024-12-31 0000883107 nanx:DepreciationMember 2023-01-01 2023-12-31 0000883107 us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0000883107 us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000883107 us-gaap:OtherIncomeMember 2024-01-01 2024-12-31 0000883107 us-gaap:OtherIncomeMember 2023-01-01 2023-12-31 0000883107 nanx:TaxExpenseMember 2024-01-01 2024-12-31 0000883107 nanx:TaxExpenseMember 2023-01-01 2023-12-31 0000883107 nanx:FacilitiesMember 2024-01-01 2024-12-31 0000883107 nanx:FacilitiesMember 2023-01-01 2023-12-31 0000883107 nanx:ShippingMember 2024-01-01 2024-12-31 0000883107 nanx:ShippingMember 2023-01-01 2023-12-31 0000883107 nanx:TestingMember 2024-01-01 2024-12-31 0000883107 nanx:TestingMember 2023-01-01 2023-12-31 0000883107 nanx:ITServicesMember 2024-01-01 2024-12-31 0000883107 nanx:ITServicesMember 2023-01-01 2023-12-31 0000883107 nanx:InsuranceMember 2024-01-01 2024-12-31 0000883107 nanx:InsuranceMember 2023-01-01 2023-12-31 0000883107 nanx:ManufacturingOtherExpenseMember 2024-01-01 2024-12-31 0000883107 nanx:ManufacturingOtherExpenseMember 2023-01-01 2023-12-31 0000883107 nanx:SellingGeneralAndAdministrativeOtherExpenseMember 2024-01-01 2024-12-31 0000883107 nanx:SellingGeneralAndAdministrativeOtherExpenseMember 2023-01-01 2023-12-31 0000883107 us-gaap:NonUsMember 2024-01-01 2024-12-31 0000883107 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000883107 nanx:ConsumerProductsMember 2024-01-01 2024-12-31 0000883107 nanx:ConsumerProductsMember 2023-01-01 2023-12-31 0000883107 nanx:PersonalCareIngredientsMember 2024-01-01 2024-12-31 0000883107 nanx:PersonalCareIngredientsMember 2023-01-01 2023-12-31 0000883107 nanx:AdvancedMaterialsMember 2024-01-01 2024-12-31 0000883107 nanx:AdvancedMaterialsMember 2023-01-01 2023-12-31 0000883107 nanx:ARRevolverInventoryFacilityAndNewTermLoanMember 2024-12-29 2024-12-31 0000883107 nanx:ARRevolverInventoryFacilityAndNewTermLoanMember us-gaap:SubsequentEventMember 2025-01-01 2025-03-31 iso4217:USD shares iso4217:USD shares pure false 2024 FY --12-31 0000883107 10-K true 2024-12-31 false 000-22333 DE 36-3687863 1319 Marquette Drive Romeoville IL 60446 (630) 771-6708 NANOPHASE TECHNOLOGIES CORPORATION Common Stock, par value $.01 per share No No Yes Yes Non-accelerated Filer true false false false 27254231 70103279 <p id="xdx_804_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_zQuLN9TLLwI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Assessment and Strategy</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company regularly evaluates cybersecurity risk from computer viruses and more sophisticated and targeted cyber-related attacks such as ransomware, as well as cybersecurity failures resulting from human error and technological errors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our overall strategy in combatting known cybersecurity risks includes a variety of individual tactics, including:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of antivirus software, virtual private networks, email security, as well as other software to prevent and detect data intrusions.</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The deployment of updates and patches as they are available and maintaining the current versions of major software to reduce the exposure to vulnerabilities.</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zZuIXvWjuGlc">If necessary, the use of third-party security experts if and when an incident is detected.</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zSSqqOpWbYY6">We are not aware of having experienced any material cybersecurity incidents in 2024. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> true We are not aware of having experienced any material cybersecurity incidents in 2024. We are not aware of any existent cybersecurity threats that would materially affect, or are reasonably likely to materially affect, our business strategy, results of operations or financial conditions. <p id="xdx_80E_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_zNBdAzp03df3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management Oversight</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zwd6DFesizlg">Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management, which then reports to the Board of Directors.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Oversight</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zLTp3tDQhFNc">The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> Day-to-day management of cybersecurity threats is conducted by our information technology consultant which is charged with identifying and reporting threats to senior management, which then reports to the Board of Directors. The Board of Directors is responsible for oversight of management’s efforts to eliminate cybersecurity risks. true true 49 RSM US LLP Milwaukee, Wisconsin 1409000 1722000 5655000 3692000 786000 225000 4869000 3467000 20267000 10031000 2803000 1082000 29348000 16302000 12734000 8668000 7917000 7907000 3000 4000 50002000 32881000 2810000 4000000 2000000 1000000 1260000 1297000 9093000 6260000 5571000 2353000 4849000 869000 25773000 15589000 9037000 9152000 5000000 1000000 246000 238000 9283000 15390000 0.01 0.01 24088 24088 0 0 0 0 0.01 0.01 95000000 60000000 70103279 70103279 49627254 49627254 700000 496000 114674000 106069000 -100428000 -104663000 14946000 1902000 50002000 32881000 51890000 36641000 457000 656000 52347000 37297000 36159000 29472000 16188000 7825000 3837000 3837000 7219000 7534000 5132000 -3546000 670000 838000 4462000 -4384000 227000 6000 4235000 -4390000 0.07 -0.09 62350459 49556305 0.07 -0.09 65028815 49556305 49320680 493000 105226000 -100070000 5649000 -203000 -203000 306574 3000 151000 154000 773000 773000 81000 81000 -4390000 -4390000 49627254 496000 106069000 -104663000 1902000 1902000 20476025 204000 7880000 8084000 725000 725000 4235000 4235000 70103279 700000 114674000 -100428000 14946000 14946000 4235000 -4390000 928000 742000 725000 773000 1402000 -1064000 10236000 1192000 1721000 216000 2399000 -503000 3218000 165000 3988000 -146000 -163000 1697000 1971000 -2006000 4558000 1051000 -4558000 -1051000 2810000 1472000 -1000000 2000000 2000000 1346000 3338000 6000000 2084000 73000 2274000 2593000 -313000 -464000 1722000 2186000 1409000 1722000 637000 752000 434000 400000 6000000 1019000 182000 <p id="xdx_803_eus-gaap--NatureOfOperations_zo6Wme5gmSd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(1)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_821_zDYnO6J5TiY2">Description of Business</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Nanophase Technologies Corporation, now known as Solesence, Inc. (“Solésence,” “Company,” “we,” “our,” or “us”), is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence consumer products subsidiary”), is focused in various skin health- and beauty-markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our consumer products line.  Additionally, we continue to sell products in legacy markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives, all of which fall into the advanced materials product category. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> We target markets<span style="text-decoration: line-through">,</span> primarily related to skin health products and ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our Solésence® products to cosmetics and skin care brands, and our other materials to various end-use applications manufacturers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Original Active Stress Defense ™ Technology — which has become the cornerstone of our new product development in consumer products line, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our consumer products line, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company recorded a net profit and positive cash flow from operations in 2024.  In addition, the company reduced outstanding debt. While the Company’s debt currently matures in the next year, management has a commitment from its related party debt holder that the debt will be refinanced with a maturity date after April 1, 2026. Management believes that <span style="background-color: white">current liquidity and expected borrowing capacity are sufficient to fund operations and substantial doubt is not raised regarding the Company's ability to continue as a going concern.</span></p> <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zFvyCR8slvvk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(2)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_822_z6sBiAC1vswd">Summary of Significant Accounting Policies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p id="xdx_845_eus-gaap--UseOfEstimates_zGr2BezFelwl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_869_z5pwHCHKWQJj">Use of Estimates and Risks and Uncertainties</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</p> <p id="xdx_852_zGYMPzrTovT6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG11PhoN360c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_86C_zDiR75GhcID">Cash</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Cash balance on December 31, 2024 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Solésence is to be the party initiating any transfers, whether to Solésence or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Solésence to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Solésence.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.</p> <p id="xdx_856_zEhskOfmJh6j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0UVsx2Fbp1j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <b><span id="xdx_862_za8powVD9q4b">Trade Accounts Receivable, Net</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zxSScyibDJX1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible <span id="xdx_8BE_zo0TVHAvZvxj">We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment.</span> Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 65%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_49E_20240101__20241231_zclB5qmmGw25" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td> <td> </td> <td colspan="2" id="xdx_496_20230101__20231231_zfAqJGgJAja8" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td></tr> <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_pn3n3_z1ZnrTOtkCE2" style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 56%"><span style="font-size: 10pt">Balance, beginning</span></td> <td style="width: 3%"> </td> <td style="vertical-align: bottom; width: 3%"><span style="font-size: 10pt">$</span></td> <td style="padding-right: 3pt; vertical-align: bottom; width: 15%; text-align: right"><span style="font-size: 10pt">225</span></td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 3%"><span style="font-size: 10pt">$</span></td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right; width: 15%"><span style="font-size: 10pt">139</span></td></tr> <tr id="xdx_407_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_zUBTvMVU4m"> <td style="padding-left: 12pt; vertical-align: bottom"><span style="font-size: 10pt">Current period provisions</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">564</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">95</span></td></tr> <tr id="xdx_40A_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_zDUFraZZizah" style="background-color: #CCEEFF"> <td style="padding-left: 12pt; vertical-align: bottom"><span style="font-size: 10pt">Write offs</span></td> <td> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(3)</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(9)</span></td></tr> <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_pn3n3_zq3ilxcgTM5g"> <td style="vertical-align: bottom"><span style="font-size: 10pt">Balance, ending</span></td> <td> </td> <td style="border-bottom: Black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.25pt double; padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">786</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.25pt double; padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">225</span></td></tr> </table> <p id="xdx_8A3_zGJJmkkjyoka" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_852_zzj8jCFce6yf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84F_eus-gaap--InventoryPolicyTextBlock_z7SbPyKoQLte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span><span id="xdx_86F_zfvzF4fdjYs7">Inventories, Net</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.</p> <p id="xdx_853_zElD37Pnrwoe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zw8YeL4Uv9S5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span><span id="xdx_860_zToMTrtvZq85">Equipment and Leasehold Improvements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Equipment is stated at cost and is being depreciated over its estimated useful life (<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zbF6vQ5bgyh5" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpgkH1QRV32b" title="Equipment leasehold improvements and leased assets useful life">20</span> years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zzr612BQoyzg" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zhcQyP5uRvvd" title="Equipment leasehold improvements and leased assets useful life">7</span> years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zuQnh89tcpd6" title="Equipment leasehold improvements and leased assets useful life">7</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWNhepB8NOhk" title="Equipment leasehold improvements and leased assets useful life">10</span> years) using the straight-line method.</p> <p id="xdx_85C_zmCpcKUrDuvf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zzQc992VOwY" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_866_zxkMsZ8oqOV5">Long Lived Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.</p> <p id="xdx_85C_zWQg6mPYRGbk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zXtDTQuuceL" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_860_z1NnzAuHg2id">Deferred Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $<span id="xdx_90F_eus-gaap--DeferredIncome_iI_pn3n3_c20241231_zj8CnVvyL1O5" title="Deferred revenue">5,571</span> in deferred revenue reported in 2024, <span id="xdx_903_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--PrepaymentsFromCertainCustomersPerCompanyPolicyMember_zm6atwoZZHMa">99%</span> related to prepayments received from certain customers per Company policy, and the remaining <span id="xdx_90B_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--PrepaymentsFromProductDevelopmentAgreementWithAPersonalCareIngredientCustomerMember_zgprJLXkpCCe">1</span>% related to prepayments from a product development agreement with a personal care ingredient customer.</p> <p id="xdx_850_z9mhBhSiYt85" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zf0bifqdlB7h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_865_z46W7Rd2kOn8">Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Our financial instruments include cash, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">There were no financial instruments adjusted to fair value on December 31, 2024 and 2023.</p> <p id="xdx_85D_zfBCmcWyeaef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zmkSTzDS5Dgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_866_zHn2B5gAwjp1">Product Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2024 one customer earned a volume rebate of <span id="xdx_908_ecustom--VolumeRebates_pp0p0_c20240101__20241231_zJXcXOOCn3d2" title="Volume rebate">$35,000</span>. In 2023 no volume rebates were recorded because the customers did not meet required volumes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer. Revenue is recognized when the goods are shipped</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company will for some customers arrange for the shipping of the finished goods. Revenues and costs associated with the shipment of the finished goods are recorded separately within product revenue and cost of revenue, respectively, on the consolidation statement of operations. With regard to revenue recognition, shipping activities that occur prior to the customers’ obtaining control of the goods are not a promised service to the customer, but rather activities to fulfill the Company’s promise to transfer the goods. As such, these activities are not deemed a performance obligation requiring allocation of the transaction price. Similarly, shipping activities that occur after the customers’ obtaining control of the goods are, as a matter of policy, also not a promised service to the customer, but rather an activity to fulfill the Company’s promise to transfer the good.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_897_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zYeJfA7m0Yb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zPuhpzl7wTV2">Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">2022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20221231_zYv0wHTYlFt6" style="width: 10%; text-align: right">4,734</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20221231_zfIBfCLtZzdf" style="width: 10%; text-align: right">2,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20231231_zozfIOQwVd15" style="text-align: right">3,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20231231_zlj7j599vEqd" style="text-align: right">2,353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20241231_z8e94k0s66Ak" style="text-align: right" title="Accounts receivable, net">4,869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20241231_zf2QGshg5ypb" style="text-align: right" title="Contract liabilities">5,571</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zUT18UWpC8Oa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was <span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zYZstmvx04Ci" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">$2,074</span> and <span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20230101__20231231_zu63NZ2MD5da" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">$2,084</span> for the years ended December 31, 2024, and 2023, respectively.</p> <p id="xdx_855_ztZkGCb01hak" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <div style="text-align: left; margin-top: 1pt; margin-bottom: 1pt"></div> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_848_ecustom--OtherRevenuePolicyTextBlock_zcbett79K9ob" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><span id="xdx_866_zxsuhPcFvqvh">Other Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20240101__20241231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zyrJQKU08bLl" title="Revenue">457</span> and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zvdYmhpKoYad" title="Revenue">656</span> for the years ended December 31, 2024 and 2023, respectively.</p> <p id="xdx_857_z3Tv7ZDdiiNf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zy5S8NHaS7Xd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_86E_zk8434v3DOzi">Research and Development Expenses</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Research and development expenses are recognized as expense when incurred.</p> <p id="xdx_85F_z5UxM0wLPed6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zIgWg9B0WoD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_864_ztV70ut6dqDf">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2024, and 2023, we had no liability for unrecognized tax benefits.</p> <p id="xdx_85B_zcfGsirWS8f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zSlDNHVqh4le" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_865_zphCZxQmhEo6">Earnings Per Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Included in the computation of diluted earnings per share for the year ended December 31, 2024, was a total of <span id="xdx_904_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_uShares_c20240101__20241231_zHLra8DWxR9d" title="Potential common stock included in computation of diluted earnings per share">2,678,000</span> in potential shares of common stock. Options to purchase approximately <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20231231_zanGQT707Kxe" title="Anti-dilutive pptions excluded from computation of earnings per share">889,000</span> shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zKppBNAdEF14" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B0_zkECILXIc7Wi">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.3in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20240101__20241231_zOupq5ilUlJj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zguGWxrb7f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zy5Bl1GPJRT3" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_za34eIow9Q0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">4,235</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(4,390</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zSix07FsNW0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zrrUqM3h32Tk" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of basic common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,350,459</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,556,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_zG4GWF9NqRY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,678,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zWwUyPpV8AVd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">65,028,815</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,556,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zlGunnyguQwb" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-bottom: 1pt">Basic earnings per common share:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zwIrLBCsHUp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zDGqDi9G24if" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_zwg6E6ydYTQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AA_znxlSIBwBfCe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p id="xdx_85D_zSTbx82mt1Jj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHtr4nRIJQag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><span id="xdx_86C_zvA32bDzRRY">Recently Adopted Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">In November 2023 the FASB issued ASU 2023-07 “<i>Improvements to Reportable Segment Disclosures</i>”, which the Company adopted in 2024. The amendments in this Update improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the Chief Operating Decision Maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this Update do not change or remove those disclosure requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The amendments in this Update also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">This Update did not have a significant impact on the Company.</p> <p id="xdx_854_zderlEP87Yd3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_840_ecustom--RecentlyIssuedPronouncementsPoliciesTextBlock_znkKI2nxXbOl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <b><span id="xdx_86E_zH6unjubryT7">Recently Issued Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> <span style="background-color: white">On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, <i>Improvements to Income Tax Disclosures</i>, applies to all entities subject to income taxes. This new requirement will be effective for Solésence for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.</span></p> <p id="xdx_85C_zPKXUNMIBHR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></p> <p id="xdx_845_eus-gaap--UseOfEstimates_zGr2BezFelwl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_869_z5pwHCHKWQJj">Use of Estimates and Risks and Uncertainties</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Certain assumptions are also necessary to assess the impact of risks and uncertainties on the financial statements, such as cash flow projections, availability of capital if needed to support the ongoing operations of the business, and our expected compliance with contractual commitments. These risks and uncertainties are further discussed in Note 12. Any changes in these assumptions or business plans could have a material impact on the financial statements.</p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zG11PhoN360c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_86C_zDiR75GhcID">Cash</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Cash balance on December 31, 2024 consists of funds borrowed from our Revolving Line of Credit, which is facilitated by Beachcorp, LLC. Our ability to access cash from our credit facilities depends on carrying an Accounts Receivable or Inventory balance greater than the outstanding loan balances in the Revolving Lines of Credit. As part of the agreement, we are required to have a bank account in place to act as a depository account for our customers. This account is referred to as the Control Account. Furthermore, there is an Account Control Agreement in place which provides Beachcorp, LLC the ability to exercise control over the account via approval of requested transfers. According to our agreements with Beachcorp, LLC, Solésence is to be the party initiating any transfers, whether to Solésence or to Beachcorp, LLC, and approval to access any monies within this account can only be withheld by Beachcorp, LLC if the borrowing base falls below the Company’s qualified receivables, or if we are in arrears with respect to interest payments due Beachcorp, LLC. The failure of Solésence to remedy the previously mentioned conditions could lead to Beachcorp, LLC gaining the right, through a “springing” feature administered by Libertyville Bank and Trust, a Wintrust Community Bank (“Libertyville”), to transfer funds to itself without direct approval from Solésence.  Cash is held at a federally insured institution, but our cash balances at times exceed insured limits. The Company has not experienced any losses related to these statutory limits.</p> <p id="xdx_845_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z0UVsx2Fbp1j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <b><span id="xdx_862_za8powVD9q4b">Trade Accounts Receivable, Net</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zxSScyibDJX1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible <span id="xdx_8BE_zo0TVHAvZvxj">We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment.</span> Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 65%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_49E_20240101__20241231_zclB5qmmGw25" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td> <td> </td> <td colspan="2" id="xdx_496_20230101__20231231_zfAqJGgJAja8" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td></tr> <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_pn3n3_z1ZnrTOtkCE2" style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 56%"><span style="font-size: 10pt">Balance, beginning</span></td> <td style="width: 3%"> </td> <td style="vertical-align: bottom; width: 3%"><span style="font-size: 10pt">$</span></td> <td style="padding-right: 3pt; vertical-align: bottom; width: 15%; text-align: right"><span style="font-size: 10pt">225</span></td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 3%"><span style="font-size: 10pt">$</span></td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right; width: 15%"><span style="font-size: 10pt">139</span></td></tr> <tr id="xdx_407_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_zUBTvMVU4m"> <td style="padding-left: 12pt; vertical-align: bottom"><span style="font-size: 10pt">Current period provisions</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">564</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">95</span></td></tr> <tr id="xdx_40A_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_zDUFraZZizah" style="background-color: #CCEEFF"> <td style="padding-left: 12pt; vertical-align: bottom"><span style="font-size: 10pt">Write offs</span></td> <td> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(3)</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(9)</span></td></tr> <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_pn3n3_zq3ilxcgTM5g"> <td style="vertical-align: bottom"><span style="font-size: 10pt">Balance, ending</span></td> <td> </td> <td style="border-bottom: Black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.25pt double; padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">786</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.25pt double; padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">225</span></td></tr> </table> <p id="xdx_8A3_zGJJmkkjyoka" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zxSScyibDJX1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Trade accounts receivable are carried at original invoice amount less an estimate made for future credit losses based on a review of all outstanding amounts on a monthly basis, and written off when deemed uncollectible <span id="xdx_8BE_zo0TVHAvZvxj">We determine the allowance for credit losses by identifying troubled accounts and by using historical experience applied to an aging of accounts, as well as expected losses based on the current and anticipated macroeconomic environment.</span> Recoveries of trade accounts receivable previously written off are recorded when received. Our typical credit terms are between thirty and sixty days from shipment and invoicing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 65%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" id="xdx_49E_20240101__20241231_zclB5qmmGw25" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td> <td> </td> <td colspan="2" id="xdx_496_20230101__20231231_zfAqJGgJAja8" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td></tr> <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iS_pn3n3_z1ZnrTOtkCE2" style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 56%"><span style="font-size: 10pt">Balance, beginning</span></td> <td style="width: 3%"> </td> <td style="vertical-align: bottom; width: 3%"><span style="font-size: 10pt">$</span></td> <td style="padding-right: 3pt; vertical-align: bottom; width: 15%; text-align: right"><span style="font-size: 10pt">225</span></td> <td style="vertical-align: bottom; width: 5%"> </td> <td style="vertical-align: bottom; width: 3%"><span style="font-size: 10pt">$</span></td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right; width: 15%"><span style="font-size: 10pt">139</span></td></tr> <tr id="xdx_407_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_zUBTvMVU4m"> <td style="padding-left: 12pt; vertical-align: bottom"><span style="font-size: 10pt">Current period provisions</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">564</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">95</span></td></tr> <tr id="xdx_40A_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_zDUFraZZizah" style="background-color: #CCEEFF"> <td style="padding-left: 12pt; vertical-align: bottom"><span style="font-size: 10pt">Write offs</span></td> <td> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(3)</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">(9)</span></td></tr> <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iE_pn3n3_zq3ilxcgTM5g"> <td style="vertical-align: bottom"><span style="font-size: 10pt">Balance, ending</span></td> <td> </td> <td style="border-bottom: Black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.25pt double; padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">786</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: Black 2.25pt double; vertical-align: bottom"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.25pt double; padding-right: 3pt; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">225</span></td></tr> </table> 225000 139000 564000 95000 3000 9000 786000 225000 <p id="xdx_84F_eus-gaap--InventoryPolicyTextBlock_z7SbPyKoQLte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span><span id="xdx_86F_zfvzF4fdjYs7">Inventories, Net</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Inventories are stated at the lower of cost, maintained on an average cost basis, or net realizable value. We have recorded allowances to reduce inventory relating to excess quantities of certain materials. Write-downs of inventories establish a new cost basis, which is not increased for future increases in market value of inventories or changes in estimated excess quantities.</p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zw8YeL4Uv9S5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span><span id="xdx_860_zToMTrtvZq85">Equipment and Leasehold Improvements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Equipment is stated at cost and is being depreciated over its estimated useful life (<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zbF6vQ5bgyh5" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpgkH1QRV32b" title="Equipment leasehold improvements and leased assets useful life">20</span> years) using the straight-line method. Leasehold improvements are stated at cost and are being amortized using the straight-line method over the shorter of the useful life of the asset or the term of the lease (<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zzr612BQoyzg" title="Equipment leasehold improvements and leased assets useful life">3</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zhcQyP5uRvvd" title="Equipment leasehold improvements and leased assets useful life">7</span> years). Depreciation expense for leased assets is included with depreciation expense for owned assets. From time to time we have self-constructed assets. These assets are stated at cost plus the capitalization of labor and are depreciated over an estimated useful life (<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zuQnh89tcpd6" title="Equipment leasehold improvements and leased assets useful life">7</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherCapitalizedPropertyPlantAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zWNhepB8NOhk" title="Equipment leasehold improvements and leased assets useful life">10</span> years) using the straight-line method.</p> P3Y P20Y P3Y P7Y P7Y P10Y <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zzQc992VOwY" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_866_zxkMsZ8oqOV5">Long Lived Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the asset’s carrying amount may not be recoverable. We conduct long-lived asset impairment analyses in accordance with ASC 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. ASC 360-10-15 requires us to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals. Based upon our analysis, there were no impairment charges recognized in either period presented.</p> <p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zXtDTQuuceL" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_860_z1NnzAuHg2id">Deferred Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company records a contract liability for development projects due to the contractual billing of these projects not always aligning with revenue recognition. In addition, it is now the Company’s policy to frequently require deposits relating to the production of our Solésence products. Of the total $<span id="xdx_90F_eus-gaap--DeferredIncome_iI_pn3n3_c20241231_zj8CnVvyL1O5" title="Deferred revenue">5,571</span> in deferred revenue reported in 2024, <span id="xdx_903_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--PrepaymentsFromCertainCustomersPerCompanyPolicyMember_zm6atwoZZHMa">99%</span> related to prepayments received from certain customers per Company policy, and the remaining <span id="xdx_90B_ecustom--PercentageOfPrepayments_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--PrepaymentsFromProductDevelopmentAgreementWithAPersonalCareIngredientCustomerMember_zgprJLXkpCCe">1</span>% related to prepayments from a product development agreement with a personal care ingredient customer.</p> 5571000 0.99 0.01 <p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zf0bifqdlB7h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_865_z46W7Rd2kOn8">Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Our financial instruments include cash, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 3. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">There were no financial instruments adjusted to fair value on December 31, 2024 and 2023.</p> <p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zmkSTzDS5Dgc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_866_zHn2B5gAwjp1">Product Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point, is the point in time at which we recognize the related revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations. For select customers the Company may pay volume rebates which are variable in nature due the amount the select customer will take. In 2024 one customer earned a volume rebate of <span id="xdx_908_ecustom--VolumeRebates_pp0p0_c20240101__20241231_zJXcXOOCn3d2" title="Volume rebate">$35,000</span>. In 2023 no volume rebates were recorded because the customers did not meet required volumes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As part of the sales process, it is common for the Company to receive customer deposits. These deposits are typically held for less than a year and do not result in a financing component to the sales. The customer deposits are recognized as revenue when the Company ships the finished goods to the customer. Revenue is recognized when the goods are shipped</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company will for some customers arrange for the shipping of the finished goods. Revenues and costs associated with the shipment of the finished goods are recorded separately within product revenue and cost of revenue, respectively, on the consolidation statement of operations. With regard to revenue recognition, shipping activities that occur prior to the customers’ obtaining control of the goods are not a promised service to the customer, but rather activities to fulfill the Company’s promise to transfer the goods. As such, these activities are not deemed a performance obligation requiring allocation of the transaction price. Similarly, shipping activities that occur after the customers’ obtaining control of the goods are, as a matter of policy, also not a promised service to the customer, but rather an activity to fulfill the Company’s promise to transfer the good.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_897_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zYeJfA7m0Yb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zPuhpzl7wTV2">Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">2022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20221231_zYv0wHTYlFt6" style="width: 10%; text-align: right">4,734</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20221231_zfIBfCLtZzdf" style="width: 10%; text-align: right">2,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20231231_zozfIOQwVd15" style="text-align: right">3,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20231231_zlj7j599vEqd" style="text-align: right">2,353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20241231_z8e94k0s66Ak" style="text-align: right" title="Accounts receivable, net">4,869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20241231_zf2QGshg5ypb" style="text-align: right" title="Contract liabilities">5,571</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zUT18UWpC8Oa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was <span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zYZstmvx04Ci" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">$2,074</span> and <span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20230101__20231231_zu63NZ2MD5da" title="Revenue recognized in the reporting period included in contract liability balance at beginning of period">$2,084</span> for the years ended December 31, 2024, and 2023, respectively.</p> 35000 <p id="xdx_897_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zYeJfA7m0Yb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zPuhpzl7wTV2">Contract balances for the years ended December 31, 2024, 2023, and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 63%; text-align: left">2022</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20221231_zYv0wHTYlFt6" style="width: 10%; text-align: right">4,734</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20221231_zfIBfCLtZzdf" style="width: 10%; text-align: right">2,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20231231_zozfIOQwVd15" style="text-align: right">3,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20231231_zlj7j599vEqd" style="text-align: right">2,353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20241231_z8e94k0s66Ak" style="text-align: right" title="Accounts receivable, net">4,869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20241231_zf2QGshg5ypb" style="text-align: right" title="Contract liabilities">5,571</td><td style="text-align: left"> </td></tr> </table> 4734000 2188000 3467000 2353000 4869000 5571000 2074000 2084000 <p id="xdx_848_ecustom--OtherRevenuePolicyTextBlock_zcbett79K9ob" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><span id="xdx_866_zxsuhPcFvqvh">Other Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Revenue recognized over time was $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20240101__20241231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zyrJQKU08bLl" title="Revenue">457</span> and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zvdYmhpKoYad" title="Revenue">656</span> for the years ended December 31, 2024 and 2023, respectively.</p> 457000 656000 <p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zy5S8NHaS7Xd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_86E_zk8434v3DOzi">Research and Development Expenses</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Research and development expenses are recognized as expense when incurred.</p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zIgWg9B0WoD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_864_ztV70ut6dqDf">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We account for income taxes using the asset-and-liability approach. As such, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are calculated using the enacted tax rates and laws that are expected to be in effect when the anticipated reversal of these differences is scheduled to occur. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for uncertain tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We have not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. We file tax returns in all appropriate jurisdictions, which includes a federal tax return and Illinois state tax return. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in selling, general and administrative expenses in the statements of operations. As of December 31, 2024, and 2023, we had no liability for unrecognized tax benefits.</p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zSlDNHVqh4le" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_865_zphCZxQmhEo6">Earnings Per Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Included in the computation of diluted earnings per share for the year ended December 31, 2024, was a total of <span id="xdx_904_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_uShares_c20240101__20241231_zHLra8DWxR9d" title="Potential common stock included in computation of diluted earnings per share">2,678,000</span> in potential shares of common stock. Options to purchase approximately <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20231231_zanGQT707Kxe" title="Anti-dilutive pptions excluded from computation of earnings per share">889,000</span> shares of common stock that were outstanding as of December 31, 2023 were not included in the computation of earnings per share for the year ended December 31, 2023, as they would have been anti-dilutive owing to the loss reported for the period. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zKppBNAdEF14" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B0_zkECILXIc7Wi">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.3in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20240101__20241231_zOupq5ilUlJj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zguGWxrb7f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zy5Bl1GPJRT3" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_za34eIow9Q0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">4,235</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(4,390</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zSix07FsNW0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zrrUqM3h32Tk" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of basic common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,350,459</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,556,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_zG4GWF9NqRY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,678,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zWwUyPpV8AVd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">65,028,815</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,556,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zlGunnyguQwb" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-bottom: 1pt">Basic earnings per common share:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zwIrLBCsHUp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zDGqDi9G24if" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_zwg6E6ydYTQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AA_znxlSIBwBfCe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> 2678000 889000 <p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zKppBNAdEF14" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B0_zkECILXIc7Wi">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.3in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20240101__20241231_zOupq5ilUlJj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zguGWxrb7f6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zy5Bl1GPJRT3" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_za34eIow9Q0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">4,235</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(4,390</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zSix07FsNW0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zrrUqM3h32Tk" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of basic common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,350,459</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,556,305</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_zG4GWF9NqRY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,678,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zWwUyPpV8AVd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">65,028,815</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,556,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zlGunnyguQwb" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-bottom: 1pt">Basic earnings per common share:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zwIrLBCsHUp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zDGqDi9G24if" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_zwg6E6ydYTQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 4235000 -4390000 62350459 49556305 2678356 65028815 49556305 0.07 -0.09 0.07 -0.09 <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHtr4nRIJQag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><span id="xdx_86C_zvA32bDzRRY">Recently Adopted Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">In November 2023 the FASB issued ASU 2023-07 “<i>Improvements to Reportable Segment Disclosures</i>”, which the Company adopted in 2024. The amendments in this Update improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the Chief Operating Decision Maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this Update do not change or remove those disclosure requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The amendments in this Update also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">This Update did not have a significant impact on the Company.</p> <p id="xdx_840_ecustom--RecentlyIssuedPronouncementsPoliciesTextBlock_znkKI2nxXbOl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> <b><span id="xdx_86E_zH6unjubryT7">Recently Issued Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> <span style="background-color: white">On December 14, 2023 the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, <i>Improvements to Income Tax Disclosures</i>, applies to all entities subject to income taxes. This new requirement will be effective for Solésence for annual periods beginning December 31, 2025. The Company is currently evaluating the impact of the adoption of this standard on the consolidated financial statements.</span></p> <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zIgaoE9sECvb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(3)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_82C_zw2kuACWgt1k">Related Party Notes and Lines of Credit</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_898_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_z9aOTra9gqub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_z50RPA99mFSl">Notes and lines of credit consist of the following</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Balance</b></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Balance</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(1)</sup></span></td><td style="width: 1%"> </td> <td id="xdx_983_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zg1fi21AMJZ1" style="width: 10%; text-align: center">8.50%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zabcFp2Cudw6" style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zS9bRUK6IPrg" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zLBlft7p5WC7" style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zzHomvOx7L8f" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(2)</sup></span></td><td> </td> <td id="xdx_98C_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zEjiAQ9cl6E5" style="text-align: center">8.50%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zjIRl3nnfBO1" style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zOtJpndYUPG1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_z6WQhh8lzOlj" style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zLUnAyiibKR3" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-size: 10pt">Beachcorp, LLC <sup>(3) </sup></span></td><td> </td> <td id="xdx_986_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zQlI2H6gouH9" style="text-align: center">8.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zZS6X2bTW5S7" style="text-align: right">5,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zXuis8whRZyj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zmxGZFXRPFf3" style="text-align: right">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zPVzYF6HGiYc" style="text-align: right">2,810</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Beachcorp, LLC <sup>(4) </sup></span></td><td> </td> <td id="xdx_98B_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zSOlvDg8KUw5" style="text-align: center">8.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_z2tFEZh3rECf" style="text-align: right">5,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_c20241230__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_z2xh8zCz8nq8" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zjxJvFIT0F46" style="text-align: right">5,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zJrpMrG6Ioe3" style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-size: 10pt">Strandler, LLC   <sup>(5) </sup></span></td><td> </td> <td id="xdx_98F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_z1yA18cwGfJi" style="text-align: center">8.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zpRcVc3wxkWl" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zKx8soYhnsck" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zV9AyjSI9igg" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zX7Ke8XaUV1a" style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Strandler, LLC <sup> (6)</sup></span></td><td> </td> <td id="xdx_98F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zCllEIMUAW98" style="text-align: center">9.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_d0_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zqw7NrO6zcUb" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LineOfCredit_iI_d0_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zp84ezv97kAl" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_d0_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zf4xthf5ZGF4" style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_d0_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_z47e0JKjmOA4" style="text-align: right">2,000</td><td style="text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F09_z3KEmOASMY7b" style="width: 0.25in">1)</td><td id="xdx_F1E_zvCrkAZ17vuj" style="text-align: justify">Since July 2014, we have maintained a bank-issued letter of credit for up to <span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20140731__us-gaap--CreditFacilityAxis__us-gaap--LetterOfCreditMember_zjihuMRrHge">$30</span> in borrowings, with interest at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zWBOQkgXdpi6" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zMZ9tJNZSBAf" title="Basis spread variable interest rate">1</span>%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F01_z5xiQQzRBJHj" style="width: 0.25in">2)</td><td id="xdx_F10_ztRI1DbBzzca" style="text-align: justify">On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the <span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20211221__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_ziotjQ4iWPD7" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20211221__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zu6ugLDEmdXa" title="Basis spread variable interest rate">1</span>%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F06_zfPJlNw5F5Yi" style="width: 0.25in">3)</td><td id="xdx_F11_zAEjVNlep4t7" style="text-align: justify">On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from <span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220126__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zOvonep42Op1" title="Line of Credit Facility, Maximum Borrowing Capacity">$6,000</span> to <span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zwqUDyW1TVuj" title="Line of Credit Facility, Maximum Borrowing Capacity">$8,000</span>, reduce the interest rate to the <span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z7vrz4DG8rv7" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zRSaO3UkvAUl" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and extend the maturity of the A/R Revolver Facility to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_ziC8I5m4hijh" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zprviFtaPxhf" title="Line of Credit Facility, Expiration Date">October 1, 2025</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F07_zo7KUUdI0f7i" style="width: 0.25in">4)</td><td id="xdx_F1C_zmxzRTNdKGoh" style="text-align: justify">On January 28, 2022, the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1xAybfxDvRh" title="Line of Credit Facility, Maximum Borrowing Capacity">$4,000</span>, with a borrowing base consisting of up to <span id="xdx_90B_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z5xuNeoba0af">50</span>% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the <span id="xdx_901_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zx8ukGRWVLM4">prime rate</span> plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsm3SzVSJ6N6">0.75</span>%, and it was set to matured on <span id="xdx_902_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z0bGYYy3dhWh">March 31, 2024</span>. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zC0oF7HWUCe3">5,200</span>, with a borrowing base consisting of up to <span id="xdx_907_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zi7OKQjrRGXh">55</span>% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the <span id="xdx_904_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsFfHjdukZV2">prime rate</span> plus <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zOYOVYlXsiK3">0.75</span>%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to <span id="xdx_902_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsEWai9wII49">October 1, 2025</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F08_zhoZOFUuzxD2" style="width: 0.25in">5)</td><td id="xdx_F1E_zsrn64Jq2zBf" style="text-align: justify">On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the <span id="xdx_905_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zbukR5Wytgs6">prime rate</span> plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zk9ptwPXk1gk">0.75</span>%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zkv3Qr4xejy6">October 1, 2025</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0B_zvUJBhKqQuw2" style="width: 0.25in">6)</td><td id="xdx_F14_zdWtHzVnTj5b" style="text-align: justify">On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zg1CZlo1xDo2">2,000</span>. The interest rate for the Bridge Note was at the <span id="xdx_909_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zau3g7mFSMi1">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zHMIxdDKZ9xf">0.75</span>%, and it was to mature on <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zJMF9DXINfO1">May 13, 2024</span>. The Bridge Note was repaid in February 2024.</td></tr></table> <p id="xdx_8A9_zVFP3LJgQoui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 31.5pt">The Company classifies the line of credit – accounts receivable as current because we are required to pay back the borrowings as cash is received from our customers. The company’s remaining debt is presented within the Consolidated Balance Sheet as of December 31, 2024, and 2023 in accordance with the maturity dates in the financing agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.5pt; text-align: justify; text-indent: 31.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white">Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank &amp; Trust. The Company’s loan agreements with Strandler, LLC and Beachcorp, LLC currently are set to expire on October 1, 2025, which could become an operating risk if we are not able to refinance or extend the maturity dates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p id="xdx_891_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zxJzULx23sL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zjWh6Df9Osmc">Related party interest expense consists of the following</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_za4D8ZKow1G7" style="width: 10%; text-align: right" title="Interest expense">656</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zqJEyLcKlZ4j" style="width: 10%; text-align: right" title="Interest expense">770</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Accrued interest consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Accrued interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zldQdG26PO7k" style="width: 10%; text-align: right" title="Accrued interest expense">36</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0lMsqKkctFc" style="width: 10%; text-align: right" title="Accrued interest expense">81</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Outstanding balances associated with related parties are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Beachcorp, LLC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zTDQwRwc2hQ7" style="width: 10%; text-align: right">4,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zBPq3NRoBMpk" style="width: 10%; text-align: right">7,810</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Strandler, LLC</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zZFoBNEEhlB7" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zhIsTaeNeKWj" style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zYmoiVFS4EYc" style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_898_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_z9aOTra9gqub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_z50RPA99mFSl">Notes and lines of credit consist of the following</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Balance</b></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Available</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Balance</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(1)</sup></span></td><td style="width: 1%"> </td> <td id="xdx_983_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zg1fi21AMJZ1" style="width: 10%; text-align: center">8.50%</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zabcFp2Cudw6" style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zS9bRUK6IPrg" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zLBlft7p5WC7" style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zzHomvOx7L8f" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(2)</sup></span></td><td> </td> <td id="xdx_98C_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zEjiAQ9cl6E5" style="text-align: center">8.50%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zjIRl3nnfBO1" style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zOtJpndYUPG1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_z6WQhh8lzOlj" style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zLUnAyiibKR3" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-size: 10pt">Beachcorp, LLC <sup>(3) </sup></span></td><td> </td> <td id="xdx_986_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zQlI2H6gouH9" style="text-align: center">8.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zZS6X2bTW5S7" style="text-align: right">5,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zXuis8whRZyj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zmxGZFXRPFf3" style="text-align: right">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fKDMp_zPVzYF6HGiYc" style="text-align: right">2,810</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Beachcorp, LLC <sup>(4) </sup></span></td><td> </td> <td id="xdx_98B_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zSOlvDg8KUw5" style="text-align: center">8.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_z2tFEZh3rECf" style="text-align: right">5,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_c20241230__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_z2xh8zCz8nq8" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zjxJvFIT0F46" style="text-align: right">5,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zJrpMrG6Ioe3" style="text-align: right">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-size: 10pt">Strandler, LLC   <sup>(5) </sup></span></td><td> </td> <td id="xdx_98F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_z1yA18cwGfJi" style="text-align: center">8.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zpRcVc3wxkWl" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCredit_iI_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zKx8soYhnsck" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zV9AyjSI9igg" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDUp_zX7Ke8XaUV1a" style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Strandler, LLC <sup> (6)</sup></span></td><td> </td> <td id="xdx_98F_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zCllEIMUAW98" style="text-align: center">9.25%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_d0_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zqw7NrO6zcUb" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LineOfCredit_iI_d0_c20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zp84ezv97kAl" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_d0_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_zf4xthf5ZGF4" style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_d0_c20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCOneMember_fKDYp_z47e0JKjmOA4" style="text-align: right">2,000</td><td style="text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F09_z3KEmOASMY7b" style="width: 0.25in">1)</td><td id="xdx_F1E_zvCrkAZ17vuj" style="text-align: justify">Since July 2014, we have maintained a bank-issued letter of credit for up to <span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20140731__us-gaap--CreditFacilityAxis__us-gaap--LetterOfCreditMember_zjihuMRrHge">$30</span> in borrowings, with interest at the <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zWBOQkgXdpi6" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPure_c20140701__20140731__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zMZ9tJNZSBAf" title="Basis spread variable interest rate">1</span>%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F01_z5xiQQzRBJHj" style="width: 0.25in">2)</td><td id="xdx_F10_ztRI1DbBzzca" style="text-align: justify">On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the <span id="xdx_902_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20211221__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_ziotjQ4iWPD7" title="Variable interest rate basis">prime rate</span> plus <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20211221__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--LetterOfCreditMember_zu6ugLDEmdXa" title="Basis spread variable interest rate">1</span>%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F06_zfPJlNw5F5Yi" style="width: 0.25in">3)</td><td id="xdx_F11_zAEjVNlep4t7" style="text-align: justify">On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from <span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220126__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zOvonep42Op1" title="Line of Credit Facility, Maximum Borrowing Capacity">$6,000</span> to <span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zwqUDyW1TVuj" title="Line of Credit Facility, Maximum Borrowing Capacity">$8,000</span>, reduce the interest rate to the <span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z7vrz4DG8rv7" title="Debt Instrument, Description of Variable Rate Basis">prime rate</span> plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zRSaO3UkvAUl" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and extend the maturity of the A/R Revolver Facility to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_ziC8I5m4hijh" title="Line of Credit Facility, Expiration Date">March 31, 2024</span>. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zprviFtaPxhf" title="Line of Credit Facility, Expiration Date">October 1, 2025</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F07_zo7KUUdI0f7i" style="width: 0.25in">4)</td><td id="xdx_F1C_zmxzRTNdKGoh" style="text-align: justify">On January 28, 2022, the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1xAybfxDvRh" title="Line of Credit Facility, Maximum Borrowing Capacity">$4,000</span>, with a borrowing base consisting of up to <span id="xdx_90B_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z5xuNeoba0af">50</span>% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the <span id="xdx_901_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zx8ukGRWVLM4">prime rate</span> plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsm3SzVSJ6N6">0.75</span>%, and it was set to matured on <span id="xdx_902_eus-gaap--LineOfCreditFacilityExpirationDate1_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z0bGYYy3dhWh">March 31, 2024</span>. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zC0oF7HWUCe3">5,200</span>, with a borrowing base consisting of up to <span id="xdx_907_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zi7OKQjrRGXh">55</span>% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the <span id="xdx_904_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsFfHjdukZV2">prime rate</span> plus <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zOYOVYlXsiK3">0.75</span>%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to <span id="xdx_902_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ReplacementPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsEWai9wII49">October 1, 2025</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F08_zhoZOFUuzxD2" style="width: 0.25in">5)</td><td id="xdx_F1E_zsrn64Jq2zBf" style="text-align: justify">On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the <span id="xdx_905_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220127__20220128__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zbukR5Wytgs6">prime rate</span> plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zk9ptwPXk1gk">0.75</span>%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20240229__20240301__us-gaap--CreditFacilityAxis__custom--TermLoanMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zkv3Qr4xejy6">October 1, 2025</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0B_zvUJBhKqQuw2" style="width: 0.25in">6)</td><td id="xdx_F14_zdWtHzVnTj5b" style="text-align: justify">On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zg1CZlo1xDo2">2,000</span>. The interest rate for the Bridge Note was at the <span id="xdx_909_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zau3g7mFSMi1">prime rate</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zHMIxdDKZ9xf">0.75</span>%, and it was to mature on <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zJMF9DXINfO1">May 13, 2024</span>. The Bridge Note was repaid in February 2024.</td></tr></table> 0.0850 30000 30000 0.0850 500000 500000 0.0825 5604000 3298000 2810000 0.0825 5200000 4000000 5200000 5000000 0.0825 1000000 1000000 1000000 1000000 0.0925 0 0 2000000 2000000 30000 prime rate 0.01 prime rate 0.01 6000000 8000000 prime rate 0.0075 2024-03-31 2025-10-01 4000000 0.50 prime rate 0.0075 2024-03-31 5200000 0.55 prime rate 0.0075 2025-10-01 prime rate 0.0075 2025-10-01 2000000 prime rate 0.0075 2024-05-13 <p id="xdx_891_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zxJzULx23sL1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zjWh6Df9Osmc">Related party interest expense consists of the following</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_za4D8ZKow1G7" style="width: 10%; text-align: right" title="Interest expense">656</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zqJEyLcKlZ4j" style="width: 10%; text-align: right" title="Interest expense">770</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Accrued interest consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Accrued interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zldQdG26PO7k" style="width: 10%; text-align: right" title="Accrued interest expense">36</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0lMsqKkctFc" style="width: 10%; text-align: right" title="Accrued interest expense">81</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Outstanding balances associated with related parties are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Beachcorp, LLC</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zTDQwRwc2hQ7" style="width: 10%; text-align: right">4,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_zBPq3NRoBMpk" style="width: 10%; text-align: right">7,810</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Strandler, LLC</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zZFoBNEEhlB7" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zhIsTaeNeKWj" style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> </table> 656000 770000 36000 81000 4000000 7810000 1000000 3000000 <p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_z75pCEk5O3o2" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(4)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_825_zbSwsgH03PXd">Inventories, net</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zokACJckIZec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B6_zJpn1yDlK3xk">Inventories consist of the following</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20241231_zeMCvBAPtjNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_497_20231231_zZrF7JqW280e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzWNM_z67VORk4OWmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17,396</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,524</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzWNM_z281GrnBebuc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,184</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzWNM_z4TltcvjHsx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,987</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(677</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWNM_zhovsnXjylJb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">      Total Inventories, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,031</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_z7eV7lwtqzk1" style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zokACJckIZec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B6_zJpn1yDlK3xk">Inventories consist of the following</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20241231_zeMCvBAPtjNa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_497_20231231_zZrF7JqW280e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzWNM_z67VORk4OWmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17,396</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,524</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzWNM_z281GrnBebuc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,184</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryValuationReserves_iNI_pn3n3_di_msINzWNM_z4TltcvjHsx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Inventory reserve</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,987</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(677</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3n3_mtINzWNM_zhovsnXjylJb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">      Total Inventories, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,031</td><td style="text-align: left"> </td></tr> </table> 17396000 8524000 4858000 2184000 1987000 677000 20267000 10031000 <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zc4RhFnMHQIk" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.5pt"><b>(5)</b></p></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b><span id="xdx_824_zeUqciN3Ue93">Equipment and Leasehold Improvements</span></b></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMXBqg8DSg5c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_8B0_zsPiAYjvCpH">Equipment and leasehold improvements consist of the following</span>: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zwSd7g00y0Ej" style="width: 10%; text-align: right" title="Machinery and equipment">23,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zRDwaS15VF3k" style="width: 10%; text-align: right" title="Machinery and equipment">23,339</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zbHJEsQdTwV7" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zsqUDhLnzn6j" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zYYs28i2AFl2" style="text-align: right" title="Office furniture">126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zVsypju6mMWj" style="text-align: right" title="Office furniture">126</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0BWfGuVHbK" style="text-align: right" title="Leasehold improvements">5,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOOJiwL4MZg" style="text-align: right" title="Leasehold improvements">5,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zVWnPrlS4xS4" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">5,706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zsy0gO0qmxX3" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">931</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20241231_zdWfGnHLdIpb" style="text-align: right" title="Property plant and equipment,gross">35,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20231231_zZmmqI9ll2ge" style="text-align: right" title="Property plant and equipment,gross">30,567</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20241231_zdYnPuQa22L4" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(22,816</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20231231_zJNIn8lY3TJ2" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(21,899</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20241231_zeZi8DTZ7KP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">12,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20231231_zDK9qvhvAA7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">8,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zf1XHs0s7mod" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Depreciation expense was <span id="xdx_90E_eus-gaap--Depreciation_pn3n3_c20240101__20241231_zgjHDAZyEAr3" title="Depreciation expense">$918</span> and <span id="xdx_90F_eus-gaap--Depreciation_pn3n3_c20230101__20231231_zWPMfbA8AxJg" title="Depreciation expense">$732</span>, for the years ended December 31, 2024 and 2023, respectively.</p> <p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMXBqg8DSg5c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_8B0_zsPiAYjvCpH">Equipment and leasehold improvements consist of the following</span>: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zwSd7g00y0Ej" style="width: 10%; text-align: right" title="Machinery and equipment">23,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zRDwaS15VF3k" style="width: 10%; text-align: right" title="Machinery and equipment">23,339</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zbHJEsQdTwV7" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zsqUDhLnzn6j" style="text-align: right" title="Office equipment">1,014</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zYYs28i2AFl2" style="text-align: right" title="Office furniture">126</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zVsypju6mMWj" style="text-align: right" title="Office furniture">126</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z0BWfGuVHbK" style="text-align: right" title="Leasehold improvements">5,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOOJiwL4MZg" style="text-align: right" title="Leasehold improvements">5,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zVWnPrlS4xS4" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">5,706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zsy0gO0qmxX3" style="border-bottom: Black 1pt solid; text-align: right" title="Construction in progress">931</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20241231_zdWfGnHLdIpb" style="text-align: right" title="Property plant and equipment,gross">35,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20231231_zZmmqI9ll2ge" style="text-align: right" title="Property plant and equipment,gross">30,567</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20241231_zdYnPuQa22L4" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(22,816</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20231231_zJNIn8lY3TJ2" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(21,899</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20241231_zeZi8DTZ7KP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">12,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20231231_zDK9qvhvAA7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, Plant and Equipment, Net, Total">8,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 23551000 23339000 1014000 1014000 126000 126000 5153000 5157000 5706000 931000 35550000 30567000 22816000 21899000 12734000 8668000 918000 732000 <p id="xdx_80A_eus-gaap--CommitmentsDisclosureTextBlock_z5hws0Pu09gg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(6)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_821_zWAD0OoVy5zh">Lease Commitments</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt">The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. The Company has one sublease of currently unused floorspace that is month-to-month.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">On September 1<sup>st</sup> of 2024 the facility located at 1319 Marquette Drive in Romeoville was extended through January 31, 2028. Additionally, on that same day, the facility located at 453 Commerce St in Burr Ridge was extended for one year. The present value of future lease payments associated with these extensions resulted in the addition of a ROU asset and lease liability totaling $<span id="xdx_90C_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_z02CPv3c9oti" title="Lease liabilities arising from obtaining right-of-use assets">1,019</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The office leases contain variable lease payments which consist primarily of taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor. The Company has elected to utilize the available practical expedient to combine lease and non-lease components for building leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zczCNAK4vcV6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span id="xdx_8B4_zuBjCTooHIyg">Quantitative information regarding the Company’s leases is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zDuDPgUegkwb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_z6agNFf89cC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zSTuRZiVGMPa" style="vertical-align: bottom"> <td style="text-align: left">Components of lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingLeaseCostComponentsAbstract_i02B_pn3n3_zGqRWQhtWIYc" style="vertical-align: bottom"> <td style="text-align: left">Operating lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzncp_maOLEzNuA_ziCSZIrAtVr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-left: 12pt">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">1,944</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">1,881</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzncp_maOLEzNuA_z0Njrh5ywejd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 12pt">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">581</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzncp_maOLEzNuA_zIGeg4ISzlp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt">Short-term lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SubleaseIncome_i02N_pn3n3_di_msOLEzNuA_zLwswWtC7kh2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Sub-lease income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(511</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(786</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--LeaseCostsOperating_i02T_pn3n3_maLCzWd6_mtOLEzNuA_zyAO20wnXpYa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 24pt"> Total operating lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,451</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,788</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_z0AIU3DR9eg6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,451</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z6O2H1IxoD68" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_89E_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_z2lgh7d4Ma2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zw4h4qQ6eB9i">Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-left: 24pt">Operating cash outflow from operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_zR85cpAK9Gg2" style="width: 10%; text-align: right" title="Operating cash outflow from operating leases">2,115</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_z0sAEIDK5VQb" style="width: 10%; text-align: right">172</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease liabilities arising from obtaining right-of-use assets</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_znVhcaEHXiPc" style="text-align: right" title="Lease liabilities arising from obtaining right-of-use assets">1,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20230101__20231231_zg8Z5da0l2P5" style="text-align: right" title="Lease liabilities arising from obtaining right-of-use assets">182</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term-operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231_z6H1E1SKcOrc" title="Weighted-average remaining lease term-operating leases (in years)">6.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231_zWMtm0yYw9ai" title="Weighted-average remaining lease term-operating leases (in years)">7.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate-operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20241231_zv3U4dDcWzBd" title="Weighted-average discount rate-operating leases">7.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20231231_zw7iAdX4biRe" title="Weighted-average discount rate-operating leases">7.1</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_zNmJXKaFeHIk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxYDBhdzf0Bj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zXkLYoEJHoL1">The future maturities of the Company’s operating leases as of December 31, 2024 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">2025</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLL_c20241231_zckN1YvWsbJ" style="width: 10%; text-align: right" title="2025">1,975</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLL_c20241231_zi5Y9ofQVn41" style="text-align: right" title="2026">1,909</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLL_c20241231_zeuZXjiNKCHk" style="text-align: right" title="2027">1,965</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLL_c20241231_zfc06N3ZS8i6" style="text-align: right" title="2028">1,587</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLL_c20241231_z07dxT0Nds42" style="text-align: right" title="2029">1,591</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLL_c20241231_zj6wnXNkmIbl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">4,021</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Total payments</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLL_c20241231_z9A5yWFuhvWb" style="text-align: right" title="Total payments">13,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Less amounts representing interest</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20241231_zknlohTUbHZd" style="text-align: right" title="Less amounts representing interest">(2,752</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_zPiFtzZK7eBf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total minimum payments required">10,296</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zjPhra8z0413" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The Company subleases a portion of a leased industrial building that is used primarily for the storage of furniture, equipment and displays used for retail sales. The arrangement is not with a related party.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Payments received by the Company for this sublease are comprised of two components, which include base rent and Common Area Maintenance (CAM) charges. While the base rent is fixed, the CAM charges are indexed directly to the Master Lease and are expected to be adjusted periodically as actual costs are incurred. However, the executed sublease agreement specifically itemizes these costs with a provision that informs the sublessee that the CAM charges will be adjusted (up or down) based on actual amounts once this information becomes known. As such, the nature of the charges is more closely representative of a fixed payment (an “in-substance fixed” charge) with the adjustments occurring simply to “true up” the listed CAM charges once actual charges from the head lessor become known. As sublessor, the Company has elected the practical expedient to not separate lease and nonlease components in disclosing future undiscounted cashflows and treats the combined components as a single lease component.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">As sublessor, the Company is subletting to one tenant on a month-to-month arrangement.</p> 1019000 <p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zczCNAK4vcV6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"><span id="xdx_8B4_zuBjCTooHIyg">Quantitative information regarding the Company’s leases is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zDuDPgUegkwb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_z6agNFf89cC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Twelve Months Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zSTuRZiVGMPa" style="vertical-align: bottom"> <td style="text-align: left">Components of lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingLeaseCostComponentsAbstract_i02B_pn3n3_zGqRWQhtWIYc" style="vertical-align: bottom"> <td style="text-align: left">Operating lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzncp_maOLEzNuA_ziCSZIrAtVr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-left: 12pt">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">1,944</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">1,881</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzncp_maOLEzNuA_z0Njrh5ywejd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 12pt">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">581</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzncp_maOLEzNuA_zIGeg4ISzlp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 12pt">Short-term lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SubleaseIncome_i02N_pn3n3_di_msOLEzNuA_zLwswWtC7kh2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 12pt">Sub-lease income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(511</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(786</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--LeaseCostsOperating_i02T_pn3n3_maLCzWd6_mtOLEzNuA_zyAO20wnXpYa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 24pt"> Total operating lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,451</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,788</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_z0AIU3DR9eg6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,451</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1944000 1881000 684000 581000 334000 112000 511000 786000 2451000 1788000 2451000 1788000 <p id="xdx_89E_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_z2lgh7d4Ma2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zw4h4qQ6eB9i">Supplemental cash flow information related to leases is as follows for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-left: 24pt">Operating cash outflow from operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_zR85cpAK9Gg2" style="width: 10%; text-align: right" title="Operating cash outflow from operating leases">2,115</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_z0sAEIDK5VQb" style="width: 10%; text-align: right">172</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease liabilities arising from obtaining right-of-use assets</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_znVhcaEHXiPc" style="text-align: right" title="Lease liabilities arising from obtaining right-of-use assets">1,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20230101__20231231_zg8Z5da0l2P5" style="text-align: right" title="Lease liabilities arising from obtaining right-of-use assets">182</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term-operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20241231_z6H1E1SKcOrc" title="Weighted-average remaining lease term-operating leases (in years)">6.8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231_zWMtm0yYw9ai" title="Weighted-average remaining lease term-operating leases (in years)">7.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate-operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20241231_zv3U4dDcWzBd" title="Weighted-average discount rate-operating leases">7.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20231231_zw7iAdX4biRe" title="Weighted-average discount rate-operating leases">7.1</span></td><td style="text-align: left">%</td></tr> </table> 2115000 172000 1019000 182000 P6Y9M18D P7Y10M24D 0.076 0.071 <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxYDBhdzf0Bj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zXkLYoEJHoL1">The future maturities of the Company’s operating leases as of December 31, 2024 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">2025</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLL_c20241231_zckN1YvWsbJ" style="width: 10%; text-align: right" title="2025">1,975</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLL_c20241231_zi5Y9ofQVn41" style="text-align: right" title="2026">1,909</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLL_c20241231_zeuZXjiNKCHk" style="text-align: right" title="2027">1,965</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLL_c20241231_zfc06N3ZS8i6" style="text-align: right" title="2028">1,587</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLL_c20241231_z07dxT0Nds42" style="text-align: right" title="2029">1,591</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLL_c20241231_zj6wnXNkmIbl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">4,021</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Total payments</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLL_c20241231_z9A5yWFuhvWb" style="text-align: right" title="Total payments">13,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Less amounts representing interest</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20241231_zknlohTUbHZd" style="text-align: right" title="Less amounts representing interest">(2,752</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">Total minimum payments required</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_zPiFtzZK7eBf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total minimum payments required">10,296</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1975000 1909000 1965000 1587000 1591000 4021000 13048000 2752000 10296000 <p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zDqFfLAImK9i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(7)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_820_ztqssnaQZHBj">Accrued Expenses</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zcp1EsFKbb9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8BD_zy78hdFojfj8">Accrued expenses consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20241231_zN23CAkGLAO6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49F_20231231_zKRSfdlPOJC3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzPuI_zPt1WztOyVE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Accrued payroll and related expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,824</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">255</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedAccountsPayable_iI_maALCzPuI_zsZO2EJZe8o8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzPuI_zsqIiTyYNtMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,428</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">486</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzPuI_zJE9mzVESkc7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.1in"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,849</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">869</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_znKhRIR88ZTa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p> <p id="xdx_894_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zcp1EsFKbb9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8BD_zy78hdFojfj8">Accrued expenses consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20241231_zN23CAkGLAO6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_49F_20231231_zKRSfdlPOJC3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maALCzPuI_zPt1WztOyVE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Accrued payroll and related expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,824</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">255</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedAccountsPayable_iI_maALCzPuI_zsZO2EJZe8o8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzPuI_zsqIiTyYNtMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,428</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">486</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzPuI_zJE9mzVESkc7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.1in"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,849</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">869</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1824000 255000 1597000 128000 1428000 486000 4849000 869000 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zPte7BMYqDff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.5in; text-align: left"><b>(8)</b></td><td style="text-align: justify"><b><span id="xdx_828_zslImlH5QJ5">Income Taxes</span></b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Our net income tax provision, including both current and deferred, related to U.S. federal and state income taxes, is $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zZqEFzX7sr09" title="Income tax provision">227</span>. Our current federal and deferred tax expenses are zero.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zAMuxdFcgzz4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_z2a1CbB5Jvk8">A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231_zuo37sFZQaL8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zYes8d4IhlIa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz3M7_maITEBzJI0_zjHHXtvV1Zf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 59%; text-align: left">Income tax credit at statutory rates</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(921</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--OverunderAccrualOfIncomeTaxes_maITEBz3M7_maITEBzJI0_zaS1bxbtv9z6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Under accrual of income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--NondeductibleExpenses_maITEBz3M7_maITEBzJI0_z197lEjTAXJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Nondeductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_maITEBz3M7_msITEBzJI0_zOMglyaKdCv5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Record tax credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(116</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(118</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBz3M7_maITEBzJI0_zzQSugQBs5N4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent tax deduction stock options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(63</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz3M7_maITEBzJI0_zqOIAUbbyuxh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(165</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ExpirationOfNolCredits_maITEBz3M7_maITEBzJI0_z4o189S3zac7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration of net operating losses and credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,492</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBz3M7_maITEBzJI0_zriQZxdLZ8h1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of change in deferred tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz3M7_maITEBzJI0_zZ7wZMi0wKUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration of stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBz3M7_maITEBzJI0_z3cyRoBQmji1" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(39</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz3M7_maITEBzJI0_zBrzY237tShe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,138</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(344</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzJI0_zJaHpIo9lmjk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">227</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$ </td><td style="border-bottom: Black 2.5pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z0Kc5FUa9661" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYfpTUFBhre" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zpGGWa39F8lf">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20241231_zETwLAnxEe64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_495_20231231_zBAsIop5Kjx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zU55PgkKl9Yf" style="vertical-align: bottom"> <td style="text-align: left">Deferred tax liabilities:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDTLzzT5_ziTF8tIp1N24" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left; padding-left: 0.125in">Excess tax depreciation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(496</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(477</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--Asc842OperatingLeaseAsset_iNI_pn3n3_di_maDTLzzT5_z66OKkDTeLJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">ASC 842 operating lease asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,938</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,975</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDTLzzT5_msDTANzkIN_zhou0gLY4Zmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Total deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,434</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,452</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z5mc0OPDxm3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqfm_zslIJeJPywka" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Net operating loss carryforwards</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,020</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGzqfm_zb3LBR7naY3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">179 Carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzqfm_zEPn7YMTTLsk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">163(j) Business interest limitation carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">302</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzqfm_zGKsDg48WF9e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Inventory and other allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzqfm_zK6unNPRKOPl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Excess book amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzqfm_zVB0HdKK0vy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">174 research and experimental expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,053</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">902</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqfm_zDrvWNppHHD5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">530</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--TaxCredits_iI_pn3n3_maDTAGzqfm_zCR54iV2sIX6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Tax credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--Asc842OperatingLeaseLiability_iI_pn3n3_maDTAGzqfm_zcpPJzlCUANd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">ASC 842 operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,610</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_maDTAGzqfm_zJrN6iFV5MU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other accrued costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">293</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzqfm_maDTANzkIN_z57mzyjkxK1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.25in">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,039</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkIN_zHHlu2aqQRTf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Less:  valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,451</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,587</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTANzkIN_zUhtU3Bwn9Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zOeXcIJO0K36" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt">The valuation allowance decreased approximately $<span id="xdx_908_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20240101__20241231_zWFisHLd9nP1" title="Increase (decrease) in valuation allowance">1.1</span> million and $<span id="xdx_909_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn5n6_di_c20230101__20231231_zAZZ1POPooX5" title="Increase (decrease) in valuation allowance">0.3</span> million for the years ended December 31, 2024 and 2023, respectively (net of approximately $<span id="xdx_908_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20241231_z2lHZ9SJdL6a" title="Valuation allowance, net operating loss carryforwards and credits">8.1</span> million and $<span id="xdx_900_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20231231_zRVK5VE84edk">7.1</span> million for the years ended December 31, 2024 and 2023, respectively, for expiring net operating loss carryforwards and credits) due principally to the change in the net operating loss carryforward and uncertainty as to whether future taxable income will be generated prior to the expiration of the carryforward period. Under the Internal Revenue Code, certain ownership changes, including the prior issuance of preferred stock and our public offering of common stock, may subject us to annual limitations on the utilization of our net operating loss carryforward. As of December 31, 2024, it has been determined that we are not subject to annual limitations on the utilization of our net operating loss carryforward.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt">We have federal net operating loss carryforwards for tax purposes of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231_zZz9t8Q5YJZ7" title="Net operating loss carryforwards">42</span> million on December 31, 2024. <span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--TaxPeriodAxis__custom--Expiring2025To2037Member_zSBGz5jNuXmj" title="Net operating loss carryforwards">$36</span> million expire between <span id="xdx_90B_ecustom--OperatingLossCarryforwardsExpirationYearStart_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWMMHo3FHRY1" title="Operating loss carryforwards expiration period start">2025</span> and <span id="xdx_90A_ecustom--OperatingLossCarryforwardsExpirationYearEnd_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zST1BZ5j8lT" title="Operating loss carryforwards expiration period end">2037</span>. All net operating loss carryforwards generated after January 1, 2018 do not expire. Therefore, $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2018Member_zduzjwJmGom6">6.8</span> million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z8Hux9YD7Dad">18.2</span> million on December 31, 2024. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between <span id="xdx_90B_ecustom--OperatingLossCarryforwardsExpirationYearStart_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zje1RSPPv4r3">2029</span> and <span id="xdx_90C_ecustom--OperatingLossCarryforwardsExpirationYearEnd_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zQHYDnngx8k7" title="Operating loss carryforwards expiration period end">2039</span>.</p> 227000 <p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zAMuxdFcgzz4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_z2a1CbB5Jvk8">A reconciliation of income tax benefit to the amount computed by applying the Federal income tax rate to loss before provision for income taxes as of December 31, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231_zuo37sFZQaL8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zYes8d4IhlIa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBz3M7_maITEBzJI0_zjHHXtvV1Zf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 59%; text-align: left">Income tax credit at statutory rates</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(921</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--OverunderAccrualOfIncomeTaxes_maITEBz3M7_maITEBzJI0_zaS1bxbtv9z6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Under accrual of income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--NondeductibleExpenses_maITEBz3M7_maITEBzJI0_z197lEjTAXJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Nondeductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_maITEBz3M7_msITEBzJI0_zOMglyaKdCv5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Record tax credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(116</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(118</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_maITEBz3M7_maITEBzJI0_zzQSugQBs5N4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent tax deduction stock options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(63</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBz3M7_maITEBzJI0_zqOIAUbbyuxh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(165</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--ExpirationOfNolCredits_maITEBz3M7_maITEBzJI0_z4o189S3zac7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration of net operating losses and credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,492</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_maITEBz3M7_maITEBzJI0_zriQZxdLZ8h1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of change in deferred tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBz3M7_maITEBzJI0_zZ7wZMi0wKUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expiration of stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBz3M7_maITEBzJI0_z3cyRoBQmji1" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(39</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz3M7_maITEBzJI0_zBrzY237tShe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,138</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(344</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzJI0_zJaHpIo9lmjk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">227</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$ </td><td style="border-bottom: Black 2.5pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 937000 -921000 -1000 -3000 5000 23000 116000 118000 -27000 -63000 179000 -165000 332000 1492000 49000 45000 46000 60000 -39000 -1138000 -344000 227000 6000 <p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYfpTUFBhre" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zpGGWa39F8lf">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred income taxes consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20241231_zETwLAnxEe64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_495_20231231_zBAsIop5Kjx9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zU55PgkKl9Yf" style="vertical-align: bottom"> <td style="text-align: left">Deferred tax liabilities:</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDTLzzT5_ziTF8tIp1N24" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left; padding-left: 0.125in">Excess tax depreciation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(496</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(477</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--Asc842OperatingLeaseAsset_iNI_pn3n3_di_maDTLzzT5_z66OKkDTeLJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">ASC 842 operating lease asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,938</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,975</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDTLzzT5_msDTANzkIN_zhou0gLY4Zmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Total deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,434</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,452</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z5mc0OPDxm3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzqfm_zslIJeJPywka" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Net operating loss carryforwards</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,020</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_maDTAGzqfm_zb3LBR7naY3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">179 Carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">245</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_pn3n3_maDTAGzqfm_zEPn7YMTTLsk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">163(j) Business interest limitation carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">302</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzqfm_zGKsDg48WF9e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Inventory and other allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">764</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzqfm_zK6unNPRKOPl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Excess book amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzqfm_zVB0HdKK0vy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">174 research and experimental expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,053</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">902</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzqfm_zDrvWNppHHD5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">788</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">530</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--TaxCredits_iI_pn3n3_maDTAGzqfm_zCR54iV2sIX6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Tax credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--Asc842OperatingLeaseLiability_iI_pn3n3_maDTAGzqfm_zcpPJzlCUANd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">ASC 842 operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,610</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_maDTAGzqfm_zJrN6iFV5MU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other accrued costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">293</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzqfm_maDTANzkIN_z57mzyjkxK1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.25in">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,039</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkIN_zHHlu2aqQRTf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Less:  valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,451</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,587</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTANzkIN_zUhtU3Bwn9Nh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 496000 477000 1938000 1975000 2434000 2452000 10218000 12020000 245000 302000 764000 239000 60000 60000 1053000 902000 788000 530000 189000 118000 2520000 2610000 293000 13000 15885000 17039000 13451000 14587000 -1100000 -300000 8100000 7100000 42000000 36000000 2025 2037 6800000 18200000 2029 2039 <p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyOeObHOPeQa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><b>(9)</b></p></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><span id="xdx_828_zJbzWDPucxN7">Capital Stock</span></b></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, and 2023, we had <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20241231_z8KBQdDJbQA1" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20231231_zqoXMmzl0c74" title="Preferred stock, shares authorized">24,088</span></span> authorized but unissued shares of preferred stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Pursuant to the Securities Purchase Agreement executed on March 1, 2024, the Company issued to Strandler <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20240229__20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zUW8VWJAOKKb" title="Number of shares issued">15,000</span> shares of the Company’s Series X Preferred Stock (the “Series X Preferred Stock”) at a purchase price per share of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pip0_uUSDPShares_c20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zQTMn3SACSv7" title="Price per share">400</span>, for total consideration of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pp0p0_c20240229__20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zGLbx9B0jhI2" title="Consideration from sale of shares">6,000,000</span>, in a transaction exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The terms of the Preferred Stock are set forth in the Company’s Certificate of Designations to its Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 4, 2024 (the “Certificate of Designations”). Under the Purchase Agreement, the Company granted Strandler customary registration rights with respect to shares of the Company’s common stock, par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20240301_zGiGUQR2unn2" title="Common stock, par value (in dollars per share)">0.01</span> per share (the “Common Stock”), it may receive in connection with any conversion of Series X Preferred Stock into Common Stock, as described below. For so long as any amount of Preferred Stock was outstanding, the Purchase Agreement also (i) prevented the Company from paying any dividend on any shares of the Company’s capital stock (other than dividends consisting solely of Common Stock or rights to purchase Common Stock), (ii) prevented the Company from repurchasing any Common Stock, and (iii) subject to certain permitted exceptions, restricted the Company’s ability to permit any lien or other encumbrance on Company assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">At any time and from time to time, in whole or in part, following the Company properly filing an amendment (the “Certificate Amendment”) to its Certificate of Incorporation to increase the number of authorized shares of its Common Stock from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20240301_zIN3RGxii5Ug" title="Common stock, authorized">60,000,000</span> to <span id="xdx_907_ecustom--CommonStockSharesAuthorizedForConversionOfPreferredStock_iI_pid_uShares_c20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zvGWJRVhjAe5" title="Common stock, authorized for conversion of preferred stock">95,000,000</span>, each share of Series X Preferred Stock was convertible, at the option of the holder, into <span id="xdx_90A_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_uShares_c20241231_zPRoo6oDSe9d">1,000</span> shares of Common Stock at no additional cost. If the Company had not properly filed, upon shareholder approval, the Certificate Amendment on or before August 1, 2024, then each share of Series X Preferred Stock would have been redeemable at the holder’s option, in whole or in part, without penalty or premium, at a redemption price equal to $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pip0_uUSDPShares_c20240301_zENHh7PJNqi2" title="Conversion price">420</span> per share (each, a “Redemption”). If the Company failed to fully pay any Redemption within five days of receiving notice, all unpaid amounts would bear interest at a rate of <span id="xdx_90A_ecustom--PreferredStockConvertibleInterestRateForUnpaidRedemption_iI_pid_dp_uPure_c20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zjjEbjREMxJb" title="Interest rate">10</span>% per annum. In addition, in the event of a Change in Control (as defined in the Certificate of Designations) of the Company, each share of the Series X Preferred Stock would have been redeemable at the option of the holder, without penalty or premium, at a redemption price equal to $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pip0_uUSDPShares_c20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zIPjk2FAu3de" title="Conversion price">420</span> per share. Upon any conversion of Preferred Stock into Common Stock by Strandler, Strandler is required to hold the Common Stock received in the conversion for a period of 12 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Holders of Series X Preferred Stock (i) were not entitled to receive dividends, subject to customary anti-dilution protections, (ii) had no voting rights, and (iii) would have received a liquidation preference of $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_iI_pip0_uUSDPShares_c20240301__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_z6DJX7kahC73" title="Liquidation preference">400</span> per share. The Series X Preferred Stock ranked senior in right of payment to all securities designated as junior securities, including Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">ASC 815-15-25-17D provides guidance for assessing host contracts in the form of preferred shares, in which 25-17D(b) states that an investor’s ability to “convert a preferred share into a fixed number of common shares generally is viewed as an equity-like characteristic”. Because conversion of the Series X Preferred Shares were at the discretion of the Holder, conversion was in a fixed number of shares, dividends are not typically paid and cash settlement would only occur in the unlikely event of change in control, the host contract had the characteristics of, and was classified as, an equity instrument, and the embedded derivatives and host contract were considered clearly and closely related. As such, the embedded derivative did not require bifurcation and the Series X Preferred Shares were reported as mezzanine equity on the balance sheet during the period when these instruments were issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Issuance costs associated with issuance of the Series X Preferred Stock were immaterial.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">On June 18, 2024, the Company held a special meeting of stockholders where the Certificate Amendment was approved. The Certificate Amendment was filed with the State of Delaware on June 19, 2024. On June 20, 2024, Strandler converted its <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_uShares_c20240618__20240620__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_znw0yy52nIDh" title="Shares converted">15,000</span> shares of Series X Preferred Stock to <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_pid_uShares_c20240618__20240620__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG7VDZb1s9uj" title="Shares issued upon conversion">15,000,000</span> shares of Common Stock.</p> 24088 24088 15000 400 6000000 0.01 60000000 95000000 1000 420 0.10 420 400 15000 15000000 <p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zRqkakIgbCRc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(10)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_829_zcTiXqoNQJel">Stock Options and Stock Grants</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We have entered into stock option agreements with certain officers, employees and directors. The stock options granted prior to the adoption of the 2019 Equity Compensation Plan (the “2019 Plan”) on November 19, 2019 expire <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--PriorTo2019PlanMember_zZydaddxhG5b" title="Expiration period">seven years</span> from the date of grant. Future options to be granted under the 2019 Plan will expire <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--Options2019PlanMember_zD9pUfIPtQG" title="Expiration period">seven years</span> from the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="text-decoration: underline">Employee Stock Options</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zhS2wFR7uWBf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B0_zmWQO6YHlUpb">We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_498_20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOoC8UNAuKE1" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="2" id="xdx_49F_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEtKFlVYiNe" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 17.25pt; text-align: center"><b>Years ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21.75pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_zbkSu7Ukx6Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">Share-based compensation expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">725</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">773</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iE_zGNeoXkdZ9Fd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining unrecognized compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,118</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Remaining weighted average-period, expense recognition (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTm6wrvaD966" title="Remaining weighted average-period, expense recognition (years)">2.4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNJyGVv8jBO" title="Remaining weighted average-period, expense recognition (years)">1.8</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zoet7PYN1Y7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We use the Black-Scholes option pricing model to determine the fair value of stock-based compensation. The Black-Scholes model requires us to make several assumptions, including the estimated length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of our common stock price over the expected term, and estimated forfeitures. Expected price volatility is based on the daily market rate changes of our stock. The active shares granted prior to fiscal 2020 had a contractual life of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--Options2010PlanMember_zhyRkh0nfiS" title="Expiration period">10 years</span> as dictated by the 2010 Plan. The Black-Scholes model also requires a risk-free interest rate, which is based on the U.S. Treasury yield curve in effect at the time of the grant, and the dividend yield on our common stock, which is assumed to be zero since we do not pay dividends and have no current plans to do so in the future. Changes in these assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related expense recognized on the statement of operations. We recognize stock-based compensation expense on a straight-line basis over the requisite service period. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zik9Ebh01DE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zpXtA7dz4x2c">The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Weighted-average risk-free interest rates:</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20240101__20241231_zApDvXJ90yK4" style="width: 10%; text-align: right" title="Weighted-average risk-free interest rates">4.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20230101__20231231_zJCaHOyBEY73" style="width: 10%; text-align: right">3.8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20240101__20241231_zXtSub21NRJ5" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20230101__20231231_zhXo9R6utgcb" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected life (years) of the option:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zxEh4XB8t0Nh" style="text-align: right" title="Weighted-average expected life (years) of the option">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zADu18dwZ96l" style="text-align: right" title="Weighted-average expected life (years) of the option">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected stock price volatility:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20240101__20241231_zZkMwWbsx8pg" style="text-align: right" title="Weighted-average expected stock price volatility">91</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20230101__20231231_zN1xxWqU7jRa" style="text-align: right" title="Weighted-average expected stock price volatility">93</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average fair value of the options granted:</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231_zO3OCnrTzR8f" style="text-align: right" title="Weighted-average fair value of the options granted">1.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231_zekloejJs2cd" style="text-align: right" title="Weighted-average fair value of the options granted">0.50</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zj7mcrzTSC87" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_891_ecustom--AdditionalDisclosuresForOptionsGrantedTableTextBlock_zDf0N5z68kpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zz3xZSq8txck">Additional disclosures for options granted for all years presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%">Vesting period (years) of shares granted in period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3VjhuTjjg6b" style="width: 10%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1ZvkntYipDc" style="width: 10%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Contractual life (years) of shares granted in period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk4pPOV77N45" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMDFmk9M1s29" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Estimated forfeitures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1pKVfWeTHy7" style="text-align: right" title="Estimated forfeitures">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZM95lNhPMVi" style="text-align: right" title="Estimated forfeitures">8</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AD_zpvxKMhAkD84" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5ao0REAs0V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_8BF_zf8P2wHXOrk">The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Rounded)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-bottom: 2.5pt">Outstanding on January 1, 2024</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231_zSwKGTKke3Mh" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Shares Outstanding, Beginning">3,525,966</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zuOVMGBfWLGk" style="width: 10%; text-align: right" title="Shares Outstanding, Beginning, (per share)">1.22</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQtqclTJ6pFj" style="width: 10%; text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end">4.2</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zBAa9kJ3Uupe" style="width: 10%; text-align: right" title="Shares Outstanding, Beginning (Intrinsic value)">160</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231_zpUepcR0gEG6" style="text-align: right" title="Granted">388,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231_zHTYPZfNyo58" style="text-align: right" title="Granted (per share)">2.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231_zHjnJXPdSCL8" style="text-align: right" title="Exercised">(455,995</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231_zGnYjwSjPVcl" style="text-align: right" title="Exercised (per share)">0.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20240101__20241231_zJmc9hRsFA7l" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired">(246,232</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231_zlE2OmnKw3fb" style="text-align: right" title="Forfeited or expired (per share)">1.13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding on December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231_z42Ah5gk1mXc" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding, Ending">3,211,739</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zrqg3wkgs9Rd" style="text-align: right" title="Shares Outstanding, Ending, (per share)">1.47</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_za2B01HCQls3" style="text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end">4.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zIALfgshmR6e" style="text-align: right" title="Shares Outstanding, Ending (Intrinsic value)">3,961</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable on December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20240101__20241231_zEKOSLralWv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Exercisable">2,206,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_ziaKfFDMlYNi" style="text-align: right" title="Shares Exercisable, (per share)">1.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zc1CVRC5V3Lk" style="text-align: right" title="Shares Exercisable (years)">3.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231_z6rrfwJbh2Ha" style="text-align: right" title="Shares Exercisable (Intrinsic value)">2,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Shares available for grant</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20241231_znZkw9pQUc2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant">62,900</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zbv0bDjC63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89C_ecustom--StockOptionsRecognizedTableTextBlock_zMf1iAEDoHX8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zrF3JxU62aqa">The aggregate intrinsic value in the table above is based on our closing stock price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHJwO9Ji9qth" title="Closing stock share price">2.26</span> on the last business day for the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_490_20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0p8c5peFw7d" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC93akbTD2Qf" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Years ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_zsGOqsPjfxo5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%">Shares exercised</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">455,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">294,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_z0BDLY8ZSRf2" style="vertical-align: bottom"> <td>Total intrinsic value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">195</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_zENBMzoMRuF" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Cash received</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">154</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zDOiqOam8Uu2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Based on our election of the “with and without” approach, no realized tax benefits from stock options were recognized for the years ended December 31, 2024 and 2023.</p> P7Y P7Y <p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zhS2wFR7uWBf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span id="xdx_8B0_zmWQO6YHlUpb">We follow ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_498_20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOoC8UNAuKE1" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="2" id="xdx_49F_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEtKFlVYiNe" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 17.25pt; text-align: center"><b>Years ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 21.75pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--StockOptionPlanExpense_zbkSu7Ukx6Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; text-align: left">Share-based compensation expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">725</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">773</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iE_zGNeoXkdZ9Fd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remaining unrecognized compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,118</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Remaining weighted average-period, expense recognition (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTm6wrvaD966" title="Remaining weighted average-period, expense recognition (years)">2.4</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNJyGVv8jBO" title="Remaining weighted average-period, expense recognition (years)">1.8</span></td><td style="text-align: left"> </td></tr> </table> 725000 773000 1057000 1118000 P2Y4M24D P1Y9M18D P10Y <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_zik9Ebh01DE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zpXtA7dz4x2c">The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for options granted for all years presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Weighted-average risk-free interest rates:</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20240101__20241231_zApDvXJ90yK4" style="width: 10%; text-align: right" title="Weighted-average risk-free interest rates">4.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_uPure_c20230101__20231231_zJCaHOyBEY73" style="width: 10%; text-align: right">3.8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20240101__20241231_zXtSub21NRJ5" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_uPure_c20230101__20231231_zhXo9R6utgcb" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected life (years) of the option:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zxEh4XB8t0Nh" style="text-align: right" title="Weighted-average expected life (years) of the option">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zADu18dwZ96l" style="text-align: right" title="Weighted-average expected life (years) of the option">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average expected stock price volatility:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20240101__20241231_zZkMwWbsx8pg" style="text-align: right" title="Weighted-average expected stock price volatility">91</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pip0_dp_uPure_c20230101__20231231_zN1xxWqU7jRa" style="text-align: right" title="Weighted-average expected stock price volatility">93</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average fair value of the options granted:</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231_zO3OCnrTzR8f" style="text-align: right" title="Weighted-average fair value of the options granted">1.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231_zekloejJs2cd" style="text-align: right" title="Weighted-average fair value of the options granted">0.50</td><td style="text-align: left"> </td></tr> </table> 0.043 0.038 0 0 P4Y P4Y 0.91 0.93 1.74 0.50 <p id="xdx_891_ecustom--AdditionalDisclosuresForOptionsGrantedTableTextBlock_zDf0N5z68kpi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zz3xZSq8txck">Additional disclosures for options granted for all years presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%">Vesting period (years) of shares granted in period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3VjhuTjjg6b" style="width: 10%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1ZvkntYipDc" style="width: 10%; text-align: right" title="Vesting period (years) of shares granted in period">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Contractual life (years) of shares granted in period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk4pPOV77N45" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardContractualLife_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMDFmk9M1s29" style="text-align: right" title="Contractual life (years) of shares granted in period">7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Estimated forfeitures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1pKVfWeTHy7" style="text-align: right" title="Estimated forfeitures">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFortfeitureRate_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZM95lNhPMVi" style="text-align: right" title="Estimated forfeitures">8</td><td style="text-align: left">%</td></tr> </table> P3Y P3Y P7Y P7Y 0.08 0.08 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5ao0REAs0V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_8BF_zf8P2wHXOrk">The following table summarizes the option activity for our employees and directors during the year ended December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Rounded)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(000s)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%; padding-bottom: 2.5pt">Outstanding on January 1, 2024</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231_zSwKGTKke3Mh" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Shares Outstanding, Beginning">3,525,966</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zuOVMGBfWLGk" style="width: 10%; text-align: right" title="Shares Outstanding, Beginning, (per share)">1.22</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zQtqclTJ6pFj" style="width: 10%; text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end">4.2</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zBAa9kJ3Uupe" style="width: 10%; text-align: right" title="Shares Outstanding, Beginning (Intrinsic value)">160</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231_zpUepcR0gEG6" style="text-align: right" title="Granted">388,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231_zHTYPZfNyo58" style="text-align: right" title="Granted (per share)">2.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231_zHjnJXPdSCL8" style="text-align: right" title="Exercised">(455,995</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231_zGnYjwSjPVcl" style="text-align: right" title="Exercised (per share)">0.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20240101__20241231_zJmc9hRsFA7l" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired">(246,232</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231_zlE2OmnKw3fb" style="text-align: right" title="Forfeited or expired (per share)">1.13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding on December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231_z42Ah5gk1mXc" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding, Ending">3,211,739</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zrqg3wkgs9Rd" style="text-align: right" title="Shares Outstanding, Ending, (per share)">1.47</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_za2B01HCQls3" style="text-align: right" title="Weighted Average Remaining Contractual Term, Outstanding, end">4.4</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zIALfgshmR6e" style="text-align: right" title="Shares Outstanding, Ending (Intrinsic value)">3,961</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable on December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20240101__20241231_zEKOSLralWv7" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Exercisable">2,206,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_ziaKfFDMlYNi" style="text-align: right" title="Shares Exercisable, (per share)">1.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zc1CVRC5V3Lk" style="text-align: right" title="Shares Exercisable (years)">3.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231_z6rrfwJbh2Ha" style="text-align: right" title="Shares Exercisable (Intrinsic value)">2,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Shares available for grant</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20241231_znZkw9pQUc2l" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant">62,900</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3525966 1.22 P4Y2M12D 160000 388000 2.40 455995 0.52 246232 1.13 3211739 1.47 P4Y4M24D 3961000 2206666 1.46 P3Y7M6D 2984000 62900 <p id="xdx_89C_ecustom--StockOptionsRecognizedTableTextBlock_zMf1iAEDoHX8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zrF3JxU62aqa">The aggregate intrinsic value in the table above is based on our closing stock price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHJwO9Ji9qth" title="Closing stock share price">2.26</span> on the last business day for the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td id="xdx_490_20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0p8c5peFw7d" style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zC93akbTD2Qf" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>Years ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_zsGOqsPjfxo5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%">Shares exercised</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">455,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">294,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_z0BDLY8ZSRf2" style="vertical-align: bottom"> <td>Total intrinsic value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">195</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProceedsFromStockOptionsExercised_zENBMzoMRuF" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Cash received</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">154</td><td style="text-align: left"> </td></tr> </table> 2.26 455995 294074 370000 195000 239000 154000 <p id="xdx_80C_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zQQF0ezFHJo4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(11)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_828_zqmRtV2QiZA8">401(k) Profit-Sharing Plan</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">We have a 401(k) profit-sharing plan covering substantially all employees who meet defined service requirements. Contributions made in 2024 and 2023 aggregated to $<span id="xdx_907_eus-gaap--DefinedContributionPlanCostRecognized_pn3n3_c20240101__20241231_z6vg668xY4Tk" title="Defined contribution plan, cost">206</span> and $<span id="xdx_90A_eus-gaap--DefinedContributionPlanCostRecognized_pn3n3_c20230101__20231231_z3ejbASawtQk" title="Defined contribution plan, cost">191</span>, respectively.</p> 206000 191000 <p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zfDx4MDDvzB8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(12)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_823_zpA1m9IMYKac">Significant Customers</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ziyGVg2xJExk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span>We had three significant customers for the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span><span id="xdx_8B0_z3d3vw25OBEc">Revenues from these three customers, as a percentage of total Company revenue, was approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the years ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 42%; text-align: left">Consumer Products</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zk8P9S5jKWK7" title="Revenue from customers">32</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zAsh3kIdBg17" title="Revenue from customers">17</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zHGJyrAA4GXj" title="Revenue from customers">13</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zA7sh8k002Aj" title="Revenue from customers">25</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Consumer Products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zFCLHsphhdga" title="Revenue from customers">7</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zeo38d5rFTK7" title="Revenue from customers">15</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zW1utyNewv4l" title="Revenue from customers">52</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyZBsdpD439a" title="Revenue from customers">57</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A2_zPLhL1e4ptZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><br/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89A_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_zXlo3SECUJGl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> <span id="xdx_8B8_zpv82TL2Cuej">Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 32%; text-align: left">Consumer Products</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerOneMember_znEQUYxMOQ0a" style="width: 10%; text-align: right" title="Total">2,366</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerOneMember_zkWRAyU19eEg" style="width: 10%; text-align: right" title="Total">1,288</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zIWqtOHy11zb" style="text-align: right" title="Total">160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zMJl5nZ1Xkgl" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1087">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Consumer Products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zSYTkuHaSgkc" style="border-bottom: Black 1pt solid; text-align: right" title="Total">309</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zLPlQZbbQYNg" style="border-bottom: Black 1pt solid; text-align: right" title="Total">864</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231_zoAiL5MOFet4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,835</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231_zFdap97cRwr" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zQYMlMZNPKH7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.3pt; text-align: justify; text-indent: 35.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.3pt; text-align: justify; text-indent: 35.7pt">We currently have exclusive supply agreements with BASF Corporation (“BASF”), our second largest customer, that have contingencies outlined which could potentially result in the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either <span id="xdx_90C_ecustom--EquipmentSaleNetBookValueEquipment_iI_pid_dp_uPure_c20241231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zp4aLvg19loc" title="Equipment sale - net book value">115</span>% of the equipment’s net book value or the greater of <span id="xdx_90F_ecustom--EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades_iI_pid_dp_uPure_c20241231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zpROBtISIp6" title="Equipment sale- original book value">30</span>% of the original book value of such equipment, and any associated upgrades to it, or <span id="xdx_90B_ecustom--EquipmentSaleNetBookValueEquipment_iI_pid_dp_uPure_c20241231__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_z1jul51wUFfj" title="Equipment sale - net book value">115</span>% of the equipment’s net book value, depending on the equipment and related products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.3pt; text-align: justify; text-indent: 35.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event could result in the loss of some of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.</p> <p id="xdx_890_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ziyGVg2xJExk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span>We had three significant customers for the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span><span id="xdx_8B0_z3d3vw25OBEc">Revenues from these three customers, as a percentage of total Company revenue, was approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the years ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 42%; text-align: left">Consumer Products</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zk8P9S5jKWK7" title="Revenue from customers">32</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zAsh3kIdBg17" title="Revenue from customers">17</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zHGJyrAA4GXj" title="Revenue from customers">13</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zA7sh8k002Aj" title="Revenue from customers">25</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Consumer Products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zFCLHsphhdga" title="Revenue from customers">7</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zeo38d5rFTK7" title="Revenue from customers">15</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zW1utyNewv4l" title="Revenue from customers">52</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyZBsdpD439a" title="Revenue from customers">57</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.32 0.17 0.13 0.25 0.07 0.15 0.52 0.57 <p id="xdx_89A_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_zXlo3SECUJGl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> <span id="xdx_8B8_zpv82TL2Cuej">Accounts receivable balances for these three customers, as a percentage of total Company accounts receivable, was approximately:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 32%; text-align: left">Consumer Products</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerOneMember_znEQUYxMOQ0a" style="width: 10%; text-align: right" title="Total">2,366</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerOneMember_zkWRAyU19eEg" style="width: 10%; text-align: right" title="Total">1,288</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zIWqtOHy11zb" style="text-align: right" title="Total">160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember_zMJl5nZ1Xkgl" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1087">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Consumer Products</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zSYTkuHaSgkc" style="border-bottom: Black 1pt solid; text-align: right" title="Total">309</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember_zLPlQZbbQYNg" style="border-bottom: Black 1pt solid; text-align: right" title="Total">864</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.5in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20241231_zoAiL5MOFet4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,835</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20231231_zFdap97cRwr" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,152</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2366000 1288000 160000 309000 864000 2835000 2152000 1.15 0.30 1.15 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zCEkdSFUjDXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(13)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_82B_zuuLiFh96Snh">Business Segmentation and Geographical Distribution</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The Company operates as a single business segment, in which the factors used to make this determination include differences in products, services, geographical areas, regulatory environment, and other such criteria considered for the appropriateness of aggregation. The types of products and services for which the sole reportable segment, which is the same as the Company as a whole, offered by the company is discussed in Note 1. Since the Company operates as a single segment, there were no intra-entity sales or transfers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The role of Chief Operating Decision Maker for the Company is comprised of a committee that includes the Chief Executive and Chief Operating Officers. The Chief Operating Decision Maker assesses performance for the single segment and decides how to allocate resources based on net income that also is reported on the income statement as net income. The measure of segment assets is reported on the balance sheet as total assets. The accounting policies of the sole segment are the same as those described in the summary of significant accounting policies in Note 2.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zVSuDLVLbaj7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zAvevySpSZO7">The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20240101__20241231_zlv4fZM1Fhv3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_496_20230101__20231231_z0LV8tgY3LX3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z54ix626xDY6" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; text-align: left">Total revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">52,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">37,297</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--EmployeeCostsMember_z0bYSzBt8NR5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Employee costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,811</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ContractorsAndProfessionalServicesMember_zSpLexDJdWPg" style="vertical-align: bottom"> <td style="text-align: left">Contractors and professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,588</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--MaterialsAndSuppliesMember_zBUCI84JsXjj" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Materials and supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,669</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--DepreciationMember_zUuZLVZbE4d3" style="vertical-align: bottom"> <td>Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">742</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__us-gaap--InterestExpenseMember_z7SQLXjwsqq" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">838</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__us-gaap--OtherIncomeMember_zvx7VTc6QqDa" style="vertical-align: bottom"> <td style="text-align: left">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--TaxExpenseMember_z4BGC4yAM8Oa" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--FacilitiesMember_zwgDiBfrq3F9" style="vertical-align: bottom"> <td>Facilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,870</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ShippingMember_z9Rq2eLGLMfe" style="vertical-align: bottom; background-color: #CCEEFF"> <td>Shipping</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">760</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--TestingMember_ztDEbKZuDLEe" style="vertical-align: bottom"> <td>Testing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">917</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ITServicesMember_zm2lI8FiH2Ih" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">IT services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,091</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,060</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--InsuranceMember_zroUqKHHGEJe" style="vertical-align: bottom"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">721</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ManufacturingOtherExpenseMember_z839UAO1Ri42" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Manufacturing other expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">992</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--SellingGeneralAndAdministrativeOtherExpenseMember_z6MEgFfJTme2" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative other expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">849</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CostsAndExpenses_zsHBZWPONsm8" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right">Total Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,687</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zI6wCttEIXLa" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right; padding-bottom: 2.5pt">Net Income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,235</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,390</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AF_zTMFjMq8z9G2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Revenue from international sources approximated $<span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zQVbw2nFrK27" title="Revenues">1,825</span> and $<span id="xdx_904_eus-gaap--Revenues_pn3n3_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zrKmgRe4zXqk" title="Revenues">2,918</span> for the years ended December 31, 2024 and 2023, respectively. As part of our revenue from international sources, we recognized approximately $<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zsPvFUyOIhec" title="Revenues">366</span> and $<span id="xdx_903_eus-gaap--Revenues_pn3n3_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zI46Y8MsHTJ4" title="Revenues">1,664</span> in product revenue from German companies, in the aggregate, for the years ended December 31, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zeSsxMNbNHHb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, personal care ingredients, advanced materials and consumer products. <span id="xdx_8B2_zyO4ezU0r7S4">The revenues for 2024 and 2023 by category are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>For the years ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>December 31</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: left">Consumer Products</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--ConsumerProductsMember_zAKpoc0LcaW" style="width: 10%; text-align: right" title="Consumer Products">44,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--ConsumerProductsMember_zgFLt7uh9Aue" style="width: 10%; text-align: right" title="Consumer Products">25,211</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zbE2HQCRna52" style="text-align: right" title="Personal Care Ingredients">6,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zfTYqv3UQN0l" style="text-align: right" title="Personal Care Ingredients">9,277</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zQtqinUZ187k" style="border-bottom: Black 1pt solid; text-align: right" title="Advanced Materials">1,147</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_z0ixpRQm2A8k" style="border-bottom: Black 1pt solid; text-align: right" title="Advanced Materials">2,809</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_z6UhZQkWV7ih" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">52,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zhkRpvgBQxUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">37,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z2hsaZtZMyoe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p> <p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zVSuDLVLbaj7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zAvevySpSZO7">The Chief Operating Decision Maker uses gross profit and net income to evaluate Company performance and in what way to allocate resources. Significant segment expenses, which are the same as the entity as a whole, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20240101__20241231_zlv4fZM1Fhv3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td colspan="2" id="xdx_496_20230101__20231231_z0LV8tgY3LX3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z54ix626xDY6" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; text-align: left">Total revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">52,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">37,297</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--EmployeeCostsMember_z0bYSzBt8NR5" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Employee costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,811</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ContractorsAndProfessionalServicesMember_zSpLexDJdWPg" style="vertical-align: bottom"> <td style="text-align: left">Contractors and professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,588</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--MaterialsAndSuppliesMember_zBUCI84JsXjj" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Materials and supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,669</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--DepreciationMember_zUuZLVZbE4d3" style="vertical-align: bottom"> <td>Depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">742</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__us-gaap--InterestExpenseMember_z7SQLXjwsqq" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">838</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__us-gaap--OtherIncomeMember_zvx7VTc6QqDa" style="vertical-align: bottom"> <td style="text-align: left">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--TaxExpenseMember_z4BGC4yAM8Oa" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--FacilitiesMember_zwgDiBfrq3F9" style="vertical-align: bottom"> <td>Facilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,870</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ShippingMember_z9Rq2eLGLMfe" style="vertical-align: bottom; background-color: #CCEEFF"> <td>Shipping</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">760</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--TestingMember_ztDEbKZuDLEe" style="vertical-align: bottom"> <td>Testing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">917</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ITServicesMember_zm2lI8FiH2Ih" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">IT services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,091</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,060</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--InsuranceMember_zroUqKHHGEJe" style="vertical-align: bottom"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">721</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--ManufacturingOtherExpenseMember_z839UAO1Ri42" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left">Manufacturing other expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">992</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">604</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CostsAndExpenses_hus-gaap--NatureOfExpenseAxis__custom--SellingGeneralAndAdministrativeOtherExpenseMember_z6MEgFfJTme2" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative other expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">849</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CostsAndExpenses_zsHBZWPONsm8" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right">Total Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,687</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zI6wCttEIXLa" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right; padding-bottom: 2.5pt">Net Income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,235</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,390</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 52347000 37297000 12933000 10811000 7815000 6588000 15559000 14669000 928000 742000 670000 838000 -2000 -4000 318000 101000 3413000 2870000 1193000 760000 917000 1078000 1091000 1060000 785000 721000 992000 604000 1500000 849000 48112000 41687000 4235000 -4390000 1825000 2918000 366000 1664000 <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zeSsxMNbNHHb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, personal care ingredients, advanced materials and consumer products. <span id="xdx_8B2_zyO4ezU0r7S4">The revenues for 2024 and 2023 by category are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>For the years ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><b>December 31</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 74%; text-align: left">Consumer Products</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--ConsumerProductsMember_zAKpoc0LcaW" style="width: 10%; text-align: right" title="Consumer Products">44,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--ConsumerProductsMember_zgFLt7uh9Aue" style="width: 10%; text-align: right" title="Consumer Products">25,211</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zbE2HQCRna52" style="text-align: right" title="Personal Care Ingredients">6,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zfTYqv3UQN0l" style="text-align: right" title="Personal Care Ingredients">9,277</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zQtqinUZ187k" style="border-bottom: Black 1pt solid; text-align: right" title="Advanced Materials">1,147</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_z0ixpRQm2A8k" style="border-bottom: Black 1pt solid; text-align: right" title="Advanced Materials">2,809</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231_z6UhZQkWV7ih" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">52,347</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zhkRpvgBQxUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">37,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 44373000 25211000 6827000 9277000 1147000 2809000 52347000 37297000 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zzxBFaMU2wqi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-size: 10pt"><b>(14)</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_829_znyOnXMm6Pah">Subsequent Event</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">On March 7, 2025, the Company announced its rebranding as Solesence, Inc., marking a new chapter in its commitment to innovation, self-expression, and inclusivity in skin health. The company’s stock will continue to trade under the NANX ticker symbol. Its corporate website transitioned to solesence.com, historic Company financials and disclosures are now available at ir.solesence.com. Nanophase Technologies Corporation changed its legal name to Solesence, Inc. by amending its certificate of incorporation with the state of Delaware on March 10, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">As of December 31, 2024, the Company’s A/R Revolver, Inventory Facility and New Term Loan mature on <span id="xdx_90C_eus-gaap--LineOfCreditFacilityExpirationDate1_c20241229__20241231__us-gaap--LineOfCreditFacilityAxis__custom--ARRevolverInventoryFacilityAndNewTermLoanMember_znNFZglKRy6k" title="Expiration date">October 1, 2025</span>. Since then, the Company’s related party debt holder for the A/R Revolver, Inventory Facility and New Term Loan has committed to refinancing the debt with a new maturity date after <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_c20250101__20250331__us-gaap--LineOfCreditFacilityAxis__custom--ARRevolverInventoryFacilityAndNewTermLoanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgzcUdfIXg8h">April 1, 2026</span>.</p> 2025-10-01 2026-04-01 Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2024 or 2023, we have recorded no related liability on our balance sheet. On December 21, 2021, the existing credit agreement with Libertyville was converted for use to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2025. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC. On January 28, 2022, the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On March 1, 2024, the company entered into a Second Amendment to the Amended and Restated Business Loan Agreement extending the maturity of the A/R Revolver Facility to October 1, 2025. On January 28, 2022, the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility was $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it was set to matured on March 31, 2024. On November 13, 2023, the Company entered into a Replacement Promissory Note with Beachcorp, LLC replacing the Inventory Facility promissory note executed on January 28, 2022. The maximum borrowing amount under the replacement Inventory Facility was increased to $5,200, with a borrowing base consisting of up to 55% of the value of qualified inventory of the Company. The interest rate for the replacement Inventory Revolver remains at the prime rate plus 0.75%. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Inventory Revolver Facility to October 1, 2025. On January 28, 2022, the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On March 1, 2024, the company entered into a Second Amendment to the Business Loan Agreement extending the maturity of the Term Maturity Note to October 1, 2025. On November 13, 2023, the Company entered into a new Promissory Note (the “Bridge Note”) with Strandler, LLC. The maximum borrowing amount under the Bridge Note was $2,000. The interest rate for the Bridge Note was at the prime rate plus 0.75%, and it was to mature on May 13, 2024. The Bridge Note was repaid in February 2024.